0000790526-20-000007.txt : 20201109 0000790526-20-000007.hdr.sgml : 20201109 20201109162423 ACCESSION NUMBER: 0000790526-20-000007 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201109 DATE AS OF CHANGE: 20201109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RadNet, Inc. CENTRAL INDEX KEY: 0000790526 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 133326724 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33307 FILM NUMBER: 201298050 BUSINESS ADDRESS: STREET 1: 1510 COTNER AVE CITY: LOS ANGELES STATE: CA ZIP: 90025 BUSINESS PHONE: 3104787808 MAIL ADDRESS: STREET 1: 1510 COTNER AVE CITY: LOS ANGELES STATE: CA ZIP: 90025 FORMER COMPANY: FORMER CONFORMED NAME: PRIMEDEX HEALTH SYSTEMS INC DATE OF NAME CHANGE: 19930518 FORMER COMPANY: FORMER CONFORMED NAME: CCC FRANCHISING CORP DATE OF NAME CHANGE: 19920703 10-Q 1 rdnt-20200930.htm 10-Q rdnt-20200930
0000790526false12/31Q32020P3YP5Y00007905262020-01-012020-09-30xbrli:shares00007905262020-11-05iso4217:USD00007905262020-09-3000007905262019-12-31iso4217:USDxbrli:shares0000790526us-gaap:HealthCarePatientServiceMember2020-07-012020-09-300000790526us-gaap:HealthCarePatientServiceMember2019-07-012019-09-300000790526us-gaap:HealthCarePatientServiceMember2020-01-012020-09-300000790526us-gaap:HealthCarePatientServiceMember2019-01-012019-09-300000790526rdnt:CapitationArrangementsMember2020-07-012020-09-300000790526rdnt:CapitationArrangementsMember2019-07-012019-09-300000790526rdnt:CapitationArrangementsMember2020-01-012020-09-300000790526rdnt:CapitationArrangementsMember2019-01-012019-09-3000007905262020-07-012020-09-3000007905262019-07-012019-09-3000007905262019-01-012019-09-300000790526us-gaap:CommonStockMember2020-06-300000790526us-gaap:AdditionalPaidInCapitalMember2020-06-300000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300000790526us-gaap:RetainedEarningsMember2020-06-300000790526rdnt:StockholdersEquityDeficitMember2020-06-300000790526us-gaap:NoncontrollingInterestMember2020-06-3000007905262020-06-300000790526us-gaap:CommonStockMember2020-07-012020-09-300000790526us-gaap:CommonStockMemberrdnt:DeepHealthInc.Member2020-07-012020-09-300000790526rdnt:DeepHealthInc.Member2020-07-012020-09-300000790526us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300000790526rdnt:StockholdersEquityDeficitMember2020-07-012020-09-300000790526us-gaap:NoncontrollingInterestMember2020-07-012020-09-300000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000790526us-gaap:RetainedEarningsMember2020-07-012020-09-300000790526us-gaap:CommonStockMember2020-09-300000790526us-gaap:AdditionalPaidInCapitalMember2020-09-300000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300000790526us-gaap:RetainedEarningsMember2020-09-300000790526rdnt:StockholdersEquityDeficitMember2020-09-300000790526us-gaap:NoncontrollingInterestMember2020-09-300000790526us-gaap:CommonStockMember2019-06-300000790526us-gaap:AdditionalPaidInCapitalMember2019-06-300000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300000790526us-gaap:RetainedEarningsMember2019-06-300000790526rdnt:StockholdersEquityDeficitMember2019-06-300000790526us-gaap:NoncontrollingInterestMember2019-06-3000007905262019-06-300000790526us-gaap:CommonStockMember2019-07-012019-09-300000790526us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300000790526rdnt:StockholdersEquityDeficitMember2019-07-012019-09-300000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300000790526us-gaap:RetainedEarningsMember2019-07-012019-09-300000790526us-gaap:NoncontrollingInterestMember2019-07-012019-09-300000790526us-gaap:CommonStockMember2019-09-300000790526us-gaap:AdditionalPaidInCapitalMember2019-09-300000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-300000790526us-gaap:RetainedEarningsMember2019-09-300000790526rdnt:StockholdersEquityDeficitMember2019-09-300000790526us-gaap:NoncontrollingInterestMember2019-09-3000007905262019-09-300000790526us-gaap:CommonStockMember2019-12-310000790526us-gaap:AdditionalPaidInCapitalMember2019-12-310000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000790526us-gaap:RetainedEarningsMember2019-12-310000790526rdnt:StockholdersEquityDeficitMember2019-12-310000790526us-gaap:NoncontrollingInterestMember2019-12-310000790526us-gaap:CommonStockMember2020-01-012020-09-300000790526us-gaap:CommonStockMemberrdnt:DeepHealthInc.Member2020-01-012020-09-300000790526rdnt:DeepHealthInc.Member2020-01-012020-09-300000790526us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300000790526rdnt:StockholdersEquityDeficitMember2020-01-012020-09-300000790526us-gaap:NoncontrollingInterestMember2020-01-012020-09-300000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000790526us-gaap:RetainedEarningsMember2020-01-012020-09-300000790526us-gaap:CommonStockMember2018-12-310000790526us-gaap:AdditionalPaidInCapitalMember2018-12-310000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000790526us-gaap:RetainedEarningsMember2018-12-310000790526rdnt:StockholdersEquityDeficitMember2018-12-310000790526us-gaap:NoncontrollingInterestMember2018-12-3100007905262018-12-310000790526us-gaap:CommonStockMember2019-01-012019-09-300000790526us-gaap:AdditionalPaidInCapitalMember2019-01-012019-09-300000790526rdnt:StockholdersEquityDeficitMember2019-01-012019-09-300000790526us-gaap:NoncontrollingInterestMember2019-01-012019-09-300000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300000790526us-gaap:RetainedEarningsMember2019-01-012019-09-300000790526rdnt:DeepHealthInc.Member2020-06-012020-06-010000790526rdnt:DeepHealthInc.Member2020-06-010000790526rdnt:NulogixMember2019-08-012019-08-01xbrli:pure0000790526rdnt:NulogixMember2019-08-0100007905262018-04-120000790526rdnt:VenturaCountyImagingGroupLLCMember2019-03-010000790526us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberrdnt:HudsonValleyRadiologyAssociatesMember2019-02-272019-02-270000790526us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberrdnt:HudsonValleyRadiologyAssociatesMember2019-02-27rdnt:Center0000790526rdnt:BeverlyRadiologyMedicalGroupIIIMembersrt:ChiefExecutiveOfficerMember2020-09-300000790526rdnt:BeverlyRadiologyMedicalGroupIIIMemberrdnt:BoardMemberMember2020-09-300000790526us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2020-09-300000790526us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2019-12-310000790526rdnt:ScriptSenderLlcMember2020-09-300000790526rdnt:CommercialInsurance1Member2020-07-012020-09-300000790526rdnt:CommercialInsurance1Member2019-07-012019-09-300000790526rdnt:CommercialInsurance1Member2020-01-012020-09-300000790526rdnt:CommercialInsurance1Member2019-01-012019-09-300000790526rdnt:Medicare1Member2020-07-012020-09-300000790526rdnt:Medicare1Member2019-07-012019-09-300000790526rdnt:Medicare1Member2020-01-012020-09-300000790526rdnt:Medicare1Member2019-01-012019-09-300000790526rdnt:Medicaid1Member2020-07-012020-09-300000790526rdnt:Medicaid1Member2019-07-012019-09-300000790526rdnt:Medicaid1Member2020-01-012020-09-300000790526rdnt:Medicaid1Member2019-01-012019-09-300000790526rdnt:WorkersCompensationPersonalInjury1Member2020-07-012020-09-300000790526rdnt:WorkersCompensationPersonalInjury1Member2019-07-012019-09-300000790526rdnt:WorkersCompensationPersonalInjury1Member2020-01-012020-09-300000790526rdnt:WorkersCompensationPersonalInjury1Member2019-01-012019-09-300000790526rdnt:HealthCarePatientServiceOtherMember2020-07-012020-09-300000790526rdnt:HealthCarePatientServiceOtherMember2019-07-012019-09-300000790526rdnt:HealthCarePatientServiceOtherMember2020-01-012020-09-300000790526rdnt:HealthCarePatientServiceOtherMember2019-01-012019-09-300000790526rdnt:HealthCareManagementServiceMember2020-07-012020-09-300000790526rdnt:HealthCareManagementServiceMember2019-07-012019-09-300000790526rdnt:HealthCareManagementServiceMember2020-01-012020-09-300000790526rdnt:HealthCareManagementServiceMember2019-01-012019-09-300000790526rdnt:TeleradiologyandSoftwareMember2020-07-012020-09-300000790526rdnt:TeleradiologyandSoftwareMember2019-07-012019-09-300000790526rdnt:TeleradiologyandSoftwareMember2020-01-012020-09-300000790526rdnt:TeleradiologyandSoftwareMember2019-01-012019-09-300000790526us-gaap:HealthCareOtherMember2020-07-012020-09-300000790526us-gaap:HealthCareOtherMember2019-07-012019-09-300000790526us-gaap:HealthCareOtherMember2020-01-012020-09-300000790526us-gaap:HealthCareOtherMember2019-01-012019-09-300000790526rdnt:COVID19PandemicMember2020-04-012020-04-300000790526rdnt:COVID19PandemicMember2020-05-012020-05-310000790526rdnt:PaycheckProtectionProgramLoansMemberrdnt:COVID19PandemicMember2020-09-300000790526rdnt:COVID19PandemicMember2020-09-300000790526rdnt:PropertyAndEquipmentMembersrt:MinimumMember2020-01-012020-09-300000790526srt:MaximumMemberrdnt:PropertyAndEquipmentMember2020-01-012020-09-300000790526us-gaap:LeaseholdImprovementsMembersrt:MinimumMember2020-01-012020-09-300000790526srt:MaximumMemberus-gaap:LeaseholdImprovementsMember2020-01-012020-09-300000790526rdnt:OlneyOpenMRILLCMember2020-01-012020-09-300000790526rdnt:MRIatWoodbridgeLLCMember2020-01-012020-09-300000790526rdnt:AZTechMember2020-01-012020-09-300000790526rdnt:RestatedPlanMember2020-09-300000790526srt:MinimumMember2020-01-012020-09-300000790526srt:MaximumMember2020-01-012020-09-30rdnt:numberOfAgreement0000790526rdnt:Caps2016Member2020-09-300000790526rdnt:September2020CapMemberrdnt:Caps2016Member2020-09-300000790526rdnt:October2020CapMemberrdnt:Caps2016Member2020-09-300000790526us-gaap:LondonInterbankOfferedRateLIBORMemberrdnt:Caps2016Member2020-09-300000790526us-gaap:InterestRateCapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-06-300000790526us-gaap:InterestRateCapMember2020-07-012020-09-300000790526us-gaap:InterestRateCapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-09-300000790526us-gaap:InterestRateCapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310000790526us-gaap:InterestRateCapMember2020-01-012020-09-300000790526rdnt:A2019SWAPSMember2020-09-300000790526rdnt:A2019SWAPSMember2019-06-300000790526rdnt:October2023Memberrdnt:A2019SWAPSMember2019-06-300000790526rdnt:October2025Memberrdnt:A2019SWAPSMember2019-06-300000790526us-gaap:LondonInterbankOfferedRateLIBORMemberrdnt:A2019SWAPSMemberus-gaap:InterestRateSwapMember2019-06-300000790526rdnt:A2019SWAPSMemberus-gaap:InterestRateSwapMember2019-06-300000790526us-gaap:LondonInterbankOfferedRateLIBORMemberrdnt:A2019SWAPS1Memberus-gaap:InterestRateSwapMember2019-06-300000790526rdnt:A2019SWAPS1Memberus-gaap:InterestRateSwapMember2019-06-300000790526us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2020-06-300000790526us-gaap:InterestRateSwapMember2020-07-012020-09-300000790526us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2020-09-300000790526us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2019-12-310000790526us-gaap:InterestRateSwapMember2020-01-012020-09-300000790526us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2020-07-012020-09-300000790526us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2020-07-012020-09-300000790526us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2020-01-012020-09-300000790526us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2020-01-012020-09-300000790526us-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel1Member2020-09-300000790526us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateCapMember2020-09-300000790526us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateCapMember2020-09-300000790526us-gaap:InterestRateCapMember2020-09-300000790526us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Member2020-09-300000790526us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMember2020-09-300000790526us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateSwapMember2020-09-300000790526us-gaap:InterestRateSwapMember2020-09-300000790526us-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel1Member2019-12-310000790526us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateCapMember2019-12-310000790526us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateCapMember2019-12-310000790526us-gaap:InterestRateCapMember2019-12-310000790526us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Member2019-12-310000790526us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMember2019-12-310000790526us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateSwapMember2019-12-310000790526us-gaap:InterestRateSwapMember2019-12-310000790526us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2020-09-300000790526us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2020-09-300000790526us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2020-09-300000790526us-gaap:EstimateOfFairValueFairValueDisclosureMember2020-09-300000790526us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2019-12-310000790526us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2019-12-310000790526us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2019-12-310000790526us-gaap:EstimateOfFairValueFairValueDisclosureMember2019-12-310000790526us-gaap:LineOfCreditMemberrdnt:BarclaysMemberrdnt:FirstLienCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2020-09-300000790526us-gaap:LineOfCreditMemberrdnt:BarclaysMemberrdnt:FirstLienCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2019-12-310000790526us-gaap:RestrictedStockMember2020-07-012020-09-300000790526us-gaap:RestrictedStockMember2019-07-012019-09-300000790526us-gaap:RestrictedStockMember2020-01-012020-09-300000790526us-gaap:RestrictedStockMember2019-01-012019-09-300000790526rdnt:MedicVisionMember2017-03-240000790526rdnt:MedicVisionMember2017-03-242017-03-240000790526rdnt:MedicVisionMember2018-03-012018-03-010000790526rdnt:MedicVisionMember2018-03-010000790526rdnt:MedicVisionMember2020-09-300000790526rdnt:TurnerImagingMember2018-02-012018-02-010000790526rdnt:TurnerImagingMemberus-gaap:CommercialPaperMember2019-01-010000790526rdnt:TurnerImagingMember2019-10-110000790526rdnt:WhiteRabbit.aiInc.Member2019-11-052019-11-050000790526rdnt:WhiteRabbit.aiInc.Member2020-09-30rdnt:joint_venture0000790526rdnt:GlendaleAdvancedImagingMemberrdnt:JointVentureMemberrdnt:DignityHealthMembersrt:MinimumMember2019-01-012019-03-310000790526rdnt:GlendaleAdvancedImagingMemberrdnt:JointVentureMemberrdnt:DignityHealthMembersrt:MaximumMember2019-01-012019-03-310000790526rdnt:SantaMonicaImagingGroupLLCMember2020-08-012020-08-310000790526rdnt:SantaMonicaImagingGroupLLCMember2020-08-310000790526rdnt:AZTechMember2020-08-312020-08-310000790526rdnt:AZTechMember2020-08-310000790526rdnt:DeepHealthIncMember2020-06-012020-06-010000790526rdnt:DeepHealthIncMember2020-06-010000790526rdnt:MRIatWoodbridgeLLCMember2020-03-022020-03-020000790526rdnt:MRIatWoodbridgeLLCMember2020-03-020000790526rdnt:OlneyOpenMRILLCMember2020-01-022020-01-020000790526rdnt:OlneyOpenMRILLCMember2020-01-020000790526rdnt:ImagingOnCallMember2020-06-012020-06-010000790526rdnt:TermLoanMemberrdnt:FirstLienTermLoanMember2020-09-300000790526rdnt:TermLoanMemberrdnt:FirstLienTermLoanMember2019-12-310000790526rdnt:TermLoanMemberrdnt:RestatedAgreementMember2020-09-300000790526rdnt:TermLoanMemberrdnt:RestatedAgreementMember2019-12-310000790526rdnt:PaycheckProtectionProgramLoansMember2020-09-300000790526rdnt:PaycheckProtectionProgramLoansMemberrdnt:TermLoanMember2020-09-300000790526us-gaap:NotesPayableOtherPayablesMember2020-09-300000790526rdnt:TermLoanMember2020-09-300000790526rdnt:FirstLienTermLoansAMember2020-09-300000790526rdnt:FirstLienCreditAgreementEighthAmendmentMemberus-gaap:LineOfCreditMemberrdnt:BarclaysMemberus-gaap:RevolvingCreditFacilityMember2020-09-300000790526us-gaap:RevolvingCreditFacilityMember2020-09-300000790526rdnt:BarclaysMemberus-gaap:RevolvingCreditFacilityMember2020-09-300000790526us-gaap:LineOfCreditMemberrdnt:FirstLienCreditAgreementMemberrdnt:SunTrustMemberus-gaap:RevolvingCreditFacilityMember2020-09-300000790526us-gaap:LineOfCreditMemberrdnt:SunTrustMemberus-gaap:RevolvingCreditFacilityMember2020-09-300000790526us-gaap:LineOfCreditMemberrdnt:FirstLienCreditAgreementMemberrdnt:LeverageRatioOneMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMember2016-07-012016-07-010000790526us-gaap:LineOfCreditMemberrdnt:FirstLienCreditAgreementMemberrdnt:LeverageRatioOneMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2016-07-012016-07-010000790526us-gaap:LineOfCreditMemberrdnt:FirstLienCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMemberrdnt:LeverageRatioTwoMember2016-07-012016-07-010000790526us-gaap:LineOfCreditMemberrdnt:FirstLienCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMemberrdnt:LeverageRatioTwoMember2016-07-012016-07-010000790526us-gaap:LineOfCreditMemberrdnt:FirstLienCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMemberrdnt:LeverageRatioThreeMember2016-07-012016-07-010000790526us-gaap:LineOfCreditMemberrdnt:FirstLienCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMemberrdnt:LeverageRatioThreeMember2016-07-012016-07-010000790526us-gaap:LineOfCreditMemberrdnt:LeverageRatioFourMemberrdnt:FirstLienCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMember2016-07-012016-07-010000790526us-gaap:LineOfCreditMemberrdnt:LeverageRatioFourMemberrdnt:FirstLienCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2016-07-012016-07-010000790526us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberrdnt:FirstLienCreditAgreementSixthAmendmentMemberus-gaap:EurodollarMember2020-09-300000790526us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberrdnt:FirstLienCreditAgreementSixthAmendmentMemberus-gaap:BaseRateMember2020-09-300000790526us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberrdnt:FirstLienCreditAgreementSixthAmendmentMemberus-gaap:EurodollarMemberrdnt:LeverageRatioThreeMember2020-01-012020-09-300000790526us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberrdnt:FirstLienCreditAgreementSixthAmendmentMemberus-gaap:BaseRateMemberrdnt:LeverageRatioThreeMember2020-01-012020-09-300000790526rdnt:BarclaysMemberrdnt:TermLoanMemberrdnt:FirstLienTermLoanMember2020-01-012020-09-300000790526rdnt:PricingLevelIMemberrdnt:RestatedAgreementMember2018-08-310000790526rdnt:PricingLevelIMemberrdnt:RestatedAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMember2018-08-312018-08-310000790526rdnt:PricingLevelIMemberrdnt:RestatedAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2018-08-312018-08-310000790526rdnt:PricingLevelIMemberrdnt:RestatedAgreementMemberus-gaap:RevolvingCreditFacilityMember2018-08-312018-08-310000790526rdnt:PricingLevelIIMemberrdnt:RestatedAgreementMember2018-08-310000790526rdnt:PricingLevelIIMemberrdnt:RestatedAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMember2018-08-312018-08-310000790526rdnt:PricingLevelIIMemberrdnt:RestatedAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2018-08-312018-08-310000790526rdnt:PricingLevelIIMemberrdnt:RestatedAgreementMemberus-gaap:RevolvingCreditFacilityMember2018-08-312018-08-310000790526rdnt:RestatedAgreementMemberrdnt:PricingLevelIIIMember2018-08-310000790526rdnt:RestatedAgreementMemberrdnt:PricingLevelIIIMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMember2018-08-312018-08-310000790526rdnt:RestatedAgreementMemberrdnt:PricingLevelIIIMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2018-08-312018-08-310000790526rdnt:RestatedAgreementMemberrdnt:PricingLevelIIIMemberus-gaap:RevolvingCreditFacilityMember2018-08-312018-08-310000790526rdnt:PricingLevelIVMemberrdnt:RestatedAgreementMember2018-08-310000790526rdnt:PricingLevelIVMemberrdnt:RestatedAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMember2018-08-312018-08-310000790526rdnt:PricingLevelIVMemberrdnt:RestatedAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2018-08-312018-08-310000790526rdnt:PricingLevelIVMemberrdnt:RestatedAgreementMemberus-gaap:RevolvingCreditFacilityMember2018-08-312018-08-310000790526rdnt:PricingLevelVMemberrdnt:RestatedAgreementMember2018-08-310000790526rdnt:PricingLevelVMemberrdnt:RestatedAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMember2018-08-312018-08-310000790526rdnt:PricingLevelVMemberrdnt:RestatedAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2018-08-312018-08-310000790526rdnt:PricingLevelVMemberrdnt:RestatedAgreementMemberus-gaap:RevolvingCreditFacilityMember2018-08-312018-08-310000790526rdnt:RestatedAgreementMemberrdnt:PricingLevelIIIMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMember2020-01-012020-09-300000790526rdnt:TermLoanMemberrdnt:SunTrustMember2018-01-012018-12-310000790526rdnt:TermLoanMemberrdnt:SunTrustMember2018-12-310000790526rdnt:BarclaysMemberus-gaap:LetterOfCreditMemberus-gaap:RevolvingCreditFacilityMember2020-01-012020-09-300000790526rdnt:FirstLienCreditAgreementSixthAmendmentMemberus-gaap:MediumTermNotesMember2017-08-220000790526us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberrdnt:FirstLienCreditAgreementSixthAmendmentMember2019-04-180000790526rdnt:FirstLienCreditAgreementSeventhAmendmentMember2019-04-180000790526rdnt:FirstLienCreditAgreementSeventhAmendmentMember2019-04-182019-04-180000790526rdnt:PaycheckProtectionProgramLoansMemberrdnt:COVID19PandemicMember2020-01-012020-09-30rdnt:loan0000790526srt:MinimumMemberrdnt:RestatedPlanMember2020-01-012020-09-300000790526srt:MaximumMemberrdnt:RestatedPlanMember2020-01-012020-09-300000790526us-gaap:StockOptionMember2020-09-300000790526us-gaap:StockOptionMember2019-12-310000790526us-gaap:StockOptionMember2020-01-012020-09-300000790526us-gaap:StockOptionMemberrdnt:DeepHealthIncMember2020-07-012020-09-300000790526rdnt:DeepHealthIncMember2020-07-012020-09-300000790526rdnt:DeepHealthIncMember2020-09-300000790526rdnt:DeepHealthIncMember2020-01-012020-09-300000790526us-gaap:StockOptionMemberrdnt:DeepHealthInc.Member2019-12-310000790526us-gaap:StockOptionMemberrdnt:DeepHealthInc.Member2020-01-012020-09-300000790526us-gaap:StockOptionMemberrdnt:DeepHealthInc.Member2020-09-300000790526us-gaap:RestrictedStockMember2020-09-300000790526us-gaap:RestrictedStockMember2019-12-310000790526us-gaap:RestrictedStockMember2020-01-012020-09-300000790526rdnt:FutureServiceMember2020-01-012020-09-300000790526rdnt:RestatedPlanMember2020-01-012020-09-300000790526us-gaap:SubsequentEventMemberus-gaap:InvestmentsInMajorityOwnedSubsidiariesMember2020-11-010000790526rdnt:SimiValleyHospitalAndHealthServicesMemberus-gaap:SubsequentEventMemberus-gaap:InvestmentsInMajorityOwnedSubsidiariesMember2020-11-01
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

FORM 10-Q
(Mark One)
     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2020
OR
     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number 001-33307
RadNet, Inc.
(Exact name of registrant as specified in charter)
Delaware13-3326724
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
 
1510 Cotner Avenue 
Los Angeles,California90025
(Address of principal executive offices)(Zip Code)
(310) 478-7808
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes   No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes No
Securities registered pursuant to Section 12(b) of the Act:
Class TitleTrading SymbolRegistered Exchange
Common StockRDNTNASDAQ
The number of shares of the registrant’s common stock outstanding on November 5, 2020 was 51,636,099 shares.


RADNET, INC.
TABLE OF CONTENTS
Page

ITEM 6.  Exhibits

i

PART I - FINANCIAL INFORMATION
Item 1 – Financial Statements
RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)
September 30,
2020
December 31,
2019
(unaudited) 
ASSETS  
CURRENT ASSETS  
   Cash and cash equivalents$89,739 $40,165 
   Accounts receivable137,411 154,763 
   Due from affiliates424 1,242 
   Prepaid expenses and other current assets31,482 45,004 
      Total current assets 259,056 241,174 
PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS
   Property and equipment, net361,950 367,795 
   Operating lease right-of-use assets451,613 445,477 
      Total property, equipment and right-of-use assets813,563 813,272 
OTHER ASSETS
   Goodwill470,685 441,973 
   Other intangible assets57,152 42,994 
   Deferred financing costs1,944 1,559 
   Investment in joint ventures35,571 34,470 
   Deferred tax assets, net of current portion42,188 34,548 
   Deposits and other37,707 36,996 
       Total assets$1,717,866 $1,646,986 
LIABILITIES AND EQUITY
CURRENT LIABILITIES
    Accounts payable, accrued expenses and other$205,701 $207,585 
    Due to affiliates12,287 14,347 
    Deferred revenue45,846 1,316 
    Current finance lease liability3,041 3,283 
    Current operating lease liability67,449 61,206 
    Current portion of notes payable39,463 39,691 
        Total current liabilities373,787 327,428 
LONG-TERM LIABILITIES
    Long-term finance lease liability1,108 3,264 
    Long-term operating lease liability428,233 420,922 
    Notes payable, net of current portion627,179 652,704 
    Other non-current liabilities41,438 9,529 
        Total liabilities1,471,745 1,413,847 
EQUITY
Common stock - $0.0001 par value, 200,000,000 shares authorized; 51,596,098 and 50,314,328 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively
5 5 
    Additional paid-in-capital306,079 262,865 
    Accumulated other comprehensive loss(24,923)(8,026)
    Accumulated deficit(123,956)(103,159)
        Total RadNet, Inc.'s stockholders' equity157,205 151,685 
Noncontrolling interests88,916 81,454 
       Total equity246,121 233,139 
       Total liabilities and equity$1,717,866 $1,646,986 

The accompanying notes are an integral part of these financial statements.

1



RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)
(unaudited)
 Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
REVENUE    
     Service fee revenue$256,730 $261,908 $660,760 $762,751 
     Revenue under capitation arrangements35,046 30,784 103,145 90,587 
Total service revenue291,776 292,692 763,905 853,338 
     Provider relief funding221  25,696  
OPERATING EXPENSES
     Cost of operations, excluding depreciation and amortization246,462 254,383 708,095 743,997 
     Depreciation and amortization21,247 20,490 64,536 60,193 
     Loss on sale and disposal of equipment and other342 917 543 1,990 
     Severance costs571 52 1,647 1,054 
Total operating expenses268,622 275,842 774,821 807,234 
INCOME FROM OPERATIONS23,375 16,850 14,780 46,104 
OTHER INCOME AND EXPENSES
     Interest expense11,061 11,895 33,443 36,589 
     Equity in earnings of joint ventures(2,276)(1,955)(5,176)(6,072)
     Non-cash change in fair value of interest rate hedge679  4,523  
     Other (income) expenses(139)2 (247)1,271 
Total other expenses9,325 9,942 32,543 31,788 
INCOME (LOSS) BEFORE INCOME TAXES14,050 6,908 (17,763)14,316 
     (Provision for) benefit from income taxes(3,825)(1,816)5,029 (3,556)
NET INCOME (LOSS)10,225 5,092 (12,734)10,760 
     Net income attributable to noncontrolling interests4,069 1,897 8,063 6,400 
NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$6,156 $3,195 $(20,797)$4,360 
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$0.12 $0.06 $(0.41)$0.09 
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$0.12 $0.06 $(0.41)$0.09 
WEIGHTED AVERAGE SHARES OUTSTANDING
Basic51,358,603 49,807,460 50,746,380 49,597,138 
Diluted51,955,815 50,360,360 50,746,380 50,113,306 
The accompanying notes are an integral part of these financial statements.
2

RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(IN THOUSANDS)
(unaudited)
 Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
NET INCOME (LOSS)$10,225 $5,092 $(12,734)$10,760 
     Foreign currency translation adjustments11 (23)6 (28)
     Change in fair value of cash flow hedge, net of taxes195 (5,283)(18,764)(14,481)
     Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes969  1,861  
COMPREHENSIVE INCOME (LOSS)11,400 (214)(29,631)(3,749)
     Less comprehensive income attributable to noncontrolling interests4,069 1,897 8,063 6,400 
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO
RADNET, INC. COMMON STOCKHOLDERS$7,331 $(2,111)$(37,694)$(10,149)
The accompanying notes are an integral part of these financial statements.

3

RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(IN THOUSANDS EXCEPT SHARE DATA)
(unaudited)
The following table summarizes changes in the Company’s consolidated stockholders' equity, including noncontrolling interest, during the three months ended September 30, 2020 and September 30, 2019.
Common StockAdditional Paid-In
Capital
Accumulated Other
Comprehensive
Income (Loss)
Accumulated
Deficit
Total
Radnet, Inc.'s
Equity
Noncontrolling
Interests
Total
Equity
SharesAmount
BALANCE - July 1, 202051,554,760 $5 $304,012 $(26,098)$(130,111)$147,808 $85,448 $233,256 
Issuance of common stock under the equity compensation plan37,000 — — — — — —  
Issuance of common stock under the DeepHealth equity compensation plan4,338 — — — — — —  
Stock-based compensation expense— — 2,067 — — 2,067 — 2,067 
Distributions paid to noncontrolling interests— — — — — — (601)(601)
Change in cumulative foreign currency translation adjustment— — — 11 — 11 — 11 
Change in fair value of cash flow hedge, net of taxes— — — 195 — 195 — 195 
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes— — — 969 — 969 — 969 
Other— — — — (1)(1)— (1)
Net income— — — — 6,156 6,156 4,069 10,225 
BALANCE-SEPTEMBER 30, 202051,596,098 $5 $306,079 $(24,923)$(123,956)$157,205 $88,916 $246,121 
BALANCE - July 1, 201950,127,234 $5 $257,607 $(6,942)$(116,752)$133,918 $78,512 $212,430 
Issuance of common stock under the equity compensation plan25,000 — — — — — —  
Stock-based compensation expense— — 1,356 — — 1,356 — 1,356 
Issuance of common stock for purchase of membership interest in HVRA101,902 — 1,500 — — 1,500 — 1,500 
Change in cumulative foreign currency translation adjustment— — — (23)— (23)— (23)
Change in fair value cash flow hedge, net of taxes— — — (5,283)— (5,283)— (5,283)
Other— — — (2)2 — —  
Net income— — — — 3,195 3,195 1,897 5,092 
BALANCE-SEPTEMBER 30, 201950,254,136 $5 $260,463 $(12,250)$(113,555)$134,663 $80,409 $215,072 
The accompanying notes are an integral part of these financial statements.
4

RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(IN THOUSANDS EXCEPT SHARE DATA)
(unaudited)
The following table summarizes changes in the Company’s consolidated stockholders' equity, including noncontrolling interest, during the nine months ended September 30, 2020 and September 30, 2019.
5

Common StockAdditional Paid-In
Capital
Accumulated Other
Comprehensive
Income (Loss)
Accumulated
Deficit
Total
Radnet, Inc.'s
Equity
Noncontrolling
Interests
Total
Equity
SharesAmount
BALANCE - January 1, 202050,314,328 $5 $262,865 $(8,026)$(103,159)$151,685 $81,454 $233,139 
Issuance of common stock under the equity compensation plan453,817 — — — — — —  
Issuance of common stock under the DeepHealth equity compensation plan4,338 — — — — — —  
Stock-based compensation expense— — 10,203 — — 10,203 — 10,203 
Issuance of common stock for sale of unregistered securities for the DeepHealth acquisition823,615 — 33,011 — — 33,011 — 33,011 
Distributions paid to noncontrolling interests— — — — — — (601)(601)
Change in cumulative foreign currency translation adjustment— — — 6 — 6 — 6 
Change in fair value cash flow hedge, net of taxes— — — (18,764)— (18,764)— (18,764)
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes— — — 1,861 — 1,861 — 1,861 
Net loss— — — — (20,797)(20,797)8,063 (12,734)
BALANCE-SEPTEMBER 30, 202051,596,098 $5 $306,079 $(24,923)$(123,956)$157,205 $88,916 $246,121 
BALANCE - January 1, 201948,977,485 $5 $242,835 $2,259 $(117,915)$127,184 $73,069 $200,253 
Issuance of common stock upon exercise of options10,000 — 50 — — 50 — 50 
Issuance of common stock under the equity compensation plan726,042 — — — — — —  
Stock-based compensation expense— — 6,993 — — 6,993 — 6,993 
Issuance of common stock for purchase of membership interest in HVRA440,207 — 6,000 — — 6,000 — 6,000 
Forfeiture of restricted stock(1,500)— (5)— — (5)— (5)
Sale of noncontrolling interests, net of taxes— — 3,090 — — 3,090 2,008 5,098 
Purchase of noncontrolling interests— — — — — — (1,818)(1,818)
Contribution from noncontrolling partner— — — — — — 750 750 
Issuance of common stock for purchase of Nulogix101,902 — 1,500 — — 1,500 — 1,500 
Change in cumulative foreign currency translation adjustment— — — (28)— (28)— (28)
Change in fair value cash flow hedge, net of taxes— — — (14,481)— (14,481)— (14,481)
Net income— — — — 4,360 4,360 6,400 10,760 
BALANCE-SEPTEMBER 30, 201950,254,136 $5 $260,463 $(12,250)$(113,555)$134,663 $80,409 $215,072 
The accompanying notes are an integral part of these financial statements.

6

RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(unaudited)
Nine Months Ended September 30,
20202019
CASH FLOWS FROM OPERATING ACTIVITIES  
Net (loss) income$(12,734)$10,760 
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization64,536 60,193 
Amortization of operating lease right-of-use assets50,769 49,948 
Equity in earnings of joint ventures, net of dividends530 (2,148)
Amortization of deferred financing costs and loan discount3,266 3,103 
Loss on sale and disposal of equipment and other543 1,990 
Amortization of cash flow hedge2,204  
Non-cash change in fair value of interest rate hedge4,523  
Stock-based compensation10,144 6,963 
Other non-cash items included in cost of operations (559)
Change in fair value of contingent consideration
(145)(1,749)
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:
Accounts receivable17,380 (3,467)
Other current assets13,522 (1,569)
Other assets(700)(5,770)
Deferred taxes(7,640)(4,230)
Operating lease liability(43,351)(49,721)
Deferred revenue44,530 (490)
Accounts payable, accrued expenses and other22,966 19,349 
Net cash provided by operating activities170,343 82,603 
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of imaging facilities and other acquisitions(10,125)(27,150)
Equity investments at fair value (143)
Purchase of property and equipment(77,303)(68,269)
Proceeds from sale of equipment779 760 
Proceeds from the sale of equity interests in a joint venture 132 
Nulogix return of capital 792 
Equity contributions in existing and purchase of interest in joint ventures(1,631)(103)
Net cash used in investing activities(88,280)(93,981)
CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on notes and leases payable(2,704)(4,778)
Payments on term loan debt(32,472)(29,918)
Additional deferred finance costs on revolving loan amendment(741) 
Proceeds from debt issuance, net of issuing costs 97,144 
Proceeds from Payment Protection Program4,023  
Distributions paid to noncontrolling interests(601)(1,818)
Proceeds from sale of noncontrolling interest 5,275 
Contribution from noncontrolling partner 750 
Proceeds from revolving credit facility250,900 251,200 
Payments on revolving credit facility(250,900)(279,200)
Proceeds from issuance of common stock upon exercise of options 50 
Net cash (used in) provided by financing activities(32,495)38,705 
EFFECT OF EXCHANGE RATE CHANGES ON CASH6 (28)
NET INCREASE IN CASH AND CASH EQUIVALENTS49,574 27,299 
CASH AND CASH EQUIVALENTS, beginning of period40,165 10,389 
CASH AND CASH EQUIVALENTS, end of period$89,739 $37,688 
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the period for interest$31,210 $36,058 
7

The accompanying notes are an integral part of these financial statements.
8

RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
(unaudited)
Supplemental Schedule of Non-Cash Investing and Financing Activities
We acquired equipment and certain leasehold improvements for approximately $28.1 million and $14.1 million during the nine months ended September 30, 2020 and 2019, respectively, which were not paid for as of September 30, 2020 and 2019, respectively. The offsetting amounts due were recorded in our condensed consolidated balance sheet under accounts payable, accrued expenses and other.
On June 1, 2020, we completed our stock purchase of DeepHealth, Inc. by issuing 823,615 shares of our common stock to purchase all of DeepHealth's shares and share equivalents. The shares were ascribed a value of $13.9 million.
On August 1, 2019 we issued RadNet common stock in the amount of $1.5 million to acquire 75% controlling interest in our formerly 25% owned joint venture Nulogix. See Note 2, Significant Accounting Policies, for further information.
We transferred approximately $4.3 million in net assets to our new joint venture, Ventura County Imaging Group, LLC in March 2019.
On February 27, 2019, we issued 440,207 shares of our common stock to the sellers of Hudson Valley Radiology Associates, P.L.L.C. ("HVRA") which permitted our variable interest entity, Lenox Hill Radiology and Medical Imaging Associates, P.C., to complete its purchase of the membership interest of HVRA. The shares were ascribed a value of $6.0 million.



9

RADNET, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION
We are a national provider of freestanding, fixed-site outpatient diagnostic imaging services with operations in seven U.S. states. At September 30, 2020, we operated, directly or indirectly through joint ventures with hospitals, 334 centers located in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services. Our multi-modality strategy diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians the convenience of a single location to serve the needs of multiple procedures. In addition to our imaging services, we design and develop software applications, Artificial Intelligence tools and other computerized systems for the diagnostic imaging industry. Our operations comprise a single segment for financial reporting purposes.

The consolidated financial statements include the accounts of RadNet, Inc as well as its subsidiaries in which RadNet has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which we are the primary beneficiary (as described in more detail below). All material intercompany transactions and balances have been eliminated upon consolidation. All of these affiliated entities are referred to collectively as “RadNet”, “we”, “us”, “our” or the “Company” in this report.
Accounting regulations stipulate that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs in which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.

VIEs that we consolidate as the primary beneficiary consist of professional corporations which are owned or controlled by individuals within our senior management, namely Howard G. Berger, M.D., our President and Chief Executive Officer, and John V. Crues, III, M.D., RadNet's Medical Director, both of whom are members of our Board of Directors. Dr. Berger owns, indirectly, 99% of the equity interests in Beverly Radiology Medical Group III (BRMG) and a controlling interest in two professional corporations in New York City. BRMG is responsible for the professional medical services at nearly all of our facilities located in California. Dr. Crues owns six professional corporations which provide medical services in Delaware, Maryland, New Jersey and New York. Additionally, Dr. Crues is a 1% owner of BRMG. These VIEs are collectively referred to as the consolidated medical group ("the Group").
RadNet provides non-medical, technical and administrative services to the Group for which it receives a management fee, pursuant to the related management agreements. Through the management agreements we have exclusive authority over all non-medical decision making related to the ongoing business operations and we determine the annual budget. The Group has insignificant operating assets and liabilities, and de minimis equity. Through management agreements with us, substantially all cash flows of the Group after expenses, including professional salaries, are transferred to us. We consolidate the revenue and expenses, assets and liabilities of the Group.

The Group on a combined basis recognized $38.3 million and $40.6 million of revenue, net of management services fees to RadNet, for the three months ended September 30, 2020 and 2019, respectively and $38.3 million and $40.6 million of operating expenses for the three months ended September 30, 2020 and 2019, respectively. RadNet recognized $169.0 million and $154.5 million of total billed net service fee revenue for the three months ended September 30, 2020, and 2019, respectively, for management services provided to the Group relating primarily to the technical portion of billed revenue.

The Group on a combined basis recognized $104.8 million and $116.9 million of revenue, net of management services fees to RadNet, for the nine months ended September 30, 2020 and 2019, respectively and $104.8 million and $116.9 million of operating expenses for the nine months ended September 30, 2020 and 2019, respectively. RadNet recognized $433.3 million
10

and $456.1 million of total billed net service fee revenue for the nine months ended September 30, 2020, and 2019, respectively, for management services provided to the Group relating primarily to the technical portion of billed revenue.

The cash flows of the Group are included in the accompanying condensed consolidated statements of cash flows. All intercompany balances and transactions have been eliminated in consolidation. In our condensed consolidated balance sheets at September 30, 2020 and December 31, 2019, we have included approximately $84.5 million and $100.3 million, respectively, of accounts receivable and approximately $10.7 million and $7.0 million of accounts payable and accrued liabilities related to the Group, respectively.

The creditors of the Group do not have recourse to our general credit and there are no other arrangements that could expose us to losses on their behalf. However, RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.

We also own a 49% economic interest in ScriptSender, LLC, which provides secure data transmission services of medical information. Through a management agreement, RadNet provides management and accounting services and receives an agreed upon fee. ScriptSender, LLC is dependent on the Company to finance its own activities, and as such we determined that it is a VIE but we are not a primary beneficiary since we do not have the power to direct the activities of the entity that most significantly impact the entity’s economic performance.

At all of our centers not serviced by the Group we have entered into long-term contracts (typically up to 40 years) with independent radiology groups to provide physician services at those centers. These radiology practices provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee based on the value of the services we provide. We own the diagnostic imaging equipment and, therefore, receive 100% of the technical reimbursements associated with imaging procedures. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us and we have no economic controlling interest in these radiology practices as such, the financial results of these practices are not consolidated in our financial statements.
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for conformity with U.S. generally accepted accounting principles for complete financial statements; however, in the opinion of our management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods ended September 30, 2020 and 2019 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto contained in our annual report on Form 10-K for the year ended December 31, 2019.
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
During the period covered in this report, there have been no material changes to the significant accounting policies we use and have explained, in our annual report on Form 10-K for the fiscal year ended December 31, 2019. The information below is intended only to supplement the disclosure in our annual report on Form 10-K for the fiscal year ended December 31, 2019.
REVENUES - Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period when our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payors. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.
11

As it relates to the Group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by them as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.
Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.
Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.
Our total service revenues during the three and nine months ended September 30, 2020 and 2019 are presented in the table below based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in thousands):
 Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
Commercial insurance$160,524 $163,152 $412,415 $475,064 
Medicare62,704 61,599 154,847 175,825 
Medicaid7,098 7,128 18,072 21,564 
Workers' compensation/personal injury7,183 10,865 25,705 32,950 
Other patient revenue8,328 6,085 17,211 17,947 
Management fee revenue2,675 1,792 8,574 5,662 
Teleradiology and Software revenue2,349 4,412 8,319 12,861 
Other5,869 6,875 15,617 20,878 
Service fee revenue256,730 261,908 660,760 762,751 
Revenue under capitation arrangements35,046 30,784 103,145 90,587 
Total service revenue$291,776 $292,692 $763,905 $853,338 

COVID-19 PANDEMIC AND CARES ACT FUNDING - On March 11, 2020 the World Health Organization (WHO) designated COVID-19 as a global pandemic. Patient volumes and the related revenues for our services were significantly impacted during the latter portion of the first quarter through the middle of the third quarter of 2020 as a result of federal, state and local government mandated restrictions requiring many people to remain at home and forced the closure of or limitations on certain businesses, as well as suspended elective procedures by health care facilities. Many of these restrictions have been eased or completely lifted across the states the Company operates in however, we are unable to predict the future impact of the pandemic on our operations.

During the nine months ended September 30, 2020, we received $39.4 million of accelerated Medicare payments, $5.0 million from Blue Cross, $25.7 million from the general distribution and $4.0 million from the Paycheck Protection Program established through the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. The accelerated Medicare payments are recorded under the caption “ Deferred Revenue“ in our condensed consolidated balance sheet and will be repaid beginning in 2021. The general distribution funds were accounted for as government grants and recognized as other revenue, once reasonable assurance that the applicable terms and conditions required to retain the funds were met, under the caption “Provider relief funding” in our condensed Consolidated Statements of Operations

During the three months ended September 30, 2020, the Department of Health and Human Services significantly changed the measurement of Provider Relief Funds that providers are able to retain. We received approximately $0.2 million in
12

funding and based on our assessment of the likelihood of meeting the applicable terms and conditions of the general distribution we continue to recognized the funds received as other revenue.

The CARES Act also providers for a payment deferral of the employer portion of Social Security tax incurred during the pandemic, allowing half of such payroll taxes to be deferred until December 2021 and the remaining half until December 2022. At September 30, 2020, the Company had deferred $10.8 million of Social Security taxes. These payment deferrals are recorded as payroll tax liability under the caption “Accounts payable, accrued expenses and other” in our condensed consolidated balance sheet.

We believe the extent of the COVID-19 pandemic’s impact on our operating results and financial condition has been and will continue to be driven by many factors, most of which are beyond our control and ability to forecast. Such factors include, but are not limited to, the scope and duration of stay-at-home practices, business closures and restrictions, suspensions of elective procedures and continued decline in procedure volumes for an indeterminable length of time and incremental expenses required for supplies and personal protective equipment. Because of these uncertainties, we cannot estimate the length or impact of the pandemic on our business. If we incur declines in cash flows and results of operations, such declines could have an impact on the inputs and assumptions used in significant accounting estimates, including implicit prices concessions related to uninsured patient accounts, and potential impairment of goodwill and long-lived assets. During the third quarter of 2020, procedure volumes increased and have had a positive impact on our patient revenue. However, the impact of COVID-19 in future periods may vary and could adversely impact our results of operations.

RECLASSIFICATION –We have reclassified certain amounts previously classified as held for sale related to property and equipment and goodwill to conform to our 2020 presentation.
ACCOUNTS RECEIVABLE - Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience. In regards to the credit loss standard, we have concluded that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses estimated under the Current Expected Credit Loss ("CECL") model.

In 2018 and 2019 we entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements in exchange for notes receivables from the buyers. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. Proceeds on notes receivables are reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long term portion. At September 30, 2020 we have $20.4 million remaining to be collected on these agreements. We do not utilize factoring arrangements as an integral part of our financing for working capital. To employ the CECL model for the notes receivable, we assess the party's ability to pay upfront at the inception of the notes receivable and subsequently by reviewing their financial statements annually and reassessing any insolvency risk on a periodic basis. In the event of a significant past due balance, as the sold receivables were already revalued and recorded at net realizable value, we can mitigate the expected credit loss by offsetting any collections from the underlying factored receivables and not remitting that to the counter party.
DEFERRED REVENUE - As noted above, in April of 2020, we received approximately $39.4 million in advanced Medicare payments from the Centers for Medicare and Medicaid Services ("CMS") as part of the expanded Accelerated and Advance Payment Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. As these payments are required to be repaid to CMS beginning 120 days after their receipt through offsets from new Medicare claims over a three month period, we have recorded amounts received to deferred revenue which will be amortized as Medicare reimbursements are earned. In addition, in May of 2020 we received $5.0 million in advance payments from an insurance carrier with similar repayment terms as the CMS.
DEFERRED FINANCING COSTS - Costs of financing are deferred and amortized using the effective interest rate method. Deferred financing costs, net of accumulated amortization, were $1.9 million and $1.6 million, as of September 30, 2020 and December 31, 2019, respectively and related to our Barclays line of credit. See Note 5, Credit Facilities and Notes Payable for more information.
PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation of property and equipment is performed using the straight-line method over the estimated useful lives of the assets acquired, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred.
13

BUSINESS COMBINATION - When the qualifications for business combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.
GOODWILL AND INDEFINITE LIVED INTANGIBLES - Goodwill at September 30, 2020 totaled $470.7 million. Indefinite lived intangible assets at September 30, 2020 were $11.3 million. Goodwill and Indefinite Lived Intangibles are recorded as a result of business combinations. When we determine the carrying value of reporting unit exceeds its fair value an impairment charge would be recognized and should not exceed the total amount of goodwill allocated to that reporting unit. We tested goodwill and indefinite lived intangibles for impairment on October 1, 2019, noting no impairment. In addition to the annual impairment test, we regularly assess if an event has occurred which would require interim impairment testing. We considered the current and expected future economic and market conditions surrounding the novel strain of coronavirus ("COVID-19") pandemic and did not identify an indication of goodwill impairment being more likely than not through September 30, 2020. Activity in goodwill for the nine months ended September 30, 2020 is provided below (in thousands):
Balance as of December 31, 2019$441,973 
Goodwill acquired through the acquisition of Olney Open MRI, LLC601 
Goodwill acquired through the acquisition of MRI at Woodbridge, LLC1,833 
Goodwill acquired through the acquisition of DeepHealth, Inc.23,396 
Goodwill acquired through the acquisition of AZ-Tech Radiology & Open MRI, LLC2,882 
Balance as of September 30, 2020$470,685 
INCOME TAXES - Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized.
We recorded an income tax expense of $3.8 million, or an effective tax rate of 27.2%, for the three months ended September 30, 2020 compared to an income tax expense of $1.8 million, or an effective tax rate of 26.3% for the three months ended September 30, 2019. We recorded an income tax benefit of $5.0 million, or an effective tax rate of 28.3%, for the nine months ended September 30, 2020 compared to an income tax expense of $3.6 million , or an effective tax rate of 24.8% for the nine months ended September 30, 2019.The income tax rates for the three and nine months ended September 30, 2020 diverge from the federal statutory rate due to (i) noncontrolling interests due to the controlled partnerships; (ii) effects of state income taxes; and (iii) excess tax benefits attributable to share-based compensation.
We believe no significant changes in the unrecognized tax benefits will occur within the next 12 months.
On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"). The CARES Act, among other things, includes certain income tax provisions for individuals and corporations; however, these benefits do not impact the Company’s current tax provision.
LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long term operating lease liability in our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liability, and long-term finance lease liability in our consolidated balance sheets.  ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed
14

payments for both lease and non-lease components, we have elected to account for the components as a single lease component, as permitted. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the ROU asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. ROU assets are tested for impairment if circumstances suggest that the carrying amount may not be recoverable. Our ROU assets consist of facility and equipment assets on operating leases. No events have occurred such as fire, flood, or other acts which have impaired the integrity of our ROU assets in 2020. Our facility leases require us to maintain insurance policies which would cover major damage to our facilities. We maintain business interruption insurance to cover loss of business due to a facility becoming non-operational under certain circumstances. Our equipment leases are covered by warranty and service contracts which cover repairs and provide regular maintenance to keep the equipment in functioning order.
EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated as of April 20, 2015, and again on March 9, 2017 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved 14,000,000 shares of common stock for issuance under the Restated Plan which can be issued in the form of options, stock awards, stock appreciation rights, stock units, and cash awards. Stock options generally vest over three to five years and expire five to ten years from date of grant. We determine the compensation expense for each stock option award using the Black Scholes, or similar valuation model. Those models require that our management make certain estimates concerning risk free interest rates and volatility in the trading price of our common stock. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. In connection with our acquisition of DeepHealth Inc. on June 1, 2020, we assumed the DeepHealth, Inc. 2017 Stock Incentive Plan, including outstanding options awards that can be exercised for our common stock. No additional awards will be granted under the DeepHealth, Inc. 2017 Equity Incentive Plan. See Note 4, Facility Acquisitions and Note 6, Stock-Based Compensation, for more information.
COMPREHENSIVE INCOME (LOSS) - ASC 220 establishes rules for reporting and displaying comprehensive income or loss and its components. Our unrealized gains or losses on foreign currency translation adjustments, interest rate cap and swap agreements are included in comprehensive loss and are included in the consolidated statements of comprehensive income (loss) for the three and nine months ended September 30, 2020 and 2019.
COMMITMENTS AND CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. Based on current information, we do not believe that reasonably possible or probable losses associated with pending legal proceedings would either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. Therefore, if one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.
DERIVATIVE INSTRUMENTS
2016 CAPS
In the fourth quarter of 2016, we entered into two forward interest rate cap agreements ("2016 Caps"). The 2016 Caps will mature in September and October 2020. The 2016 Caps had notional amounts of $150,000,000 and $350,000,000, respectively. Under these arrangements, the Company purchased a cap on 3 month LIBOR at 2.0%. We incurred a $5.3 million premium to enter into the 2016 Caps which is being accrued over the life of the agreements.
At inception, we designated our 2016 Caps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss of the hedge (i.e. change in fair value) is reported as a component of comprehensive loss in the consolidated statement of equity since such hedge has been determined to be effective. See Fair Value Measurements section below for the fair value of the 2016 Caps at September 30, 2020.
A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss of the 2016 Caps is as follows (amounts in thousands):
15

For the three months ended September 30, 2020
AccountJuly 1, 2020 BalanceAmount of comprehensive gain recognized on derivative net of taxesSeptember 30, 2020 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes(1,409)195 (1,214)Liabilities and Equity
For the nine months ended September 30, 2020
AccountJanuary 1, 2020 BalanceAmount of comprehensive gain recognized on derivative net of taxesSeptember 30, 2020 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes(1,877)663 (1,214)Liabilities and Equity
2019 SWAPS
In the second quarter of 2019, we entered into four forward interest rate agreements ("2019 Swaps"). The 2019 Swaps have total notional amounts of $500,000,000, consisting of two agreements of $50,000,000 each and two agreements of $200,000,000 each. The 2019 Swaps will secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They will mature in October 2023 for the smaller notional and October 2025 for the larger notional. Under these arrangements, we arranged the 2019 Swaps with locked in 1 month LIBOR rates at 1.96% for the $100,000,000 notional and at 2.05% for the $400,000,000 notional. As of the effective date, we will be liable for premium payments if interest rates decline below arranged rates, but will receive interest payments if rates remain above the arranged rates.
At inception, we designated our 2019 Swaps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e. change in fair value) is reported as a component of comprehensive loss in the consolidated statement of equity. The remaining gain or loss, if any, is recognized currently in earnings. As a result of the economic impact of the coronavirus pandemic, which precipitated a reduction in interest rates , the cash flows for both our $400,000,000 notional interest rate swap contract locked in at 2.05% due October 2025 and our $100,000,000 notional interest rate swap contract locked in at 1.96% do not match the cash flows for our First Lien Term Loans and so we have determined that they are not currently effective as cash flow hedges. Accordingly, all changes in their fair value after April 1, 2020 for the $400,000,000 notional and after July 1, 2020 for the $100,000,000 notional will be recognized in earnings. As of July 1, 2020, the total change in fair value relating to swaps included in other comprehensive income was approximately $24.4 million, net of taxes. This amount will be amortized to interest expense through October 2025 at approximately $0.4 million per month.
A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss of the 2019 swaps which remain ineffective is as follows (amounts in thousands):
For the three months ended September 30, 2020
AccountJuly 1, 2020 BalanceAmount of comprehensive loss recognized on derivative net of taxesAmount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxesSeptember 30, 2020 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes$(24,406)$ $969 $(23,437)Liabilities and Equity

16

For the nine months ended September 30, 2020
AccountJanuary 1, 2020 BalanceAmount of comprehensive loss recognized on derivative net of taxesAmount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxesSeptember 30, 2020 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes$(5,870)$(19,428)$1,861 $(23,437)Liabilities and Equity
A tabular presentation of the effect of derivative instruments on our statement of operations of the 2019 Swaps for the Swaps that became ineffective during the third quarter is as follows (amounts in thousands):
For the three months ended September 30, 2020
Ineffective interest rate swapAmount of loss recognized in income on derivative (current period ineffective portion)Location of loss recognized in Income on derivative (current period ineffective portion)Amount of loss reclassified from accumulated OCI into income (prior period effective portion)Location of gain (Loss) reclassified from accumulated OCI into income (prior period effective portion)
Interest rate contracts$(679)Other income (expense)$(1,312)Equity and Interest Expense
For the nine months ended September 30, 2020
Ineffective interest rate swapAmount of loss recognized in income on derivative (current period ineffective portion)Location of loss recognized in Income on derivative (current period ineffective portion)Amount of loss reclassified from accumulated OCI into income (prior period effective portion)Location of gain (Loss) reclassified from accumulated OCI into income (prior period effective portion)
Interest rate contracts$(4,523)Other income (expense)$(2,204)Equity and Interest Expense
See Fair Value Measurements section below for the fair value of the 2016 caps and 2019 swaps at September 30, 2020.
FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:
Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.
Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.
Derivatives:
The tables below summarize the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets on our condensed consolidated balance sheets, as follows (in thousands):
17

 As of September 30, 2020
Level 1Level 2Level 3Total
Current and long term liabilities    
2016 caps - Interest Rate Contracts$ $182 $ $182 
2019 swaps - Interest Rate Contracts$ $39,983 $ $39,983 
 As of December 31, 2019
Level 1Level 2Level 3Total
Current and long term liabilities    
2016 caps - Interest Rate Contracts$ $1,081 $ $1,081 
2019 swaps - Interest Rate Contracts$ $9,477 $ $9,477 
The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty’s forward LIBOR curve. The forward LIBOR curve is readily available in the public markets or can be derived from information available in the public markets.
Long Term Debt:
The table below summarizes the estimated fair value compared to our face value of our long-term debt as follows (in thousands):
 As of September 30, 2020
Level 1Level 2Level 3Total Fair ValueTotal Face Value
First Lien Term Loans and SunTrust Term Loan$ $663,140 $ $663,140 $673,227 
 As of December 31, 2019
Level 1Level 2Level 3TotalTotal Face Value
First Lien Term Loans and SunTrust Term Loan$ $708,948 $ $708,948 $705,699 
As of September 30, 2020 and at December 31, 2019 our Barclays revolving credit facility had no balance outstanding. Our SunTrust revolving credit facility relating to our consolidated subsidiary NJIN, had no principal amount outstanding at September 30, 2020 and at December 31, 2019.
The estimated fair value of our long-term debt, which is discussed in Note 5, was determined using Level 2 inputs primarily related to comparable market prices.
We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our finance lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.
EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):
18

 Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Net income (loss) attributable to RadNet, Inc.'s common stockholders$6,156 $3,195 $(20,797)$4,360 
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period51,358,603 49,807,460 50,746,380 49,597,138 
Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders$0.12 $0.06 $(0.41)$0.09 
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period51,358,603 49,807,460 50,746,380 49,597,138 
Add nonvested restricted stock subject only to service vesting120,605 200,567 191,375 
Add additional shares issuable upon exercise of stock options and warrants476,607 352,333 324,793 
Weighted average number of common shares used in calculating diluted net income per share51,955,815 50,360,360 50,746,380 50,113,306 
Diluted net income (loss) per share attributable to RadNet, Inc.'s common stockholders$0.12 $0.06 $(0.41)$0.09 
Stock options and non vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:
Nonvested restricted stock subject to service vesting  331,659  
Shares issuable upon the exercise of stock options:48,948  933,370  

EQUITY INVESTMENTS AT FAIR VALUE–Accounting guidance requires entities to measure equity investments at fair value, with any changes in fair value recognized in net income. If there is no readily determinable fair value, the guidance allows entities the ability to measure investments at cost, adjusted for observable price changes and impairments, with changes recognized in net income.
As of September 30, 2020, we have three equity investments for which a fair value is not readily determinable and therefore the total amounts invested are recognized at cost as follows:
Medic Vision Imaging Solutions Ltd., based in Israel, specializes in software packages that provide compliant radiation dose structured reporting and enhanced images from reduced dose CT scans. On March 24, 2017, we acquired an initial 12.5% equity interest in Medic Vision for $1.0 million. We also received an option to exercise warrants to acquire up to an additional 12.5% equity interest for $1.4 million within one year from the initial share purchase date, if exercised in full. On March 1, 2018 we exercised our warrant in part and acquired an additional 1.96% for $0.2 million. Our initial equity interest has been diluted to 12.25% and our total equity investment stands at 14.21%. In accordance with accounting guidance, as we exercise no significant influence over Medic Vision’s operations, the investment is recorded at its cost of $1.2 million, given that the fair value is not readily determinable. No observable price changes or impairment in our investment was identified as of September 30, 2020.
Turner Imaging Systems, based in Utah, develops and markets portable X-ray imaging systems that provide a user the ability to acquire X-ray images wherever and whenever they are needed. On February 1, 2018, we purchased 2.1 million preferred shares in Turner Imaging Systems for $2.0 million. On January 1, 2019 we funded a convertible promissory note in the amount of $0.1 million that converted to additional 80,000 shares December 21, 2019. No observable price changes impairment in our investment was identified as of September 30, 2020.
19


WhiteRabbit.ai Inc., based in California, is currently developing an artificial intelligence suite which aims to improve the speed and accuracy of cancer detection in radiology and improve patient care. On November 5, 2019 we acquired an equity interest in the company for $1.0 million and also loaned the company $2.5 million, the principal of which is due November 2022. To leverage their artificial intelligence expertise, we entered into a software subscription service contract to assist our radiology work flow and advanced them $4.0 million for future software subscription fees that is recorded as a prepaid expense in Prepaid and Other Current assets in our consolidated balance sheets. No observable price changes or impairment in our investment or the loan receivable was identified as of September 30, 2020.
INVESTMENT IN JOINT VENTURES – We have 12 unconsolidated joint ventures with ownership interests ranging from 35% to 55%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures is accounted for under the equity method, since RadNet does not have a controlling financial interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of September 30, 2020.
Joint venture investment contribution
In the month of August 2020, we made additional cash contributions to our Santa Monica Imaging Group, LLC partnership in the amount of $1.6 million in support of its expanded operations. We maintain our 35% economic interest in the partnership.

Joint venture investment and financial information
The following table is a summary of our investment in joint ventures during the nine months ended September 30, 2020 (in thousands):
Balance as of December 31, 2019$34,470 
Equity in earnings in these joint ventures5,176 
Distribution of earnings(5,706)
Equity contributions in existing joint ventures1,631 
Balance as of September 30, 2020$35,571 
We charged management service fees from the centers underlying these joint ventures of approximately $2.7 million and $1.8 million for the three months ended September 30, 2020 and 2019, respectively, and $8.6 million and $7.8 million for the nine months ended September 30, 2020 and 2019, respectively. We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures.
The following table is a summary of key balance sheet data for these joint ventures as of September 30, 2020 and December 31, 2019 and income statement data for the nine months ended September 30, 2020 and 2019 (in thousands):
Balance Sheet Data:September 30, 2020December 31, 2019
Current assets$26,618 $27,427 
Noncurrent assets70,576 61,037 
Current liabilities(10,487)(9,217)
Noncurrent liabilities(22,751)(18,872)
Total net assets$63,956 $60,375 
Book value of RadNet joint venture interests$29,121 $28,001 
Cost in excess of book value of acquired joint venture interests and other6,450 6,469 
Total value of Radnet joint venture interests$35,571 $34,470 
Total book value of other joint venture partner interests$34,835 $32,374 
20

Income statement data for the nine months ended September 30,20202019
Net revenue$78,988 $80,115 
Net income$13,651 $13,718 
 
NOTE 3 – RECENT ACCOUNTING AND REPORTING STANDARDS

Accounting standards adopted

In June 2016, the FASB issued ASU No. 2016-13 ("ASU 2016-13), Financial Instruments - Credit Losses. ASU 2016-13 replaces the incurred loss methodology previously utilized for valuing financial instruments with an expected loss methodology that is referred to as the current expected credit loss (CECL) methodology. We prospectively adopted the standard on January 1, 2020 and the adoption did not have a material impact to the condensed consolidated financial statements, resulting in no adjustments to our prior year earnings. See the Accounts Receivable section to Note 2 for further information on our allowances for credit losses.

In August 2018, the FASB issued ASU No. 2018-15 (“ASU 2018-15”), Intangibles-Goodwill and Other-Internal-Use Software. ASU 2018-15 aligns the requirements for deferring implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This ASU is effective in the first quarter of 2020 with early adoption permitted and can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The adoption of this standard did not have a material impact on our condensed consolidated balance sheet.

In March 2020, the FASB issued ASU 2020-03 ("ASU 2020-03"), Codification Improvements to Financial Instruments. The amendments in this update represent changes to clarify or improve the codification and correct unintended application. ASU 2020-03 was effective immediately upon issuance and its adoption did not have a material impact on our financial statements.

In August 2018, the FASB issued ASU No. 2018-13 ("ASU 2018-13"), Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurements. This standard removes, modifies and adds certain disclosures related to recurring and nonrecurring fair value measurements. We adopted ASC 2018-13 effective January 1, 2020 and it had no effect on our disclosures.

Accounting standards not yet adopted
 
In December 2019, the FASB issued ASU 2019-12 ("ASU 2019-12"), Income Taxes (Topic 740). ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other areas of the standard. ASU 2019-12 will be effective beginning in the first quarter of 2021. Early adoption is permitted. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. We are currently evaluating the impact this ASU will have on our financial statements and related disclosures as well as the timing of adoption.

In January 2020, the FASB issued ASU 2020-01 ("ASU 2020-01"), Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), clarifying the interaction between accounting standards related to equity securities, equity method investments, and certain derivatives. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020. We do not expect the adoption of this guidance will have a material impact on our financial statements.

In March 2020, the FASB issued ASU 2020-04 ("ASU 2020-04"), Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting. ASU 2020-04 provides optional expedients and exceptions for applying generally accepted accounting principles to certain contract modifications and hedging relationships that reference London Inter-bank Offered Rate (LIBOR) or another reference rate expected to be discontinued. The guidance is effective upon issuance and generally can be applied through December 31, 2022. We are currently evaluating the potential impact of ASU 2020-04 on our financial statements.
21


NOTE 4 – FACILITY ACQUISITIONS AND DISPOSITIONS
Acquisitions:

On August 31, 2020 we completed our acquisition of certain assets of AZ-Tech Radiology & Open MRI, LLC, consisting of eight multi-modality imaging centers located in the Phoenix, Arizona area for purchase consideration of $5.5 million. We made a preliminary fair value determination of the acquired assets and assumed liabilities and approximately $2.5 million in property and equipment, $7.6 million in right-of-use assets, $0.1 million in other assets, $7.6 million in operating lease liabilities, and $2.9 million in goodwill were recorded.

On June 1, 2020, we completed our acquisition of all the equity interests of DeepHealth Inc., ("DeepHealth") an artificial intelligence and machine learning company in an all stock purchase. As initial purchase consideration, we issued 915,132 shares at $16.93 per share (823,615 issued at execution, with up to 91,517 shares to be issued 18 months after acquisition subject to adjustment for any indemnification claims). The transaction was accounted for as an acquisition of a business and total purchase consideration determined to be approximately $34.6 million including i) 823,615 shares issued on the date of closing with fair value of $13.9 million, ii) a liability of 91,517 shares with a fair value of $1.5 million to be issued 18 months after acquisition subject to adjustment for any indemnification claims and will be marked to market in subsequent periods, iii) replacement awards attributable to pre-combination service issued to DeepHealth option holders with allocated fair value of $2.0 million, iv) acquisition date fair value of contingent consideration of $17.0 million and v) $0.1 million in closing costs reimbursed to the seller. The fair values of replacement awards attributable to pre-combination service and contingent consideration are recorded in additional paid in capital upon closing of the transaction. For the contingent consideration, there are three arrangements that will be settled in a fixed number of shares upon achievement of three individual specific milestones which are mutually exclusive of each other, with 390,789, 586,184, and 195,393 shares, respectively, issuable for each milestone arrangement. The fair value of the contingent consideration was estimated at the date of acquisition based on our share price and estimated probability of the achievement of the respective milestones. We preliminarily recorded $0.1 million in current assets, $3.5 million in deferred tax liabilities, $14.8 million in intangible assets, primarily in-process research and development ("IPR&D'), and $23.4 million in goodwill. The goodwill is primarily attributable to expected post-acquisition synergies from integrating DeepHealth’s assembled workforce and IPR&D technologies. The fair values of the identifiable intangible assets related to IPR&D were determined by the income method and the assets will not be amortized until completion.

On March 2, 2020 our consolidated subsidiary New Jersey Imaging Networks ("NJIN") completed the acquisition of certain assets of MRI at Woodbridge, LLC consisting of a single multi-modality imaging center located in Avenel, New Jersey for cash consideration of $2.6 million. NJIN made a fair value determination of the acquired assets and assumed liabilities and approximately $0.5 million in property and equipment, $1.1 million in right-of-use assets, $0.3 million in intangible assets, $1.1 million in operating lease liabilities, $0.1 million in finance lease liabilities, and $1.8 million in goodwill were recorded.

    On January 2, 2020 we completed our acquisition of certain assets of Olney Open MRI, LLC, consisting of a single multi-modality imaging center located in Columbia, Maryland for cash consideration of $1.8 million. We have made a fair value determination of the acquired assets and assumed liabilities and approximately $0.8 million in property and equipment, $1.3 million in right-of-use assets, $0.3 million in intangible assets, $1.3 million in operating lease liabilities and $0.6 million in goodwill were recorded.
Dispositions:
On June 1, 2020 we completed our sale of certain assets of our Imaging On Call subsidiary to RadVantage P.C. (an unrelated corporation) for approximately $1.0 thousand. With this transaction, we have exited the teleradiology business.

22

NOTE 5 – CREDIT FACILITIES AND NOTES PAYABLE
As of September 30, 2020 and December 31, 2019 our debt obligations consisted of the following (in thousands):
September 30,
2020
December 31,
2019
First Lien Term Loans collateralized by RadNet's tangible and intangible assets$620,727 $649,824 
Discounts on First Lien Term Loans(10,669)(13,579)
SunTrust Term Loan Agreement collateralized by NJIN's tangible and intangible assets52,500 55,875 
Paycheck Protection Program loans at 1% due April 2022
4,037 — 
Equipment note payable at 4.6%, due through 2020, collateralized by medical equipment
47 275 
Total debt obligations666,642 692,395 
Less: current portion(39,463)(39,691)
Long term portion debt obligations$627,179 $652,704 

Included in our condensed consolidated balance sheets at September 30, 2020 are $620.7 million of First Lien Term Loans and $52.5 million of SunTrust Term Loan debt for a combined total of $673.2 million of total term loan debt (exclusive of unamortized discounts of $10.7 million) in thousands:
 Face ValueDiscountTotal Carrying
Value
First Lien Term Loans$620,727 $(10,669)$610,058 
SunTrust Term Loan52,500  52,500 
Total Term Loans$673,227 $(10,669)$662,558 
We had no balance under our $195.0 million Barclays Revolving Credit Facility at September 30, 2020 and have reserved $6.3 million for certain letters of credit. The remaining $188.7 million of our Barclays Revolving Credit Facility was available to draw upon as of September 30, 2020. We had no balance under our $30.0 million SunTrust Revolving Credit Facility related to our consolidated subsidiary NJIN at September 30, 2020.
Senior Secured Credit Facilities
Barclays Credit Facilities:
At September 30, 2020, (a) our Barclays credit facilities were comprised of one tranche of term loans (“First Lien Term Loans”) and a revolving credit facility of $195.0 million (the “Barclays Revolving Credit Facility”) and (b) our SunTrust credit facilities, which relate to our consolidated subsidiary NJIN, were comprised of one term loan (the "SunTrust Term Loan") and a revolving credit facility of $30.0 million (the "SunTrust Revolving Credit Facility").
As of September 30, 2020, we were in compliance with all covenants under our credit facilities. Deferred financing costs at September 30, 2020, net of accumulated amortization, was $1.9 million and is specifically related to our Barclays Revolving Credit Facility.

Our First Lien Term Loans bear interest at either an Adjusted Eurodollar Rate or a Base Rate, plus an applicable margin according to the following schedule:
First Lien Leverage RatioEurodollar Rate SpreadBase Rate Spread
> 5.50x4.50%3.50%
> 4.00x but ≤ 5.50x3.75%2.75%
>3.50x but ≤ 4.00x3.50%2.50%
≤ 3.50x3.25%2.25%

At September 30, 2020 the effective Adjusted Eurodollar Rate and the Base Rate for the First Lien Term Loans was 1.00% and 3.25%, respectively and the applicable margin for Adjusted Eurodollar Rate and Base Rate borrowings was 3.75% and 2.75%, respectively.
23


The First Lien Credit Agreement provides for quarterly payments of principal under the First Lien Term Loans in the amount of approximately $9.7 million. The First Lien Term Loans will mature on July 21, 2023 unless otherwise accelerated under the terms of the First Lien Credit Agreement.
SunTrust Credit Facilities:

Our SunTrust Term Loan bears interest at either an Adjusted Eurodollar Rate or a Base Rate, plus an applicable margin according to the following schedule:

Pricing LevelLeverage RatioApplicable Margin for Eurodollar LoansApplicable Margin for Base Rate LoansApplicable Margin for Letter of Credit FeesApplicable Percentage for Commitment Fee
I
Greater than or equal to 3.00:1.00
2.75%
per annum
1.75%
per annum
2.75%
per annum
0.45%
per annum
II
Less than 3.00:1.00 but greater than or equal to 2.50:1.00
2.25%
per annum
1.25%
per annum
2.25%
per annum
0.40%
per annum
III
Less than 2.50:1.00 but greater than or equal to
2.00:1.00
2.00%
per annum
1.00%
per annum
2.00%
per annum
0.35%
per annum
IV
Less than 2.00:1.00 but greater than or equal to 1.50:1.00
1.75%
per annum
0.75%
per annum
1.75%
per annum
0.30%
per annum
V
Less than 1.50:1.00
1.50%
per annum
0.50%
per annum
1.50%
per annum
0.30%
per annum

The loans and other obligations outstanding under the SunTrust Restated Credit Agreement currently bear applicable margin and fees based on Pricing Level III described above. The loans outstanding under the SunTrust Restated Credit Agreement currently bear interest based on a three month Eurodollar election of 2.00%, plus the applicable margin.

The scheduled amortization of the SunTrust Term Loan began December 31, 2018 with quarterly payments of $0.8 million, representing annual amortization equal to 5.00% of the original principal amount of the SunTrust Term Loan. At scheduled intervals, the quarterly amortization increases by $0.4 million, with the remaining balance to be paid at maturity. The SunTrust Term Loan will mature on August 1, 2023 unless otherwise accelerated under the terms of the SunTrust credit facility.


Revolving Credit Facilities
Barclays Revolving Credit Facility

Revolving loans borrowed under the Barclays Revolving Credit Facility bear interest at either an Adjusted Eurodollar Rate or a Base Rate plus an applicable margin. Rates of the applicable margin for borrowing under the Revolving Credit Facility also change depending on our leverage ratio and are the same rates as noted in the schedule above for First Lien Term Loans. As of September 30, 2020, the effective interest rate payable on revolving loans was 6.00%.
Letters of credit issued under the Barclays Revolving Credit Facility, letter of credit fees accrue at the applicable margin of Adjusted Eurodollar Rate, currently 3.75% , and fronting fees accrue at 0.25% per annum, in each case on the average aggregate daily maximum amount available to be drawn under all letters of credit issued under the First Lien Credit Agreement. In addition, a commitment fee of 0.50% per annum accrues on the unused revolver commitments under the Revolving Credit Facility.
The Barclays Revolving Credit Facility will terminate on the earliest to occur of July 1, 2023 or its earlier termination to specific events of default pursuant to the First Lien Credit Agreement.

24

Our Barclays Revolving Credit Facility was amended in August 2020 to add $57.5 million of revolving commitments and extend the maximum borrowing capacity to $195.0 million. Total issue costs added in relation to the eighth amendment amounted to approximately $0.7 million and was capitalized as deferred financing costs and will be amortized over the remaining term of the agreement.

SunTrust Revolving Credit Facility

Our SunTrust Revolving Credit Facility is available to NJIN for funding requirements, with an available borrowing limit of $30.0 million. Revolving loan borrowed under the SunTrust Revolving Credit Facility bear interest at either an Adjusted Eurodollar Rate or a Base Rate plus an applicable margin. Rates of the applicable margin for borrowing under the Revolving Credit Facility also change depending on our leverage ration and are the same rates noted in the schedule above for the SunTrust Term Loan. The SunTrust Revolving Credit Facility terminates on August 31, 2023 unless all amounts outstanding otherwise have been declared or have automatically become due and payable (whether by acceleration or otherwise). NJIN has not borrowed against the revolving credit line.
 
Recent Amendments to credit facilities:
Barclays Credit Facilities:

On August 28, 2020, RadNet, Inc. entered into Amendment No. 8, Consent and Incremental Joinder Agreement to Credit and Guaranty Agreement "the Eighth Amendment". The Eighth Amendment amends the First Lien Credit Agreement to add $57.5 million of revolving commitments to the Barclays Revolving Credit Facility extending the maximum borrowing capacity under the revolving credit facility to $195.0 million while leaving the maturity date of July 1, 2023 unchanged. Total issue costs added in relation to the Eighth Amendment amounted to approximately $0.7 million and was capitalized as deferred financing costs and will be amortized over the remaining term of the agreement.

On April 18, 2019 we entered into the following two amendments to the First Lien Credit Agreement: (i) Amendment No. 6, Consent and Incremental Joinder Agreement to Credit and Guaranty Agreement (the “Sixth Amendment”); and (ii) Amendment No. 7 to Credit and Guaranty Agreement (the “Seventh Amendment”). The Sixth Amendment amended the First Lien Credit Agreement to issue $100.0 million in incremental First Lien Term Loans and to add an additional $20.0 million of revolving commitments to the Barclay's Revolving Credit Facility. The Seventh Amendment amended the First Lien Credit Agreement to extend the maturity date of the Barclays Revolving Credit Facility by an additional two years to July 1, 2023, unless sooner terminated in accordance with the terms of the First Lien Credit Agreement. Total issue costs added in relation to the Sixth and Seventh amendments in 2019 amounted to approximately $4.4 million. Of this amount, $2.1 million was identified and capitalized as discount on debt, $0.7 million was capitalized as deferred financing costs, and $1.6 million was expensed. Amounts capitalized will be amortized over the remaining term of the agreement.

Paycheck Protection Program
The Paycheck Protection Program (PPP) includes funds available for loans to small business and Medicare providers to support operations during the COVID-19 pandemic. The funds are administered by the Small Business Administration (SBA), through approved lenders and do not require collateral or personal guarantees. We received our loans based on being a Medicare provider. The terms and conditions for participation require entities to certify that economic uncertainty related to the COVID-19 pandemic makes the loan necessary to support their current operations, and that they will use the funds to retain workers (e.g., by paying salaries, providing paid sick/medical leave and health insurance benefits) and pay certain debts (mortgage obligations) and expenses (e.g. rent, utilities, telephone). The loans have a 1.0% fixed interest rate and are due in 2 years. Initial repayments have been deferred for six months. The loans are eligible for forgiveness subject to salary limitations and employee retention levels. Certain of our consolidated subsidiaries received four loans totaling $4.0 million. We have accounted for the funds received as debt and recorded a liability for the full amount of proceeds received. Interest will be accrued over the term of the loans. If we meet the eligibility requirements for forgiveness the amounts forgiven will be recognized in the income statement as a gain on loan extinguishment in accordance with accounting guidance.

NOTE 6 – STOCK-BASED COMPENSATION
Stock Incentive Plans
25

We have one long-term equity incentive plan which we refer to as the 2006 Equity Incentive Plan, which we first amended and restated as of April 20, 2015 and again on March 9, 2017 (the "Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved for issuance under the Restated Plan 14,000,000 shares of common stock. We can issue options (incentive and non-qualified), stock awards, stock appreciation rights, stock units and cash awards under the Restated Plan.
Options
Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options generally vest over 3 to 5 years and expire 5 to 10 years from the date of grant.
As of September 30, 2020, we had outstanding options to acquire 527,899 shares of our common stock, of which options to acquire 298,863 shares were exercisable. The following summarizes all of our option transactions for the nine months ended September 30, 2020:
Outstanding Options
Under the 2006 Plan
SharesWeighted Average
Exercise price
Per Common Share
Weighted Average
Remaining
Contractual Life
(in years)
Aggregate
Intrinsic
Value
Balance, December 31, 2019478,951 $8.21 
Granted48,948 20.43 
Balance, September 30, 2020527,899 9.34 6.59$3,419,956 
Exercisable at September 30, 2020298,863 7.48 5.852,353,438 
Aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on September 30, 2020 and the exercise price, multiplied by the number of in-the-money options as applicable) that would have been received by the holder had all holders exercised their options on September 30, 2020. No options were exercised during the nine months ended September 30, 2020. As of September 30, 2020, total unrecognized stock-based compensation expense related to non-vested employee awards was $0.7 million which is expected to be recognized over a weighted average period of approximately 1.68 years.
DeepHealth Options
During the second quarter of fiscal 2020, in connection with the completion of the DeepHealth acquisition, we granted 412,434 options at a grant date fair value of $16.93 per share unit to DeepHealth employees in replacement of their stock options that were outstanding as of the closing date. As of September 30, 2020, total unrecognized stock based compensation expense related to non-vested DeepHealth options was approximately $4.3 million which is expected to be recognized over a weighted average period of approximately 2.53 years.
Outstanding Options
Under the Deep Health Plan
SharesWeighted Average
Exercise price
Per Common Share
Weighted Average
Remaining
Contractual Life
(in years)
Aggregate
Intrinsic
Value
Balance, December 31, 2019 
Granted, June 1, 2020412,434 $— 
Exercised(6,963)— 
Balance, September 30, 2020405,471 — 8.65$6,223,980 
Exercisable at September 30, 202024,211 — 8.65371,639 
Restricted Stock Awards
The Restated Plan permits the award of restricted stock awards (“RSA’s”). As of September 30, 2020, we have issued a total of 6,551,872 RSA’s of which 331,659 were unvested at September 30, 2020. The following summarizes all unvested RSA’s activities during the nine months ended September 30, 2020:
26

 RSA'sWeighted-Average
Remaining
Contractual
Term (Years)
Weighted-Average
Fair Value
RSA's unvested at December 31, 2019387,934 $11.61 
Changes during the period
Granted457,596 $19.66 
Vested(513,871)$15.47 
RSA's unvested at September 30, 2020331,659 1.11$16.67 
We determine the fair value of all RSA’s based on the closing price of our common stock on the award date.
Other stock bonus awards
The Restated Plan also permits the award of stock bonuses not subject to any future service period. These awards are valued and expensed based on the closing price of our common stock on the date of award. During the nine months ended September 30, 2020 awards totaling 26,078 shares were granted.
Plan summary
In summary, of the 14,000,000 shares of common stock reserved for issuance under the Restated Plan, at September 30, 2020, we had issued 15,384,316 total shares between options, RSA’s and other stock awards. With options canceled and RSA’s forfeited amounting to 3,281,040 and 61,703 shares, respectively, there remain 1,958,427 shares available under the Restated Plan for future issuance.
The DeepHealth options were issued outside of the Restated Plan and are a direct result of our acquisition and not included in the share count of the Restated Plan.

NOTE 7 – SUBSEQUENT EVENTS
Formation of majority owned subsidiary
On November 1, 2020 we formed in conjunction with Simi Valley Hospital and Health Services ("Simi Adventist") the Simi Valley Imaging Group, LLC (“SVIG”), consisting of three multi-modality imaging centers located in Simi Valley, CA. RadNet will hold a 60% economic interest in SVIG and Simi Adventist will have the remaining 40% interest.
ITEM 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and notes thereto for the year ended December 31, 2019 included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission (SEC) on March 11, 2020.
Forward-Looking Statements
This quarterly report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect current views about future events and are based on our currently available financial, economic and competitive data and on current business plans. Actual events or results may differ materially depending on risks and uncertainties that may affect our operations, markets, services, prices and other factors.
In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “assumption” or the negative of these terms or other comparable terminology. Forward-looking statements in this current report include, among others, statements we make regarding
27

our ability to successfully integrate new operations, to our business and the anticipated benefits to be derived from our investments, acquisitions, and joint ventures;
anticipated trends in our revenues, operating expenses and liquidity and cash flows, including our financial guidance and anticipated effects of cost-savings efforts;

the ongoing impact of the COVID-19 pandemic on our business, suppliers, payors, customers, referral sources, partners, patients and employees, including (i) government’s unprecedented action regarding existing and potential restrictions and/or obligations related to citizen and business activity to contain the virus; (ii) the consequences of an economic downturn resulting from the impacts of COVID-19 and the possibility of a global economic recession; (iii) the impact of the volume of canceled or rescheduled procedures, whether as a result of government action or patient choice; (iv) measures we are taking to respond to the COVID-19 pandemic, including changes to business practices; (v) the impact of government and administrative regulation, guidance and appropriations; (vi) changes in our revenues due to declining patient procedure volumes, changes in payor mix; (vii) potential increased expenses or workforce disruptions related to our employees that could lead to unavailability of key personnel; (viii) workforce disruptions related to our key partners, suppliers, vendors and others we do business with; (ix) the impact of return to work orders in certain states in which we operate; and (x) increased credit and collectability risks; and

our future liquidity and our continuing ability to service and remain in compliance with applicable debt covenants or refinance our current indebtedness.
Forward-looking statements are not guarantees of future performance and our actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, the factors included in “Risk Factors,” in our annual report on Form 10-K for the fiscal year ended December 31, 2019 and quarterly report on form 10Q for the quarters ended March 31, and June 30, 2020, or supplemented by the information in Part II– Item 1A below. You should consider the inherent limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of predictions contained in such forward-looking statements.
These forward-looking statements speak only as of the date when they are made. We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law.

Overview

We are a leading national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States based on number of locations and annual imaging revenue. At September 30, 2020, we operated, directly or indirectly through joint ventures with hospitals, 334 centers located in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often reducing the cost and amount of care for patients. Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. In addition to our imaging services, we own and operate a number of technology businesses that are complementary to our imaging business. Our subsidiary eRAD, Inc., develops and sells computerized systems for the diagnostic imaging industry, which provide the technology to distribute, display, store and retrieve digital images. Over 2019 and 2020 we have made a number of investments in Artificial Intelligence (AI) with our purchases of Nulogix and DeepHealth, combined with our investment in Whiterabbit.ai and our collaborative arrangement with Hologic. Our current AI focus is to develop solutions in machine learning to assist radiologists and other clinicians in interpreting images and improving patient care, initially in the field of mammography.

We derive substantially all of our revenue, directly or indirectly, from fees charged for the diagnostic imaging services performed at our facilities. The following table shows our facilities in operation and revenues for the nine months ended September 30, 2020 and September 30, 2019:
28

 Nine Months Ended September 30,
 20202019
Facilities in operation334340 
Net revenues (millions)$763.9 $853.3 
Our revenue is derived from a diverse mix of payors, including private payors, managed care capitated payors and government payors. We believe our payor diversity mitigates our exposure to possible unfavorable reimbursement trends within any one payor class. In addition, our experience with capitation arrangements over the last several years has provided us with the expertise to manage utilization and pricing effectively, resulting in a predictable stream of revenue.
The Company’s total service revenue during the three and nine months ended September 30, 2020 and 2019 are presented in the table below based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
 2020201920202019
Commercial insurance$160,524 $163,152 $412,415 $475,064 
Medicare62,704 61,599 154,847 175,825 
Medicaid7,098 7,128 18,072 21,564 
Workers' compensation/personal injury7,183 10,865 25,705 32,950 
Other patient revenue8,328 6,085 17,211 17,947 
Management fee revenue2,675 1,792 8,574 5,662 
Teleradiology and Software revenue2,349 4,412 8,319 12,861 
Other5,869 6,875 15,617 20,878 
Service fee revenue256,730 261,908 660,760 762,751 
Revenue under capitation arrangements35,046 30,784 103,145 90,587 
Total service revenue$291,776 $292,692 $763,905 $853,338 

We typically experience some seasonality to our revenue stream. During the first quarter of each year we generally experience the lowest volumes of procedures and the lowest level of revenue for any quarter during the year. It is common for inclement weather to result in patient appointment cancellations and, in some cases, imaging center closures. Second, in recent years, we have observed greater participation in high deductible health plans by patients.  As these high deductibles reset in January for most of these patients, we have observed that patients utilize medical services less during the first quarter, when securing medical care will result in significant out-of-pocket expenditures.

Recent Developments

The discussion below of our results centers on our performance in the third quarter ending September 30, 2020. As discussed in our Form 8-K filed on April 3, 2020, the overall impact of the coronavirus pandemic on RadNet’s business has had and could continue to have a material impact on our operating results, cash flows and financial position. The magnitude of the impact will ultimately depend on the duration and extent of the COVID-19 pandemic and the impact of governmental actions and patient behavior in response to the pandemic, which remains ongoing.

As as result of the pandemic we began experiencing reduced procedure volumes in mid-March which intensified through the early part of the second quarter of 2020. As economic activity has begun to ramp-up, our procedure volumes have returned to our pre-COVID-19 pace, from a low of 28% pre-COVID-19 volumes experienced in April 2020. Our experience has shown that lost imaging slots in one quarter are not made up within that period or in subsequent quarters. We continue to adapt our operations in response to the pandemic where needed and implemented several cost-saving measures such as concentrating patient traffic to larger imaging centers, negotiating payment terms with vendors and landlords, adjusting staff levels and telecommuting.
29

Equity Investments, Acquisitions and Dispositions, and Joint Venture Activity
We have developed our medical imaging business through a combination of organic growth, equity investments, acquisitions and joint venture formations. The information below updates our activity of such matters contained in our annual report on Form 10-K for the year ended December 31, 2019.
Equity Investments
As of September 30, 2020, we have three equity investments for which a fair value is not readily determinable and therefore the total amounts invested are recognized at cost as follows
Medic Vision Imaging Solutions Ltd., based in Israel, specializes in software packages that provide compliant radiation dose structured reporting and enhanced images from reduced dose CT scans. On March 24, 2017, we acquired an initial 12.5% equity interest in Medic Vision for $1.0 million. We also received an option to exercise warrants to acquire up to an additional 12.5% equity interest for $1.4 million within one year from the initial share purchase date, if exercised in full. On March 1, 2018 we exercised our warrant in part and acquired an additional 1.96% for $0.2 million. Our initial equity interest has been diluted to 12.25% and our total equity investment stands at 14.21%. In accordance with accounting guidance, as we exercise no significant influence over Medic Vision’s operations, the investment is recorded at its cost of $1.2 million, given that the fair value is not readily determinable. No observable price changes or impairment in our investment was identified as of September 30, 2020.
Turner Imaging Systems, based in Utah, develops and markets portable X-ray imaging systems that provide a user the ability to acquire X-ray images wherever and whenever they are needed. On February 1, 2018, we purchased 2.1 million preferred shares in Turner Imaging Systems for $2.0 million. On January 1, 2019 we funded a convertible promissory note in the amount of $0.1 million that converted to additional 80,000 shares December 21, 2019. No observable price changes or impairment in our investment was identified as of September 30, 2020.

WhiteRabbit.ai Inc., based in California, is currently developing an artificial intelligence suite which aims to improve the speed and accuracy of cancer detection in radiology and improve patient care. On November 5, 2019 we acquired an equity interest in the company for $1.0 million and also loaned the company $2.5 million, the principal of which is due November 2022. To leverage their artificial intelligence expertise, we entered into a software subscription service contract to assist our radiology work flow and advanced them $4.0 million for future software subscription fees that is recorded as a prepaid expense in Prepaid and Other Current assets in our consolidated balance sheets. No observable price changes or impairment in our investment or the loan receivable was identified as of September 30, 2020.

Facility acquisitions
On August 31, 2020 we completed our acquisition of certain assets of AZ-Tech Radiology & Open MRI, LLC, consisting of eight multi-modality imaging centers located in the Phoenix, Arizona area for purchase consideration of $5.5 million. We made a preliminary fair value determination of the acquired assets and assumed liabilities and approximately $2.5 million in property and equipment, $7.6 million in right-of-use assets, $0.1 million in other assets, $7.6 million in operating lease liabilities, and $2.9 million in goodwill were recorded.
On June 1, 2020, we completed our acquisition of all the equity interests of DeepHealth Inc., ("DeepHealth") an artificial intelligence and machine learning company in an all stock purchase. As initial purchase consideration, we issued 915,132 shares at $16.93 per share (823,615 issued at execution, with up to 91,517 shares to be issued 18 months after acquisition subject to adjustment for any indemnification claims). The transaction was accounted for as an acquisition of a business and total purchase consideration determined to be approximately $34.6 million including i) 823,615 shares issued on the date of closing with fair value of $13.9 million, ii) a liability of 91,517 shares with a fair value of $1.5 million to be issued 18 months after acquisition subject to adjustment for any indemnification claims and will be marked to market in subsequent periods, iii) replacement awards attributable to pre-combination service issued to DeepHealth option holders with allocated fair value of $2.0 million, iv) acquisition date fair value of contingent consideration of $17.0 million and v) $0.1 million in closing costs reimbursed to the seller. The fair values of replacement awards attributable to pre-combination service and contingent consideration are recorded in additional paid in capital upon closing of the transaction. For the contingent consideration, there are three arrangements that will be settled in a fixed number of shares upon achievement of three individual specific milestones which are mutually exclusive of each other, with 390,789, 586,184, and 195,393 shares, respectively, issuable for each milestone arrangement. The fair value of the contingent consideration was estimated at the date of acquisition based on our share price and estimated probability of the achievement of the respective milestones. We preliminarily recorded $0.1 million in current assets, $3.5 million in deferred tax liabilities, $14.8 million in intangible assets, primarily in-process research and
30

development ("IPR&D'), and $23.4 million in goodwill. The goodwill is primarily attributable to expected post-acquisition synergies from integrating DeepHealth’s assembled workforce and IPR&D technologies. The fair values of the identifiable intangible assets related to IPR&D were determined by the income method and the assets will not be amortized until completion.
On March 2, 2020 our consolidated subsidiary New Jersey Imaging Networks ("NJIN") completed the acquisition of certain assets of MRI at Woodbridge, LLC consisting of a single multi-modality imaging center located in Avenel, New Jersey for consideration of $2.6 million. NJIN made a fair value determination of the acquired assets and assumed liabilities and approximately $0.5 million in property and equipment, $1.1 million in right-of-use assets, $0.3 million in intangible assets, $1.1 million in operating lease liabilities, $0.1 million in finance lease liabilities, and $1.8 million in goodwill were recorded.

    On January 2, 2020 we completed our acquisition of certain assets of Olney Open MRI, LLC, consisting of a single multi-modality imaging center located in Columbia, Maryland for consideration of $1.8 million. We have made a fair value determination of the acquired assets and assumed liabilities and approximately $0.8 million in property and equipment, $1.3 million in right-of-use assets, $0.3 million in intangible assets, $1.3 million in operating lease liabilities and $0.6 million in goodwill were recorded.
Dispositions:
On June 1, 2020 we completed our sale of certain assets of our Imaging On Call subsidiary to RadVantage P.C. (an unrelated corporation) for approximately $1.0 thousand. With this transaction, we have exited the teleradiology business.
Joint venture investment contribution
During the month of August 2020, we made additional cash contributions to our Santa Monica Imaging Group, LLC partnership in the amount of $1.6 million in support of its expanded operations. We maintain our 35% economic interest in the partnership.
Joint Venture Activity
The following table is a summary of our investment in joint ventures during the nine months ended September 30, 2020 (in thousands):
Balance as of December 31, 2019$34,470 
Equity in earnings in these joint ventures5,176 
Balance as of September 30, 2020$35,571 
We charged management service fees from the centers underlying these joint ventures of approximately $2.7 million and $1.8 million for the three months ended September 30, 2020 and 2019, respectively. and $8.6 million and $7.8 million for the nine months ended September 30, 2020 and 2019, respectively. We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures.
31

The following table is a summary of key balance sheet data for these joint ventures as of September 30, 2020 and December 31, 2019 and income statement data for the nine months ended September 30, 2020 and 2019 (in thousands):
Balance Sheet Data:September 30,
2020
December 31,
2019
Current assets$26,618 $27,427 
Noncurrent assets70,576 61,037 
Current liabilities(10,487)(9,217)
Noncurrent liabilities(22,751)(18,872)
Total net assets$63,956 $60,375 
Book value of RadNet joint venture interests$29,121 $28,001 
Cost in excess of book value of acquired joint venture interests6,450 6,469 
Total value of Radnet joint venture interests$35,571 $34,470 
Total book value of other joint venture partner interests$34,835 $32,374 
Income statement data for the nine months ended September 30,20202019
Net revenue$78,988 $80,115 
Net income$13,651 $13,718 
Critical Accounting Policies
The Securities and Exchange Commission defines critical accounting estimates as those that are both most important to the portrayal of a company’s financial condition and results of operations and require management’s most difficult, subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. In Note 2 to our consolidated financial statements in this quarterly report and in our annual report on Form 10-K for the year ended December 31, 2019, we discuss our significant accounting policies, including those that do not require management to make difficult, subjective or complex judgments or estimates. The most significant areas involving management’s judgments and estimates are described below.
Revenues

Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period when our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payors. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. 

As it relates to the Group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by them as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to other centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities. 

32

Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under managed care and commercial insurance plans are based upon historical collection experience of the payments received from such payors in accordance with the underlying contractual agreements. Revenues related to uninsured patients and copayment and deductible amounts for patients who have health care coverage may have price concessions applied. We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.

Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.
Provider Relief Fund (COVID-19 Stimulus Funding)
The Provider Relief Fund offers government assistance to eligible providers throughout the healthcare system in support of certain expenses or lost revenue attributable to the coronavirus pandemic. In the third quarter of 2020, we received approximately $0.2 million in funding and for nine months ended September 30, 2020 we have received funding of $25.7 million. Generally, the department of Health and Human Services ("HHS") does not intend to recoup funds as long as a provider's lost revenue and increased expenses exceed the amount of provider relief funding one has received. HHS reserves the right to audit Relief Fund recipients in the future to ensure that this requirement is met and collect any Relief Fund amounts that were made in error or exceed lost revenue or increased expenses due to the pandemic. Failure to comply with the terms and conditions may be grounds for recoupment. During the quarter ended September 30, 2020, we continued to evaluate our operating results and gave consideration to the updated reporting guidelines issued in September by the U.S. Department of Health and Human Services that significantly changed the measurement of Provider Relief Fund distributions providers are able to retain. Based on our assessment recognition of the revenue previously recognized remained appropriate.
Accounts Receivable
Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. Receivables generally are collected within industry norms for third-party payors. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience. In regards to the credit loss standard, our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the CECL model.
Income Taxes
Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income, including tax planning strategies, in determining whether our net deferred tax assets are more likely than not to be realized.
Deferred Revenue
In April of 2020, we received approximately $39.4 million in advanced Medicare payments from the Centers for Medicare and Medicaid Services ("CMS") as part of the expanded Accelerated and Advance Payment Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. As these payments are required to be repaid to CMS beginning 120 days after their receipt through offsets from new Medicare claims over a three month period, we have recorded amounts received to deferred revenue which will be amortized as Medicare reimbursements are earned. In addition, in May of 2020 we received $5.0 million in advance payments from an insurance carrier with similar repayment terms as the CMS.
Property and Equipment
Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation of property and equipment is performed using the straight-line method over the estimated useful lives of the assets acquired, which range
33

from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred.
Business Combination
We evaluate all purchases under the framework in ASU No. 2017-01 (“ASU 2017-01”), Clarifying the Definition of a Business. Once the purchase has been determined to be the acquisition of a business, we are required to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.
Goodwill and Indefinite Lived Intangibles
Goodwill at September 30, 2020 totaled $470.7 million. Indefinite Lived Intangible Assets at September 30, 2020 were $11.3 million and are associated with the value of certain trade name intangibles. Goodwill and trade name intangibles are recorded as a result of business combinations. When we determine the carrying value of a reporting unit exceeds its fair value an impairment charge would be recognized and should not exceed the total amount of goodwill allocated to that reporting unit. We tested goodwill for impairment on October 1, 2019. In addition to the annual impairment test, we regularly assess if an event has occurred which would require interim impairment testing. We considered the current and expected future economic and market conditions surrounding the novel strain of coronavirus ("COVID-19") pandemic and did not identify an indication of goodwill impairment being more likely than not through September 30, 2020.
Long-Lived Assets
We evaluate our long-lived assets (property and equipment) and intangibles, other than goodwill, for impairment whenever indicators of impairment exist. To evaluate the long-lived assets our management estimates the undiscounted future cash flows expected to be derived from the asset. The accounting standards require that if the sum of the undiscounted expected future cash flows from a long-lived asset or definite-lived intangible is less than the carrying value of that asset, an asset impairment charge must be recognized. The amount of the impairment charge is calculated as the excess of the asset’s carrying value over its fair value, which generally represents the discounted future cash flows from that asset or in the case of assets we expect to sell, at fair value less costs to sell. No indicators of impairment were identified with respect to our long-lived assets as of September 30, 2020.
Depreciation and Amortization of Long-Lived Assets
We depreciate our long-lived assets over their estimated economic useful lives with the exception of leasehold improvements where we use the shorter of the assets useful lives or the lease term of the facility for which these assets are associated. We estimate the economic useful lives of assets, other than leasehold improvements, to be between 3 and 15 years depending on the type of asset.
Leases
We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long term operating lease liability in our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liability, and long-term finance lease liability in our consolidated balance sheets.  ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have elected to account for the components as a single lease component, as permitted. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the ROU asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. ROU assets
34

are tested for impairment if circumstances suggest that the carrying amount may not be recoverable. Our ROU assets consist of facility and equipment assets on operating leases. No events have occurred such as fire, flood, or other acts which have impaired the integrity of our ROU assets in 2020. Our facility leases require us to maintain insurance policies which would cover major damage to our facilities. We maintain business interruption insurance to cover loss of business due to a facility becoming non-operational under certain circumstances. Our equipment leases are covered by warranty and service contracts which cover repairs and provide regular maintenance to keep the equipment in functioning order.
Equity Based Compensation
We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated as of April 20, 2015, and again on March 9, 2017 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved 14,000,000 shares of common stock for issuance under the Restated Plan which can be issued in the form of options, stock awards, stock appreciation rights, and cash awards. Stock options generally vest over three to five years and expire five to ten years from date of grant. We determine the compensation expense for each stock option award using the Black Scholes, or similar valuation model. Those models require that our management make certain estimates concerning risk free interest rates and volatility in the trading price of our common stock. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. In connection with our acquisition of DeepHealth Inc. on June 1, 2020, we assumed the DeepHealth, Inc. 2017 Stock Incentive Plan, including outstanding options awards that can be exercised for our common stock. No additional awards will be granted under the DeepHealth, Inc. 2017 Equity Incentive Plan. See Note 4, Facility Acquisitions and Note 6, Stock-Based Compensation, for more information.
Commitments and Contingencies
We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. Based on current information, we do not believe that reasonably possible or probable losses associated with pending legal proceedings would either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. Therefore, if one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.

Recent Accounting Standards
See Note 3, Recent Accounting and Reporting Standards to the financial statements included in this report or further information.
35

Results of Operations
The following table sets forth, for the three and nine months ended September 30, 2020 and 2019, the percentage that certain items in the statements of operations bears to total service revenue, inclusive of revenue under capitation contracts.
RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS EXCEPT SHARE DATA)
(unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
 2020201920202019
REVENUE    
     Service fee revenue88.0 %89.5 %86.5 %89.4 %
     Revenue under capitation arrangements12.0 %10.5 %13.5 %10.6 %
Total service revenue100.0 %100.0 %100.0 %100.0 %
     Provider relief funding0.1 %— %3.4 %— %
OPERATING EXPENSES  
     Cost of operations, excluding depreciation and amortization84.5 %86.9 %92.7 %87.2 %
     Depreciation and amortization7.3 %7.0 %8.4 %7.1 %
     Loss on sale and disposal of equipment and other0.1 %0.3 %0.1 %0.2 %
     Severance costs0.2 %— %0.2 %0.1 %
Total operating expenses92.1 %94.2 %101.4 %94.6 %
INCOME FROM OPERATIONS8.0 %5.8 %1.9 %5.4 %
OTHER INCOME AND EXPENSES    
     Interest expense3.8 %4.1 %4.4 %4.3 %
     Equity in earnings of joint ventures(0.8)%(0.7)%(0.7)%(0.7)%
     Non-cash change in fair value of interest rate hedge0.2 %— %0.6 %— %
     Other (income) expenses— %— %— %0.1 %
Total other expenses3.2 %3.4 %4.3 %3.7 %
INCOME (LOSS) BEFORE INCOME TAXES4.8 %2.4 %(2.3)%1.7 %
     (Provision for) benefit from income taxes(1.3)%(0.6)%0.7 %(0.4)%
NET INCOME (LOSS)3.5 %1.7 %-1.7 %1.3 %
     Net income attributable to noncontrolling interests1.4 %0.6 %1.1 %0.7 %
NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS2.1 %1.1 %(2.6)%0.5 %

We have developed our medical imaging business through a combination of organic growth, equity investments, acquisitions and joint venture formations. We have segregated some of our information to demonstrate which is attributable to centers that were in operation through the entirety of the comparison period, and which is attributable to those that were acquired or disposed of during the period. The discussion below shows a breakdown and analysis of revenue and expenses for the three and nine months ended September 30, 2020 and 2019 for our operations at a total company and same center level.
Three Months Ended September 30, 2020 Compared to the Three Months Ended September 30, 2019
Total Revenue inclusive of Provider Relief funding for 2020
36

In ThousandsThree Months Ended September 30,
Revenue20202019$ Increase/(Decrease)% Change
Total Revenue$291,997$292,692$(695)(0.2)%
Same Center Revenue$288,919$288,700$2190.1%
Our nationwide operations were affected by the COVID-19 pandemic starting mid March 2020 and has resulted in an approximate 5% decrease in same center procedural volumes compared to the same period last year. Same Center Revenue however remained flat due to a 14% rise in revenue under capitation arrangements stemming from a combination of rate increases, plan membership growth and higher copays. This comparison excludes revenue contributions from centers that were acquired or divested subsequent to July 1, 2019. For the three months ended September 30, 2020, net service fee revenue from centers that were acquired or divested subsequent to July 1, 2019 and excluded from the above comparison was $3.1 million. For the three months ended September 30, 2019, net service fee revenue from centers that were acquired or divested subsequent to July 1, 2019 and excluded from the above comparison was $4.0 million.

Operating Expenses

Total operating expenses for the three months ended September 30, 2020 decreased approximately $7.2 million, or 2.6%, from $275.8 million for the three months ended September 30, 2019 to $268.6 million for the three months ended September 30, 2020. The following table sets forth a breakdown of our cost of operations and total operating expenses for the three months ended September 30, 2020 and 2019 (in thousands): 
 Three Months Ended
September 30,
 20202019
Salaries and professional reading fees, excluding stock-based compensation$149,970 $160,757 
Stock-based compensation2,067 1,381 
Building and equipment rental26,703 26,850 
Medical supplies12,498 12,313 
Other operating expenses *
55,225 53,082 
Cost of operations246,463 254,383 
Depreciation and amortization21,247 20,490 
(Gain) loss on sale and disposal of equipment342 917 
Severance costs571 52 
Total operating expenses$268,623 $275,842 
    *Includes billing fees, office supplies, repairs and maintenance, insurance, business tax and license, outside services, telecom, utilities, marketing, travel and other expenses.
Salaries and professional reading fees, excluding stock-based compensation and severance
In ThousandsThree Months Ended September 30,
Salaries and Professional Fees20202019$ Increase/(Decrease)% Change
Total Salaries$149,970$160,757$(10,787)(6.7)%
Same Center Salaries$146,698$158,270$(11,572)(7.3)%

The decrease in salaries expense was a result of staff furloughs and salary reductions initiated in response to the COVID-19 pandemic. During this time, we have reengineered our workflow to improve efficiency and make workforce adjustments as necessary resulting in reductions to payroll overall. This comparison excludes expenses from centers that were acquired or divested subsequent to July 1, 2019. For the three months ended September 30, 2020, salaries and professional reading fees from centers that were acquired or divested subsequent to July 1, 2019 and excluded from the above comparison was $3.3 million. For the three months ended September 30, 2019, salaries and professional reading fees from centers that were acquired or divested subsequent to July 1, 2019 and excluded from the above comparison was approximately $2.5 million.
37

Stock-based compensation

Stock-based compensation increased $0.7 million, or 49.7% to approximately $2.1 million for the three months ended September 30, 2020 compared to $1.4 million for three months ended September 30, 2019. This increase was driven by the higher fair value of RSA’s awarded and vested in the third quarter of 2020 as compared to RSA’s awarded and vested in the prior year’s third quarter.
Building and equipment rental
In ThousandsThree Months Ended September 30,
Building & Equipment Rental20202019$ Increase/(Decrease)% Change
Total$26,703$26,850$(147)(0.6)%
Same Center $25,839$25,968$(129)(0.5)%

This comparison excludes expenses from centers that were acquired or divested subsequent to July 1, 2019. For the three months ended September 30, 2020, building and equipment rental expenses from centers that were acquired or divested subsequent to July 1, 2019 and excluded from the above comparison was $0.9 million. For the three months ended September 30, 2019, building and equipment rental expenses from centers that were acquired or divested subsequent to July 1, 2019 and excluded from the above comparison was approximately $0.9 million.
Medical supplies
In ThousandsThree Months Ended September 30,
Medical Supplies Expense20202019$ Increase/(Decrease)% Change
Total$12,498$12,313$1851.5%
Same Center$12,374$12,143$2311.9%

Medical supplies expense remained essentially flat compared to the same period in the prior year, with the nominal increase related to securing personal protective equipment for center staff. This comparison excludes expenses from centers that were acquired or divested subsequent to July 1, 2019. For the three months ended September 30, 2020, medical supplies expenses from centers that were acquired or divested subsequent to July 1, 2019 and excluded from the above comparison was $0.1 million. For the three months ended September 30, 2019, medical supplies expense from centers that were acquired or divested subsequent to July 1, 2019 and excluded from the above comparison was $0.2 million.
Other operating expenses
In ThousandsThree Months Ended September 30,
Other Operating Expenses20202019$ Increase/(Decrease)% Change
Total$55,225$53,082$2,1424.0%
Same Center$54,053$52,165$1,8883.6%

The rise in other operating expenses resulted from seasonal utilities usage and outside services, offset by reductions in insurance charges and other expenses. This comparison excludes expenses from centers that were acquired or divested subsequent to July 1, 2019. For the three months ended September 30, 2020, other operating expense from centers that were acquired or divested subsequent July 1, 2019 and excluded from the above comparison was $1.2 million. For the three months ended September 30, 2019, other operating expense from centers that were acquired or divested subsequent to July 1, 2019 was $0.9 million.
Depreciation and amortization
In ThousandsThree Months Ended September 30,
Depreciation & Amortization20202019$ Increase/(Decrease)% Change
Total$21,247$20,490$7583.7%
Same Center$20,505$19,912$5933.0%
38


The increase in same center depreciation and amortization is primarily due to additional equipment and leasehold improvements placed in service in the third quarter in 2020 over the third quarter in 2019. This comparison excludes expenses from centers that were acquired or divested subsequent to July 1, 2019. For the three months ended September 30, 2020, depreciation expense from centers that were acquired or divested subsequent to July 1, 2019 and excluded from the above comparison was $0.7 million. For the three months ended September 30, 2019, depreciation and amortization from centers that were acquired or divested subsequent to July 1, 2019 and excluded from the above comparison was $0.6 million.
Loss on sale and disposal of equipment and other

We recorded losses on the disposal of equipment and other items of approximately $0.3 million for the three months ended September 30, 2020 and approximately $0.9 million for the three months ended September 30, 2019.
Non-cash change in fair value of interest rate hedge

We recorded expense of $0.7 million for the ineffective portion of our 2019 Swaps for the three months ended September 30, 2020.
Other (income) expenses

We recorded other income of approximately $0.1 million for the three months ended September 30, 2020 and other expenses of approximately $0.0 million for the three months ended September 30, 2019 related to refinancing of our term loan debt and legal contingency charges.
Severance Costs

We incurred severance expenses of $0.6 million for the three months ended September 30, 2020 and $0.1 million for the three months ended September 30, 2019.
Interest expense
In ThousandsThree Months Ended September 30,
Interest Expense20202019$ Increase/(Decrease)% Change
Total Interest Expense$11,061$11,895
Interest related to derivatives*$1,603$(288)
Interest payable on debt obligations**$9,458$12,183$(2,725)(22.4)%
Interest related to amortization***$1,103$1,081
Adjusted Interest Expense$8,355$11,102$(2,747)(24.7)%
* Includes interest on 2016 caps and 2019 swaps not related to debt obligations.
** Includes interest related to on our term loans, revolving credit line, notes, finance leases, and other
***Includes combined noncash amortization of deferred loan costs and discount on issuance of debt.

Excluding interest expense for derivatives and amortization for the three months ended September 30, 2020 compared to the three months ended September 30, 2019, interest expense decreased $2.7 million, or 24.7%. The reduction in interest expense corresponds to lowered variable LIBOR and Prime interest rates paid on our term loan and revolving debt in reaction to market conditions surrounding COVID-19. See “Liquidity and Capital Resources” below for more details on our credit facilities.
Equity in earnings from unconsolidated joint ventures

For the three months ended September 30, 2020 we recognized equity in earnings from unconsolidated joint ventures in the amount of $2.3 million and for three months ended September 30, 2019 we recognized equity in earnings from unconsolidated joint ventures of $2.0 million, an increase of $0.3 million or 16.4% and was related to improved procedure volumes specifically at our joint venture sites located within hospital campuses.
Income tax provision
39

We recorded an income tax provision of $3.8 million, or an effective tax rate of 27.2%, for the three months ended September 30, 2020 compared to an income tax provision of $1.8 million, or an effective tax rate of 26.3% for the three months ended September 30, 2019. The income tax rates for the three and nine months ended September 30, 2020 diverge from the federal statutory rate due to (i) noncontrolling interests due to the controlled partnerships; (ii) effects of state income taxes; and (iii) excess tax benefits attributable to share-based compensation.
Nine Months Ended September 30, 2020 Compared to the Nine Months Ended September 30, 2019
Total Revenue inclusive of Provider Relief funding for 2020
In ThousandsNine Months Ended September 30, 2020
Revenue20202019$ Increase/(Decrease)% Change
Total Revenue$789,601$853,338$(63,737)(7.5)%
Same Center Revenue$750,358$817,492$(67,134)(8.2)%
Our procedure volumes were affected by the COVID-19 pandemic, which has precipitated an approximate 17% decrease in same center procedural volumes year over year. Mitigating the income decline is $25.7 million received in Provider Relief funding, which, per the official designation of the program, was used to offset lost revenues. This comparison excludes revenue contributions from centers that were acquired or divested subsequent to January 1, 2019. For the nine months ended September 30, 2020, net service fee revenue from centers that were acquired or divested subsequent to January 1, 2019 and excluded from the above comparison was $39.2 million. For the nine months ended September 30, 2019, net service fee revenue from centers that were acquired or divested subsequent to January 1, 2019 and excluded from the above comparison was $35.8 million.

Operating Expenses

Total operating expenses for the nine months ended September 30, 2020 decreased approximately $32.4 million, or 4.0%, from $807.2 million for the nine months ended September 30, 2020 to $774.8 million for the nine months ended September 30, 2019. The following table sets forth a breakdown of our cost of operations and total operating expenses for the nine months ended September 30, 2020 and 2019 (in thousands): 
 Nine Months Ended September 30, 2020
 20202019
Salaries and professional reading fees, excluding stock-based compensation$429,292 $471,792 
Stock-based compensation10,144 6,964 
Building and equipment rental80,148 79,017 
Medical supplies33,812 33,713 
Other operating expenses *
154,700 152,512 
Cost of operations708,096 743,998 
Depreciation and amortization64,536 60,193 
Loss on sale and disposal of equipment543 1,990 
Severance costs1,647 1,054 
Total operating expenses$774,822 $807,235 
    *Includes billing fees, office supplies, repairs and maintenance, insurance, business tax and license, outside services, telecom, utilities, marketing, travel and other expenses.
Salaries and professional reading fees, excluding stock-based compensation and severance
40

In ThousandsNine Months Ended September 30, 2020
Salaries and Professional Fees20202019$ Increase/(Decrease)% Change
Total Salaries$429,292$471,792$(42,501)(9.0)%
Same Center Salaries$409,010$451,738$(42,728)(9.5)%

The decrease in salaries expense was a result of staff furloughs and salary reductions initiated in response to the COVID-19 crisis. As noted in our quarterly explanation above, our review of operational workflows has provided greater efficiencies and resulted in payroll reductions. Additionally certain of our subsidiaries have accepted approximately $4.0 million in loans from the Paycheck Protection Program (PPP) and the funds were used to pay program approved payroll expenses to both maintain and rehire furloughed employees. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2019. For the nine months ended September 30, 2020, salaries and professional reading fees from centers that were acquired or divested subsequent to January 1, 2019 and excluded from the above comparison was $20.3 million. For the nine months ended September 30, 2019, salaries and professional reading fees from centers that were acquired or divested subsequent to January 1, 2019 and excluded from the above comparison was approximately $20.1 million.
Stock-based compensation

Stock-based compensation increased $3.2 million, or 45.7% to approximately $10.1 million for the nine months ended September 30, 2020 compared to $7.0 million for nine months ended September 30, 2019. This increase was driven by the higher fair value of RSA’s awarded and vested in the nine months of 2020 as compared to RSA’s awarded and vested in the prior year’s same period.
Building and equipment rental
In ThousandsNine Months Ended September 30, 2020
Building & Equipment Rental20202019$ Increase/(Decrease)% Change
Total$80,148$79,017$1,1311.4%
Same Center $74,705$74,485$2190.3%

This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2019. For the nine months ended September 30, 2020, building and equipment rental expenses from centers that were acquired or divested subsequent to January 1, 2019 and excluded from the above comparison was $5.4 million. For the nine months ended September 30, 2019, building and equipment rental expenses from centers that were acquired or divested subsequent to January 1, 2019 and excluded from the above comparison was approximately $4.5 million.
Medical supplies
In ThousandsNine Months Ended September 30, 2020
Medical Supplies Expense20202019$ Increase/(Decrease)% Change
Total$33,812$33,713$990.3%
Same Center$31,155$30,971$1840.6%

Year over year medical supplies expense remained relatively flat due to varying factors. The first quarter noted a 21% same store increase stemming from securing personal protective equipment and procurement of specialized imaging agents, while in the second quarter, a 25% same store expense reduction was correlated to lower procedural volumes. In the third quarter we consumed medical supplies ordered in prior periods to meet patient demands. The cumulative effect of these factors has resulted in the year over year stability of medical supplies expense. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2019. For the nine months ended September 30, 2020, medical supplies expenses from centers that were acquired or divested subsequent to April 1, 2018 and excluded from the above comparison was $2.7 million. For the nine months ended September 30, 2019, medical supplies expense from centers that were acquired or divested subsequent to January 1, 2019 and excluded from the above comparison was $2.7 million.
Other operating expenses
41

In ThousandsNine Months Ended September 30, 2020
Other Operating Expenses20202019$ Increase/(Decrease)% Change
Total$154,700$152,512$2,1881.4%
Same Center$148,358$146,397$1,9621.3%

This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2019. For the nine months ended September 30, 2020, other operating expense from centers that were acquired or divested subsequent January 1, 2019 and excluded from the above comparison was $6.3 million. For the nine months ended September 30, 2019, other operating expense from centers that were acquired or divested subsequent to January 1, 2019 was $6.1 million.
Depreciation and amortization
In ThousandsNine Months Ended September 30, 2020
Depreciation & Amortization20202019$ Increase/(Decrease)% Change
Total$64,536$60,193$4,3437.2%
Same Center$60,923$57,086$3,8376.7%

The increase in same center depreciation and amortization is primarily due to additional equipment and leasehold improvements placed in service in the nine months of 2020 over the same period in 2019. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2019. For the nine months ended September 30, 2020, depreciation expense from centers that were acquired or divested subsequent to January 1, 2019 and excluded from the above comparison was $3.6 million. For the nine months ended September 30, 2019, depreciation and amortization from centers that were acquired or divested subsequent to January 1, 2019 and excluded from the above comparison was $3.1 million.
Loss on sale and disposal of equipment and other

We recorded losses on the disposal of equipment and other items of approximately $0.5 million for the nine months ended September 30, 2020 and approximately $2.0 million for the nine months ended September 30, 2019.

Non-cash change in fair value of interest rate hedge

We recorded expense of $4.5 million for the ineffective portion of our 2019 Swaps for the nine months ended September 30, 2020.
Other (income) expenses

We recorded other income of approximately $0.2 million for the nine months ended September 30, 2020 and other expenses of approximately $1.3 million for the nine months ended September 30, 2019 related to refinancing of our term loan debt and legal contingency charges.
Severance Costs

We incurred severance expenses of $1.6 million for the nine months ended September 30, 2020 and $1.1 million for the nine months ended September 30, 2019.
42

Interest expense
In ThousandsNine Months Ended September 30, 2020
Interest Expense20202019$ Increase/(Decrease)% Change
Total Interest Expense$33,443$36,589
Interest related to derivatives*$3,152$(1,182)
Interest payable on debt obligations**$30,291$37,771$(7,480)(19.8)%
Interest related to amortization***$3,266$3,103
Adjusted Interest Expense$27,025$34,668$(7,643)(22.0)%
* Includes interest on 2016 caps and 2019 swaps not related to debt obligations.
** Includes interest related to our term loans, revolving credit line, notes, finance leases, and other
***Includes combined noncash amortization of deferred loan costs and discount on issuance of debt.

Excluding interest expense for derivatives and amortization for the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019, interest expense decreased $7.6 million, or 22.0%. The reduction in interest expense corresponds to lowered variable LIBOR and Prime interest rates paid on our term loan and revolving debt in reaction to market conditions surrounding COVID-19. See “Liquidity and Capital Resources” below for more details on our credit facilities.
Equity in earnings from unconsolidated joint ventures

For the nine months ended September 30, 2020 we recognized equity in earnings from unconsolidated joint ventures in the amount of $5.2 million and for nine months ended September 30, 2019 we recognized equity in earnings from unconsolidated joint ventures of $6.1 million, an decrease of $0.9 million or 14.8%, related to market conditions stemming from the COVID-19 pandemic.
Income tax benefit
We recorded an income tax benefit of $5.0 million, or an effective tax rate of 28.3%, for the nine months ended September 30, 2020 compared to an income tax provision of $3.6 million , or an effective tax rate of 24.8% for the nine months ended September 30, 2019. The income tax rates for the three and nine months ended September 30, 2020 diverge from the federal statutory rate due to (i) noncontrolling interests due to the controlled partnerships; (ii) effects of state income taxes; and (iii) excess tax benefits attributable to share-based compensation.
Adjusted EBITDA
We use both GAAP and non-GAAP metrics to measure our financial results. We believe that, in addition to GAAP metrics, these non-GAAP metrics assist us in measuring our cash generated from operations and ability to service our debt obligations. We believe this information is useful to investors and other interested parties because we are highly leveraged and our non-GAAP metrics remove non-cash and certain other charges that occur in the affected period and provide a basis for measuring the Company's financial condition against other quarters.
One non-GAAP measure we believe assists us is Adjusted EBITDA. We define Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and excluding losses or gains on the disposal of equipment, other income or loss, loss on debt extinguishment, bargain purchase gains and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to noncontrolling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taking place during the period. We have not made specific adjustments to our calculation of Adjusted EBITDA in response to COVID 19. Our net income reflected below includes the effect of the $25 million in other revenue received under the Provider Relief Fund. We have treated the PPP loans as debt, and accordingly will be liable for an interest charge related to those loans which will be included in interest expense, although the loans may ultimately be forgiven.
Adjusted EBITDA is a non-GAAP financial measure used as an analytical indicator by us and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or
43

other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.
Adjusted EBITDA is most comparable to the GAAP financial measure, net income (loss) attributable to RadNet, Inc. common stockholders. The following is a reconciliation of GAAP net income (loss) attributable to RadNet, Inc. common stockholders to Adjusted EBITDA for the three and nine months ended September 30, 2020 and 2019, respectively.
 Three Months Ended September 30,Nine Months Ended September 30,
 2020201920202019
Net income (loss) attributable to RadNet, Inc. common stockholders$6,156 $3,195 $(20,797)$4,360 
Provision for (benefit from) income taxes3,825 1,816 (5,029)3,557 
Interest expense11,061 11,895 33,443 36,589 
Severance costs571 52 1,647 1,054 
Depreciation and amortization21,247 20,490 64,536 60,193 
Non-cash employee stock-based compensation2,067 1,381 10,144 6,964 
Loss on sale and disposal of equipment and other342 917 543 1,989 
Non-cash change in fair value of interest rate hedge679 — 4,523 — 
Other expenses(139)(247)1,271 
Legal settlements— 1,248 — 1,248 
Adjusted EBITDA$45,809 $40,996 $88,763 $117,225 

Liquidity and Capital Resources
The following table is a summary of key balance sheet data as of September 30, 2020 and December 31, 2019 and income statement data for the nine months ended September 30, 2020 and 2019 (in thousands):
Balance Sheet Data:September 30, 2020December 31, 2019
Cash and cash equivalents$89,739 $40,165 
Accounts receivable137,411 154,763 
Working capital (exclusive of current operating lease liabilities)(47,282)(25,048)
Stockholders' equity246,121 233,139 
Income statement data for the nine months ended September 30,20202019
Total net revenue$763,905 $853,338 
Net (loss) income attributable to RadNet common stockholders(20,797)4,360 
We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations. In addition to operations, we require a significant amount of capital for the initial start-up and development of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment. Because our cash flows from operations have been insufficient to fund all of these capital requirements, we have depended on the availability of financing under credit arrangements with third parties.
As noted in our forward looking statements, the COVID 19 pandemic has resulted in a reduction of procedure volumes and corresponding operating revenues. We are uncertain of the duration and ultimate severity of its effects. Although we are undertaking measures to reduce operating expenses and have received government stimulus funding, we may continue to experience operating losses. We have credit available from our current credit facilities and borrowing under those facilities is subject to continued compliance with lending covenants. We currently meet those requirements, but substantial and sustained operating losses could impact our ability to borrow under those facilities. If we are not able to meet such requirements, we may
44

be required to seek additional financing and there can be no assurance that we will be able to obtain financing from other sources on terms acceptable to us, if at all.
On a continuing basis, we also consider various transactions to increase shareholder value and enhance our business results, including acquisitions, divestitures and joint ventures. These types of transactions may result in future cash proceeds or payments but the general timing, size or success of any acquisition, divestiture or joint venture effort and the related potential capital commitments cannot be predicted. We expect to fund any future acquisitions primarily with cash flow from operations and borrowings, including borrowing from amounts available under our senior secured credit facilities or through new equity or debt issuances.
We and our subsidiaries or affiliates may from time to time, in our sole discretion, purchase, repay, redeem or retire any of our outstanding debt or equity securities in privately negotiated or open market transactions, by tender offer or otherwise.
Sources and Uses of Cash
The following table summarizes key components of our sources and uses of cash for the nine months ended September 30, 2020 and 2019:
Cash Flow DataSeptember 30, 2020September 30, 2019
Cash provided by operating activities$170,343 $82,603 
Cash used in investing activities(88,280)(93,981)
Cash (used in) provided by financing activities(32,495)38,705 
Cash provided by operating activities for the nine months ended September 30, 2020 was $170.3 million and $82.6 million for the nine months ended September 30, 2019. Our cash provided by operating activities was benefited by the reciept of $39.4 million in CMS advances recorded as deferred revenue.
Cash used in investing activities for the nine months ended September 30, 2020, included purchases of property and equipment for approximately $77.3 million and the acquisition of imaging and software business assets for $10.1 million.
Cash used in financing activities for the nine months ended September 30, 2020, was due to principal payments on our term loans and equipment debt obligations.

In 2018 and 2019 we entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. Payments on the associated notes receivables will be reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long term portion. At September 30, 2020 we have $20.4 million, net of discount, remaining to be collected on these agreements. We do not utilize factoring arrangements as an integral part of our financing for working capital.
Senior Secured Credit Facilities
We maintain secured credit facilities with Barclays Bank PLC and with SunTrust. The Barclays credit facilities are comprised of first lien term loans and a revolving credit facility. On August 28, 2020 we amended the Barclays credit facilities to increase the amount available under the revolving line of credit to $195.0 million. The SunTrust credit facilities are comprised of a term loan and a revolving credit facility of $30.0 million. As of September 30, 2020, we were in compliance with all covenants under our credit facilities. Deferred financing costs at September 30, 2020, net of accumulated amortization, was $1.9 million and is specifically related to our Barclays revolving credit facility.
Included in our condensed consolidated balance sheets at September 30, 2020 are $673.2 million of total term loan debt (exclusive of unamortized discounts of $10.7 million) in thousands:
45

 Face ValueDiscountTotal Carrying
Value
First Lien Term Loans$620,727 $(10,669)$610,058 
SunTrust Term Loan52,500 — 52,500 
Total Term Loans$673,227 $(10,669)$662,558 

At September 30, 2020, we had no borrowings under our Barclays or SunTrust revolving credit facilities. After reserves for outstanding letters of credit of $6.3 million on our Barclays Revolving Credit Facility, we have $188.7 million available for borrowing and $30.0 million available under our SunTrust revolving credit facility. For more information on our secured credit facilities see Note 5 to our condensed consolidated financial statements in this quarterly report.
ITEM 3.  Quantitative and Qualitative Disclosures about Market Risk
Foreign Currency Exchange Risk: We receive payment for our services exclusively in United States dollars. As a result, our financial results are unlikely to be affected by factors such as changes in foreign currency, exchange rates or weak economic conditions in foreign markets.
We maintain research and development facilities in Prince Edward Island, Canada and Budapest, Hungary for which expenses are paid in the local currency. Accordingly, we do have currency risk resulting from fluctuations between such local currency and the United States Dollar. At the present time, we do not have any foreign currency exchange contracts to mitigate this risk. At September 30, 2020, a hypothetical 1% decline in the currency exchange rates between the U.S. dollar against the Canadian dollar and the Hungarian Forint would have resulted in an annual increase of approximately $27,500 in operating expenses.
Interest Rate Sensitivity: We pay interest on various types of debt instruments to our suppliers and lending institutions. The agreements entail either fixed or variable interest rates.  Instruments which have fixed rates are mainly leases on radiology equipment. Variable rate interest obligations relate primarily to amounts borrowed under our outstanding credit facilities. Accordingly, our interest expense and consequently, our earnings, are affected by changes in short term interest rates. However due to our purchase of caps, described below, the effects of interest rate changes are limited.
At September 30, 2020, we had $620.7 million outstanding subject to an adjusted Eurodollar election on First Lien Term Loans. We can elect Eurodollar or Base Rate (Prime) interest rate options on amounts outstanding under the First Lien Term Loans. To mitigate interest rate risk sensitivity, in the fourth quarter of 2016 we entered into two forward interest rate cap agreements (the “2016 Caps”) which were designated at inception as cash flow hedges of future cash interest payments. The 2016 Caps are designed to provide a hedge against interest rate increases. Under these arrangements, we purchased a cap on 3 month LIBOR at 2.0%. At September 30, 2020, our effective 6 month LIBOR was 1.00%. A hypothetical 1% increase in the adjusted Eurodollar rates under the First Lien Credit Agreement over the current Eurodollar rate would result in an increase of $6.2 million in annual interest expense and a corresponding decrease in income before taxes. See Note 2, Significant Accounting Policies, for further information.

At September 30, 2020, we had $52.5 million outstanding subject to an adjusted Eurodollar election on the SunTrust Restated Credit Agreement. We can elect Eurodollar or Base Rate (Prime) interest rate options on amounts outstanding under the SunTrust Restated Credit Agreement. At September 30, 2020, our effective LIBOR rate plus applicable margin was 2.31%. A hypothetical 1% increase in the adjusted Eurodollar rates under the SunTrust Restated Credit Agreement would result in an increase of approximately $0.5 million in annual interest expense and a corresponding decrease in income before taxes.

In the second quarter of 2019, we entered into four forward interest rate agreements ("2019 Swaps"). The 2019 Swaps have total notional amounts of $500,000,000, consisting of two agreements of $50,000,000 each and two agreements of $200,000,000 each. The 2019 Swaps will secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They will mature in October 2023 for the smaller notional and October 2025 for the larger notional. Under these arrangements, we arranged the 2019 Swaps with locked in 1 month LIBOR rates at 1.96% for the $100,000,000 notional and at 2.05% for the $400,000,000 notional. As of the effective date, we will be liable for premium payments if interest rates decline below arranged rates, but will receive interest payments if rates remain above the arranged rates.

ITEM 4.  Controls and Procedures
46

Evaluation of Disclosure Controls and Procedures
We maintain controls and procedures designed to ensure that we are able to collect the information we are required to disclose in the reports we file with the SEC, and to process, summarize and disclose this information within the time periods specified in the rules of the SEC. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has conducted an evaluation of the design and operation of our “disclosure controls and procedures” as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective as of the end of the period covered by this report for the purposes set forth above.


Changes in Internal Control over Financial Reporting
 
There has been no change in our internal control over financial reporting during three months ended September 30, 2020 that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.
47

PART II – OTHER INFORMATION

ITEM 1.  Legal Proceedings
We are engaged from time to time in the defense of lawsuits arising out of the ordinary course and conduct of our business. We do not believe that the outcome of any of our current litigation will have a material adverse impact on our business, financial condition and results of operations. However, we could be subsequently named as a defendant in other lawsuits that could adversely affect us.

ITEM 1A.  Risk Factors
For information about the risks and uncertainties related to our business, please see the risk factors described in our annual report on Form 10-K for the year ended December 31, 2019 and our quarterly report on Form 10-Q for the quarters ended March 31 and June 30, 2020. The risks described in our Form 10-K and Form 10-Q are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

ITEM 2.  Unregistered Sales of Equity Securities and Use of Proceeds

None.


ITEM 3.  Defaults Upon Senior Securities
None.
ITEM 4.  Mine Safety Disclosures
Not applicable.
ITEM 5.  Other Information
None.
48

INDEX TO EXHIBITS
Exhibit
Number
Description
10.17
31.1
31.2
32.1
32.2
101The following financial information from RadNet, Inc.'s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 formatted in Inline XBRL (Extensible Business Reporting Language) includes: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Comprehensive Loss, (iv) the Condensed Consolidated Statements of Changes in Stockholders Equity, (v) the Condensed Consolidated Statements of Cash Flows, and (vi) Notes to the Condensed Consolidated Financial Statements.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
*    This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. 1350, and is not being filed for purposes of Section 18 of the Exchange Act and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

49

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
RADNET, INC.
(Registrant)
Date: November 9, 2020By:/s/ Howard G. Berger, M.D.
Howard G. Berger, M.D., President and Chief Executive Officer
(Principal Executive Officer)
  
  
Date: November 9, 2020By:/s/ Mark D. Stolper
Mark D. Stolper, Chief Financial Officer
(Principal Financial and Accounting Officer)

50
EX-31.1 2 q32020exhibit311.htm EX-31.1 Document

EXHIBIT 31.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Howard G. Berger, M.D., certify that:
 
1.       I have reviewed this report on Form 10-Q of RadNet, Inc.;
 
2.       Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.       Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.       The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.       The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Dated: November 9, 2020
 



 /s/    Howard G. Berger, M.D.
 Howard G. Berger, M.D.
 President, Chief Executive Officer and Chairman of the Board of Directors

EX-31.2 3 q32020exhibit312.htm EX-31.2 Document

EXHIBIT 31.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Mark D. Stolper, certify that:
 
1.       I have reviewed this report on Form 10-Q of RadNet, Inc.;
 
2.       Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.       Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.       The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
 
a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.       The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 



Dated: November 9, 2020
  
 /s/   Mark D. Stolper
 Mark D. Stolper
 Executive Vice President
 and Chief Financial Officer

EX-32.1 4 q32020exhibit321.htm EX-32.1 Document

EXHIBIT 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of RadNet, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2020, as filed with the Securities and Exchange Commission on November 9, 2020 (the “Report”), I, Howard G. Berger, M.D., Chairman of the Board of Directors and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
 
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
 
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for the periods presented in the Report.
 
 /s/    Howard G. Berger, M.D.
 Howard G. Berger, M.D.
 Chairman, President and Chief Executive Officer
 (Principal Executive Officer)
 November 9, 2020
 
A signed original of this written statement required by Section 906 has been provided to the Company and will be furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 q32020exhibit322.htm EX-32.2 Document

EXHIBIT 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of RadNet, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2020, as filed with the Securities and Exchange Commission on November 9, 2020 (the “Report”), I, Mark D. Stolper, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
 
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for the periods presented in the Report.
 
 /s/    Mark D. Stolper
 Mark D. Stolper
 Chief Financial Officer
 (Principal Financial Officer)
 November 9, 2020
 
A signed original of this written statement required by Section 906 has been provided to the Company and will be furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.SCH 6 rdnt-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - NATURE OF BUSINESS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details - Revenue) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details - Goodwill) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details - Gain on Derivative) link:presentationLink link:calculationLink link:definitionLink 2410406 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details - Fair Value Measurements) link:presentationLink link:calculationLink link:definitionLink 2411407 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details - Earnings Per Share) link:presentationLink link:calculationLink link:definitionLink 2412408 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details - Investment in Joint Ventures) link:presentationLink link:calculationLink link:definitionLink 2413409 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details - Key Financial Data on Joint Ventures) link:presentationLink link:calculationLink link:definitionLink 2114103 - Disclosure - RECENT ACCOUNTING AND REPORTING STANDARDS link:presentationLink link:calculationLink link:definitionLink 2115104 - Disclosure - FACILITY ACQUISITIONS AND DISPOSITIONS link:presentationLink link:calculationLink link:definitionLink 2416410 - Disclosure - FACILITY ACQUISITIONS AND DISPOSITIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 2117105 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 2318302 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 2419411 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Details - Schedule of debt) link:presentationLink link:calculationLink link:definitionLink 2420412 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 2421413 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Details - Term Loans) link:presentationLink link:calculationLink link:definitionLink 2422414 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Details - Margin Spread Based on Leverage Ratio) link:presentationLink link:calculationLink link:definitionLink 2423415 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Details - Margin Spread Based on Leverage Ratio, Debt Instrument) link:presentationLink link:calculationLink link:definitionLink 2124106 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2325303 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2426416 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 2427417 - Disclosure - STOCK-BASED COMPENSATION (Details-Outstanding options and warrants) link:presentationLink link:calculationLink link:definitionLink 2428418 - Disclosure - STOCK-BASED COMPENSATION (Details - RSU's) link:presentationLink link:calculationLink link:definitionLink 2129107 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 2430419 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 rdnt-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 rdnt-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 rdnt-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Total equity Beginning balance, value Ending balance, value Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Imaging On Call Imaging On Call [Member] Imaging On Call [Member] First Lien Credit Agreement Seventh Amendment First Lien Credit Agreement Seventh Amendment [Member] First Lien Credit Agreement Seventh Amendment [Member] Additional deferred finance costs on revolving loan amendment Payments of Debt Issuance Costs Pricing Level II Pricing Level II [Member] Pricing Level II [Member] INVESTMENTS IN JOINT VENTURES Investment, Policy [Policy Text Block] Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 3 [Member] Equity contributions in existing and purchase of interest in joint ventures Payments to Acquire Interest in Joint Venture And Contributions To Existing Joint Venture Payments to Acquire Interest in Joint Venture And Contributions To Existing Joint Venture Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Total credit facilities outstanding Long-term Line of Credit LEASES Lessee, Leases [Policy Text Block] Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Total current liabilities Liabilities, Current Goodwill [Line Items] Goodwill [Line Items] Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Roll Forward] Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Roll Forward] Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Indefinite-lived intangible assets Indefinite-lived Intangible Assets (Excluding Goodwill) Variable Interest Entity, Classification [Domain] Variable Interest Entity, Classification [Domain] Goodwill acquired through acquisitions Goodwill, Acquired During Period Current portion of notes payable Notes Payable, Current Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Other assets Increase (Decrease) in Other Noncurrent Assets Other current assets Increase (Decrease) in Other Current Assets Payments on revolving credit facility Repayments of Lines of Credit RSA's granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Initial ownership percentage after dilution Equity Method Investment, Initial Ownership Percentage After Dilution Equity Method Investment, Initial Ownership Percentage After Dilution RECENT ACCOUNTING AND REPORTING STANDARDS New Accounting Pronouncements, Policy [Policy Text Block] RSA's vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Current Fiscal Year End Date Current Fiscal Year End Date Total service revenue Revenues Diluted (in shares) Weighted average number of common shares used in calculating diluted net income per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Entity Address, Postal Zip Code Entity Address, Postal Zip Code Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Fixed assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Credit Derivatives Contract Type [Domain] Credit Derivatives Contract Type [Domain] Options outstanding (in shares) Begining Balance (in shares) Ending Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Beverly Radiology Medical Group III Beverly Radiology Medical Group III [Member] Beverly Radiology Medical Group III [Member] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Property and equipment, net Property, Plant and Equipment, Net Medium-term Notes Medium-term Notes [Member] EQUITY INVESTMENTS AT FAIR VALUE Equity Method Investments [Policy Text Block] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Total assets BRMG and NY Groups accounts receivable Assets Entity Shell Company Entity Shell Company Cover [Abstract] Cover [Abstract] Document Type Document Type Operating lease liability Increase Decrease in Operating Lease Liability Increase Decrease in Operating Lease Liability Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Subsequent Event Subsequent Event [Member] Variable Rate [Domain] Variable Rate [Domain] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Term Loan Term Loan [Member] Variable interest entity, ownership percentage Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Restricted Stock Restricted Stock [Member] Accounts receivable Increase (Decrease) in Accounts Receivable CURRENT LIABILITIES Liabilities, Current [Abstract] Credit Facility [Axis] Credit Facility [Axis] Current finance lease liability Finance Lease, Liability, Current Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Medicaid Medicaid1 [Member] Medicaid1 [Member] Number of forward interest rate cap agreements Derivative Asset, Number of Instruments Held Due to affiliates Due to Affiliate, Current Olney Open MRI, LLC Olney Open MRI, LLC [Member] Olney Open MRI, LLC [Member] Business Combination, Separately Recognized Transactions [Domain] Business Combination, Separately Recognized Transactions [Domain] DeepHealth, Inc. DeepHealth, Inc. [Member] DeepHealth, Inc. [Member] SunTrust Term Loan Agreement collateralized by NJIN's tangible and intangible assets Restated Agreement Restated Agreement [Member] Restated Agreement [Member] Discounts on First Lien Term Loans Discounts on term loans Debt Instrument, Unamortized Discount EFFECT OF EXCHANGE RATE CHANGES ON CASH Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Options cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Line of credit facility, remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Change in fair value of cash flow hedge, net of taxes Change in fair value of cash flow hedge, net of taxes Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Document Quarterly Report Document Quarterly Report Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] CASH AND CASH EQUIVALENTS, beginning of period CASH AND CASH EQUIVALENTS, end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Debt Instrument [Line Items] Debt Instrument [Line Items] Aggregate cost Total net assets Equity Method Investment, Aggregate Cost Disposal Group Classification [Axis] Disposal Group Classification [Axis] Exercisable shares (in shares) Exercisable at the end (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Option to purchase additional equity method investment Equity Method Investments, Option To Purchase Additional Equity Method Investment Equity Method Investments, Option To Purchase Additional Equity Method Investment Total Radnet, Inc.'s Equity Total Radnet, Inc.'s Equity [Member] Monthly amortization of deferred hedge gains Monthly Amortization Of Deferred Hedge Gains Monthly Amortization Of Deferred Hedge Gains > 4.00x but ≤ 5.50x Leverage Ratio Two [Member] Leverage Ratio Two [Member] AZ Tech Radiology & Open MRI, LLC AZ Tech [Member] AZ Tech Radiology & Open MRI, LLC [Member] Periodic payment amortization increase Debt Instrument, Periodic Payment Terms, Amortization Increase Debt Instrument, Periodic Payment Terms, Amortization Increase Entity File Number Entity File Number Share-based payment award, award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 2019 SWAPS 2019 SWAPS [Member] 2019 SWAPS [Member] Current assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets Leverage Ratio [Axis] Leverage Ratio [Axis] Leverage Ratio [Axis] Ventura County Imaging Group, LLC Ventura County Imaging Group, LLC [Member] Ventura County Imaging Group, LLC [Member] Document Fiscal Period Focus Document Fiscal Period Focus Issuance of common stock under the equity compensation plan Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture OTHER ASSETS Other Assets [Abstract] Santa Monica Imaging Group, LLC Santa Monica Imaging Group, LLC [Member] Santa Monica Imaging Group, LLC Goodwill [Roll Forward] Goodwill [Roll Forward] Product and Service [Domain] Product and Service [Domain] Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Weighted-average fair value, vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Promissory Note Commercial Paper [Member] Non-cash change in fair value of interest rate hedge Unrealized Gain (Loss) on Derivatives INCOME FROM OPERATIONS Operating Income (Loss) Long term portion debt obligations Long-term Debt, Short-term Debt and Capital Lease Obligations, Excluding Current Maturities Long-term Debt, Short-term Debt and Capital Lease Obligations, Excluding Current Maturities Other Comprehensive Income Location [Domain] Other Comprehensive Income Location [Domain] Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill acquired Goodwill Asset Acquisition [Axis] Asset Acquisition [Axis] Asset Acquisition [Axis] Statement [Line Items] Statement [Line Items] Total service revenue Service fee revenue, net of contractual allowances and discounts Revenue from Contract with Customer, Excluding Assessed Tax Fair value of shares issued after execution Business Acquisition, Equity Interest Issued or Issuable, Fair Value Of Shares Issued After Execution Business Acquisition, Equity Interest Issued or Issuable, Fair Value Of Shares Issued After Execution Balance Sheet Data: Key financial data for joint ventures Key financial data for joint ventures BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS (in dollars per share) Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders (in dollars per share) Earnings Per Share, Basic Begining Balance (in dollars per share) Ending Balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Turner Imaging Turner Imaging [Member] EARNINGS PER SHARE Earnings Per Share, Policy [Policy Text Block] COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS Comprehensive Income (Loss), Net of Tax, Attributable to Parent Contracts receivable, factoring receivable Contracts Receivable, Factoring Receivable Contracts Receivable, Factoring Receivable Plan Name [Axis] Plan Name [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] BRMG and NY Groups operating expenses Variable Interest Entity, Measure of Activity, Expense Issuance of common stock for purchase of Nulogix (in shares) Stock Issued During Period, Shares, Issued for Return of Capital Stock Issued During Period, Shares, Issued for Return of Capital Exercisable at the end Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Amendment Flag Amendment Flag October 2023 October 2023 [Member] October 2023 [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] INCOME (LOSS) BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Common stock - shares outstanding (in shares) Common Stock, Shares, Outstanding Fair Value, Inputs, Level 1 Fair Value, Inputs, Level 1 [Member] Unrecognized stock-based compensation expense Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Shares issued after execution (in shares) Business Acquisition, Equity Interest Issued or Issuable, Maximum Number of Shares Issued After Execution Business Acquisition, Equity Interest Issued or Issuable, Maximum Number of Shares Issued After Execution Plan Name [Domain] Plan Name [Domain] Equity and Interest Expense Interest Expense [Member] ScriptSender LLC ScriptSender LLC [Member] Future Service Future Service [Member] Future Services [Member] Issuance of common stock for purchase of Nulogix Stock Issued During Period, Value, Issued for Return of Capital Stock Issued During Period, Value, Issued for Return of Capital Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Equity in earnings of joint ventures Equity in earnings in these joint ventures Income (Loss) from Equity Method Investments Local Phone Number Local Phone Number Fair value of replacement awards attributable to pre-combination Business Acquisition, Equity Interest Issued or Issuable, Fair Value Of Replacement Awards Business Acquisition, Equity Interest Issued or Issuable, Fair Value Of Replacement Awards Other Health Care, Other [Member] Pricing Level III Pricing Level III [Member] Pricing Level III [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Amortization of cash flow hedge Amortization of Deferred Hedge Gains Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Line of credit facility, increase borrowing capacity Line of Credit Facility, Increase Borrowing Capacity Line of Credit Facility, Increase Borrowing Capacity Total other expenses Nonoperating Income (Expense) Additional paid-in-capital Additional Paid in Capital Schedule of leverage ratio Schedule Of Leverage Ratio [Table Text Block] Schedule Of Leverage Ratio [Table Text Block] Prepaid expenses and other current assets Advance for future software subscription fees Prepaid Expense and Other Assets, Current Issuance of common stock upon exercise of options (in shares) Options granted (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Options exercised (in shares) Options exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Business Combination, Separately Recognized Transactions [Axis] Business Combination, Separately Recognized Transactions [Axis] Less comprehensive income attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Fair value of shares issued at execution Business Acquisition, Equity Interest Issued or Issuable, Fair Value Of Shares Issued At Execution Business Acquisition, Equity Interest Issued or Issuable, Fair Value Of Shares Issued At Execution Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] DERIVATIVE INSTRUMENTS Derivatives, Policy [Policy Text Block] Letters of credit outstanding Letters of Credit Outstanding, Amount Total current assets Assets, Current Entity Current Reporting Current Entity Current Reporting Status Intangible assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles New Accounting Pronouncements and Changes in Accounting Principles [Abstract] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] NET INCREASE IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Equity in earnings of joint ventures Income (Loss) from Equity Method Investments, Net of Dividends or Distributions LONG-TERM LIABILITIES Liabilities, Noncurrent [Abstract] Net income Equity Method Investment, Summarized Financial Information, Net Income (Loss) Teleradiology and Software revenue Teleradiology and Software [Member] Teleradiology and Software [Member] Contingent consideration, milestone one, shares issued (in shares) Business Acquisition, Contingent Consideration Arrangements, Equity Interest Issued or Issuable, Number of Shares Business Acquisition, Contingent Consideration Arrangements, Milestone One, Equity Interest Issued or Issuable, Number of Shares NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS Net income (loss) attributable to RadNet, Inc.'s common stockholders Net Income (Loss) Attributable to Parent Common Stock Common Stock [Member] CURRENT ASSETS Assets, Current [Abstract] ACCOUNTS RECEIVABLE Receivable [Policy Text Block] Joint Venture Joint Venture [Member] Purchase of imaging facilities and other acquisitions Payments to Acquire Buildings Debt Instrument [Axis] Debt Instrument [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Amount of loss recognized in income on derivative (current period ineffective portion) Derivative, Gain (Loss) on Derivative, Net Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] NET INCOME (LOSS) NET INCOME (LOSS) Net (loss) income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Business acquisition, percentage of voting interests acquired Business Acquisition, Percentage of Voting Interests Acquired Product and Service [Axis] Product and Service [Axis] SunTrust SunTrust [Member] SunTrust [Member] Entity Small Business Entity Small Business Equity investments at fair value Payments to Acquire Investments Entity Filer Category Entity Filer Category Leverage Ratio [Domain] Leverage Ratio [Domain] [Domain] for Leverage Ratio [Axis] Letter of Credit Letter of Credit [Member] ≤ 3.50x Leverage Ratio Four [Member] Leverage Ratio Four [Member] 2019 swaps - Interest Rate Contracts Interest Rate Swap [Member] Total liabilities and equity Liabilities and Equity Amortization of deferred issuance costs Amortization of Deferred Charges Issuance of common stock for purchase of membership interest in HVRA (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Entity Address, City or Town Entity Address, City or Town Securities Financing Transaction [Axis] Securities Financing Transaction [Axis] Glendale Advanced Imaging Glendale Advanced Imaging [Member] Awards issued to date (in shares) Awards issued to date Awards issued to date Convertible promissory note Short-term Debt Long-term operating lease liability Operating Lease, Liability, Noncurrent Variable Interest Entities [Axis] Variable Interest Entities [Axis] OPERATING EXPENSES Operating Expenses [Abstract] Shares available for future issuance, options, warrants, shares of restricted stock and other bonus awards (in shares) Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Weighted Average Remaining Contractual Life Weighted Average Remaining Contractual Life Weighted Average Remaining Contractual Life abstract Forfeiture of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Simi Valley Hospital and Health Services Simi Valley Hospital and Health Services [Member] Simi Valley Hospital and Health Services EQUITY Stockholders' Equity Attributable to Parent [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Offsetting Assets [Line Items] Offsetting Assets [Line Items] Options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule of fair value of assets and liabilities Fair Value, by Balance Sheet Grouping [Table Text Block] SUBSEQUENT EVENTS Subsequent Events [Text Block] REVENUE Revenues [Abstract] Proceeds from sale of noncontrolling interest Proceeds from Sales of Business, Affiliate and Productive Assets Schedule of notes payable, line of credit and capital lease obligations Schedule of Debt [Table Text Block] Severance costs Severance Costs Board Member Board Member [Member] Board Member [Member] 2016 Caps 2016 Caps [Member] Award Type [Axis] Award Type [Axis] Other (income) expenses Other Nonoperating Income (Expense) Subsequent Events [Abstract] Subsequent Events [Abstract] Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Axis] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Weighted-Average Remaining Contractual Term (Years) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax OTHER INCOME AND EXPENSES Other Expenses [Abstract] Line of Credit Facility [Table] Line of Credit Facility [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accumulated Deficit Retained Earnings [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Amortization of deferred financing costs and loan discount Amortization of Debt Issuance Costs Subsequent Event [Line Items] Subsequent Event [Line Items] Document Period End Date Document Period End Date WEIGHTED AVERAGE SHARES OUTSTANDING Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Statement [Table] Statement [Table] 2016 caps - Interest Rate Contracts Interest Rate Cap [Member] Entity Registrant Name Entity Registrant Name Investment, Name [Domain] Investment, Name [Domain] PPE estimated useful lives Property, Plant and Equipment, Useful Life Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Aggregate Intrinsic Value Aggregate Intrinsic Value Aggregate Intrinsic Value CASH FLOWS FROM INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Securities Financing Transaction [Domain] Securities Financing Transaction [Domain] Shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Maximum Maximum [Member] Number of centers Number Of Centers Number Of Centers Schedule of RSA activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Related Party [Domain] Related Party [Domain] Proceeds from Payment Protection Program Proceeds From Government Assistance Proceeds From Government Assistance Premium liability for 2016 Caps Financial Guarantee Insurance Contracts, Unearned Premium Revenue Balance at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit) Pricing Level I Pricing Level I [Member] Pricing Level I [Member] Entity Tax Identification Number Entity Tax Identification Number Investments in and Advances to Affiliates Categorization [Domain] Investments in and Advances to Affiliates Categorization [Domain] REVENUES Revenue [Policy Text Block] Face Value Debt instrument face value Debt Instrument, Face Amount DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS (in dollars per share) Diluted net income per share attributable to RadNet, Inc.'s common stockholders (in dollars per share) Earnings Per Share, Diluted Other income (expense) Other Nonoperating Income (Expense) [Member] Equity interest issued, value assigned Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Trading Symbol Trading Symbol First Lien Term Loan First Lien Term Loan [Member] Management service fees Management service fees Management service fees. Minimum Minimum [Member] Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Nonvested restricted stock subject to service vesting Earnings Per Share, Diluted, Other Disclosures [Abstract] Nulogix return of capital Proceeds from Equity Method Investment, Distribution, Return of Capital Preferred stock issued upon conversion (in shares) Convertible Preferred Stock, Shares Issued upon Conversion Operating lease liabilities acquired Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Liabilities Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Liabilities Number of unconsolidated joint ventures Number of Unconsolidated Joint Ventures Number of Unconsolidated Joint Ventures Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax PPP loans, maturity term Debt Instrument, Term Equity Option Equity Option [Member] Legal Entity [Axis] Legal Entity [Axis] Other non-cash items included in cost of operations Increase Decrease In Other Noncash Item Increase Decrease In Other Noncash Item Statistical Measurement [Domain] Statistical Measurement [Domain] Long-term finance lease liability Finance Lease, Liability, Noncurrent Adjustments to reconcile net (loss) income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Distributions from joint ventures Proceeds from Equity Method Investment, Distribution Schedule of options activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Equipment acquired and leasehold improvements Equipment acquired and leasehold improvements Aggregate value exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Entity [Domain] Entity [Domain] Purchase of property and equipment Payments to Acquire Other Property, Plant, and Equipment Investment in joint ventures Beginning balance Ending balance Total value of Radnet joint venture interests Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures (Provision for) benefit from income taxes Income tax expense Income Tax Expense (Benefit) Provider relief funding Revenue Not from Contract with Customer STOCK-BASED COMPENSATION Share-based Payment Arrangement [Text Block] Interest Rate Contracts Accrued Liabilities, Fair Value Disclosure Issuance of common stock for acquisition Stock Issued During Period, Value, Acquisitions Barclays Barclays [Member] Barclays [Member] Non-cash change in fair value of interest rate hedge Increase (Decrease) in Fair Value of Hedged Item in Interest Rate Fair Value Hedge Other non-current liabilities Other Liabilities, Noncurrent Unusual or Infrequent Item, or Both [Axis] Unusual or Infrequent Item, or Both [Axis] Shares issued at execution (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares At Execution Business Acquisition, Equity Interest Issued or Issuable, Number of Shares At Execution City Area Code City Area Code Contribution from noncontrolling partner Contributions from noncontrolling interests Unused capacity, commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Other intangible assets Intangible Assets, Net (Excluding Goodwill) Title of 12(b) Security Title of 12(b) Security Exercisable at the end (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Related Party [Axis] Related Party [Axis] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Counterparty Name [Axis] Counterparty Name [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Distributions paid to noncontrolling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Derivative instrument, beginning balance Derivative instrument, ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance PROPERTY AND EQUIPMENT Property, Plant and Equipment, Policy [Policy Text Block] Deferred tax assets, net of current portion Deferred Income Tax Assets, Net Weighted-average fair value, granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Total Carrying Value Long-term Debt, Gross Contingent consideration, milestone three, shares issued (in shares) Business Acquisition, Contingent Consideration Arrangements, Milestone Three, Equity Interest Issued or Issuable, Number of Shares Business Acquisition, Contingent Consideration Arrangements, Milestone Three, Equity Interest Issued or Issuable, Number of Shares ASSETS Assets [Abstract] DeepHealth Inc. Deep Health Inc [Member] Deep Health, Inc. [Member] Nulogix Nulogix [Member] Nulogix Contribution from noncontrolling partner Proceeds from Contributed Capital Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Leverage ratio, greater than Debt Instrument, Covenant, Liquidity Ratio Required, Minimum Debt Instrument, Covenant, Liquidity Ratio Required, Minimum BUSINESS COMBINATION Business Combinations Policy [Policy Text Block] Discount Debt Instrument, Unamortized Discount (Premium), Net Proceeds from debt issuance, net of issuing costs Proceeds from Issuance of Debt CASH FLOWS FROM OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Total operating expenses Operating Expenses RSA's outstanding, beginning balance (in shares) RSA's outstanding, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Investment in joint ventures Equity Method Investments [Table Text Block] Medicare Medicare1 [Member] Medicare1 [Member] Cost of operations, excluding depreciation and amortization Operating Costs and Expenses Forfeiture of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Credit Derivatives Contract Type [Axis] Credit Derivatives Contract Type [Axis] First Lien Credit Agreement First Lien Credit Agreement [Member] Measurement Basis [Axis] Measurement Basis [Axis] Payments on term loan debt Repayments of Debt > 5.50x Leverage Ratio One [Member] Leverage Ratio One [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Income Statement Location [Domain] Income Statement Location [Domain] Statistical Measurement [Axis] Statistical Measurement [Axis] SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] September 2020 September 2020 [Member] Periodic payment, percent Debt Instrument, Periodic Payment, Percent Debt Instrument, Periodic Payment, Percent COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss) Note [Text Block] Accounts payable, accrued expenses and other Accounts Payable and Accrued Liabilities, Current Aggregate value outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Ownership percentage diluted Equity Method Investments, Ownership Interest Percentage Acquired Equity Method Investments, Ownership Interest Percentage Acquired COVID-19 Pandemic COVID-19 Pandemic [Member] COVID-19 Pandemic [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Shares issued after acquisition, term Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Issued After Acquisition Term Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Issued After Acquisition Term DEFERRED REVENUE Revenue from Contract with Customer [Policy Text Block] BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS Earnings Per Share, Basic [Abstract] Paycheck Protection Program loans at 1% due April 2022 Paycheck Protection Program Loans Paycheck Protection Program Loans [Member] Paycheck Protection Program Loans [Member] Workers' compensation/personal injury Workers' Compensation/Personal Injury1 [Member] Workers' Compensation/Personal Injury1 [Member] Ownership percentage Equity Method Investment, Ownership Percentage Number of PPP loans received Debt Instrument, Number of Loans Received Debt Instrument, Number of Loans Received NATURE OF BUSINESS AND BASIS OF PRESENTATION Business Description and Basis of Presentation [Text Block] Schedule of goodwill and other intangible assets Schedule of Intangible Assets and Goodwill [Table Text Block] Total debt obligations Long-term Debt, Short-term Debt and Capital Lease Obligations, Including Current Maturities Long-term Debt, Short-term Debt and Capital Lease Obligations, Including Current Maturities Investment, Name [Axis] Investment, Name [Axis] Lender Name [Axis] Lender Name [Axis] Common stock - shares authorized (in shares) Common Stock, Shares Authorized Equity contributions in existing joint ventures Equity Contributions In Joint Ventures Equity Contributions In Joint Ventures EQUITY BASED COMPENSATION Compensation Related Costs, Policy [Policy Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Central Index Key Entity Central Index Key Contingent consideration, milestone two, shares issued (in shares) Business Acquisition, Contingent Consideration Arrangements, Milestone Two, Equity Interest Issued or Issuable, Number of Shares Business Acquisition, Contingent Consideration Arrangements, Milestone Two, Equity Interest Issued or Issuable, Number of Shares RSA's unvested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Entity Emerging Growth Company Entity Emerging Growth Company Noncontrolling Interests Noncontrolling Interest [Member] Unusual or Infrequent Item, or Both [Domain] Unusual or Infrequent Item, or Both [Domain] First Lien Credit Agreement Eighth Amendment First Lien Credit Agreement Eighth Amendment [Member] First Lien Credit Agreement Eighth Amendment Stock-based compensation Share-based Payment Arrangement, Noncash Expense Current operating lease liability Operating Lease, Liability, Current Earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Management services provided to BRMG and NY Groups Variable Interest Entity, Measure of Activity, Income or Loss before Tax Proceeds from revolving credit facility Proceeds from Lines of Credit Distributions paid to noncontrolling interests Payments to Noncontrolling Interests October 2025 October 2025 [Member] October 2025 [Member] INCOME TAXES Income Tax, Policy [Policy Text Block] Credit Facility [Domain] Credit Facility [Domain] Shares issued (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Base Rate Base Rate [Member] Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] RECENT ACCOUNTING AND REPORTING STANDARDS New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Current assets Equity Method Investment, Summarized Financial Information, Current Assets Antidilutive Securities [Axis] Antidilutive Securities [Axis] Deferred revenue Increase (Decrease) in Deferred Revenue Commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Advance insurance carrier payments Proceeds Received From Insurance Proceeds Received From Insurance Medic Vision Medic Vision [Member] Effect of derivative instruments on comprehensive income Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Issuance of common stock under the equity compensation plan (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Right-of-use asset required Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Right Of Use Asset Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Right Of Use Asset CASH FLOWS FROM FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Derivative Contract [Domain] Derivative Contract [Domain] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Accounts payable, accrued expenses and other Increase (Decrease) in Accounts Payable and Accrued Liabilities Management fee revenue Health Care, Management Service [Member] Health Care, Management Service [Member] Debt Long-term Debt Equipment note payable at 4.6%, due through 2020, collateralized by medical equipment Loans Payable, Noncurrent Total book value of other joint venture partner interests Total book value of other joint venture partner interests Total book value of other joint venture partner interests Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Deposits and other Deposits Assets Total property, equipment and right-of-use assets Property Plant and Equipment Net Including Right of Use Assets Property Plant and Equipment Net Including Right of Use Assets Loss on sale and disposal of equipment and other Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Variable Interest Entity, Not Primary Beneficiary Variable Interest Entity, Not Primary Beneficiary [Member] Service fee revenue Service fee revenue Health Care, Patient Service [Member] Notional amounts Derivative Asset, Notional Amount Subsequent Event [Table] Subsequent Event [Table] Unrecognized expense weighted average period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Current liabilities Equity Method Investment, Summarized Financial Information, Current Liabilities Accounting Policies [Abstract] Accounting Policies [Abstract] Additional Paid-In Capital Additional Paid-in Capital [Member] Deferred social security taxes Social Security Tax, Employer, Deferral, CARES Act Social Security Tax, Employer, Deferral, CARES Act Issuance of common stock for acquisition (in shares) Stock Issued During Period, Shares, Acquisitions Finance lease liabilities acquired Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Finance Lease Liabilities Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Finance Lease Liabilities Fair Value Measurement [Domain] Fair Value Measurement [Domain] Interest rate, stated percentage Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Issuance of common stock upon exercise of options Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Gross, Value Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Gross, Value Entity Address, Address Line One Entity Address, Address Line One Chief Executive Officer Chief Executive Officer [Member] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Additional shares issuable upon exercise of stock options and warrants (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Business Combinations [Abstract] Business Combinations [Abstract] Number of shares purchased (in shares) Equity Method Investment, Shares Purchased Equity Method Investment, Shares Purchased Other patient revenue Health Care, Patient Service Other [Member] Health Care, Patient Service Other [Member] Restated Plan Restated Plan [Member] Amount of loss reclassified from accumulated OCI into income (prior period effective portion) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax WhiteRabbit.ai Inc. WhiteRabbit.ai Inc. [Member] WhiteRabbit.ai Inc. [Member] Entity Address, State or Province Entity Address, State or Province Income Statement Location [Axis] Income Statement Location [Axis] Leverage ratio, less than Debt Instrument, Covenant, Leverage Ratio, Maximum Debt Instrument, Covenant, Leverage Ratio, Maximum Business Acquisition [Axis] Business Acquisition [Axis] Net revenue Equity Method Investment, Summarized Financial Information, Revenue Share-based payment award, expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Purchase consideration Business Combination, Consideration Transferred GOODWILL AND INDEFINITE LIVED INTANGIBLES Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block] Number of businesses acquired Number of Businesses Acquired Proceeds from sale of equipment Proceeds from Sale of Property, Plant, and Equipment Business Acquisition [Line Items] Business Acquisition [Line Items] Amount of loss recognized in income on derivative (current period ineffective portion) Gain (Loss) on Fair Value Hedges Recognized in Earnings Principal payments on notes and leases payable Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Dignity Health Dignity Health [Member] Investments in Majority-owned Subsidiaries Investments in Majority-owned Subsidiaries [Member] Entity Interactive Data Current Entity Interactive Data Current COMMITMENTS AND CONTINGENCIES Commitments and Contingencies, Policy [Policy Text Block] Common stock - shares issued (in shares) Common Stock, Shares, Issued Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Common stock - par value (in dollars per share) Common Stock, Par or Stated Value Per Share Equipment Notes Payable Notes Payable, Other Payables [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] First Lien Term Loans and SunTrust Term Loan Debt Instrument, Fair Value Disclosure Weighted-average fair value, beginning balance (in dollars per share) Weighted-average fair value, ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Other assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Other Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Interest expense Interest Expense, Debt Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Noncurrent liabilities Equity Method Investment, Summarized Financial Information, Liabilities October 2020 October 2020 [Member] Award Type [Domain] Award Type [Domain] Deferred revenue Deferred Revenue Revolving Credit Facility Revolving Credit Facility [Member] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Leasehold Improvements Leasehold Improvements [Member] Pricing Level IV Pricing Level IV [Member] Pricing Level IV [Member] Schedule of first lien credit agreement Schedule of Long-term Debt Instruments [Table Text Block] Business acquisition, closing costs Business Acquisition, Transaction Costs Effective tax rate Effective Income Tax Rate Reconciliation, Percent Consolidated Entities [Axis] Consolidated Entities [Axis] Periodic payment, principal Debt Instrument, Periodic Payment, Principal Total liabilities BRMG and NY Groups accounts payable Liabilities Amounts returned to property and equipment Propery and equipment, net [Member] Number of assets acquired Number Of Assets Acquired Number Of Assets Acquired RECLASSIFICATION Reclassification, Policy [Policy Text Block] Common stock - $0.0001 par value, 200,000,000 shares authorized; 51,596,098 and 50,314,328 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively Common Stock, Value, Issued Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Counterparty Name [Domain] Counterparty Name [Domain] Proceeds from issuance of common stock upon exercise of options Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised Purchase of noncontrolling interests Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests FACILITY ACQUISITIONS AND DISPOSITIONS Mergers, Acquisitions and Dispositions Disclosures [Text Block] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Commercial insurance Commercial Insurance1 [Member] Commercial Insurance1 [Member] Hudson Valley Radiology Associates Hudson Valley Radiology Associates [Member] Hudson Valley Radiology Associates [Member] Investments in and Advances to Affiliates Categorization [Axis] Investments in and Advances to Affiliates Categorization [Axis] Advance medicare payments Advance Medicare Payments Advance Medicare Payments Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value CREDIT FACILITY AND NOTES PAYABLE Debt and Capital Leases Disclosures [Text Block] MRI at Woodbridge, LLC MRI at Woodbridge, LLC [Member] MRI at Woodbridge, LLC [Member] Other Stockholders' Equity, Other Basic (in shares) Weighted average number of common shares outstanding during the period (in shares) Weighted Average Number of Shares Outstanding, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Equity Components [Axis] Equity Components [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] >3.50x but ≤ 4.00x Leverage Ratio Three [Member] Leverage Ratio Three [Member] Offsetting Assets [Table] Offsetting Assets [Table] Service Fee Revenue Schedule of Principal Transactions Revenue [Table Text Block] First Lien Credit Agreement, Sixth Amendment First Lien Credit Agreement Sixth Amendment [Member] First Lien Credit Agreement Sixth Amendment [Member] Payments to acquire equity method investments Payments to Acquire Equity Method Investments Total RadNet, Inc.'s stockholders' equity Stockholders' Equity Attributable to Parent Debt discount Debt Instrument, Unamortized Discount, Current Notes payable, net of current portion Notes Payable, Noncurrent Joint venture investment and financial information Joint Venture Investment And Financial Information [Table Text Block] Joint Venture Investment And Financial Information Cost in excess of book value of acquired joint venture interests and other Equity Method Investment, Underlying Equity in Net Assets RSA's forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Payments to acquire additional interest in subsidiaries Payments to Acquire Interest in Joint Venture Less: current portion Long-term Debt, Short-term Debt and Capital Lease Obligations, Current Maturities Long-term Debt, Short-term Debt and Capital Lease Obligations, Current Maturities Sale of noncontrolling interests, net of taxes Noncontrolling Interest, Increase from Sale of Parent Equity Interest FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Deferred taxes Increase (Decrease) in Deferred Income Taxes Amortization of operating lease right-of-use assets Operating Lease Right of Use Asset Amortization Operating Lease Right of Use Asset Amortization Due from affiliates Due from Related Parties, Current PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS Property, Plant and Equipment, Net, Including and Excluding Capital Leased Asset [Abstract] Asset Acquisition [Domain] Asset Acquisition [Domain] [Domain] for Asset Acquisition [Axis] Proceeds from the sale of equity interests in a joint venture Proceeds from Divestiture of Interest in Joint Venture Accumulated Other Comprehensive Loss, net of taxes Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization Change in cumulative foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent Issuance of common stock for purchase of membership interest in HVRA Stock Issued During Period, Value, Conversion of Convertible Securities Cash paid during the period for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Eurodollar Eurodollar [Member] Variable Rate [Axis] Variable Rate [Axis] Security Exchange Name Security Exchange Name FirstLienTermLoansAMember FirstLienTermLoansAMember Deferred tax liabilities acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Weighted average shares for which the exercise price exceeds average market price of common stock (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Nonvested restricted stock subject only to service vesting (in shares) Weighted Average Number of Shares, Restricted Stock Disposal Group Classification [Domain] Disposal Group Classification [Domain] Pricing Level V Pricing Level V [Member] Pricing Level V [Member] Book value of RadNet joint venture interests Equity Method Investments Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Payments to fund loan to related parties Payments to Fund Long-term Loans to Related Parties Basis spread on variable rate Derivative, Basis Spread on Variable Rate Equity Component [Domain] Equity Component [Domain] Document Transition Report Document Transition Report Revenue under capitation arrangements Revenue under capitation arrangements Capitation Arrangements [Member] Capitation Arrangements [Member] Deferred financing costs, net of accumulated amortization Debt Issuance Costs, Net DEFERRED FINANCING COSTS Deferred Charges, Policy [Policy Text Block] Debt issuance costs Debt Issuance Costs, Gross Consolidated Entities [Domain] Consolidated Entities [Domain] 2019 SWAPS1 2019 SWAPS1 [Member] 2019 SWAPS1 [Member] Line of Credit Line of Credit [Member] Contingent consideration, fair value Equity Issued in Business Combination, Fair Value Disclosure BRMG and NY Groups revenues Variable Interest Entity, Measure of Activity, Revenues Noncurrent assets Equity Method Investment, Summarized Financial Information, Assets Income Statement [Abstract] Income Statement [Abstract] Deferred financing costs Debt Issuance Costs, Noncurrent, Net EX-101.PRE 10 rdnt-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 rdnt-20200930_htm.xml IDEA: XBRL DOCUMENT 0000790526 2020-01-01 2020-09-30 0000790526 2020-11-05 0000790526 2020-09-30 0000790526 2019-12-31 0000790526 us-gaap:HealthCarePatientServiceMember 2020-07-01 2020-09-30 0000790526 us-gaap:HealthCarePatientServiceMember 2019-07-01 2019-09-30 0000790526 us-gaap:HealthCarePatientServiceMember 2020-01-01 2020-09-30 0000790526 us-gaap:HealthCarePatientServiceMember 2019-01-01 2019-09-30 0000790526 rdnt:CapitationArrangementsMember 2020-07-01 2020-09-30 0000790526 rdnt:CapitationArrangementsMember 2019-07-01 2019-09-30 0000790526 rdnt:CapitationArrangementsMember 2020-01-01 2020-09-30 0000790526 rdnt:CapitationArrangementsMember 2019-01-01 2019-09-30 0000790526 2020-07-01 2020-09-30 0000790526 2019-07-01 2019-09-30 0000790526 2019-01-01 2019-09-30 0000790526 us-gaap:CommonStockMember 2020-06-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000790526 us-gaap:RetainedEarningsMember 2020-06-30 0000790526 rdnt:StockholdersEquityDeficitMember 2020-06-30 0000790526 us-gaap:NoncontrollingInterestMember 2020-06-30 0000790526 2020-06-30 0000790526 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000790526 rdnt:DeepHealthInc.Member us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000790526 rdnt:DeepHealthInc.Member 2020-07-01 2020-09-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000790526 rdnt:StockholdersEquityDeficitMember 2020-07-01 2020-09-30 0000790526 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000790526 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000790526 us-gaap:CommonStockMember 2020-09-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000790526 us-gaap:RetainedEarningsMember 2020-09-30 0000790526 rdnt:StockholdersEquityDeficitMember 2020-09-30 0000790526 us-gaap:NoncontrollingInterestMember 2020-09-30 0000790526 us-gaap:CommonStockMember 2019-06-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000790526 us-gaap:RetainedEarningsMember 2019-06-30 0000790526 rdnt:StockholdersEquityDeficitMember 2019-06-30 0000790526 us-gaap:NoncontrollingInterestMember 2019-06-30 0000790526 2019-06-30 0000790526 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000790526 rdnt:StockholdersEquityDeficitMember 2019-07-01 2019-09-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000790526 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000790526 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-09-30 0000790526 us-gaap:CommonStockMember 2019-09-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000790526 us-gaap:RetainedEarningsMember 2019-09-30 0000790526 rdnt:StockholdersEquityDeficitMember 2019-09-30 0000790526 us-gaap:NoncontrollingInterestMember 2019-09-30 0000790526 2019-09-30 0000790526 us-gaap:CommonStockMember 2019-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000790526 us-gaap:RetainedEarningsMember 2019-12-31 0000790526 rdnt:StockholdersEquityDeficitMember 2019-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2019-12-31 0000790526 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000790526 rdnt:DeepHealthInc.Member us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000790526 rdnt:DeepHealthInc.Member 2020-01-01 2020-09-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000790526 rdnt:StockholdersEquityDeficitMember 2020-01-01 2020-09-30 0000790526 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-09-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000790526 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000790526 us-gaap:CommonStockMember 2018-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000790526 us-gaap:RetainedEarningsMember 2018-12-31 0000790526 rdnt:StockholdersEquityDeficitMember 2018-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2018-12-31 0000790526 2018-12-31 0000790526 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0000790526 rdnt:StockholdersEquityDeficitMember 2019-01-01 2019-09-30 0000790526 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-09-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000790526 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0000790526 rdnt:DeepHealthInc.Member 2020-06-01 2020-06-01 0000790526 rdnt:DeepHealthInc.Member 2020-06-01 0000790526 rdnt:NulogixMember 2019-08-01 2019-08-01 0000790526 rdnt:NulogixMember 2019-08-01 0000790526 2018-04-12 0000790526 rdnt:VenturaCountyImagingGroupLLCMember 2019-03-01 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2019-02-27 2019-02-27 0000790526 rdnt:HudsonValleyRadiologyAssociatesMember us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2019-02-27 0000790526 srt:ChiefExecutiveOfficerMember rdnt:BeverlyRadiologyMedicalGroupIIIMember 2020-09-30 0000790526 rdnt:BoardMemberMember rdnt:BeverlyRadiologyMedicalGroupIIIMember 2020-09-30 0000790526 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2020-09-30 0000790526 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2019-12-31 0000790526 rdnt:ScriptSenderLlcMember 2020-09-30 0000790526 rdnt:CommercialInsurance1Member 2020-07-01 2020-09-30 0000790526 rdnt:CommercialInsurance1Member 2019-07-01 2019-09-30 0000790526 rdnt:CommercialInsurance1Member 2020-01-01 2020-09-30 0000790526 rdnt:CommercialInsurance1Member 2019-01-01 2019-09-30 0000790526 rdnt:Medicare1Member 2020-07-01 2020-09-30 0000790526 rdnt:Medicare1Member 2019-07-01 2019-09-30 0000790526 rdnt:Medicare1Member 2020-01-01 2020-09-30 0000790526 rdnt:Medicare1Member 2019-01-01 2019-09-30 0000790526 rdnt:Medicaid1Member 2020-07-01 2020-09-30 0000790526 rdnt:Medicaid1Member 2019-07-01 2019-09-30 0000790526 rdnt:Medicaid1Member 2020-01-01 2020-09-30 0000790526 rdnt:Medicaid1Member 2019-01-01 2019-09-30 0000790526 rdnt:WorkersCompensationPersonalInjury1Member 2020-07-01 2020-09-30 0000790526 rdnt:WorkersCompensationPersonalInjury1Member 2019-07-01 2019-09-30 0000790526 rdnt:WorkersCompensationPersonalInjury1Member 2020-01-01 2020-09-30 0000790526 rdnt:WorkersCompensationPersonalInjury1Member 2019-01-01 2019-09-30 0000790526 rdnt:HealthCarePatientServiceOtherMember 2020-07-01 2020-09-30 0000790526 rdnt:HealthCarePatientServiceOtherMember 2019-07-01 2019-09-30 0000790526 rdnt:HealthCarePatientServiceOtherMember 2020-01-01 2020-09-30 0000790526 rdnt:HealthCarePatientServiceOtherMember 2019-01-01 2019-09-30 0000790526 rdnt:HealthCareManagementServiceMember 2020-07-01 2020-09-30 0000790526 rdnt:HealthCareManagementServiceMember 2019-07-01 2019-09-30 0000790526 rdnt:HealthCareManagementServiceMember 2020-01-01 2020-09-30 0000790526 rdnt:HealthCareManagementServiceMember 2019-01-01 2019-09-30 0000790526 rdnt:TeleradiologyandSoftwareMember 2020-07-01 2020-09-30 0000790526 rdnt:TeleradiologyandSoftwareMember 2019-07-01 2019-09-30 0000790526 rdnt:TeleradiologyandSoftwareMember 2020-01-01 2020-09-30 0000790526 rdnt:TeleradiologyandSoftwareMember 2019-01-01 2019-09-30 0000790526 us-gaap:HealthCareOtherMember 2020-07-01 2020-09-30 0000790526 us-gaap:HealthCareOtherMember 2019-07-01 2019-09-30 0000790526 us-gaap:HealthCareOtherMember 2020-01-01 2020-09-30 0000790526 us-gaap:HealthCareOtherMember 2019-01-01 2019-09-30 0000790526 rdnt:COVID19PandemicMember 2020-04-01 2020-04-30 0000790526 rdnt:COVID19PandemicMember 2020-05-01 2020-05-31 0000790526 rdnt:PaycheckProtectionProgramLoansMember rdnt:COVID19PandemicMember 2020-09-30 0000790526 rdnt:COVID19PandemicMember 2020-09-30 0000790526 srt:MinimumMember rdnt:PropertyAndEquipmentMember 2020-01-01 2020-09-30 0000790526 srt:MaximumMember rdnt:PropertyAndEquipmentMember 2020-01-01 2020-09-30 0000790526 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-09-30 0000790526 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-09-30 0000790526 rdnt:OlneyOpenMRILLCMember 2020-01-01 2020-09-30 0000790526 rdnt:MRIatWoodbridgeLLCMember 2020-01-01 2020-09-30 0000790526 rdnt:AZTechMember 2020-01-01 2020-09-30 0000790526 rdnt:RestatedPlanMember 2020-09-30 0000790526 srt:MinimumMember 2020-01-01 2020-09-30 0000790526 srt:MaximumMember 2020-01-01 2020-09-30 0000790526 rdnt:Caps2016Member 2020-09-30 0000790526 rdnt:September2020CapMember rdnt:Caps2016Member 2020-09-30 0000790526 rdnt:October2020CapMember rdnt:Caps2016Member 2020-09-30 0000790526 rdnt:Caps2016Member us-gaap:LondonInterbankOfferedRateLIBORMember 2020-09-30 0000790526 us-gaap:InterestRateCapMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-06-30 0000790526 us-gaap:InterestRateCapMember 2020-07-01 2020-09-30 0000790526 us-gaap:InterestRateCapMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-09-30 0000790526 us-gaap:InterestRateCapMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000790526 us-gaap:InterestRateCapMember 2020-01-01 2020-09-30 0000790526 rdnt:A2019SWAPSMember 2020-09-30 0000790526 rdnt:A2019SWAPSMember 2019-06-30 0000790526 rdnt:October2023Member rdnt:A2019SWAPSMember 2019-06-30 0000790526 rdnt:October2025Member rdnt:A2019SWAPSMember 2019-06-30 0000790526 us-gaap:InterestRateSwapMember rdnt:A2019SWAPSMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-06-30 0000790526 us-gaap:InterestRateSwapMember rdnt:A2019SWAPSMember 2019-06-30 0000790526 us-gaap:InterestRateSwapMember rdnt:A2019SWAPS1Member us-gaap:LondonInterbankOfferedRateLIBORMember 2019-06-30 0000790526 us-gaap:InterestRateSwapMember rdnt:A2019SWAPS1Member 2019-06-30 0000790526 us-gaap:InterestRateSwapMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-06-30 0000790526 us-gaap:InterestRateSwapMember 2020-07-01 2020-09-30 0000790526 us-gaap:InterestRateSwapMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-09-30 0000790526 us-gaap:InterestRateSwapMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000790526 us-gaap:InterestRateSwapMember 2020-01-01 2020-09-30 0000790526 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-07-01 2020-09-30 0000790526 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2020-07-01 2020-09-30 0000790526 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-09-30 0000790526 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2020-01-01 2020-09-30 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel3Member 2020-09-30 0000790526 us-gaap:InterestRateCapMember 2020-09-30 0000790526 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0000790526 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0000790526 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member 2020-09-30 0000790526 us-gaap:InterestRateSwapMember 2020-09-30 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000790526 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000790526 us-gaap:InterestRateCapMember 2019-12-31 0000790526 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000790526 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000790526 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000790526 us-gaap:InterestRateSwapMember 2019-12-31 0000790526 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-09-30 0000790526 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-09-30 0000790526 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-09-30 0000790526 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-09-30 0000790526 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000790526 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000790526 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000790526 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember rdnt:BarclaysMember us-gaap:LineOfCreditMember 2020-09-30 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember rdnt:BarclaysMember us-gaap:LineOfCreditMember 2019-12-31 0000790526 us-gaap:RestrictedStockMember 2020-07-01 2020-09-30 0000790526 us-gaap:RestrictedStockMember 2019-07-01 2019-09-30 0000790526 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0000790526 us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0000790526 rdnt:MedicVisionMember 2017-03-24 0000790526 rdnt:MedicVisionMember 2017-03-24 2017-03-24 0000790526 rdnt:MedicVisionMember 2018-03-01 2018-03-01 0000790526 rdnt:MedicVisionMember 2018-03-01 0000790526 rdnt:MedicVisionMember 2020-09-30 0000790526 rdnt:TurnerImagingMember 2018-02-01 2018-02-01 0000790526 rdnt:TurnerImagingMember us-gaap:CommercialPaperMember 2019-01-01 0000790526 rdnt:TurnerImagingMember 2019-10-11 0000790526 rdnt:WhiteRabbit.aiInc.Member 2019-11-05 2019-11-05 0000790526 rdnt:WhiteRabbit.aiInc.Member 2020-09-30 0000790526 rdnt:DignityHealthMember srt:MinimumMember rdnt:JointVentureMember rdnt:GlendaleAdvancedImagingMember 2019-01-01 2019-03-31 0000790526 rdnt:DignityHealthMember srt:MaximumMember rdnt:JointVentureMember rdnt:GlendaleAdvancedImagingMember 2019-01-01 2019-03-31 0000790526 rdnt:SantaMonicaImagingGroupLLCMember 2020-08-01 2020-08-31 0000790526 rdnt:SantaMonicaImagingGroupLLCMember 2020-08-31 0000790526 rdnt:AZTechMember 2020-08-31 2020-08-31 0000790526 rdnt:AZTechMember 2020-08-31 0000790526 rdnt:DeepHealthIncMember 2020-06-01 2020-06-01 0000790526 rdnt:DeepHealthIncMember 2020-06-01 0000790526 rdnt:MRIatWoodbridgeLLCMember 2020-03-02 2020-03-02 0000790526 rdnt:MRIatWoodbridgeLLCMember 2020-03-02 0000790526 rdnt:OlneyOpenMRILLCMember 2020-01-02 2020-01-02 0000790526 rdnt:OlneyOpenMRILLCMember 2020-01-02 0000790526 rdnt:ImagingOnCallMember 2020-06-01 2020-06-01 0000790526 rdnt:FirstLienTermLoanMember rdnt:TermLoanMember 2020-09-30 0000790526 rdnt:FirstLienTermLoanMember rdnt:TermLoanMember 2019-12-31 0000790526 rdnt:RestatedAgreementMember rdnt:TermLoanMember 2020-09-30 0000790526 rdnt:RestatedAgreementMember rdnt:TermLoanMember 2019-12-31 0000790526 rdnt:PaycheckProtectionProgramLoansMember 2020-09-30 0000790526 rdnt:PaycheckProtectionProgramLoansMember rdnt:TermLoanMember 2020-09-30 0000790526 us-gaap:NotesPayableOtherPayablesMember 2020-09-30 0000790526 rdnt:TermLoanMember 2020-09-30 0000790526 rdnt:FirstLienTermLoansAMember 2020-09-30 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementEighthAmendmentMember rdnt:BarclaysMember us-gaap:LineOfCreditMember 2020-09-30 0000790526 us-gaap:RevolvingCreditFacilityMember 2020-09-30 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:BarclaysMember 2020-09-30 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember rdnt:SunTrustMember us-gaap:LineOfCreditMember 2020-09-30 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:SunTrustMember us-gaap:LineOfCreditMember 2020-09-30 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember rdnt:LeverageRatioOneMember 2016-07-01 2016-07-01 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember rdnt:LeverageRatioOneMember 2016-07-01 2016-07-01 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember rdnt:LeverageRatioTwoMember 2016-07-01 2016-07-01 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember rdnt:LeverageRatioTwoMember 2016-07-01 2016-07-01 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember rdnt:LeverageRatioThreeMember 2016-07-01 2016-07-01 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember rdnt:LeverageRatioThreeMember 2016-07-01 2016-07-01 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember rdnt:LeverageRatioFourMember 2016-07-01 2016-07-01 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember rdnt:LeverageRatioFourMember 2016-07-01 2016-07-01 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember 2020-09-30 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2020-09-30 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:LineOfCreditMember us-gaap:EurodollarMember rdnt:LeverageRatioThreeMember 2020-01-01 2020-09-30 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember rdnt:LeverageRatioThreeMember 2020-01-01 2020-09-30 0000790526 rdnt:FirstLienTermLoanMember rdnt:BarclaysMember rdnt:TermLoanMember 2020-01-01 2020-09-30 0000790526 rdnt:RestatedAgreementMember rdnt:PricingLevelIMember 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:EurodollarMember rdnt:PricingLevelIMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:BaseRateMember rdnt:PricingLevelIMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember rdnt:PricingLevelIMember 2018-08-31 2018-08-31 0000790526 rdnt:RestatedAgreementMember rdnt:PricingLevelIIMember 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:EurodollarMember rdnt:PricingLevelIIMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:BaseRateMember rdnt:PricingLevelIIMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember rdnt:PricingLevelIIMember 2018-08-31 2018-08-31 0000790526 rdnt:RestatedAgreementMember rdnt:PricingLevelIIIMember 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:EurodollarMember rdnt:PricingLevelIIIMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:BaseRateMember rdnt:PricingLevelIIIMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember rdnt:PricingLevelIIIMember 2018-08-31 2018-08-31 0000790526 rdnt:RestatedAgreementMember rdnt:PricingLevelIVMember 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:EurodollarMember rdnt:PricingLevelIVMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:BaseRateMember rdnt:PricingLevelIVMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember rdnt:PricingLevelIVMember 2018-08-31 2018-08-31 0000790526 rdnt:RestatedAgreementMember rdnt:PricingLevelVMember 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:EurodollarMember rdnt:PricingLevelVMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:BaseRateMember rdnt:PricingLevelVMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember rdnt:PricingLevelVMember 2018-08-31 2018-08-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:RestatedAgreementMember us-gaap:EurodollarMember rdnt:PricingLevelIIIMember 2020-01-01 2020-09-30 0000790526 rdnt:SunTrustMember rdnt:TermLoanMember 2018-01-01 2018-12-31 0000790526 rdnt:SunTrustMember rdnt:TermLoanMember 2018-12-31 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:BarclaysMember us-gaap:LetterOfCreditMember 2020-01-01 2020-09-30 0000790526 rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:MediumTermNotesMember 2017-08-22 0000790526 us-gaap:RevolvingCreditFacilityMember rdnt:FirstLienCreditAgreementSixthAmendmentMember us-gaap:LineOfCreditMember 2019-04-18 0000790526 rdnt:FirstLienCreditAgreementSeventhAmendmentMember 2019-04-18 0000790526 rdnt:FirstLienCreditAgreementSeventhAmendmentMember 2019-04-18 2019-04-18 0000790526 rdnt:PaycheckProtectionProgramLoansMember rdnt:COVID19PandemicMember 2020-01-01 2020-09-30 0000790526 srt:MinimumMember rdnt:RestatedPlanMember 2020-01-01 2020-09-30 0000790526 srt:MaximumMember rdnt:RestatedPlanMember 2020-01-01 2020-09-30 0000790526 us-gaap:StockOptionMember 2020-09-30 0000790526 us-gaap:StockOptionMember 2019-12-31 0000790526 us-gaap:StockOptionMember 2020-01-01 2020-09-30 0000790526 us-gaap:StockOptionMember rdnt:DeepHealthIncMember 2020-07-01 2020-09-30 0000790526 rdnt:DeepHealthIncMember 2020-07-01 2020-09-30 0000790526 rdnt:DeepHealthIncMember 2020-09-30 0000790526 rdnt:DeepHealthIncMember 2020-01-01 2020-09-30 0000790526 us-gaap:StockOptionMember rdnt:DeepHealthInc.Member 2019-12-31 0000790526 us-gaap:StockOptionMember rdnt:DeepHealthInc.Member 2020-01-01 2020-09-30 0000790526 us-gaap:StockOptionMember rdnt:DeepHealthInc.Member 2020-09-30 0000790526 us-gaap:RestrictedStockMember 2020-09-30 0000790526 us-gaap:RestrictedStockMember 2019-12-31 0000790526 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0000790526 rdnt:FutureServiceMember 2020-01-01 2020-09-30 0000790526 rdnt:RestatedPlanMember 2020-01-01 2020-09-30 0000790526 us-gaap:InvestmentsInMajorityOwnedSubsidiariesMember us-gaap:SubsequentEventMember 2020-11-01 0000790526 us-gaap:InvestmentsInMajorityOwnedSubsidiariesMember us-gaap:SubsequentEventMember rdnt:SimiValleyHospitalAndHealthServicesMember 2020-11-01 shares iso4217:USD iso4217:USD shares pure rdnt:Center rdnt:numberOfAgreement rdnt:joint_venture rdnt:loan 0000790526 false --12-31 Q3 2020 P3Y P5Y 10-Q true 2020-09-30 false 001-33307 RadNet, Inc. DE 13-3326724 1510 Cotner Avenue Los Angeles, CA 90025 310 478-7808 Yes Yes Accelerated Filer false false false Common Stock RDNT NASDAQ 51636099 89739000 40165000 137411000 154763000 424000 1242000 31482000 45004000 259056000 241174000 361950000 367795000 451613000 445477000 813563000 813272000 470685000 441973000 57152000 42994000 1944000 1559000 35571000 34470000 42188000 34548000 37707000 36996000 1717866000 1646986000 205701000 207585000 12287000 14347000 45846000 1316000 3041000 3283000 67449000 61206000 39463000 39691000 373787000 327428000 1108000 3264000 428233000 420922000 627179000 652704000 41438000 9529000 1471745000 1413847000 0.0001 0.0001 200000000 200000000 51596098 51596098 50314328 50314328 5000 5000 306079000 262865000 -24923000 -8026000 -123956000 -103159000 157205000 151685000 88916000 81454000 246121000 233139000 1717866000 1646986000 256730000 261908000 660760000 762751000 35046000 30784000 103145000 90587000 291776000 292692000 763905000 853338000 221000 0 25696000 0 246462000 254383000 708095000 743997000 21247000 20490000 64536000 60193000 -342000 -917000 -543000 -1990000 571000 52000 1647000 1054000 268622000 275842000 774821000 807234000 23375000 16850000 14780000 46104000 11061000 11895000 33443000 36589000 2276000 1955000 5176000 6072000 -679000 0 -4523000 0 139000 -2000 247000 -1271000 -9325000 -9942000 -32543000 -31788000 14050000 6908000 -17763000 14316000 3825000 1816000 -5029000 3556000 10225000 5092000 -12734000 10760000 4069000 1897000 8063000 6400000 6156000 3195000 -20797000 4360000 0.12 0.06 -0.41 0.09 0.12 0.06 -0.41 0.09 51358603 49807460 50746380 49597138 51955815 50360360 50746380 50113306 10225000 5092000 -12734000 10760000 11000 -23000 6000 -28000 195000 -5283000 -18764000 -14481000 -969000 0 -1861000 0 11400000 -214000 -29631000 -3749000 4069000 1897000 8063000 6400000 7331000 -2111000 -37694000 -10149000 51554760 5000 304012000 -26098000 -130111000 147808000 85448000 233256000 37000 0 4338 0 2067000 2067000 2067000 601000 601000 11000 11000 11000 195000 195000 195000 -969000 -969000 -969000 1000 1000 1000 6156000 6156000 4069000 10225000 51596098 5000 306079000 -24923000 -123956000 157205000 88916000 246121000 50127234 5000 257607000 -6942000 -116752000 133918000 78512000 212430000 25000 0 1356000 1356000 1356000 101902 1500000 1500000 1500000 -23000 -23000 -23000 -5283000 -5283000 -5283000 2000 -2000 0 3195000 3195000 1897000 5092000 50254136 5000 260463000 -12250000 -113555000 134663000 80409000 215072000 50314328 5000 262865000 -8026000 -103159000 151685000 81454000 233139000 453817 0 4338 0 10203000 10203000 10203000 823615 33011000 33011000 33011000 601000 601000 6000 6000 6000 -18764000 -18764000 -18764000 -1861000 -1861000 -1861000 -20797000 -20797000 8063000 -12734000 51596098 5000 306079000 -24923000 -123956000 157205000 88916000 246121000 48977485 5000 242835000 2259000 -117915000 127184000 73069000 200253000 10000 50000 50000 50000 726042 0 6993000 6993000 6993000 440207 6000000 6000000 6000000 1500 5000 5000 5000 3090000 3090000 2008000 5098000 1818000 1818000 750000 750000 101902 -1500000 -1500000 -1500000 -28000 -28000 -28000 -14481000 -14481000 -14481000 4360000 4360000 6400000 10760000 50254136 5000 260463000 -12250000 -113555000 134663000 80409000 215072000 -12734000 10760000 64536000 60193000 50769000 49948000 -530000 2148000 3266000 3103000 -543000 -1990000 2204000 0 -4523000 0 10144000 6963000 0 559000 -145000 -1749000 -17380000 3467000 -13522000 1569000 700000 5770000 7640000 4230000 43351000 49721000 44530000 -490000 22966000 19349000 170343000 82603000 10125000 27150000 0 143000 77303000 68269000 779000 760000 0 132000 0 792000 1631000 103000 -88280000 -93981000 2704000 4778000 32472000 29918000 741000 0 0 97144000 4023000 0 601000 1818000 0 5275000 0 750000 250900000 251200000 250900000 279200000 0 50000 -32495000 38705000 6000 -28000 49574000 27299000 40165000 10389000 89739000 37688000 31210000 36058000 28100000 14100000 823615 13900000 1500000 0.75 0.25 4300000 440207 6000000.0 NATURE OF BUSINESS AND BASIS OF PRESENTATION<div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a national provider of freestanding, fixed-site outpatient diagnostic imaging services with operations in seven U.S. states. At September 30, 2020, we operated, directly or indirectly through joint ventures with hospitals, 334 centers located in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services. Our multi-modality strategy diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians the convenience of a single location to serve the needs of multiple procedures. In addition to our imaging services, we design and develop software applications, Artificial Intelligence tools and other computerized systems for the diagnostic imaging industry. Our operations comprise a single segment for financial reporting purposes.</span></div><div style="text-align:right;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of RadNet, Inc as well as its subsidiaries in which RadNet has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which we are the primary beneficiary (as described in more detail below). All material intercompany transactions and balances have been eliminated upon consolidation. All of these affiliated entities are referred to collectively as “RadNet”, “we”, “us”, “our” or the “Company” in this report.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting regulations stipulate that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs in which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIEs that we consolidate as the primary beneficiary consist of professional corporations which are owned or controlled by individuals within our senior management, namely Howard G. Berger, M.D., our President and Chief Executive Officer, and John V. Crues, III, M.D., RadNet's Medical Director, both of whom are members of our Board of Directors. Dr. Berger owns, indirectly, 99% of the equity interests in Beverly Radiology Medical Group III (BRMG) and a controlling interest in two professional corporations in New York City. BRMG is responsible for the professional medical services at nearly all of our facilities located in California. Dr. Crues owns six professional corporations which provide medical services in Delaware, Maryland, New Jersey and New York. Additionally, Dr. Crues is a 1% owner of BRMG. These VIEs are collectively referred to as the consolidated medical group ("the Group").</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RadNet provides non-medical, technical and administrative services to the Group for which it receives a management fee, pursuant to the related management agreements. Through the management agreements we have exclusive authority over all non-medical decision making related to the ongoing business operations and we determine the annual budget. The Group has insignificant operating assets and liabilities, and de minimis equity. Through management agreements with us, substantially all cash flows of the Group after expenses, including professional salaries, are transferred to us. We consolidate the revenue and expenses, assets and liabilities of the Group.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group on a combined basis recognized $38.3 million and $40.6 million of revenue, net of management services fees to RadNet, for the three months ended September 30, 2020 and 2019, respectively and $38.3 million and $40.6 million of operating expenses for the three months ended September 30, 2020 and 2019, respectively. RadNet recognized $169.0 million and $154.5 million of total billed net service fee revenue for the three months ended September 30, 2020, and 2019, respectively, for management services provided to the Group relating primarily to the technical portion of billed revenue.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group on a combined basis recognized $104.8 million and $116.9 million of revenue, net of management services fees to RadNet, for the nine months ended September 30, 2020 and 2019, respectively and $104.8 million and $116.9 million of operating expenses for the nine months ended September 30, 2020 and 2019, respectively. RadNet recognized $433.3 million </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $456.1 million of total billed net service fee revenue for the nine months ended September 30, 2020, and 2019, respectively, for management services provided to the Group relating primarily to the technical portion of billed revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flows of the Group are included in the accompanying condensed consolidated statements of cash flows. All intercompany balances and transactions have been eliminated in consolidation. In our condensed consolidated balance sheets at September 30, 2020 and December 31, 2019, we have included approximately $84.5 million and $100.3 million, respectively, of accounts receivable and approximately $10.7 million and $7.0 million of accounts payable and accrued liabilities related to the Group, respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The creditors of the Group do not have recourse to our general credit and there are no other arrangements that could expose us to losses on their behalf. However, RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also own a 49% economic interest in ScriptSender, LLC, which provides secure data transmission services of medical information. Through a management agreement, RadNet provides management and accounting services and receives an agreed upon fee. ScriptSender, LLC is dependent on the Company to finance its own activities, and as such we determined that it is a VIE but we are not a primary beneficiary since we do not have the power to direct the activities of the entity that most significantly impact the entity’s economic performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At all of our centers not serviced by the Group we have entered into long-term contracts (typically up to 40 years) with independent radiology groups to provide physician services at those centers. These radiology practices provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee based on the value of the services we provide. We own the diagnostic imaging equipment and, therefore, receive 100% of the technical reimbursements associated with imaging procedures. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us and we have no economic controlling interest in these radiology practices as such, the financial results of these practices are not consolidated in our financial statements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for conformity with U.S. generally accepted accounting principles for complete financial statements; however, in the opinion of our management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods ended September 30, 2020 and 2019 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto contained in our annual report on Form 10-K for the year ended December 31, 2019.</span></div> 334 0.99 0.01 38300000 40600000 38300000 40600000 169000000.0 154500000 104800000 116900000 104800000 116900000 433300000 456100000 84500000 100300000 10700000 7000000.0 0.49 SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period covered in this report, there have been no material changes to the significant accounting policies we use and have explained, in our annual report on Form 10-K for the fiscal year ended December 31, 2019. The information below is intended only to supplement the disclosure in our annual report on Form 10-K for the fiscal year ended December 31, 2019.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">REVENUES - Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period when our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payors. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As it relates to the Group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by them as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total service revenues during the three and nine months ended September 30, 2020 and 2019 are presented in the table below based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:49.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.738%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial insurance</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,524 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,152 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,415 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,064 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,098 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,128 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,072 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,564 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers' compensation/personal injury</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other patient revenue</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,328 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,085 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,211 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,947 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teleradiology and Software revenue</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,412 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,319 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,861 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service fee revenue</span></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,730 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,908 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,760 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,751 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under capitation arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total service revenue</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,776 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,692 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763,905 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,338 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COVID-19 PANDEMIC AND CARES ACT FUNDING - On March 11, 2020 the World Health Organization (WHO) designated COVID-19 as a global pandemic. Patient volumes and the related revenues for our services were significantly impacted during the latter portion of the first quarter through the middle of the third quarter of 2020 as a result of federal, state and local government mandated restrictions requiring many people to remain at home and forced the closure of or limitations on certain businesses, as well as suspended elective procedures by health care facilities. Many of these restrictions have been eased or completely lifted across the states the Company operates in however, we are unable to predict the future impact of the pandemic on our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the nine months ended September 30, 2020, we received $39.4 million of accelerated Medicare payments, $5.0 million from Blue Cross, $25.7 million from the general distribution and $4.0 million from the Paycheck Protection Program established through the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. The accelerated Medicare payments are recorded under the caption “ Deferred Revenue“ in our condensed consolidated balance sheet and will be repaid beginning in 2021. The general distribution funds were accounted for as government grants and recognized as other revenue, once reasonable assurance that the applicable terms and conditions required to retain the funds were met, under the caption “Provider relief funding” in our condensed Consolidated Statements of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended September 30, 2020, the Department of Health and Human Services significantly changed the measurement of Provider Relief Funds that providers are able to retain. We received approximately $0.2 million in </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">funding and based on our assessment of the likelihood of meeting the applicable terms and conditions of the general distribution we continue to recognized the funds received as other revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The CARES Act also providers for a payment deferral of the employer portion of Social Security tax incurred during the pandemic, allowing half of such payroll taxes to be deferred until December 2021 and the remaining half until December 2022. At September 30, 2020, the Company had deferred $10.8 million of Social Security taxes. These payment deferrals are recorded as payroll tax liability under the caption “Accounts payable, accrued expenses and other” in our condensed consolidated balance sheet.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe the extent of the COVID-19 pandemic’s impact on our operating results and financial condition has been and will continue to be driven by many factors, most of which are beyond our control and ability to forecast. Such factors include, but are not limited to, the scope and duration of stay-at-home practices, business closures and restrictions, suspensions of elective procedures and continued decline in procedure volumes for an indeterminable length of time and incremental expenses required for supplies and personal protective equipment. Because of these uncertainties, we cannot estimate the length or impact of the pandemic on our business. If we incur declines in cash flows and results of operations, such declines could have an impact on the inputs and assumptions used in significant accounting estimates, including implicit prices concessions related to uninsured patient accounts, and potential impairment of goodwill and long-lived assets. During the third quarter of 2020, procedure volumes increased and have had a positive impact on our patient revenue. However, the impact of COVID-19 in future periods may vary and could adversely impact our results of operations. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RECLASSIFICATION –We have reclassified certain amounts previously classified as held for sale related to property and equipment and goodwill to conform to our 2020 presentation.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACCOUNTS RECEIVABLE - Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience. In regards to the credit loss standard, we have concluded that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses estimated under the Current Expected Credit Loss ("CECL") model.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018 and 2019 we entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements in exchange for notes receivables from the buyers. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. Proceeds on notes receivables are reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long term portion. At September 30, 2020 we have $20.4 million remaining to be collected on these agreements. We do not utilize factoring arrangements as an integral part of our financing for working capital. To employ the CECL model for the notes receivable, we assess the party's ability to pay upfront at the inception of the notes receivable and subsequently by reviewing their financial statements annually and reassessing any insolvency risk on a periodic basis. In the event of a significant past due balance, as the sold receivables were already revalued and recorded at net realizable value, we can mitigate the expected credit loss by offsetting any collections from the underlying factored receivables and not remitting that to the counter party.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DEFERRED REVENUE - As noted above, in April of 2020, we received approximately $39.4 million in advanced Medicare payments from the Centers for Medicare and Medicaid Services ("CMS") as part of the expanded Accelerated and Advance Payment Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. As these payments are required to be repaid to CMS beginning 120 days after their receipt through offsets from new Medicare claims over a three month period, we have recorded amounts received to deferred revenue which will be amortized as Medicare reimbursements are earned. In addition, in May of 2020 we received $5.0 million in advance payments from an insurance carrier with similar repayment terms as the CMS.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DEFERRED FINANCING COSTS - Costs of financing are deferred and amortized using the effective interest rate method. Deferred financing costs, net of accumulated amortization, were $1.9 million and $1.6 million, as of September 30, 2020 and December 31, 2019, respectively and related to our Barclays line of credit. See Note 5, Credit Facilities and Notes Payable for more information.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation of property and equipment is performed using the straight-line method over the estimated useful lives of the assets acquired, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BUSINESS COMBINATION - When the qualifications for business combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GOODWILL AND INDEFINITE LIVED INTANGIBLES - Goodwill at September 30, 2020 totaled $470.7 million. Indefinite lived intangible assets at September 30, 2020 were $11.3 million. Goodwill and Indefinite Lived Intangibles are recorded as a result of business combinations. When we determine the carrying value of reporting unit exceeds its fair value an impairment charge would be recognized and should not exceed the total amount of goodwill allocated to that reporting unit. We tested goodwill and indefinite lived intangibles for impairment on October 1, 2019, noting no impairment. In addition to the annual impairment test, we regularly assess if an event has occurred which would require interim impairment testing. We considered the current and expected future economic and market conditions surrounding the novel strain of coronavirus ("COVID-19") pandemic and did not identify an indication of goodwill impairment being more likely than not through September 30, 2020. Activity in goodwill for the nine months ended September 30, 2020 is provided below (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,973 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired through the acquisition of Olney Open MRI, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired through the acquisition of MRI at Woodbridge, LLC</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired through the acquisition of DeepHealth, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired through the acquisition of AZ-Tech Radiology &amp; Open MRI, LLC</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,685 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INCOME TAXES - Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded an income tax expense of $3.8 million, or an effective tax rate of 27.2%, for the three months ended September 30, 2020 compared to an income tax expense of $1.8 million, or an effective tax rate of 26.3% for the three months ended September 30, 2019. We recorded an income tax benefit of $5.0 million, or an effective tax rate of 28.3%, for the nine months ended September 30, 2020 compared to an income tax expense of $3.6 million , or an effective tax rate of 24.8% for the nine months ended September 30, 2019.The income tax rates for the three and nine months ended September 30, 2020 diverge from the federal statutory rate due to (i) noncontrolling interests due to the controlled partnerships; (ii) effects of state income taxes; and (iii) excess tax benefits attributable to share-based compensation.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe no significant changes in the unrecognized tax benefits will occur within the next 12 months.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"). The CARES Act, among other things, includes certain income tax provisions for individuals and corporations; however, these benefits do not impact the Company’s current tax provision.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long term operating lease liability in our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liability, and long-term finance lease liability in our consolidated balance sheets.  ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments for both lease and non-lease components, we have elected to account for the components as a single lease component, as permitted. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the ROU asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tested for impairment if circumstances suggest that the carrying amount may not be recoverable. Our ROU assets consist of facility and equipment assets on operating leases. No events have occurred such as fire, flood, or other acts which have impaired the integrity of our ROU assets in 2020. Our facility leases require us to maintain insurance policies which would cover major damage to our facilities. We maintain business interruption insurance to cover loss of business due to a facility becoming non-operational under certain circumstances. Our equipment leases are covered by warranty and service contracts which cover repairs and provide regular maintenance to keep the equipment in functioning order.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated as of April 20, 2015, and again on March 9, 2017 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved 14,000,000 shares of common stock for issuance under the Restated Plan which can be issued in the form of options, stock awards, stock appreciation rights, stock units, and cash awards. Stock options generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmYzBiNTk3MDViZjRjZmY5MzZmNjE5MjkzYjFhMzA2L3NlYzpmZmMwYjU5NzA1YmY0Y2ZmOTM2ZjYxOTI5M2IxYTMwNl80My9mcmFnOjg0MWYyZmEzYjczMjRjYTk4YjlhNWU4MTg4OGZkNTVhL3RleHRyZWdpb246ODQxZjJmYTNiNzMyNGNhOThiOWE1ZTgxODg4ZmQ1NWFfMTY2Mzg_7bbe4cad-8aac-4d51-9911-a759df597876">three</span> to five years and expire <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmYzBiNTk3MDViZjRjZmY5MzZmNjE5MjkzYjFhMzA2L3NlYzpmZmMwYjU5NzA1YmY0Y2ZmOTM2ZjYxOTI5M2IxYTMwNl80My9mcmFnOjg0MWYyZmEzYjczMjRjYTk4YjlhNWU4MTg4OGZkNTVhL3RleHRyZWdpb246ODQxZjJmYTNiNzMyNGNhOThiOWE1ZTgxODg4ZmQ1NWFfMTY2NTg_8014eae6-0e25-46ab-80ed-ec3b42b893fd">five</span> to ten years from date of grant. We determine the compensation expense for each stock option award using the Black Scholes, or similar valuation model. Those models require that our management make certain estimates concerning risk free interest rates and volatility in the trading price of our common stock. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. In connection with our acquisition of DeepHealth Inc. on June 1, 2020, we assumed the DeepHealth, Inc. 2017 Stock Incentive Plan, including outstanding options awards that can be exercised for our common stock. No additional awards will be granted under the DeepHealth, Inc. 2017 Equity Incentive Plan. See Note 4, Facility Acquisitions and Note 6, Stock-Based Compensation, for more information.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COMPREHENSIVE INCOME (LOSS) - ASC 220 establishes rules for reporting and displaying comprehensive income or loss and its components. Our unrealized gains or losses on foreign currency translation adjustments, interest rate cap and swap agreements are included in comprehensive loss and are included in the consolidated statements of comprehensive income (loss) for the three and nine months ended September 30, 2020 and 2019.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COMMITMENTS AND CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. Based on current information, we do not believe that reasonably possible or probable losses associated with pending legal proceedings would either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. Therefore, if one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DERIVATIVE INSTRUMENTS</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2016 CAPS</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2016, we entered into two forward interest rate cap agreements ("2016 Caps"). The 2016 Caps will mature in September and October 2020. The 2016 Caps had notional amounts of $150,000,000 and $350,000,000, respectively. Under these arrangements, the Company purchased a cap on 3 month LIBOR at 2.0%. We incurred a $5.3 million premium to enter into the 2016 Caps which is being accrued over the life of the agreements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception, we designated our 2016 Caps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss of the hedge (i.e. change in fair value) is reported as a component of comprehensive loss in the consolidated statement of equity since such hedge has been determined to be effective. See Fair Value Measurements section below for the fair value of the 2016 Caps at September 30, 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss of the 2016 Caps is as follows (amounts in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Account</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 1, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of comprehensive gain recognized on derivative net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss, net of taxes</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,409)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,214)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Equity</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the nine months ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Account</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of comprehensive gain recognized on derivative net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss, net of taxes</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,877)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,214)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Equity</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2019 SWAPS</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2019, we entered into four forward interest rate agreements ("2019 Swaps"). The 2019 Swaps have total notional amounts of $500,000,000, consisting of two agreements of $50,000,000 each and two agreements of $200,000,000 each. The 2019 Swaps will secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They will mature in October 2023 for the smaller notional and October 2025 for the larger notional. Under these arrangements, we arranged the 2019 Swaps with locked in 1 month LIBOR rates at 1.96% for the $100,000,000 notional and at 2.05% for the $400,000,000 notional. As of the effective date, we will be liable for premium payments if interest rates decline below arranged rates, but will receive interest payments if rates remain above the arranged rates.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception, we designated our 2019 Swaps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e. change in fair value) is reported as a component of comprehensive loss in the consolidated statement of equity. The remaining gain or loss, if any, is recognized currently in earnings. As a result of the economic impact of the coronavirus pandemic, which precipitated a reduction in interest rates , the cash flows for both our $400,000,000 notional interest rate swap contract locked in at 2.05% due October 2025 and our $100,000,000 notional interest rate swap contract locked in at 1.96% do not match the cash flows for our First Lien Term Loans and so we have determined that they are not currently effective as cash flow hedges. Accordingly, all changes in their fair value after April 1, 2020 for the $400,000,000 notional and after July 1, 2020 for the $100,000,000 notional will be recognized in earnings. As of July 1, 2020, the total change in fair value relating to swaps included in other comprehensive income was approximately $24.4 million, net of taxes. This amount will be amortized to interest expense through October 2025 at approximately $0.4 million per month.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss of the 2019 swaps which remain ineffective is as follows (amounts in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"/><td style="width:36.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.534%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Account</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 1, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of comprehensive loss recognized on derivative net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss, net of taxes</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,406)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,437)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Equity</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:35.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.709%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the nine months ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Account</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of comprehensive loss recognized on derivative net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss, net of taxes</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,870)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,428)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,861 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,437)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Equity</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A tabular presentation of the effect of derivative instruments on our statement of operations of the 2019 Swaps for the Swaps that became ineffective during the third quarter is as follows (amounts in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:23.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.114%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ineffective interest rate swap</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of loss recognized in income on derivative (current period ineffective portion)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of loss recognized in Income on derivative (current period ineffective portion)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of loss reclassified from accumulated OCI into income (prior period effective portion)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of gain (Loss) reclassified from accumulated OCI into income (prior period effective portion)</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(679)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,312)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity and Interest Expense</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:23.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.114%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the nine months ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ineffective interest rate swap</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of loss recognized in income on derivative (current period ineffective portion)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of loss recognized in Income on derivative (current period ineffective portion)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of loss reclassified from accumulated OCI into income (prior period effective portion)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of gain (Loss) reclassified from accumulated OCI into income (prior period effective portion)</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,523)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,204)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity and Interest Expense</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Fair Value Measurements section below for the fair value of the 2016 caps and 2019 swaps at September 30, 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Derivatives:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below summarize the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets on our condensed consolidated balance sheets, as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current and long term liabilities</span></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 caps - Interest Rate Contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 swaps - Interest Rate Contracts</span></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,983 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,983 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current and long term liabilities</span></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 caps - Interest Rate Contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 swaps - Interest Rate Contracts</span></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,477 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,477 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty’s forward LIBOR curve. The forward LIBOR curve is readily available in the public markets or can be derived from information available in the public markets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Long Term Debt:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the estimated fair value compared to our face value of our long-term debt as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Face Value</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Lien Term Loans and SunTrust Term Loan</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,140 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,140 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673,227 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Face Value</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Lien Term Loans and SunTrust Term Loan</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,948 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,948 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705,699 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and at December 31, 2019 our Barclays revolving credit facility had no balance outstanding. Our SunTrust revolving credit facility relating to our consolidated subsidiary NJIN, had no principal amount outstanding at September 30, 2020 and at December 31, 2019.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our long-term debt, which is discussed in Note 5, was determined using Level 2 inputs primarily related to comparable market prices.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our finance lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"/><td style="width:51.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.182%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#eeeeee;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="9" style="background-color:#eeeeee;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to RadNet, Inc.'s common stockholders</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,156 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,195 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,797)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,360 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,358,603 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,807,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,746,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,597,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,358,603 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,807,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,746,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,597,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add nonvested restricted stock subject only to service vesting</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,605 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,567 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,375 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add additional shares issuable upon exercise of stock options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares used in calculating diluted net income per share</span></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,955,815 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,360,360 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,746,380 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,113,306 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income (loss) per share attributable to RadNet, Inc.'s common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and non vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested restricted stock subject to service vesting</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,659 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon the exercise of stock options:</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,948 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933,370 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EQUITY INVESTMENTS AT FAIR VALUE–Accounting guidance requires entities to measure equity investments at fair value, with any changes in fair value recognized in net income. If there is no readily determinable fair value, the guidance allows entities the ability to measure investments at cost, adjusted for observable price changes and impairments, with changes recognized in net income. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, we have three equity investments for which a fair value is not readily determinable and therefore the total amounts invested are recognized at cost as follows:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medic Vision Imaging Solutions Ltd., based in Israel, specializes in software packages that provide compliant radiation dose structured reporting and enhanced images from reduced dose CT scans. On March 24, 2017, we acquired an initial 12.5% equity interest in Medic Vision for $1.0 million. We also received an option to exercise warrants to acquire up to an additional 12.5% equity interest for $1.4 million within one year from the initial share purchase date, if exercised in full. On March 1, 2018 we exercised our warrant in part and acquired an additional 1.96% for $0.2 million. Our initial equity interest has been diluted to 12.25% and our total equity investment stands at 14.21%. In accordance with accounting guidance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as we exercise no significant influence over Medic Vision’s operations, the investment is recorded at its cost of $1.2 million, given that the fair value is not readily determinable. No observable price changes or impairment in our investment was identified as of September 30, 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Turner Imaging Systems, based in Utah, develops and markets portable X-ray imaging systems that provide a user the ability to acquire X-ray images wherever and whenever they are needed. On February 1, 2018, we purchased 2.1 million preferred shares in Turner Imaging Systems for $2.0 million. On January 1, 2019 we funded a convertible promissory note in the amount of $0.1 million that converted to additional 80,000 shares December 21, 2019. No observable price changes impairment in our investment was identified as of September 30, 2020.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WhiteRabbit.ai Inc., based in California, is currently developing an artificial intelligence suite which aims to improve the speed and accuracy of cancer detection in radiology and improve patient care. On November 5, 2019 we acquired an equity interest in the company for $1.0 million and also loaned the company $2.5 million, the principal of which is due November 2022. To leverage their artificial intelligence expertise, we entered into a software subscription service contract to assist our radiology work flow and advanced them $4.0 million for future software subscription fees that is recorded as a prepaid expense in Prepaid and Other Current assets in our consolidated balance sheets. No observable price changes or impairment in our investment or the loan receivable was identified as of September 30, 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVESTMENT IN JOINT VENTURES – We have </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> unconsolidated joint ventures with ownership interests ranging from 35% to 55%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures is accounted for under the equity method, since RadNet does not have a controlling financial interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of September 30, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joint venture investment contribution</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the month of August 2020, we made additional cash contributions to our Santa Monica Imaging Group, LLC partnership in the amount of $1.6 million in support of its expanded operations. We maintain our 35% economic interest in the partnership.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joint venture investment and financial information</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of our investment in joint ventures during the nine months ended September 30, 2020 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,470 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings in these joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution of earnings</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,706)</span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity contributions in existing joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,571 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We charged management service fees from the centers underlying these joint ventures of approximately $2.7 million and $1.8 million for the three months ended September 30, 2020 and 2019, respectively, and $8.6 million and $7.8 million for the nine months ended September 30, 2020 and 2019, respectively. We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of key balance sheet data for these joint ventures as of September 30, 2020 and December 31, 2019 and income statement data for the nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Sheet Data:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,618 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,427 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,487)</span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,217)</span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,751)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net assets</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,956 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,375 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Book value of RadNet joint venture interests</span></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,121 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,001 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost in excess of book value of acquired joint venture interests and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total value of Radnet joint venture interests</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,571 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,470 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total book value of other joint venture partner interests</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,835 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,374 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income statement data for the nine months ended September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,988 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,115 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,651 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> REVENUES - Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period when our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payors. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.<div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As it relates to the Group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by them as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total service revenues during the three and nine months ended September 30, 2020 and 2019 are presented in the table below based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:49.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.738%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial insurance</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,524 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,152 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,415 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,064 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,098 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,128 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,072 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,564 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers' compensation/personal injury</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other patient revenue</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,328 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,085 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,211 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,947 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teleradiology and Software revenue</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,412 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,319 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,861 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service fee revenue</span></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,730 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,908 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,760 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,751 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under capitation arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total service revenue</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,776 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,692 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763,905 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,338 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COVID-19 PANDEMIC AND CARES ACT FUNDING - On March 11, 2020 the World Health Organization (WHO) designated COVID-19 as a global pandemic. Patient volumes and the related revenues for our services were significantly impacted during the latter portion of the first quarter through the middle of the third quarter of 2020 as a result of federal, state and local government mandated restrictions requiring many people to remain at home and forced the closure of or limitations on certain businesses, as well as suspended elective procedures by health care facilities. Many of these restrictions have been eased or completely lifted across the states the Company operates in however, we are unable to predict the future impact of the pandemic on our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the nine months ended September 30, 2020, we received $39.4 million of accelerated Medicare payments, $5.0 million from Blue Cross, $25.7 million from the general distribution and $4.0 million from the Paycheck Protection Program established through the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. The accelerated Medicare payments are recorded under the caption “ Deferred Revenue“ in our condensed consolidated balance sheet and will be repaid beginning in 2021. The general distribution funds were accounted for as government grants and recognized as other revenue, once reasonable assurance that the applicable terms and conditions required to retain the funds were met, under the caption “Provider relief funding” in our condensed Consolidated Statements of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended September 30, 2020, the Department of Health and Human Services significantly changed the measurement of Provider Relief Funds that providers are able to retain. We received approximately $0.2 million in </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">funding and based on our assessment of the likelihood of meeting the applicable terms and conditions of the general distribution we continue to recognized the funds received as other revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The CARES Act also providers for a payment deferral of the employer portion of Social Security tax incurred during the pandemic, allowing half of such payroll taxes to be deferred until December 2021 and the remaining half until December 2022. At September 30, 2020, the Company had deferred $10.8 million of Social Security taxes. These payment deferrals are recorded as payroll tax liability under the caption “Accounts payable, accrued expenses and other” in our condensed consolidated balance sheet.</span></div>We believe the extent of the COVID-19 pandemic’s impact on our operating results and financial condition has been and will continue to be driven by many factors, most of which are beyond our control and ability to forecast. Such factors include, but are not limited to, the scope and duration of stay-at-home practices, business closures and restrictions, suspensions of elective procedures and continued decline in procedure volumes for an indeterminable length of time and incremental expenses required for supplies and personal protective equipment. Because of these uncertainties, we cannot estimate the length or impact of the pandemic on our business. If we incur declines in cash flows and results of operations, such declines could have an impact on the inputs and assumptions used in significant accounting estimates, including implicit prices concessions related to uninsured patient accounts, and potential impairment of goodwill and long-lived assets. During the third quarter of 2020, procedure volumes increased and have had a positive impact on our patient revenue. However, the impact of COVID-19 in future periods may vary and could adversely impact our results of operations. <div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total service revenues during the three and nine months ended September 30, 2020 and 2019 are presented in the table below based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:49.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.738%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial insurance</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,524 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,152 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,415 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,064 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,098 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,128 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,072 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,564 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers' compensation/personal injury</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other patient revenue</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,328 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,085 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,211 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,947 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teleradiology and Software revenue</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,412 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,319 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,861 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service fee revenue</span></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,730 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,908 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,760 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,751 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under capitation arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total service revenue</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,776 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,692 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763,905 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,338 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 160524000 163152000 412415000 475064000 62704000 61599000 154847000 175825000 7098000 7128000 18072000 21564000 7183000 10865000 25705000 32950000 8328000 6085000 17211000 17947000 2675000 1792000 8574000 5662000 2349000 4412000 8319000 12861000 5869000 6875000 15617000 20878000 256730000 261908000 660760000 762751000 35046000 30784000 103145000 90587000 291776000 292692000 763905000 853338000 39400000 5000000.0 25700000 4000000.0 200000 10800000 RECLASSIFICATION –We have reclassified certain amounts previously classified as held for sale related to property and equipment and goodwill to conform to our 2020 presentation. ACCOUNTS RECEIVABLE - Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience. In regards to the credit loss standard, we have concluded that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses estimated under the Current Expected Credit Loss ("CECL") model. 20400000 DEFERRED REVENUE - As noted above, in April of 2020, we received approximately $39.4 million in advanced Medicare payments from the Centers for Medicare and Medicaid Services ("CMS") as part of the expanded Accelerated and Advance Payment Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. As these payments are required to be repaid to CMS beginning 120 days after their receipt through offsets from new Medicare claims over a three month period, we have recorded amounts received to deferred revenue which will be amortized as Medicare reimbursements are earned. In addition, in May of 2020 we received $5.0 million in advance payments from an insurance carrier with similar repayment terms as the CMS. 39400000 5000000.0 DEFERRED FINANCING COSTS - Costs of financing are deferred and amortized using the effective interest rate method. Deferred financing costs, net of accumulated amortization, were $1.9 million and $1.6 million, as of September 30, 2020 and December 31, 2019, respectively and related to our Barclays line of credit. See Note 5, Credit Facilities and Notes Payable for more information. 1900000 1600000 PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation of property and equipment is performed using the straight-line method over the estimated useful lives of the assets acquired, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred. P3Y P15Y P3Y P15Y BUSINESS COMBINATION - When the qualifications for business combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations. <div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GOODWILL AND INDEFINITE LIVED INTANGIBLES - Goodwill at September 30, 2020 totaled $470.7 million. Indefinite lived intangible assets at September 30, 2020 were $11.3 million. Goodwill and Indefinite Lived Intangibles are recorded as a result of business combinations. When we determine the carrying value of reporting unit exceeds its fair value an impairment charge would be recognized and should not exceed the total amount of goodwill allocated to that reporting unit. We tested goodwill and indefinite lived intangibles for impairment on October 1, 2019, noting no impairment. In addition to the annual impairment test, we regularly assess if an event has occurred which would require interim impairment testing. We considered the current and expected future economic and market conditions surrounding the novel strain of coronavirus ("COVID-19") pandemic and did not identify an indication of goodwill impairment being more likely than not through September 30, 2020. Activity in goodwill for the nine months ended September 30, 2020 is provided below (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,973 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired through the acquisition of Olney Open MRI, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired through the acquisition of MRI at Woodbridge, LLC</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired through the acquisition of DeepHealth, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired through the acquisition of AZ-Tech Radiology &amp; Open MRI, LLC</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,685 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 470700000 11300000 Activity in goodwill for the nine months ended September 30, 2020 is provided below (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,973 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired through the acquisition of Olney Open MRI, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired through the acquisition of MRI at Woodbridge, LLC</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired through the acquisition of DeepHealth, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired through the acquisition of AZ-Tech Radiology &amp; Open MRI, LLC</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,685 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 441973000 601000 1833000 23396000 2882000 470685000 <div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INCOME TAXES - Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded an income tax expense of $3.8 million, or an effective tax rate of 27.2%, for the three months ended September 30, 2020 compared to an income tax expense of $1.8 million, or an effective tax rate of 26.3% for the three months ended September 30, 2019. We recorded an income tax benefit of $5.0 million, or an effective tax rate of 28.3%, for the nine months ended September 30, 2020 compared to an income tax expense of $3.6 million , or an effective tax rate of 24.8% for the nine months ended September 30, 2019.The income tax rates for the three and nine months ended September 30, 2020 diverge from the federal statutory rate due to (i) noncontrolling interests due to the controlled partnerships; (ii) effects of state income taxes; and (iii) excess tax benefits attributable to share-based compensation.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe no significant changes in the unrecognized tax benefits will occur within the next 12 months.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"). The CARES Act, among other things, includes certain income tax provisions for individuals and corporations; however, these benefits do not impact the Company’s current tax provision.</span></div> 3800000 0.272 1800000 0.263 -5000000.0 0.283 3600000 0.248 LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long term operating lease liability in our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liability, and long-term finance lease liability in our consolidated balance sheets.  ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments for both lease and non-lease components, we have elected to account for the components as a single lease component, as permitted. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the ROU asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tested for impairment if circumstances suggest that the carrying amount may not be recoverable. Our ROU assets consist of facility and equipment assets on operating leases. No events have occurred such as fire, flood, or other acts which have impaired the integrity of our ROU assets in 2020. Our facility leases require us to maintain insurance policies which would cover major damage to our facilities. We maintain business interruption insurance to cover loss of business due to a facility becoming non-operational under certain circumstances. Our equipment leases are covered by warranty and service contracts which cover repairs and provide regular maintenance to keep the equipment in functioning order.</span> EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated as of April 20, 2015, and again on March 9, 2017 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved 14,000,000 shares of common stock for issuance under the Restated Plan which can be issued in the form of options, stock awards, stock appreciation rights, stock units, and cash awards. Stock options generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmYzBiNTk3MDViZjRjZmY5MzZmNjE5MjkzYjFhMzA2L3NlYzpmZmMwYjU5NzA1YmY0Y2ZmOTM2ZjYxOTI5M2IxYTMwNl80My9mcmFnOjg0MWYyZmEzYjczMjRjYTk4YjlhNWU4MTg4OGZkNTVhL3RleHRyZWdpb246ODQxZjJmYTNiNzMyNGNhOThiOWE1ZTgxODg4ZmQ1NWFfMTY2Mzg_7bbe4cad-8aac-4d51-9911-a759df597876">three</span> to five years and expire <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmYzBiNTk3MDViZjRjZmY5MzZmNjE5MjkzYjFhMzA2L3NlYzpmZmMwYjU5NzA1YmY0Y2ZmOTM2ZjYxOTI5M2IxYTMwNl80My9mcmFnOjg0MWYyZmEzYjczMjRjYTk4YjlhNWU4MTg4OGZkNTVhL3RleHRyZWdpb246ODQxZjJmYTNiNzMyNGNhOThiOWE1ZTgxODg4ZmQ1NWFfMTY2NTg_8014eae6-0e25-46ab-80ed-ec3b42b893fd">five</span> to ten years from date of grant. We determine the compensation expense for each stock option award using the Black Scholes, or similar valuation model. Those models require that our management make certain estimates concerning risk free interest rates and volatility in the trading price of our common stock. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. In connection with our acquisition of DeepHealth Inc. on June 1, 2020, we assumed the DeepHealth, Inc. 2017 Stock Incentive Plan, including outstanding options awards that can be exercised for our common stock. No additional awards will be granted under the DeepHealth, Inc. 2017 Equity Incentive Plan. See Note 4, Facility Acquisitions and Note 6, Stock-Based Compensation, for more information. 14000000 P5Y P10Y COMPREHENSIVE INCOME (LOSS) - ASC 220 establishes rules for reporting and displaying comprehensive income or loss and its components. Our unrealized gains or losses on foreign currency translation adjustments, interest rate cap and swap agreements are included in comprehensive loss and are included in the consolidated statements of comprehensive income (loss) for the three and nine months ended September 30, 2020 and 2019 COMMITMENTS AND CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. Based on current information, we do not believe that reasonably possible or probable losses associated with pending legal proceedings would either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. Therefore, if one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected. <div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DERIVATIVE INSTRUMENTS</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2016 CAPS</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2016, we entered into two forward interest rate cap agreements ("2016 Caps"). The 2016 Caps will mature in September and October 2020. The 2016 Caps had notional amounts of $150,000,000 and $350,000,000, respectively. Under these arrangements, the Company purchased a cap on 3 month LIBOR at 2.0%. We incurred a $5.3 million premium to enter into the 2016 Caps which is being accrued over the life of the agreements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception, we designated our 2016 Caps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss of the hedge (i.e. change in fair value) is reported as a component of comprehensive loss in the consolidated statement of equity since such hedge has been determined to be effective. See Fair Value Measurements section below for the fair value of the 2016 Caps at September 30, 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss of the 2016 Caps is as follows (amounts in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Account</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 1, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of comprehensive gain recognized on derivative net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss, net of taxes</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,409)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,214)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Equity</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the nine months ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Account</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of comprehensive gain recognized on derivative net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss, net of taxes</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,877)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,214)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Equity</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2019 SWAPS</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2019, we entered into four forward interest rate agreements ("2019 Swaps"). The 2019 Swaps have total notional amounts of $500,000,000, consisting of two agreements of $50,000,000 each and two agreements of $200,000,000 each. The 2019 Swaps will secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They will mature in October 2023 for the smaller notional and October 2025 for the larger notional. Under these arrangements, we arranged the 2019 Swaps with locked in 1 month LIBOR rates at 1.96% for the $100,000,000 notional and at 2.05% for the $400,000,000 notional. As of the effective date, we will be liable for premium payments if interest rates decline below arranged rates, but will receive interest payments if rates remain above the arranged rates.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception, we designated our 2019 Swaps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e. change in fair value) is reported as a component of comprehensive loss in the consolidated statement of equity. The remaining gain or loss, if any, is recognized currently in earnings. As a result of the economic impact of the coronavirus pandemic, which precipitated a reduction in interest rates , the cash flows for both our $400,000,000 notional interest rate swap contract locked in at 2.05% due October 2025 and our $100,000,000 notional interest rate swap contract locked in at 1.96% do not match the cash flows for our First Lien Term Loans and so we have determined that they are not currently effective as cash flow hedges. Accordingly, all changes in their fair value after April 1, 2020 for the $400,000,000 notional and after July 1, 2020 for the $100,000,000 notional will be recognized in earnings. As of July 1, 2020, the total change in fair value relating to swaps included in other comprehensive income was approximately $24.4 million, net of taxes. This amount will be amortized to interest expense through October 2025 at approximately $0.4 million per month.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss of the 2019 swaps which remain ineffective is as follows (amounts in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"/><td style="width:36.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.534%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Account</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 1, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of comprehensive loss recognized on derivative net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss, net of taxes</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,406)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,437)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Equity</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:35.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.709%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the nine months ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Account</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of comprehensive loss recognized on derivative net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss, net of taxes</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,870)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,428)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,861 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,437)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Equity</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A tabular presentation of the effect of derivative instruments on our statement of operations of the 2019 Swaps for the Swaps that became ineffective during the third quarter is as follows (amounts in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:23.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.114%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ineffective interest rate swap</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of loss recognized in income on derivative (current period ineffective portion)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of loss recognized in Income on derivative (current period ineffective portion)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of loss reclassified from accumulated OCI into income (prior period effective portion)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of gain (Loss) reclassified from accumulated OCI into income (prior period effective portion)</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(679)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,312)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity and Interest Expense</span></td></tr></table></div> 2 150000000 350000000 0.020 5300000 A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss of the 2016 Caps is as follows (amounts in thousands):<div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Account</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 1, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of comprehensive gain recognized on derivative net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss, net of taxes</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,409)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,214)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Equity</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the nine months ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Account</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of comprehensive gain recognized on derivative net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss, net of taxes</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,877)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,214)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Equity</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss of the 2019 swaps which remain ineffective is as follows (amounts in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"/><td style="width:36.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.534%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Account</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 1, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of comprehensive loss recognized on derivative net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss, net of taxes</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,406)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,437)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Equity</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:35.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.709%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the nine months ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Account</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of comprehensive loss recognized on derivative net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020 Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss, net of taxes</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,870)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,428)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,861 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,437)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Equity</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A tabular presentation of the effect of derivative instruments on our statement of operations of the 2019 Swaps for the Swaps that became ineffective during the third quarter is as follows (amounts in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:23.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.114%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ineffective interest rate swap</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of loss recognized in income on derivative (current period ineffective portion)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of loss recognized in Income on derivative (current period ineffective portion)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of loss reclassified from accumulated OCI into income (prior period effective portion)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of gain (Loss) reclassified from accumulated OCI into income (prior period effective portion)</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(679)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,312)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity and Interest Expense</span></td></tr></table></div> -1409000 195000 -1214000 -1877000 663000 -1214000 4 500000000 50000000 200000000 0.0196 100000000 0.0205 400000000 400000000 0.0205 100000000 0.0196 400000000 100000000 24400000 400000 -24406000 0 -969000 -23437000 -5870000 -19428000 -1861000 -23437000 679000 1312000 4523000 2204000 <div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Derivatives:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below summarize the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets on our condensed consolidated balance sheets, as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current and long term liabilities</span></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 caps - Interest Rate Contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 swaps - Interest Rate Contracts</span></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,983 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,983 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current and long term liabilities</span></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 caps - Interest Rate Contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 swaps - Interest Rate Contracts</span></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,477 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,477 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty’s forward LIBOR curve. The forward LIBOR curve is readily available in the public markets or can be derived from information available in the public markets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Long Term Debt:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the estimated fair value compared to our face value of our long-term debt as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Face Value</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Lien Term Loans and SunTrust Term Loan</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,140 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,140 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673,227 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Face Value</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Lien Term Loans and SunTrust Term Loan</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,948 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,948 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705,699 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and at December 31, 2019 our Barclays revolving credit facility had no balance outstanding. Our SunTrust revolving credit facility relating to our consolidated subsidiary NJIN, had no principal amount outstanding at September 30, 2020 and at December 31, 2019.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our long-term debt, which is discussed in Note 5, was determined using Level 2 inputs primarily related to comparable market prices.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our finance lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.</span></div> The tables below summarize the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets on our condensed consolidated balance sheets, as follows (in thousands):<div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current and long term liabilities</span></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 caps - Interest Rate Contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 swaps - Interest Rate Contracts</span></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,983 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,983 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current and long term liabilities</span></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 caps - Interest Rate Contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 swaps - Interest Rate Contracts</span></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,477 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,477 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the estimated fair value compared to our face value of our long-term debt as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Face Value</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Lien Term Loans and SunTrust Term Loan</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,140 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,140 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673,227 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Face Value</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Lien Term Loans and SunTrust Term Loan</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,948 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,948 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705,699 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 182000 0 182000 0 39983000 0 39983000 0 1081000 0 1081000 0 9477000 0 9477000 0 663140000 0 663140000 673227000 0 708948000 0 708948000 705699000 0 0 0 0 EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"/><td style="width:51.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.182%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#eeeeee;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="9" style="background-color:#eeeeee;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to RadNet, Inc.'s common stockholders</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,156 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,195 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,797)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,360 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,358,603 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,807,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,746,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,597,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,358,603 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,807,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,746,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,597,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add nonvested restricted stock subject only to service vesting</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,605 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,567 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,375 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add additional shares issuable upon exercise of stock options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares used in calculating diluted net income per share</span></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,955,815 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,360,360 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,746,380 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,113,306 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income (loss) per share attributable to RadNet, Inc.'s common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and non vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested restricted stock subject to service vesting</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,659 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon the exercise of stock options:</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,948 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933,370 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"/><td style="width:51.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.182%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#eeeeee;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="9" style="background-color:#eeeeee;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to RadNet, Inc.'s common stockholders</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,156 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,195 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,797)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,360 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,358,603 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,807,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,746,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,597,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,358,603 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,807,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,746,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,597,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add nonvested restricted stock subject only to service vesting</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,605 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,567 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,375 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add additional shares issuable upon exercise of stock options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares used in calculating diluted net income per share</span></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,955,815 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,360,360 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,746,380 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,113,306 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income (loss) per share attributable to RadNet, Inc.'s common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and non vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested restricted stock subject to service vesting</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,659 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon the exercise of stock options:</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,948 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933,370 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 6156000 3195000 -20797000 4360000 51358603 49807460 50746380 49597138 0.12 0.06 -0.41 0.09 51358603 49807460 50746380 49597138 120605 200567 191375 476607 352333 324793 51955815 50360360 50746380 50113306 0.12 0.06 -0.41 0.09 0 0 331659 0 48948 0 933370 0 EQUITY INVESTMENTS AT FAIR VALUE–Accounting guidance requires entities to measure equity investments at fair value, with any changes in fair value recognized in net income. If there is no readily determinable fair value, the guidance allows entities the ability to measure investments at cost, adjusted for observable price changes and impairments, with changes recognized in net income. 0.125 1000000.0 0.125 1400000 0.0196 200000 0.1225 0.1421 1200000 2100000 2000000.0 100000 80000 1000000.0 2500000 4000000.0 <div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVESTMENT IN JOINT VENTURES – We have </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> unconsolidated joint ventures with ownership interests ranging from 35% to 55%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures is accounted for under the equity method, since RadNet does not have a controlling financial interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of September 30, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joint venture investment contribution</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the month of August 2020, we made additional cash contributions to our Santa Monica Imaging Group, LLC partnership in the amount of $1.6 million in support of its expanded operations. We maintain our 35% economic interest in the partnership.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joint venture investment and financial information</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of our investment in joint ventures during the nine months ended September 30, 2020 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,470 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings in these joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution of earnings</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,706)</span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity contributions in existing joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,571 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We charged management service fees from the centers underlying these joint ventures of approximately $2.7 million and $1.8 million for the three months ended September 30, 2020 and 2019, respectively, and $8.6 million and $7.8 million for the nine months ended September 30, 2020 and 2019, respectively. We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of key balance sheet data for these joint ventures as of September 30, 2020 and December 31, 2019 and income statement data for the nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Sheet Data:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,618 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,427 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,487)</span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,217)</span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,751)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net assets</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,956 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,375 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Book value of RadNet joint venture interests</span></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,121 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,001 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost in excess of book value of acquired joint venture interests and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total value of Radnet joint venture interests</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,571 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,470 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total book value of other joint venture partner interests</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,835 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,374 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income statement data for the nine months ended September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,988 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,115 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,651 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 12 0.35 0.55 1600000 0.35 <div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of our investment in joint ventures during the nine months ended September 30, 2020 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,470 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings in these joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution of earnings</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,706)</span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity contributions in existing joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,571 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 34470000 5176000 5706000 1631000 35571000 2700000 1800000 8600000 7800000 <div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of key balance sheet data for these joint ventures as of September 30, 2020 and December 31, 2019 and income statement data for the nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Sheet Data:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,618 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,427 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,487)</span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,217)</span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,751)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net assets</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,956 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,375 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Book value of RadNet joint venture interests</span></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,121 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,001 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost in excess of book value of acquired joint venture interests and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total value of Radnet joint venture interests</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,571 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,470 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total book value of other joint venture partner interests</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,835 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,374 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income statement data for the nine months ended September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,988 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,115 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,651 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 26618000 27427000 70576000 61037000 10487000 9217000 22751000 18872000 63956000 60375000 29121000 28001000 6450000 6469000 35571000 34470000 34835000 32374000 78988000 80115000 13651000 13718000 RECENT ACCOUNTING AND REPORTING STANDARDS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting standards adopted</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13 ("ASU 2016-13), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2016-13 replaces the incurred loss methodology previously utilized for valuing financial instruments with an expected loss methodology that is referred to as the current expected credit loss (CECL) methodology. We prospectively adopted the standard on January 1, 2020 and the adoption did not have a material impact to the condensed consolidated financial statements, resulting in no adjustments to our prior year earnings. See the Accounts Receivable section to Note 2 for further information on our allowances for credit losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-15 (“ASU 2018-15”), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles-Goodwill and Other-Internal-Use Software.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2018-15 aligns the requirements for deferring implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This ASU is effective in the first quarter of 2020 with early adoption permitted and can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The adoption of this standard did not have a material impact on our condensed consolidated balance sheet.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-03 ("ASU 2020-03"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments in this update represent changes to clarify or improve the codification and correct unintended application. ASU 2020-03 was effective immediately upon issuance and its adoption did not have a material impact on our financial statements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-13 ("ASU 2018-13"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard removes, modifies and adds certain disclosures related to recurring and nonrecurring fair value measurements. We adopted ASC 2018-13 effective January 1, 2020 and it had no effect on our disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting standards not yet adopted</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12 ("ASU 2019-12"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other areas of the standard. ASU 2019-12 will be effective beginning in the first quarter of 2021. Early adoption is permitted. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. We are currently evaluating the impact this ASU will have on our financial statements and related disclosures as well as the timing of adoption.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU 2020-01 ("ASU 2020-01"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clarifying the interaction between accounting standards related to equity securities, equity method investments, and certain derivatives. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020. We do not expect the adoption of this guidance will have a material impact on our financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04 ("ASU 2020-04"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2020-04 provides optional expedients and exceptions for applying generally accepted accounting principles to certain contract modifications and hedging relationships that reference London Inter-bank Offered Rate (LIBOR) or another reference rate expected to be discontinued. The guidance is effective upon issuance and generally can be applied through December 31, 2022. We are currently evaluating the potential impact of ASU 2020-04 on our financial statements.</span></div> RECENT ACCOUNTING AND REPORTING STANDARDS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting standards adopted</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13 ("ASU 2016-13), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2016-13 replaces the incurred loss methodology previously utilized for valuing financial instruments with an expected loss methodology that is referred to as the current expected credit loss (CECL) methodology. We prospectively adopted the standard on January 1, 2020 and the adoption did not have a material impact to the condensed consolidated financial statements, resulting in no adjustments to our prior year earnings. See the Accounts Receivable section to Note 2 for further information on our allowances for credit losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-15 (“ASU 2018-15”), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles-Goodwill and Other-Internal-Use Software.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2018-15 aligns the requirements for deferring implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This ASU is effective in the first quarter of 2020 with early adoption permitted and can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The adoption of this standard did not have a material impact on our condensed consolidated balance sheet.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-03 ("ASU 2020-03"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments in this update represent changes to clarify or improve the codification and correct unintended application. ASU 2020-03 was effective immediately upon issuance and its adoption did not have a material impact on our financial statements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-13 ("ASU 2018-13"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard removes, modifies and adds certain disclosures related to recurring and nonrecurring fair value measurements. We adopted ASC 2018-13 effective January 1, 2020 and it had no effect on our disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting standards not yet adopted</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12 ("ASU 2019-12"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other areas of the standard. ASU 2019-12 will be effective beginning in the first quarter of 2021. Early adoption is permitted. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. We are currently evaluating the impact this ASU will have on our financial statements and related disclosures as well as the timing of adoption.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU 2020-01 ("ASU 2020-01"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clarifying the interaction between accounting standards related to equity securities, equity method investments, and certain derivatives. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020. We do not expect the adoption of this guidance will have a material impact on our financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04 ("ASU 2020-04"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2020-04 provides optional expedients and exceptions for applying generally accepted accounting principles to certain contract modifications and hedging relationships that reference London Inter-bank Offered Rate (LIBOR) or another reference rate expected to be discontinued. The guidance is effective upon issuance and generally can be applied through December 31, 2022. We are currently evaluating the potential impact of ASU 2020-04 on our financial statements.</span></div> FACILITY ACQUISITIONS AND DISPOSITIONS<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions:</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31, 2020 we completed our acquisition of certain assets of AZ-Tech Radiology &amp; Open MRI, LLC, consisting of eight multi-modality imaging centers located in the Phoenix, Arizona area for purchase consideration of $5.5 million. We made a preliminary fair value determination of the acquired assets and assumed liabilities and approximately $2.5 million in property and equipment, $7.6 million in right-of-use assets, $0.1 million in other assets, $7.6 million in operating lease liabilities, and $2.9 million in goodwill were recorded.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2020, we completed our acquisition of all the equity interests of DeepHealth Inc., ("DeepHealth") an artificial intelligence and machine learning company in an all stock purchase. As initial purchase consideration, we issued 915,132 shares at $16.93 per share (823,615 issued at execution, with up to 91,517 shares to be issued 18 months after acquisition subject to adjustment for any indemnification claims). The transaction was accounted for as an acquisition of a business and total purchase consideration determined to be approximately $34.6 million including i) 823,615 shares issued on the date of closing with fair value of $13.9 million, ii) a liability of 91,517 shares with a fair value of $1.5 million to be issued 18 months after acquisition subject to adjustment for any indemnification claims and will be marked to market in subsequent periods, iii) replacement awards attributable to pre-combination service issued to DeepHealth option holders with allocated fair value of $2.0 million, iv) acquisition date fair value of contingent consideration of $17.0 million and v) $0.1 million in closing costs reimbursed to the seller. The fair values of replacement awards attributable to pre-combination service and contingent consideration are recorded in additional paid in capital upon closing of the transaction. For the contingent consideration, there are three arrangements that will be settled in a fixed number of shares upon achievement of three individual specific milestones which are mutually exclusive of each other, with 390,789, 586,184, and 195,393 shares, respectively, issuable for each milestone arrangement. The fair value of the contingent consideration was estimated at the date of acquisition based on our share price and estimated probability of the achievement of the respective milestones. We preliminarily recorded $0.1 million in current assets, $3.5 million in deferred tax liabilities, $14.8 million in intangible assets, primarily in-process research and development ("IPR&amp;D'), and $23.4 million in goodwill. The goodwill is primarily attributable to expected post-acquisition synergies from integrating DeepHealth’s assembled workforce and IPR&amp;D technologies. The fair values of the identifiable intangible assets related to IPR&amp;D were determined by the income method and the assets will not be amortized until completion. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 2, 2020 our consolidated subsidiary New Jersey Imaging Networks ("NJIN") completed the acquisition of certain assets of MRI at Woodbridge, LLC consisting of a single multi-modality imaging center located in Avenel, New Jersey for cash consideration of $2.6 million. NJIN made a fair value determination of the acquired assets and assumed liabilities and approximately $0.5 million in property and equipment, $1.1 million in right-of-use assets, $0.3 million in intangible assets, $1.1 million in operating lease liabilities, $0.1 million in finance lease liabilities, and $1.8 million in goodwill were recorded.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    On January 2, 2020 we completed our acquisition of certain assets of Olney Open MRI, LLC, consisting of a single multi-modality imaging center located in Columbia, Maryland for cash consideration of $1.8 million. We have made a fair value determination of the acquired assets and assumed liabilities and approximately $0.8 million in property and equipment, $1.3 million in right-of-use assets, $0.3 million in intangible assets, $1.3 million in operating lease liabilities and $0.6 million in goodwill were recorded.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dispositions:</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2020 we completed our sale of certain assets of our Imaging On Call subsidiary to RadVantage P.C. (an unrelated corporation) for approximately $1.0 thousand. With this transaction, we have exited the teleradiology business.</span></div> 8 5500000 2500000 7600000 100000 7600000 2900000 915132 16.93 823615 91517 P18M 34600000 823615 13900000 91517 1500000 P18M 2000000.0 17000000.0 100000 390789 586184 195393 100000 3500000 14800000 23400000 2600000 500000 1100000 300000 1100000 100000 1800000 1800000 800000 1300000 300000 1300000 600000 1000.0 CREDIT FACILITIES AND NOTES PAYABLE<div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and December 31, 2019 our debt obligations consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.953%"><tr><td style="width:1.0%"/><td style="width:74.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.841%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Lien Term Loans collateralized by RadNet's tangible and intangible assets</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,727 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649,824 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts on First Lien Term Loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SunTrust Term Loan Agreement collateralized by NJIN's tangible and intangible assets</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,500 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,875 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paycheck Protection Program loans at 1% due April 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment note payable at 4.6%, due through 2020, collateralized by medical equipment</span></div></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,642 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692,395 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,463)</span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,691)</span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term portion debt obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,179 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652,704 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in our condensed consolidated balance sheets at September 30, 2020 are $620.7 million of First Lien Term Loans and $52.5 million of SunTrust Term Loan debt for a combined total of $673.2 million of total term loan debt (exclusive of unamortized discounts of $10.7 million) in thousands: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:61.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Face Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Lien Term Loans</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,727 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,669)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610,058 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SunTrust Term Loan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Term Loans</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673,227 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,669)</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662,558 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no balance under our $195.0 million Barclays Revolving Credit Facility at September 30, 2020 and have reserved $6.3 million for certain letters of credit. The remaining $188.7 million of our Barclays Revolving Credit Facility was available to draw upon as of September 30, 2020. We had no balance under our $30.0 million SunTrust Revolving Credit Facility related to our consolidated subsidiary NJIN at September 30, 2020.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Barclays Credit Facilities:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020, (a) our Barclays credit facilities were comprised of one tranche of term loans (“First Lien Term Loans”) and a revolving credit facility of $195.0 million (the “Barclays Revolving Credit Facility”) and (b) our SunTrust credit facilities, which relate to our consolidated subsidiary NJIN, were comprised of one term loan (the "SunTrust Term Loan") and a revolving credit facility of $30.0 million (the "SunTrust Revolving Credit Facility").</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, we were in compliance with all covenants under our credit facilities. Deferred financing costs at September 30, 2020, net of accumulated amortization, was $1.9 million and is specifically related to our Barclays Revolving Credit Facility.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our First Lien Term Loans bear interest at either an Adjusted Eurodollar Rate or a Base Rate, plus an applicable margin according to the following schedule:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.181%"><tr><td style="width:1.0%"/><td style="width:31.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.508%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First Lien Leverage Ratio</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eurodollar Rate Spread</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Base Rate Spread</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; 5.50x</span></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; 4.00x but ≤ 5.50x</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75%</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75%</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;3.50x but ≤ 4.00x</span></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">≤ 3.50x</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25%</span></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020 the effective Adjusted Eurodollar Rate and the Base Rate for the First Lien Term Loans was 1.00% and 3.25%, respectively and the applicable margin for Adjusted Eurodollar Rate and Base Rate borrowings was 3.75% and 2.75%, respectively. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The First Lien Credit Agreement provides for quarterly payments of principal under the First Lien Term Loans in the amount of approximately $9.7 million. The First Lien Term Loans will mature on July 21, 2023 unless otherwise accelerated under the terms of the First Lien Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">SunTrust Credit Facilities:</span></div><div style="margin-top:1pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our SunTrust Term Loan bears interest at either an Adjusted Eurodollar Rate or a Base Rate, plus an applicable margin according to the following schedule:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.859%"><tr><td style="width:1.0%"/><td style="width:8.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.099%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.099%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Level</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leverage Ratio</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Applicable Margin for Eurodollar Loans</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Applicable Margin for Base Rate Loans</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Applicable Margin for Letter of Credit Fees</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Applicable Percentage for Commitment Fee</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than or equal to 3.00:1.00</span></div></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.85pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.85pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.85pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.85pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 3.00:1.00 but greater than or equal to 2.50:1.00</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.85pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.85pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.85pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.85pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 2.50:1.00 but greater than or equal to</span></div><div style="margin-top:2.9pt;padding-left:4.5pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00:1.00</span></div></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 2.00:1.00 but greater than or equal to 1.50:1.00</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></div><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></div><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></div><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></div><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">V</span></td><td colspan="3" style="background-color:#eeeeee;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1.50:1.00</span></div></td><td colspan="3" style="background-color:#eeeeee;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></div><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</span></div><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></div><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></div><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loans and other obligations outstanding under the SunTrust Restated Credit Agreement currently bear applicable margin and fees based on Pricing Level III described above. The loans outstanding under the SunTrust Restated Credit Agreement currently bear interest based on a three month Eurodollar election of 2.00%, plus the applicable margin. </span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:31.5pt"><span><br/></span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scheduled amortization of the SunTrust Term Loan began December 31, 2018 with quarterly payments of $0.8 million, representing annual amortization equal to 5.00% of the original principal amount of the SunTrust Term Loan. At scheduled intervals, the quarterly amortization increases by $0.4 million, with the remaining balance to be paid at maturity. The SunTrust Term Loan will mature on August 1, 2023 unless otherwise accelerated under the terms of the SunTrust credit facility.</span></div><div><span><br/></span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:31.5pt"><span><br/></span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revolving Credit Facilities</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Barclays Revolving Credit Facility</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revolving loans borrowed under the Barclays Revolving Credit Facility bear interest at either an Adjusted Eurodollar Rate or a Base Rate plus an applicable margin. Rates of the applicable margin for borrowing under the Revolving Credit Facility also change depending on our leverage ratio and are the same rates as noted in the schedule above for First Lien Term Loans. As of September 30, 2020, the effective interest rate payable on revolving loans was 6.00%.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Letters of credit issued under the Barclays Revolving Credit Facility, letter of credit fees accrue at the applicable margin of Adjusted Eurodollar Rate, currently 3.75% , and fronting fees accrue at 0.25% per annum, in each case on the average aggregate daily maximum amount available to be drawn under all letters of credit issued under the First Lien Credit Agreement. In addition, a commitment fee of 0.50% per annum accrues on the unused revolver commitments under the Revolving Credit Facility.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Barclays Revolving Credit Facility will terminate on the earliest to occur of July 1, 2023 or its earlier termination to specific events of default pursuant to the First Lien Credit Agreement.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Barclays Revolving Credit Facility was amended in August 2020 to add $57.5 million of revolving commitments and extend the maximum borrowing capacity to $195.0 million. Total issue costs added in relation to the eighth amendment amounted to approximately $0.7 million and was capitalized as deferred financing costs and will be amortized over the remaining term of the agreement.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">SunTrust Revolving Credit Facility</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our SunTrust Revolving Credit Facility is available to NJIN for funding requirements, with an available borrowing limit of $30.0 million. Revolving loan borrowed under the SunTrust Revolving Credit Facility bear interest at either an Adjusted Eurodollar Rate or a Base Rate plus an applicable margin. Rates of the applicable margin for borrowing under the Revolving Credit Facility also change depending on our leverage ration and are the same rates noted in the schedule above for the SunTrust Term Loan. The SunTrust Revolving Credit Facility terminates on August 31, 2023 unless all amounts outstanding otherwise have been declared or have automatically become due and payable (whether by acceleration or otherwise). NJIN has not borrowed against the revolving credit line.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recent Amendments to credit facilities:</span></div><div style="margin-top:10pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Barclays Credit Facilities:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 28, 2020, RadNet, Inc. entered into Amendment No. 8, Consent and Incremental Joinder Agreement to Credit and Guaranty Agreement "the Eighth Amendment". The Eighth Amendment amends the First Lien Credit Agreement to add $57.5 million of revolving commitments to the Barclays Revolving Credit Facility extending the maximum borrowing capacity under the revolving credit facility to $195.0 million while leaving the maturity date of July 1, 2023 unchanged. Total issue costs added in relation to the Eighth Amendment amounted to approximately $0.7 million and was capitalized as deferred financing costs and will be amortized over the remaining term of the agreement.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2019 we entered into the following two amendments to the First Lien Credit Agreement: (i) Amendment No. 6, Consent and Incremental Joinder Agreement to Credit and Guaranty Agreement (the “Sixth Amendment”); and (ii) Amendment No. 7 to Credit and Guaranty Agreement (the “Seventh Amendment”). The Sixth Amendment amended the First Lien Credit Agreement to issue $100.0 million in incremental First Lien Term Loans and to add an additional $20.0 million of revolving commitments to the Barclay's Revolving Credit Facility. The Seventh Amendment amended the First Lien Credit Agreement to extend the maturity date of the Barclays Revolving Credit Facility by an additional two years to July 1, 2023, unless sooner terminated in accordance with the terms of the First Lien Credit Agreement. Total issue costs added in relation to the Sixth and Seventh amendments in 2019 amounted to approximately $4.4 million. Of this amount, $2.1 million was identified and capitalized as discount on debt, $0.7 million was capitalized as deferred financing costs, and $1.6 million was expensed. Amounts capitalized will be amortized over the remaining term of the agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:10pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paycheck Protection Program</span></div>The Paycheck Protection Program (PPP) includes funds available for loans to small business and Medicare providers to support operations during the COVID-19 pandemic. The funds are administered by the Small Business Administration (SBA), through approved lenders and do not require collateral or personal guarantees. We received our loans based on being a Medicare provider. The terms and conditions for participation require entities to certify that economic uncertainty related to the COVID-19 pandemic makes the loan necessary to support their current operations, and that they will use the funds to retain workers (e.g., by paying salaries, providing paid sick/medical leave and health insurance benefits) and pay certain debts (mortgage obligations) and expenses (e.g. rent, utilities, telephone). The loans have a 1.0% fixed interest rate and are due in 2 years. Initial repayments have been deferred for six months. The loans are eligible for forgiveness subject to salary limitations and employee retention levels. Certain of our consolidated subsidiaries received four loans totaling $4.0 million. We have accounted for the funds received as debt and recorded a liability for the full amount of proceeds received. Interest will be accrued over the term of the loans. If we meet the eligibility requirements for forgiveness the amounts forgiven will be recognized in the income statement as a gain on loan extinguishment in accordance with accounting guidance. <div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and December 31, 2019 our debt obligations consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.953%"><tr><td style="width:1.0%"/><td style="width:74.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.841%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Lien Term Loans collateralized by RadNet's tangible and intangible assets</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,727 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649,824 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts on First Lien Term Loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SunTrust Term Loan Agreement collateralized by NJIN's tangible and intangible assets</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,500 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,875 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paycheck Protection Program loans at 1% due April 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment note payable at 4.6%, due through 2020, collateralized by medical equipment</span></div></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,642 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692,395 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,463)</span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,691)</span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term portion debt obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,179 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652,704 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 620727000 649824000 10669000 13579000 52500000 55875000 0.01 4037000 0.046 47000 275000 666642000 692395000 39463000 39691000 627179000 652704000 <div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in our condensed consolidated balance sheets at September 30, 2020 are $620.7 million of First Lien Term Loans and $52.5 million of SunTrust Term Loan debt for a combined total of $673.2 million of total term loan debt (exclusive of unamortized discounts of $10.7 million) in thousands: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:61.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Face Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Lien Term Loans</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,727 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,669)</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610,058 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SunTrust Term Loan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Term Loans</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673,227 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,669)</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662,558 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 620700000 52500000 673200000 10700000 620727000 10669000 610058000 52500000 0 52500000 673227000 10669000 662558000 0 0 195000000.0 6300000 188700000 0 30000000.0 195000000.0 30000000.0 1900000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our First Lien Term Loans bear interest at either an Adjusted Eurodollar Rate or a Base Rate, plus an applicable margin according to the following schedule:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.181%"><tr><td style="width:1.0%"/><td style="width:31.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.508%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First Lien Leverage Ratio</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eurodollar Rate Spread</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Base Rate Spread</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; 5.50x</span></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; 4.00x but ≤ 5.50x</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75%</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75%</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;3.50x but ≤ 4.00x</span></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">≤ 3.50x</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25%</span></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our SunTrust Term Loan bears interest at either an Adjusted Eurodollar Rate or a Base Rate, plus an applicable margin according to the following schedule:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.859%"><tr><td style="width:1.0%"/><td style="width:8.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.099%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.099%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Level</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leverage Ratio</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Applicable Margin for Eurodollar Loans</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Applicable Margin for Base Rate Loans</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Applicable Margin for Letter of Credit Fees</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Applicable Percentage for Commitment Fee</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than or equal to 3.00:1.00</span></div></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.85pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.85pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.85pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.85pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 3.00:1.00 but greater than or equal to 2.50:1.00</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.85pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.85pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.85pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.85pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 2.50:1.00 but greater than or equal to</span></div><div style="margin-top:2.9pt;padding-left:4.5pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00:1.00</span></div></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35%</span></div><div style="margin-top:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 2.00:1.00 but greater than or equal to 1.50:1.00</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></div><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></div><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></div><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></div><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">V</span></td><td colspan="3" style="background-color:#eeeeee;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1.50:1.00</span></div></td><td colspan="3" style="background-color:#eeeeee;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></div><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</span></div><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></div><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td><td colspan="3" style="background-color:#eeeeee;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></div><div style="margin-top:2.9pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">per annum</span></div></td></tr></table></div> 0.0450 0.0350 0.0375 0.0275 0.0350 0.0250 0.0325 0.0225 0.0100 0.0325 0.0375 0.0275 9700000 3.00 0.0275 0.0175 0.0275 0.0045 3.00 2.50 0.0225 0.0125 0.0225 0.0040 2.50 2.00 0.0200 0.0100 0.0200 0.0035 2.00 1.50 0.0175 0.0075 0.0175 0.0030 1.50 0.0150 0.0050 0.0150 0.0030 0.0200 800000 0.0500 400000 0.0600 0.0375 0.0025 0.0050 57500000 195000000.0 700000 30000000.0 57500000 195000000.0 700000 100000000.0 20000000.0 4400000 2100000 700000 1600000 0.010 P2Y 4 4000000.0 STOCK-BASED COMPENSATIONStock Incentive Plans<div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one long-term equity incentive plan which we refer to as the 2006 Equity Incentive Plan, which we first amended and restated as of April 20, 2015 and again on March 9, 2017 (the "Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved for issuance under the Restated Plan 14,000,000 shares of common stock. We can issue options (incentive and non-qualified), stock awards, stock appreciation rights, stock units and cash awards under the Restated Plan.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options generally vest over 3 to 5 years and expire 5 to 10 years from the date of grant.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, we had outstanding options to acquire 527,899 shares of our common stock, of which options to acquire 298,863 shares were exercisable. The following summarizes all of our option transactions for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:48.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Options<br/>Under the 2006 Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise price<br/>Per Common Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,951 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.21 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527,899 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.34 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.59</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,419,956 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,863 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on September 30, 2020 and the exercise price, multiplied by the number of in-the-money options as applicable) that would have been received by the holder had all holders exercised their options on September 30, 2020. No options were exercised during the nine months ended September 30, 2020. As of September 30, 2020, total unrecognized stock-based compensation expense related to non-vested employee awards was $0.7 million which is expected to be recognized over a weighted average period of approximately 1.68 years.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">DeepHealth Options</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of fiscal 2020, in connection with the completion of the DeepHealth acquisition, we granted 412,434 options at a grant date fair value of $16.93 per share unit to DeepHealth employees in replacement of their stock options that were outstanding as of the closing date. As of September 30, 2020, total unrecognized stock based compensation expense related to non-vested DeepHealth options was approximately $4.3 million which is expected to be recognized over a weighted average period of approximately 2.53 years.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"><tr><td style="width:1.0%"/><td style="width:48.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.711%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.711%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.711%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Options<br/>Under the Deep Health Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise price<br/>Per Common Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted, June 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,963)</span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.65</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,223,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,211 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.65</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,639 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Plan permits the award of restricted stock awards (“RSA’s”). As of September 30, 2020, we have issued a total of 6,551,872 RSA’s of which 331,659 were unvested at September 30, 2020. The following summarizes all unvested RSA’s activities during the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSA's</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSA's unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,934 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.61 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,596 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.66 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513,871)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSA's unvested at September 30, 2020</span></td><td colspan="2" style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,659 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.11</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.67 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of all RSA’s based on the closing price of our common stock on the award date.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other stock bonus awards</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Plan also permits the award of stock bonuses not subject to any future service period. These awards are valued and expensed based on the closing price of our common stock on the date of award. During the nine months ended September 30, 2020 awards totaling 26,078 shares were granted.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan summary</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In summary, of the 14,000,000 shares of common stock reserved for issuance under the Restated Plan, at September 30, 2020, we had issued 15,384,316 total shares between options, RSA’s and other stock awards. With options canceled and RSA’s forfeited amounting to 3,281,040 and 61,703 shares, respectively, there remain 1,958,427 shares available under the Restated Plan for future issuance.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DeepHealth options were issued outside of the Restated Plan and are a direct result of our acquisition and not included in the share count of the Restated Plan.</span></div> 14000000 P3Y P5Y P5Y P10Y 527899 298863 The following summarizes all of our option transactions for the nine months ended September 30, 2020:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:48.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Options<br/>Under the 2006 Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise price<br/>Per Common Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,951 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.21 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527,899 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.34 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.59</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,419,956 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,863 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"><tr><td style="width:1.0%"/><td style="width:48.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.711%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.711%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.711%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Options<br/>Under the Deep Health Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise price<br/>Per Common Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted, June 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,963)</span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.65</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,223,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,211 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.65</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,639 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 478951 8.21 48948 20.43 527899 9.34 P6Y7M2D 3419956000 298863 7.48 P5Y10M6D 2353438000 0 700000 P1Y8M4D 412434 16.93 4300000 P2Y6M10D 0 412434 6963 405471 P8Y7M24D 6223980000 24211 P8Y7M24D 371639000 6551872 331659 The following summarizes all unvested RSA’s activities during the nine months ended September 30, 2020:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSA's</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSA's unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,934 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.61 </span></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,596 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.66 </span></td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513,871)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSA's unvested at September 30, 2020</span></td><td colspan="2" style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,659 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td colspan="3" style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.11</span></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"/><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.67 </span></td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 387934 11.61 457596 19.66 513871 15.47 331659 P1Y1M9D 16.67 26078 14000000 15384316 3281040 61703 1958427 SUBSEQUENT EVENTS<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Formation of majority owned subsidiary</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2020 we formed in conjunction with Simi Valley Hospital and Health Services ("Simi Adventist") the Simi Valley Imaging Group, LLC (“SVIG”), consisting of three multi-modality imaging centers located in Simi Valley, CA. RadNet will hold a 60% economic interest in SVIG and Simi Adventist will have the remaining 40% interest.</span></div> 3 0.60 0.40 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page - shares
9 Months Ended
Sep. 30, 2020
Nov. 05, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2020  
Document Transition Report false  
Entity File Number 001-33307  
Entity Registrant Name RadNet, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 13-3326724  
Entity Address, Address Line One 1510 Cotner Avenue  
Entity Address, City or Town Los Angeles,  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 90025  
City Area Code 310  
Local Phone Number 478-7808  
Entity Current Reporting Current Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Title of 12(b) Security Common Stock  
Trading Symbol RDNT  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   51,636,099
Entity Central Index Key 0000790526  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2020  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
CURRENT ASSETS    
Cash and cash equivalents $ 89,739 $ 40,165
Accounts receivable 137,411 154,763
Due from affiliates 424 1,242
Prepaid expenses and other current assets 31,482 45,004
Total current assets 259,056 241,174
PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS    
Property and equipment, net 361,950 367,795
Operating lease right-of-use assets 451,613 445,477
Total property, equipment and right-of-use assets 813,563 813,272
OTHER ASSETS    
Goodwill 470,685 441,973
Other intangible assets 57,152 42,994
Deferred financing costs 1,944 1,559
Investment in joint ventures 35,571 34,470
Deferred tax assets, net of current portion 42,188 34,548
Deposits and other 37,707 36,996
Total assets 1,717,866 1,646,986
CURRENT LIABILITIES    
Accounts payable, accrued expenses and other 205,701 207,585
Due to affiliates 12,287 14,347
Deferred revenue 45,846 1,316
Current finance lease liability 3,041 3,283
Current operating lease liability 67,449 61,206
Current portion of notes payable 39,463 39,691
Total current liabilities 373,787 327,428
LONG-TERM LIABILITIES    
Long-term finance lease liability 1,108 3,264
Long-term operating lease liability 428,233 420,922
Notes payable, net of current portion 627,179 652,704
Other non-current liabilities 41,438 9,529
Total liabilities 1,471,745 1,413,847
EQUITY    
Common stock - $0.0001 par value, 200,000,000 shares authorized; 51,596,098 and 50,314,328 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively 5 5
Additional paid-in-capital 306,079 262,865
Accumulated other comprehensive loss (24,923) (8,026)
Accumulated deficit (123,956) (103,159)
Total RadNet, Inc.'s stockholders' equity 157,205 151,685
Noncontrolling interests 88,916 81,454
Total equity 246,121 233,139
Total liabilities and equity $ 1,717,866 $ 1,646,986
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares
Sep. 30, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Common stock - par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock - shares authorized (in shares) 200,000,000 200,000,000
Common stock - shares issued (in shares) 51,596,098 50,314,328
Common stock - shares outstanding (in shares) 51,596,098 50,314,328
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
REVENUE        
Total service revenue $ 291,776 $ 292,692 $ 763,905 $ 853,338
Provider relief funding 221 0 25,696 0
OPERATING EXPENSES        
Cost of operations, excluding depreciation and amortization 246,462 254,383 708,095 743,997
Depreciation and amortization 21,247 20,490 64,536 60,193
Loss on sale and disposal of equipment and other 342 917 543 1,990
Severance costs 571 52 1,647 1,054
Total operating expenses 268,622 275,842 774,821 807,234
INCOME FROM OPERATIONS 23,375 16,850 14,780 46,104
OTHER INCOME AND EXPENSES        
Interest expense 11,061 11,895 33,443 36,589
Equity in earnings of joint ventures (2,276) (1,955) (5,176) (6,072)
Non-cash change in fair value of interest rate hedge 679 0 4,523 0
Other (income) expenses (139) 2 (247) 1,271
Total other expenses 9,325 9,942 32,543 31,788
INCOME (LOSS) BEFORE INCOME TAXES 14,050 6,908 (17,763) 14,316
(Provision for) benefit from income taxes (3,825) (1,816) 5,029 (3,556)
NET INCOME (LOSS) 10,225 5,092 (12,734) 10,760
Net income attributable to noncontrolling interests 4,069 1,897 8,063 6,400
NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS $ 6,156 $ 3,195 $ (20,797) $ 4,360
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS (in dollars per share) $ 0.12 $ 0.06 $ (0.41) $ 0.09
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS (in dollars per share) $ 0.12 $ 0.06 $ (0.41) $ 0.09
WEIGHTED AVERAGE SHARES OUTSTANDING        
Basic (in shares) 51,358,603 49,807,460 50,746,380 49,597,138
Diluted (in shares) 51,955,815 50,360,360 50,746,380 50,113,306
Service fee revenue        
REVENUE        
Total service revenue $ 256,730 $ 261,908 $ 660,760 $ 762,751
Revenue under capitation arrangements        
REVENUE        
Total service revenue $ 35,046 $ 30,784 $ 103,145 $ 90,587
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Statement of Comprehensive Income [Abstract]        
NET INCOME (LOSS) $ 10,225 $ 5,092 $ (12,734) $ 10,760
Foreign currency translation adjustments 11 (23) 6 (28)
Change in fair value of cash flow hedge, net of taxes 195 (5,283) (18,764) (14,481)
Amount of loss reclassified from accumulated OCI into income (prior period effective portion) 969 0 1,861 0
COMPREHENSIVE INCOME (LOSS) 11,400 (214) (29,631) (3,749)
Less comprehensive income attributable to noncontrolling interests 4,069 1,897 8,063 6,400
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS $ 7,331 $ (2,111) $ (37,694) $ (10,149)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)
$ in Thousands
Total
DeepHealth, Inc.
Total Radnet, Inc.'s Equity
Common Stock
Common Stock
DeepHealth, Inc.
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2018       48,977,485          
Beginning balance, value at Dec. 31, 2018 $ 200,253   $ 127,184 $ 5   $ 242,835 $ 2,259 $ (117,915) $ 73,069
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock upon exercise of options (in shares)       10,000          
Issuance of common stock upon exercise of options 50   50     50      
Issuance of common stock under the equity compensation plan (in shares)       726,042          
Issuance of common stock under the equity compensation plan 0                
Stock-based compensation expense 6,993   6,993     6,993      
Issuance of common stock for acquisition (in shares)       440,207          
Issuance of common stock for acquisition 6,000   6,000     6,000      
Forfeiture of restricted stock (in shares)       (1,500)          
Forfeiture of restricted stock (5)   (5)     (5)      
Sale of noncontrolling interests, net of taxes 5,098   3,090     3,090     2,008
Purchase of noncontrolling interests (1,818)               (1,818)
Contribution from noncontrolling partner 750               750
Issuance of common stock for purchase of Nulogix (in shares)       101,902          
Issuance of common stock for purchase of Nulogix 1,500   1,500     1,500      
Change in cumulative foreign currency translation adjustment (28)   (28)       (28)    
Change in fair value of cash flow hedge, net of taxes (14,481)   (14,481)       (14,481)    
Amount of loss reclassified from accumulated OCI into income (prior period effective portion) 0                
Net (loss) income 10,760   4,360         4,360 6,400
Ending balance (in shares) at Sep. 30, 2019       50,254,136          
Ending balance, value at Sep. 30, 2019 215,072   134,663 $ 5   260,463 (12,250) (113,555) 80,409
Beginning balance (in shares) at Jun. 30, 2019       50,127,234          
Beginning balance, value at Jun. 30, 2019 212,430   133,918 $ 5   257,607 (6,942) (116,752) 78,512
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock under the equity compensation plan (in shares)       25,000          
Issuance of common stock under the equity compensation plan 0                
Stock-based compensation expense 1,356   1,356     1,356      
Issuance of common stock for purchase of membership interest in HVRA (in shares)       101,902          
Issuance of common stock for purchase of membership interest in HVRA 1,500   1,500     1,500      
Change in cumulative foreign currency translation adjustment (23)   (23)       (23)    
Change in fair value of cash flow hedge, net of taxes (5,283)   (5,283)       (5,283)    
Amount of loss reclassified from accumulated OCI into income (prior period effective portion) 0                
Other 0           (2) 2  
Net (loss) income 5,092   3,195         3,195 1,897
Ending balance (in shares) at Sep. 30, 2019       50,254,136          
Ending balance, value at Sep. 30, 2019 215,072   134,663 $ 5   260,463 (12,250) (113,555) 80,409
Beginning balance (in shares) at Dec. 31, 2019       50,314,328          
Beginning balance, value at Dec. 31, 2019 233,139   151,685 $ 5   262,865 (8,026) (103,159) 81,454
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock under the equity compensation plan (in shares)       453,817 4,338        
Issuance of common stock under the equity compensation plan 0 $ 0              
Stock-based compensation expense 10,203   10,203     10,203      
Issuance of common stock for acquisition (in shares)       823,615          
Issuance of common stock for acquisition 33,011   33,011     33,011      
Distributions paid to noncontrolling interests (601)               (601)
Change in cumulative foreign currency translation adjustment 6   6       6    
Change in fair value of cash flow hedge, net of taxes (18,764)   (18,764)       (18,764)    
Amount of loss reclassified from accumulated OCI into income (prior period effective portion) 1,861   1,861       1,861    
Net (loss) income (12,734)   (20,797)         (20,797) 8,063
Ending balance (in shares) at Sep. 30, 2020       51,596,098          
Ending balance, value at Sep. 30, 2020 246,121   157,205 $ 5   306,079 (24,923) (123,956) 88,916
Beginning balance (in shares) at Jun. 30, 2020       51,554,760          
Beginning balance, value at Jun. 30, 2020 233,256   147,808 $ 5   304,012 (26,098) (130,111) 85,448
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock under the equity compensation plan (in shares)       37,000 4,338        
Issuance of common stock under the equity compensation plan 0 $ 0              
Stock-based compensation expense 2,067   2,067     2,067      
Distributions paid to noncontrolling interests (601)               (601)
Change in cumulative foreign currency translation adjustment 11   11       11    
Change in fair value of cash flow hedge, net of taxes 195   195       195    
Amount of loss reclassified from accumulated OCI into income (prior period effective portion) 969   969       969    
Other (1)   (1)         (1)  
Net (loss) income 10,225   6,156         6,156 4,069
Ending balance (in shares) at Sep. 30, 2020       51,596,098          
Ending balance, value at Sep. 30, 2020 $ 246,121   $ 157,205 $ 5   $ 306,079 $ (24,923) $ (123,956) $ 88,916
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES    
Net (loss) income $ (12,734) $ 10,760
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Depreciation and amortization 64,536 60,193
Amortization of operating lease right-of-use assets 50,769 49,948
Equity in earnings of joint ventures 530 (2,148)
Amortization of deferred financing costs and loan discount 3,266 3,103
Loss on sale and disposal of equipment and other 543 1,990
Amortization of cash flow hedge 2,204 0
Non-cash change in fair value of interest rate hedge 4,523 0
Stock-based compensation 10,144 6,963
Other non-cash items included in cost of operations 0 (559)
Change in fair value of contingent consideration (145) (1,749)
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:    
Accounts receivable 17,380 (3,467)
Other current assets 13,522 (1,569)
Other assets (700) (5,770)
Deferred taxes (7,640) (4,230)
Operating lease liability (43,351) (49,721)
Deferred revenue 44,530 (490)
Accounts payable, accrued expenses and other 22,966 19,349
Net cash provided by operating activities 170,343 82,603
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of imaging facilities and other acquisitions (10,125) (27,150)
Equity investments at fair value 0 (143)
Purchase of property and equipment (77,303) (68,269)
Proceeds from sale of equipment 779 760
Proceeds from the sale of equity interests in a joint venture 0 132
Nulogix return of capital 0 792
Equity contributions in existing and purchase of interest in joint ventures (1,631) (103)
Net cash used in investing activities (88,280) (93,981)
CASH FLOWS FROM FINANCING ACTIVITIES    
Principal payments on notes and leases payable (2,704) (4,778)
Payments on term loan debt (32,472) (29,918)
Additional deferred finance costs on revolving loan amendment (741) 0
Proceeds from debt issuance, net of issuing costs 0 97,144
Proceeds from Payment Protection Program 4,023 0
Distributions paid to noncontrolling interests (601) (1,818)
Proceeds from sale of noncontrolling interest 0 5,275
Contribution from noncontrolling partner 0 750
Proceeds from revolving credit facility 250,900 251,200
Payments on revolving credit facility (250,900) (279,200)
Proceeds from issuance of common stock upon exercise of options 0 50
Net cash (used in) provided by financing activities (32,495) 38,705
EFFECT OF EXCHANGE RATE CHANGES ON CASH 6 (28)
NET INCREASE IN CASH AND CASH EQUIVALENTS 49,574 27,299
CASH AND CASH EQUIVALENTS, beginning of period 40,165 10,389
CASH AND CASH EQUIVALENTS, end of period 89,739 37,688
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION    
Cash paid during the period for interest 31,210 36,058
Equipment acquired and leasehold improvements $ 28,100 $ 14,100
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.20.2
NATURE OF BUSINESS AND BASIS OF PRESENTATION
9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF BUSINESS AND BASIS OF PRESENTATION NATURE OF BUSINESS AND BASIS OF PRESENTATION
We are a national provider of freestanding, fixed-site outpatient diagnostic imaging services with operations in seven U.S. states. At September 30, 2020, we operated, directly or indirectly through joint ventures with hospitals, 334 centers located in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services. Our multi-modality strategy diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians the convenience of a single location to serve the needs of multiple procedures. In addition to our imaging services, we design and develop software applications, Artificial Intelligence tools and other computerized systems for the diagnostic imaging industry. Our operations comprise a single segment for financial reporting purposes.

The consolidated financial statements include the accounts of RadNet, Inc as well as its subsidiaries in which RadNet has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which we are the primary beneficiary (as described in more detail below). All material intercompany transactions and balances have been eliminated upon consolidation. All of these affiliated entities are referred to collectively as “RadNet”, “we”, “us”, “our” or the “Company” in this report.
Accounting regulations stipulate that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs in which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.

VIEs that we consolidate as the primary beneficiary consist of professional corporations which are owned or controlled by individuals within our senior management, namely Howard G. Berger, M.D., our President and Chief Executive Officer, and John V. Crues, III, M.D., RadNet's Medical Director, both of whom are members of our Board of Directors. Dr. Berger owns, indirectly, 99% of the equity interests in Beverly Radiology Medical Group III (BRMG) and a controlling interest in two professional corporations in New York City. BRMG is responsible for the professional medical services at nearly all of our facilities located in California. Dr. Crues owns six professional corporations which provide medical services in Delaware, Maryland, New Jersey and New York. Additionally, Dr. Crues is a 1% owner of BRMG. These VIEs are collectively referred to as the consolidated medical group ("the Group").
RadNet provides non-medical, technical and administrative services to the Group for which it receives a management fee, pursuant to the related management agreements. Through the management agreements we have exclusive authority over all non-medical decision making related to the ongoing business operations and we determine the annual budget. The Group has insignificant operating assets and liabilities, and de minimis equity. Through management agreements with us, substantially all cash flows of the Group after expenses, including professional salaries, are transferred to us. We consolidate the revenue and expenses, assets and liabilities of the Group.

The Group on a combined basis recognized $38.3 million and $40.6 million of revenue, net of management services fees to RadNet, for the three months ended September 30, 2020 and 2019, respectively and $38.3 million and $40.6 million of operating expenses for the three months ended September 30, 2020 and 2019, respectively. RadNet recognized $169.0 million and $154.5 million of total billed net service fee revenue for the three months ended September 30, 2020, and 2019, respectively, for management services provided to the Group relating primarily to the technical portion of billed revenue.

The Group on a combined basis recognized $104.8 million and $116.9 million of revenue, net of management services fees to RadNet, for the nine months ended September 30, 2020 and 2019, respectively and $104.8 million and $116.9 million of operating expenses for the nine months ended September 30, 2020 and 2019, respectively. RadNet recognized $433.3 million
and $456.1 million of total billed net service fee revenue for the nine months ended September 30, 2020, and 2019, respectively, for management services provided to the Group relating primarily to the technical portion of billed revenue.

The cash flows of the Group are included in the accompanying condensed consolidated statements of cash flows. All intercompany balances and transactions have been eliminated in consolidation. In our condensed consolidated balance sheets at September 30, 2020 and December 31, 2019, we have included approximately $84.5 million and $100.3 million, respectively, of accounts receivable and approximately $10.7 million and $7.0 million of accounts payable and accrued liabilities related to the Group, respectively.

The creditors of the Group do not have recourse to our general credit and there are no other arrangements that could expose us to losses on their behalf. However, RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.

We also own a 49% economic interest in ScriptSender, LLC, which provides secure data transmission services of medical information. Through a management agreement, RadNet provides management and accounting services and receives an agreed upon fee. ScriptSender, LLC is dependent on the Company to finance its own activities, and as such we determined that it is a VIE but we are not a primary beneficiary since we do not have the power to direct the activities of the entity that most significantly impact the entity’s economic performance.

At all of our centers not serviced by the Group we have entered into long-term contracts (typically up to 40 years) with independent radiology groups to provide physician services at those centers. These radiology practices provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee based on the value of the services we provide. We own the diagnostic imaging equipment and, therefore, receive 100% of the technical reimbursements associated with imaging procedures. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us and we have no economic controlling interest in these radiology practices as such, the financial results of these practices are not consolidated in our financial statements.
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for conformity with U.S. generally accepted accounting principles for complete financial statements; however, in the opinion of our management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods ended September 30, 2020 and 2019 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto contained in our annual report on Form 10-K for the year ended December 31, 2019.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.20.2
SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES SIGNIFICANT ACCOUNTING POLICIES
During the period covered in this report, there have been no material changes to the significant accounting policies we use and have explained, in our annual report on Form 10-K for the fiscal year ended December 31, 2019. The information below is intended only to supplement the disclosure in our annual report on Form 10-K for the fiscal year ended December 31, 2019.
REVENUES - Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period when our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payors. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.
As it relates to the Group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by them as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.
Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.
Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.
Our total service revenues during the three and nine months ended September 30, 2020 and 2019 are presented in the table below based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in thousands):
 Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
Commercial insurance$160,524 $163,152 $412,415 $475,064 
Medicare62,704 61,599 154,847 175,825 
Medicaid7,098 7,128 18,072 21,564 
Workers' compensation/personal injury7,183 10,865 25,705 32,950 
Other patient revenue8,328 6,085 17,211 17,947 
Management fee revenue2,675 1,792 8,574 5,662 
Teleradiology and Software revenue2,349 4,412 8,319 12,861 
Other5,869 6,875 15,617 20,878 
Service fee revenue256,730 261,908 660,760 762,751 
Revenue under capitation arrangements35,046 30,784 103,145 90,587 
Total service revenue$291,776 $292,692 $763,905 $853,338 

COVID-19 PANDEMIC AND CARES ACT FUNDING - On March 11, 2020 the World Health Organization (WHO) designated COVID-19 as a global pandemic. Patient volumes and the related revenues for our services were significantly impacted during the latter portion of the first quarter through the middle of the third quarter of 2020 as a result of federal, state and local government mandated restrictions requiring many people to remain at home and forced the closure of or limitations on certain businesses, as well as suspended elective procedures by health care facilities. Many of these restrictions have been eased or completely lifted across the states the Company operates in however, we are unable to predict the future impact of the pandemic on our operations.

During the nine months ended September 30, 2020, we received $39.4 million of accelerated Medicare payments, $5.0 million from Blue Cross, $25.7 million from the general distribution and $4.0 million from the Paycheck Protection Program established through the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. The accelerated Medicare payments are recorded under the caption “ Deferred Revenue“ in our condensed consolidated balance sheet and will be repaid beginning in 2021. The general distribution funds were accounted for as government grants and recognized as other revenue, once reasonable assurance that the applicable terms and conditions required to retain the funds were met, under the caption “Provider relief funding” in our condensed Consolidated Statements of Operations

During the three months ended September 30, 2020, the Department of Health and Human Services significantly changed the measurement of Provider Relief Funds that providers are able to retain. We received approximately $0.2 million in
funding and based on our assessment of the likelihood of meeting the applicable terms and conditions of the general distribution we continue to recognized the funds received as other revenue.

The CARES Act also providers for a payment deferral of the employer portion of Social Security tax incurred during the pandemic, allowing half of such payroll taxes to be deferred until December 2021 and the remaining half until December 2022. At September 30, 2020, the Company had deferred $10.8 million of Social Security taxes. These payment deferrals are recorded as payroll tax liability under the caption “Accounts payable, accrued expenses and other” in our condensed consolidated balance sheet.

We believe the extent of the COVID-19 pandemic’s impact on our operating results and financial condition has been and will continue to be driven by many factors, most of which are beyond our control and ability to forecast. Such factors include, but are not limited to, the scope and duration of stay-at-home practices, business closures and restrictions, suspensions of elective procedures and continued decline in procedure volumes for an indeterminable length of time and incremental expenses required for supplies and personal protective equipment. Because of these uncertainties, we cannot estimate the length or impact of the pandemic on our business. If we incur declines in cash flows and results of operations, such declines could have an impact on the inputs and assumptions used in significant accounting estimates, including implicit prices concessions related to uninsured patient accounts, and potential impairment of goodwill and long-lived assets. During the third quarter of 2020, procedure volumes increased and have had a positive impact on our patient revenue. However, the impact of COVID-19 in future periods may vary and could adversely impact our results of operations.

RECLASSIFICATION –We have reclassified certain amounts previously classified as held for sale related to property and equipment and goodwill to conform to our 2020 presentation.
ACCOUNTS RECEIVABLE - Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience. In regards to the credit loss standard, we have concluded that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses estimated under the Current Expected Credit Loss ("CECL") model.

In 2018 and 2019 we entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements in exchange for notes receivables from the buyers. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. Proceeds on notes receivables are reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long term portion. At September 30, 2020 we have $20.4 million remaining to be collected on these agreements. We do not utilize factoring arrangements as an integral part of our financing for working capital. To employ the CECL model for the notes receivable, we assess the party's ability to pay upfront at the inception of the notes receivable and subsequently by reviewing their financial statements annually and reassessing any insolvency risk on a periodic basis. In the event of a significant past due balance, as the sold receivables were already revalued and recorded at net realizable value, we can mitigate the expected credit loss by offsetting any collections from the underlying factored receivables and not remitting that to the counter party.
DEFERRED REVENUE - As noted above, in April of 2020, we received approximately $39.4 million in advanced Medicare payments from the Centers for Medicare and Medicaid Services ("CMS") as part of the expanded Accelerated and Advance Payment Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. As these payments are required to be repaid to CMS beginning 120 days after their receipt through offsets from new Medicare claims over a three month period, we have recorded amounts received to deferred revenue which will be amortized as Medicare reimbursements are earned. In addition, in May of 2020 we received $5.0 million in advance payments from an insurance carrier with similar repayment terms as the CMS.
DEFERRED FINANCING COSTS - Costs of financing are deferred and amortized using the effective interest rate method. Deferred financing costs, net of accumulated amortization, were $1.9 million and $1.6 million, as of September 30, 2020 and December 31, 2019, respectively and related to our Barclays line of credit. See Note 5, Credit Facilities and Notes Payable for more information.
PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation of property and equipment is performed using the straight-line method over the estimated useful lives of the assets acquired, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred.
BUSINESS COMBINATION - When the qualifications for business combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.
GOODWILL AND INDEFINITE LIVED INTANGIBLES - Goodwill at September 30, 2020 totaled $470.7 million. Indefinite lived intangible assets at September 30, 2020 were $11.3 million. Goodwill and Indefinite Lived Intangibles are recorded as a result of business combinations. When we determine the carrying value of reporting unit exceeds its fair value an impairment charge would be recognized and should not exceed the total amount of goodwill allocated to that reporting unit. We tested goodwill and indefinite lived intangibles for impairment on October 1, 2019, noting no impairment. In addition to the annual impairment test, we regularly assess if an event has occurred which would require interim impairment testing. We considered the current and expected future economic and market conditions surrounding the novel strain of coronavirus ("COVID-19") pandemic and did not identify an indication of goodwill impairment being more likely than not through September 30, 2020. Activity in goodwill for the nine months ended September 30, 2020 is provided below (in thousands):
Balance as of December 31, 2019$441,973 
Goodwill acquired through the acquisition of Olney Open MRI, LLC601 
Goodwill acquired through the acquisition of MRI at Woodbridge, LLC1,833 
Goodwill acquired through the acquisition of DeepHealth, Inc.23,396 
Goodwill acquired through the acquisition of AZ-Tech Radiology & Open MRI, LLC2,882 
Balance as of September 30, 2020$470,685 
INCOME TAXES - Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized.
We recorded an income tax expense of $3.8 million, or an effective tax rate of 27.2%, for the three months ended September 30, 2020 compared to an income tax expense of $1.8 million, or an effective tax rate of 26.3% for the three months ended September 30, 2019. We recorded an income tax benefit of $5.0 million, or an effective tax rate of 28.3%, for the nine months ended September 30, 2020 compared to an income tax expense of $3.6 million , or an effective tax rate of 24.8% for the nine months ended September 30, 2019.The income tax rates for the three and nine months ended September 30, 2020 diverge from the federal statutory rate due to (i) noncontrolling interests due to the controlled partnerships; (ii) effects of state income taxes; and (iii) excess tax benefits attributable to share-based compensation.
We believe no significant changes in the unrecognized tax benefits will occur within the next 12 months.
On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"). The CARES Act, among other things, includes certain income tax provisions for individuals and corporations; however, these benefits do not impact the Company’s current tax provision.
LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long term operating lease liability in our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liability, and long-term finance lease liability in our consolidated balance sheets.  ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed
payments for both lease and non-lease components, we have elected to account for the components as a single lease component, as permitted. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the ROU asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. ROU assets are tested for impairment if circumstances suggest that the carrying amount may not be recoverable. Our ROU assets consist of facility and equipment assets on operating leases. No events have occurred such as fire, flood, or other acts which have impaired the integrity of our ROU assets in 2020. Our facility leases require us to maintain insurance policies which would cover major damage to our facilities. We maintain business interruption insurance to cover loss of business due to a facility becoming non-operational under certain circumstances. Our equipment leases are covered by warranty and service contracts which cover repairs and provide regular maintenance to keep the equipment in functioning order.
EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated as of April 20, 2015, and again on March 9, 2017 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved 14,000,000 shares of common stock for issuance under the Restated Plan which can be issued in the form of options, stock awards, stock appreciation rights, stock units, and cash awards. Stock options generally vest over three to five years and expire five to ten years from date of grant. We determine the compensation expense for each stock option award using the Black Scholes, or similar valuation model. Those models require that our management make certain estimates concerning risk free interest rates and volatility in the trading price of our common stock. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. In connection with our acquisition of DeepHealth Inc. on June 1, 2020, we assumed the DeepHealth, Inc. 2017 Stock Incentive Plan, including outstanding options awards that can be exercised for our common stock. No additional awards will be granted under the DeepHealth, Inc. 2017 Equity Incentive Plan. See Note 4, Facility Acquisitions and Note 6, Stock-Based Compensation, for more information.
COMPREHENSIVE INCOME (LOSS) - ASC 220 establishes rules for reporting and displaying comprehensive income or loss and its components. Our unrealized gains or losses on foreign currency translation adjustments, interest rate cap and swap agreements are included in comprehensive loss and are included in the consolidated statements of comprehensive income (loss) for the three and nine months ended September 30, 2020 and 2019.
COMMITMENTS AND CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. Based on current information, we do not believe that reasonably possible or probable losses associated with pending legal proceedings would either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. Therefore, if one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.
DERIVATIVE INSTRUMENTS
2016 CAPS
In the fourth quarter of 2016, we entered into two forward interest rate cap agreements ("2016 Caps"). The 2016 Caps will mature in September and October 2020. The 2016 Caps had notional amounts of $150,000,000 and $350,000,000, respectively. Under these arrangements, the Company purchased a cap on 3 month LIBOR at 2.0%. We incurred a $5.3 million premium to enter into the 2016 Caps which is being accrued over the life of the agreements.
At inception, we designated our 2016 Caps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss of the hedge (i.e. change in fair value) is reported as a component of comprehensive loss in the consolidated statement of equity since such hedge has been determined to be effective. See Fair Value Measurements section below for the fair value of the 2016 Caps at September 30, 2020.
A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss of the 2016 Caps is as follows (amounts in thousands):
For the three months ended September 30, 2020
AccountJuly 1, 2020 BalanceAmount of comprehensive gain recognized on derivative net of taxesSeptember 30, 2020 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes(1,409)195 (1,214)Liabilities and Equity
For the nine months ended September 30, 2020
AccountJanuary 1, 2020 BalanceAmount of comprehensive gain recognized on derivative net of taxesSeptember 30, 2020 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes(1,877)663 (1,214)Liabilities and Equity
2019 SWAPS
In the second quarter of 2019, we entered into four forward interest rate agreements ("2019 Swaps"). The 2019 Swaps have total notional amounts of $500,000,000, consisting of two agreements of $50,000,000 each and two agreements of $200,000,000 each. The 2019 Swaps will secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They will mature in October 2023 for the smaller notional and October 2025 for the larger notional. Under these arrangements, we arranged the 2019 Swaps with locked in 1 month LIBOR rates at 1.96% for the $100,000,000 notional and at 2.05% for the $400,000,000 notional. As of the effective date, we will be liable for premium payments if interest rates decline below arranged rates, but will receive interest payments if rates remain above the arranged rates.
At inception, we designated our 2019 Swaps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e. change in fair value) is reported as a component of comprehensive loss in the consolidated statement of equity. The remaining gain or loss, if any, is recognized currently in earnings. As a result of the economic impact of the coronavirus pandemic, which precipitated a reduction in interest rates , the cash flows for both our $400,000,000 notional interest rate swap contract locked in at 2.05% due October 2025 and our $100,000,000 notional interest rate swap contract locked in at 1.96% do not match the cash flows for our First Lien Term Loans and so we have determined that they are not currently effective as cash flow hedges. Accordingly, all changes in their fair value after April 1, 2020 for the $400,000,000 notional and after July 1, 2020 for the $100,000,000 notional will be recognized in earnings. As of July 1, 2020, the total change in fair value relating to swaps included in other comprehensive income was approximately $24.4 million, net of taxes. This amount will be amortized to interest expense through October 2025 at approximately $0.4 million per month.
A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss of the 2019 swaps which remain ineffective is as follows (amounts in thousands):
For the three months ended September 30, 2020
AccountJuly 1, 2020 BalanceAmount of comprehensive loss recognized on derivative net of taxesAmount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxesSeptember 30, 2020 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes$(24,406)$— $969 $(23,437)Liabilities and Equity
For the nine months ended September 30, 2020
AccountJanuary 1, 2020 BalanceAmount of comprehensive loss recognized on derivative net of taxesAmount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxesSeptember 30, 2020 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes$(5,870)$(19,428)$1,861 $(23,437)Liabilities and Equity
A tabular presentation of the effect of derivative instruments on our statement of operations of the 2019 Swaps for the Swaps that became ineffective during the third quarter is as follows (amounts in thousands):
For the three months ended September 30, 2020
Ineffective interest rate swapAmount of loss recognized in income on derivative (current period ineffective portion)Location of loss recognized in Income on derivative (current period ineffective portion)Amount of loss reclassified from accumulated OCI into income (prior period effective portion)Location of gain (Loss) reclassified from accumulated OCI into income (prior period effective portion)
Interest rate contracts$(679)Other income (expense)$(1,312)Equity and Interest Expense
For the nine months ended September 30, 2020
Ineffective interest rate swapAmount of loss recognized in income on derivative (current period ineffective portion)Location of loss recognized in Income on derivative (current period ineffective portion)Amount of loss reclassified from accumulated OCI into income (prior period effective portion)Location of gain (Loss) reclassified from accumulated OCI into income (prior period effective portion)
Interest rate contracts$(4,523)Other income (expense)$(2,204)Equity and Interest Expense
See Fair Value Measurements section below for the fair value of the 2016 caps and 2019 swaps at September 30, 2020.
FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:
Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.
Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.
Derivatives:
The tables below summarize the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets on our condensed consolidated balance sheets, as follows (in thousands):
 As of September 30, 2020
Level 1Level 2Level 3Total
Current and long term liabilities    
2016 caps - Interest Rate Contracts$— $182 $— $182 
2019 swaps - Interest Rate Contracts$— $39,983 $— $39,983 
 As of December 31, 2019
Level 1Level 2Level 3Total
Current and long term liabilities    
2016 caps - Interest Rate Contracts$— $1,081 $— $1,081 
2019 swaps - Interest Rate Contracts$— $9,477 $— $9,477 
The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty’s forward LIBOR curve. The forward LIBOR curve is readily available in the public markets or can be derived from information available in the public markets.
Long Term Debt:
The table below summarizes the estimated fair value compared to our face value of our long-term debt as follows (in thousands):
 As of September 30, 2020
Level 1Level 2Level 3Total Fair ValueTotal Face Value
First Lien Term Loans and SunTrust Term Loan$— $663,140 $— $663,140 $673,227 
 As of December 31, 2019
Level 1Level 2Level 3TotalTotal Face Value
First Lien Term Loans and SunTrust Term Loan$— $708,948 $— $708,948 $705,699 
As of September 30, 2020 and at December 31, 2019 our Barclays revolving credit facility had no balance outstanding. Our SunTrust revolving credit facility relating to our consolidated subsidiary NJIN, had no principal amount outstanding at September 30, 2020 and at December 31, 2019.
The estimated fair value of our long-term debt, which is discussed in Note 5, was determined using Level 2 inputs primarily related to comparable market prices.
We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our finance lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.
EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):
 Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Net income (loss) attributable to RadNet, Inc.'s common stockholders$6,156 $3,195 $(20,797)$4,360 
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period51,358,603 49,807,460 50,746,380 49,597,138 
Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders$0.12 $0.06 $(0.41)$0.09 
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period51,358,603 49,807,460 50,746,380 49,597,138 
Add nonvested restricted stock subject only to service vesting120,605 200,567 191,375 
Add additional shares issuable upon exercise of stock options and warrants476,607 352,333 324,793 
Weighted average number of common shares used in calculating diluted net income per share51,955,815 50,360,360 50,746,380 50,113,306 
Diluted net income (loss) per share attributable to RadNet, Inc.'s common stockholders$0.12 $0.06 $(0.41)$0.09 
Stock options and non vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:
Nonvested restricted stock subject to service vesting— — 331,659 — 
Shares issuable upon the exercise of stock options:48,948 — 933,370 — 

EQUITY INVESTMENTS AT FAIR VALUE–Accounting guidance requires entities to measure equity investments at fair value, with any changes in fair value recognized in net income. If there is no readily determinable fair value, the guidance allows entities the ability to measure investments at cost, adjusted for observable price changes and impairments, with changes recognized in net income.
As of September 30, 2020, we have three equity investments for which a fair value is not readily determinable and therefore the total amounts invested are recognized at cost as follows:
Medic Vision Imaging Solutions Ltd., based in Israel, specializes in software packages that provide compliant radiation dose structured reporting and enhanced images from reduced dose CT scans. On March 24, 2017, we acquired an initial 12.5% equity interest in Medic Vision for $1.0 million. We also received an option to exercise warrants to acquire up to an additional 12.5% equity interest for $1.4 million within one year from the initial share purchase date, if exercised in full. On March 1, 2018 we exercised our warrant in part and acquired an additional 1.96% for $0.2 million. Our initial equity interest has been diluted to 12.25% and our total equity investment stands at 14.21%. In accordance with accounting guidance, as we exercise no significant influence over Medic Vision’s operations, the investment is recorded at its cost of $1.2 million, given that the fair value is not readily determinable. No observable price changes or impairment in our investment was identified as of September 30, 2020.
Turner Imaging Systems, based in Utah, develops and markets portable X-ray imaging systems that provide a user the ability to acquire X-ray images wherever and whenever they are needed. On February 1, 2018, we purchased 2.1 million preferred shares in Turner Imaging Systems for $2.0 million. On January 1, 2019 we funded a convertible promissory note in the amount of $0.1 million that converted to additional 80,000 shares December 21, 2019. No observable price changes impairment in our investment was identified as of September 30, 2020.
WhiteRabbit.ai Inc., based in California, is currently developing an artificial intelligence suite which aims to improve the speed and accuracy of cancer detection in radiology and improve patient care. On November 5, 2019 we acquired an equity interest in the company for $1.0 million and also loaned the company $2.5 million, the principal of which is due November 2022. To leverage their artificial intelligence expertise, we entered into a software subscription service contract to assist our radiology work flow and advanced them $4.0 million for future software subscription fees that is recorded as a prepaid expense in Prepaid and Other Current assets in our consolidated balance sheets. No observable price changes or impairment in our investment or the loan receivable was identified as of September 30, 2020.
INVESTMENT IN JOINT VENTURES – We have 12 unconsolidated joint ventures with ownership interests ranging from 35% to 55%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures is accounted for under the equity method, since RadNet does not have a controlling financial interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of September 30, 2020.
Joint venture investment contribution
In the month of August 2020, we made additional cash contributions to our Santa Monica Imaging Group, LLC partnership in the amount of $1.6 million in support of its expanded operations. We maintain our 35% economic interest in the partnership.

Joint venture investment and financial information
The following table is a summary of our investment in joint ventures during the nine months ended September 30, 2020 (in thousands):
Balance as of December 31, 2019$34,470 
Equity in earnings in these joint ventures5,176 
Distribution of earnings(5,706)
Equity contributions in existing joint ventures1,631 
Balance as of September 30, 2020$35,571 
We charged management service fees from the centers underlying these joint ventures of approximately $2.7 million and $1.8 million for the three months ended September 30, 2020 and 2019, respectively, and $8.6 million and $7.8 million for the nine months ended September 30, 2020 and 2019, respectively. We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures.
The following table is a summary of key balance sheet data for these joint ventures as of September 30, 2020 and December 31, 2019 and income statement data for the nine months ended September 30, 2020 and 2019 (in thousands):
Balance Sheet Data:September 30, 2020December 31, 2019
Current assets$26,618 $27,427 
Noncurrent assets70,576 61,037 
Current liabilities(10,487)(9,217)
Noncurrent liabilities(22,751)(18,872)
Total net assets$63,956 $60,375 
Book value of RadNet joint venture interests$29,121 $28,001 
Cost in excess of book value of acquired joint venture interests and other6,450 6,469 
Total value of Radnet joint venture interests$35,571 $34,470 
Total book value of other joint venture partner interests$34,835 $32,374 
Income statement data for the nine months ended September 30,20202019
Net revenue$78,988 $80,115 
Net income$13,651 $13,718 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.20.2
RECENT ACCOUNTING AND REPORTING STANDARDS
9 Months Ended
Sep. 30, 2020
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
RECENT ACCOUNTING AND REPORTING STANDARDS RECENT ACCOUNTING AND REPORTING STANDARDS
Accounting standards adopted

In June 2016, the FASB issued ASU No. 2016-13 ("ASU 2016-13), Financial Instruments - Credit Losses. ASU 2016-13 replaces the incurred loss methodology previously utilized for valuing financial instruments with an expected loss methodology that is referred to as the current expected credit loss (CECL) methodology. We prospectively adopted the standard on January 1, 2020 and the adoption did not have a material impact to the condensed consolidated financial statements, resulting in no adjustments to our prior year earnings. See the Accounts Receivable section to Note 2 for further information on our allowances for credit losses.

In August 2018, the FASB issued ASU No. 2018-15 (“ASU 2018-15”), Intangibles-Goodwill and Other-Internal-Use Software. ASU 2018-15 aligns the requirements for deferring implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This ASU is effective in the first quarter of 2020 with early adoption permitted and can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The adoption of this standard did not have a material impact on our condensed consolidated balance sheet.

In March 2020, the FASB issued ASU 2020-03 ("ASU 2020-03"), Codification Improvements to Financial Instruments. The amendments in this update represent changes to clarify or improve the codification and correct unintended application. ASU 2020-03 was effective immediately upon issuance and its adoption did not have a material impact on our financial statements.

In August 2018, the FASB issued ASU No. 2018-13 ("ASU 2018-13"), Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurements. This standard removes, modifies and adds certain disclosures related to recurring and nonrecurring fair value measurements. We adopted ASC 2018-13 effective January 1, 2020 and it had no effect on our disclosures.

Accounting standards not yet adopted
 
In December 2019, the FASB issued ASU 2019-12 ("ASU 2019-12"), Income Taxes (Topic 740). ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other areas of the standard. ASU 2019-12 will be effective beginning in the first quarter of 2021. Early adoption is permitted. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. We are currently evaluating the impact this ASU will have on our financial statements and related disclosures as well as the timing of adoption.

In January 2020, the FASB issued ASU 2020-01 ("ASU 2020-01"), Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), clarifying the interaction between accounting standards related to equity securities, equity method investments, and certain derivatives. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020. We do not expect the adoption of this guidance will have a material impact on our financial statements.

In March 2020, the FASB issued ASU 2020-04 ("ASU 2020-04"), Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting. ASU 2020-04 provides optional expedients and exceptions for applying generally accepted accounting principles to certain contract modifications and hedging relationships that reference London Inter-bank Offered Rate (LIBOR) or another reference rate expected to be discontinued. The guidance is effective upon issuance and generally can be applied through December 31, 2022. We are currently evaluating the potential impact of ASU 2020-04 on our financial statements.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.20.2
FACILITY ACQUISITIONS AND DISPOSITIONS
9 Months Ended
Sep. 30, 2020
Business Combinations [Abstract]  
FACILITY ACQUISITIONS AND DISPOSITIONS FACILITY ACQUISITIONS AND DISPOSITIONS
Acquisitions:

On August 31, 2020 we completed our acquisition of certain assets of AZ-Tech Radiology & Open MRI, LLC, consisting of eight multi-modality imaging centers located in the Phoenix, Arizona area for purchase consideration of $5.5 million. We made a preliminary fair value determination of the acquired assets and assumed liabilities and approximately $2.5 million in property and equipment, $7.6 million in right-of-use assets, $0.1 million in other assets, $7.6 million in operating lease liabilities, and $2.9 million in goodwill were recorded.

On June 1, 2020, we completed our acquisition of all the equity interests of DeepHealth Inc., ("DeepHealth") an artificial intelligence and machine learning company in an all stock purchase. As initial purchase consideration, we issued 915,132 shares at $16.93 per share (823,615 issued at execution, with up to 91,517 shares to be issued 18 months after acquisition subject to adjustment for any indemnification claims). The transaction was accounted for as an acquisition of a business and total purchase consideration determined to be approximately $34.6 million including i) 823,615 shares issued on the date of closing with fair value of $13.9 million, ii) a liability of 91,517 shares with a fair value of $1.5 million to be issued 18 months after acquisition subject to adjustment for any indemnification claims and will be marked to market in subsequent periods, iii) replacement awards attributable to pre-combination service issued to DeepHealth option holders with allocated fair value of $2.0 million, iv) acquisition date fair value of contingent consideration of $17.0 million and v) $0.1 million in closing costs reimbursed to the seller. The fair values of replacement awards attributable to pre-combination service and contingent consideration are recorded in additional paid in capital upon closing of the transaction. For the contingent consideration, there are three arrangements that will be settled in a fixed number of shares upon achievement of three individual specific milestones which are mutually exclusive of each other, with 390,789, 586,184, and 195,393 shares, respectively, issuable for each milestone arrangement. The fair value of the contingent consideration was estimated at the date of acquisition based on our share price and estimated probability of the achievement of the respective milestones. We preliminarily recorded $0.1 million in current assets, $3.5 million in deferred tax liabilities, $14.8 million in intangible assets, primarily in-process research and development ("IPR&D'), and $23.4 million in goodwill. The goodwill is primarily attributable to expected post-acquisition synergies from integrating DeepHealth’s assembled workforce and IPR&D technologies. The fair values of the identifiable intangible assets related to IPR&D were determined by the income method and the assets will not be amortized until completion.

On March 2, 2020 our consolidated subsidiary New Jersey Imaging Networks ("NJIN") completed the acquisition of certain assets of MRI at Woodbridge, LLC consisting of a single multi-modality imaging center located in Avenel, New Jersey for cash consideration of $2.6 million. NJIN made a fair value determination of the acquired assets and assumed liabilities and approximately $0.5 million in property and equipment, $1.1 million in right-of-use assets, $0.3 million in intangible assets, $1.1 million in operating lease liabilities, $0.1 million in finance lease liabilities, and $1.8 million in goodwill were recorded.

    On January 2, 2020 we completed our acquisition of certain assets of Olney Open MRI, LLC, consisting of a single multi-modality imaging center located in Columbia, Maryland for cash consideration of $1.8 million. We have made a fair value determination of the acquired assets and assumed liabilities and approximately $0.8 million in property and equipment, $1.3 million in right-of-use assets, $0.3 million in intangible assets, $1.3 million in operating lease liabilities and $0.6 million in goodwill were recorded.
Dispositions:
On June 1, 2020 we completed our sale of certain assets of our Imaging On Call subsidiary to RadVantage P.C. (an unrelated corporation) for approximately $1.0 thousand. With this transaction, we have exited the teleradiology business.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.20.2
CREDIT FACILITY AND NOTES PAYABLE
9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
CREDIT FACILITY AND NOTES PAYABLE CREDIT FACILITIES AND NOTES PAYABLE
As of September 30, 2020 and December 31, 2019 our debt obligations consisted of the following (in thousands):
September 30,
2020
December 31,
2019
First Lien Term Loans collateralized by RadNet's tangible and intangible assets$620,727 $649,824 
Discounts on First Lien Term Loans(10,669)(13,579)
SunTrust Term Loan Agreement collateralized by NJIN's tangible and intangible assets52,500 55,875 
Paycheck Protection Program loans at 1% due April 2022
4,037 — 
Equipment note payable at 4.6%, due through 2020, collateralized by medical equipment
47 275 
Total debt obligations666,642 692,395 
Less: current portion(39,463)(39,691)
Long term portion debt obligations$627,179 $652,704 

Included in our condensed consolidated balance sheets at September 30, 2020 are $620.7 million of First Lien Term Loans and $52.5 million of SunTrust Term Loan debt for a combined total of $673.2 million of total term loan debt (exclusive of unamortized discounts of $10.7 million) in thousands:
 Face ValueDiscountTotal Carrying
Value
First Lien Term Loans$620,727 $(10,669)$610,058 
SunTrust Term Loan52,500 — 52,500 
Total Term Loans$673,227 $(10,669)$662,558 
We had no balance under our $195.0 million Barclays Revolving Credit Facility at September 30, 2020 and have reserved $6.3 million for certain letters of credit. The remaining $188.7 million of our Barclays Revolving Credit Facility was available to draw upon as of September 30, 2020. We had no balance under our $30.0 million SunTrust Revolving Credit Facility related to our consolidated subsidiary NJIN at September 30, 2020.
Senior Secured Credit Facilities
Barclays Credit Facilities:
At September 30, 2020, (a) our Barclays credit facilities were comprised of one tranche of term loans (“First Lien Term Loans”) and a revolving credit facility of $195.0 million (the “Barclays Revolving Credit Facility”) and (b) our SunTrust credit facilities, which relate to our consolidated subsidiary NJIN, were comprised of one term loan (the "SunTrust Term Loan") and a revolving credit facility of $30.0 million (the "SunTrust Revolving Credit Facility").
As of September 30, 2020, we were in compliance with all covenants under our credit facilities. Deferred financing costs at September 30, 2020, net of accumulated amortization, was $1.9 million and is specifically related to our Barclays Revolving Credit Facility.

Our First Lien Term Loans bear interest at either an Adjusted Eurodollar Rate or a Base Rate, plus an applicable margin according to the following schedule:
First Lien Leverage RatioEurodollar Rate SpreadBase Rate Spread
> 5.50x4.50%3.50%
> 4.00x but ≤ 5.50x3.75%2.75%
>3.50x but ≤ 4.00x3.50%2.50%
≤ 3.50x3.25%2.25%

At September 30, 2020 the effective Adjusted Eurodollar Rate and the Base Rate for the First Lien Term Loans was 1.00% and 3.25%, respectively and the applicable margin for Adjusted Eurodollar Rate and Base Rate borrowings was 3.75% and 2.75%, respectively.
The First Lien Credit Agreement provides for quarterly payments of principal under the First Lien Term Loans in the amount of approximately $9.7 million. The First Lien Term Loans will mature on July 21, 2023 unless otherwise accelerated under the terms of the First Lien Credit Agreement.
SunTrust Credit Facilities:

Our SunTrust Term Loan bears interest at either an Adjusted Eurodollar Rate or a Base Rate, plus an applicable margin according to the following schedule:

Pricing LevelLeverage RatioApplicable Margin for Eurodollar LoansApplicable Margin for Base Rate LoansApplicable Margin for Letter of Credit FeesApplicable Percentage for Commitment Fee
I
Greater than or equal to 3.00:1.00
2.75%
per annum
1.75%
per annum
2.75%
per annum
0.45%
per annum
II
Less than 3.00:1.00 but greater than or equal to 2.50:1.00
2.25%
per annum
1.25%
per annum
2.25%
per annum
0.40%
per annum
III
Less than 2.50:1.00 but greater than or equal to
2.00:1.00
2.00%
per annum
1.00%
per annum
2.00%
per annum
0.35%
per annum
IV
Less than 2.00:1.00 but greater than or equal to 1.50:1.00
1.75%
per annum
0.75%
per annum
1.75%
per annum
0.30%
per annum
V
Less than 1.50:1.00
1.50%
per annum
0.50%
per annum
1.50%
per annum
0.30%
per annum

The loans and other obligations outstanding under the SunTrust Restated Credit Agreement currently bear applicable margin and fees based on Pricing Level III described above. The loans outstanding under the SunTrust Restated Credit Agreement currently bear interest based on a three month Eurodollar election of 2.00%, plus the applicable margin.

The scheduled amortization of the SunTrust Term Loan began December 31, 2018 with quarterly payments of $0.8 million, representing annual amortization equal to 5.00% of the original principal amount of the SunTrust Term Loan. At scheduled intervals, the quarterly amortization increases by $0.4 million, with the remaining balance to be paid at maturity. The SunTrust Term Loan will mature on August 1, 2023 unless otherwise accelerated under the terms of the SunTrust credit facility.


Revolving Credit Facilities
Barclays Revolving Credit Facility

Revolving loans borrowed under the Barclays Revolving Credit Facility bear interest at either an Adjusted Eurodollar Rate or a Base Rate plus an applicable margin. Rates of the applicable margin for borrowing under the Revolving Credit Facility also change depending on our leverage ratio and are the same rates as noted in the schedule above for First Lien Term Loans. As of September 30, 2020, the effective interest rate payable on revolving loans was 6.00%.
Letters of credit issued under the Barclays Revolving Credit Facility, letter of credit fees accrue at the applicable margin of Adjusted Eurodollar Rate, currently 3.75% , and fronting fees accrue at 0.25% per annum, in each case on the average aggregate daily maximum amount available to be drawn under all letters of credit issued under the First Lien Credit Agreement. In addition, a commitment fee of 0.50% per annum accrues on the unused revolver commitments under the Revolving Credit Facility.
The Barclays Revolving Credit Facility will terminate on the earliest to occur of July 1, 2023 or its earlier termination to specific events of default pursuant to the First Lien Credit Agreement.
Our Barclays Revolving Credit Facility was amended in August 2020 to add $57.5 million of revolving commitments and extend the maximum borrowing capacity to $195.0 million. Total issue costs added in relation to the eighth amendment amounted to approximately $0.7 million and was capitalized as deferred financing costs and will be amortized over the remaining term of the agreement.

SunTrust Revolving Credit Facility

Our SunTrust Revolving Credit Facility is available to NJIN for funding requirements, with an available borrowing limit of $30.0 million. Revolving loan borrowed under the SunTrust Revolving Credit Facility bear interest at either an Adjusted Eurodollar Rate or a Base Rate plus an applicable margin. Rates of the applicable margin for borrowing under the Revolving Credit Facility also change depending on our leverage ration and are the same rates noted in the schedule above for the SunTrust Term Loan. The SunTrust Revolving Credit Facility terminates on August 31, 2023 unless all amounts outstanding otherwise have been declared or have automatically become due and payable (whether by acceleration or otherwise). NJIN has not borrowed against the revolving credit line.
 
Recent Amendments to credit facilities:
Barclays Credit Facilities:

On August 28, 2020, RadNet, Inc. entered into Amendment No. 8, Consent and Incremental Joinder Agreement to Credit and Guaranty Agreement "the Eighth Amendment". The Eighth Amendment amends the First Lien Credit Agreement to add $57.5 million of revolving commitments to the Barclays Revolving Credit Facility extending the maximum borrowing capacity under the revolving credit facility to $195.0 million while leaving the maturity date of July 1, 2023 unchanged. Total issue costs added in relation to the Eighth Amendment amounted to approximately $0.7 million and was capitalized as deferred financing costs and will be amortized over the remaining term of the agreement.

On April 18, 2019 we entered into the following two amendments to the First Lien Credit Agreement: (i) Amendment No. 6, Consent and Incremental Joinder Agreement to Credit and Guaranty Agreement (the “Sixth Amendment”); and (ii) Amendment No. 7 to Credit and Guaranty Agreement (the “Seventh Amendment”). The Sixth Amendment amended the First Lien Credit Agreement to issue $100.0 million in incremental First Lien Term Loans and to add an additional $20.0 million of revolving commitments to the Barclay's Revolving Credit Facility. The Seventh Amendment amended the First Lien Credit Agreement to extend the maturity date of the Barclays Revolving Credit Facility by an additional two years to July 1, 2023, unless sooner terminated in accordance with the terms of the First Lien Credit Agreement. Total issue costs added in relation to the Sixth and Seventh amendments in 2019 amounted to approximately $4.4 million. Of this amount, $2.1 million was identified and capitalized as discount on debt, $0.7 million was capitalized as deferred financing costs, and $1.6 million was expensed. Amounts capitalized will be amortized over the remaining term of the agreement.

Paycheck Protection Program
The Paycheck Protection Program (PPP) includes funds available for loans to small business and Medicare providers to support operations during the COVID-19 pandemic. The funds are administered by the Small Business Administration (SBA), through approved lenders and do not require collateral or personal guarantees. We received our loans based on being a Medicare provider. The terms and conditions for participation require entities to certify that economic uncertainty related to the COVID-19 pandemic makes the loan necessary to support their current operations, and that they will use the funds to retain workers (e.g., by paying salaries, providing paid sick/medical leave and health insurance benefits) and pay certain debts (mortgage obligations) and expenses (e.g. rent, utilities, telephone). The loans have a 1.0% fixed interest rate and are due in 2 years. Initial repayments have been deferred for six months. The loans are eligible for forgiveness subject to salary limitations and employee retention levels. Certain of our consolidated subsidiaries received four loans totaling $4.0 million. We have accounted for the funds received as debt and recorded a liability for the full amount of proceeds received. Interest will be accrued over the term of the loans. If we meet the eligibility requirements for forgiveness the amounts forgiven will be recognized in the income statement as a gain on loan extinguishment in accordance with accounting guidance.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.20.2
STOCK-BASED COMPENSATION
9 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATIONStock Incentive Plans
We have one long-term equity incentive plan which we refer to as the 2006 Equity Incentive Plan, which we first amended and restated as of April 20, 2015 and again on March 9, 2017 (the "Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved for issuance under the Restated Plan 14,000,000 shares of common stock. We can issue options (incentive and non-qualified), stock awards, stock appreciation rights, stock units and cash awards under the Restated Plan.
Options
Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options generally vest over 3 to 5 years and expire 5 to 10 years from the date of grant.
As of September 30, 2020, we had outstanding options to acquire 527,899 shares of our common stock, of which options to acquire 298,863 shares were exercisable. The following summarizes all of our option transactions for the nine months ended September 30, 2020:
Outstanding Options
Under the 2006 Plan
SharesWeighted Average
Exercise price
Per Common Share
Weighted Average
Remaining
Contractual Life
(in years)
Aggregate
Intrinsic
Value
Balance, December 31, 2019478,951 $8.21 
Granted48,948 20.43 
Balance, September 30, 2020527,899 9.34 6.59$3,419,956 
Exercisable at September 30, 2020298,863 7.48 5.852,353,438 
Aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on September 30, 2020 and the exercise price, multiplied by the number of in-the-money options as applicable) that would have been received by the holder had all holders exercised their options on September 30, 2020. No options were exercised during the nine months ended September 30, 2020. As of September 30, 2020, total unrecognized stock-based compensation expense related to non-vested employee awards was $0.7 million which is expected to be recognized over a weighted average period of approximately 1.68 years.
DeepHealth Options
During the second quarter of fiscal 2020, in connection with the completion of the DeepHealth acquisition, we granted 412,434 options at a grant date fair value of $16.93 per share unit to DeepHealth employees in replacement of their stock options that were outstanding as of the closing date. As of September 30, 2020, total unrecognized stock based compensation expense related to non-vested DeepHealth options was approximately $4.3 million which is expected to be recognized over a weighted average period of approximately 2.53 years.
Outstanding Options
Under the Deep Health Plan
SharesWeighted Average
Exercise price
Per Common Share
Weighted Average
Remaining
Contractual Life
(in years)
Aggregate
Intrinsic
Value
Balance, December 31, 2019— 
Granted, June 1, 2020412,434 $— 
Exercised(6,963)— 
Balance, September 30, 2020405,471 — 8.65$6,223,980 
Exercisable at September 30, 202024,211 — 8.65371,639 
Restricted Stock Awards
The Restated Plan permits the award of restricted stock awards (“RSA’s”). As of September 30, 2020, we have issued a total of 6,551,872 RSA’s of which 331,659 were unvested at September 30, 2020. The following summarizes all unvested RSA’s activities during the nine months ended September 30, 2020:
 RSA'sWeighted-Average
Remaining
Contractual
Term (Years)
Weighted-Average
Fair Value
RSA's unvested at December 31, 2019387,934 $11.61 
Changes during the period
Granted457,596 $19.66 
Vested(513,871)$15.47 
RSA's unvested at September 30, 2020331,659 1.11$16.67 
We determine the fair value of all RSA’s based on the closing price of our common stock on the award date.
Other stock bonus awards
The Restated Plan also permits the award of stock bonuses not subject to any future service period. These awards are valued and expensed based on the closing price of our common stock on the date of award. During the nine months ended September 30, 2020 awards totaling 26,078 shares were granted.
Plan summary
In summary, of the 14,000,000 shares of common stock reserved for issuance under the Restated Plan, at September 30, 2020, we had issued 15,384,316 total shares between options, RSA’s and other stock awards. With options canceled and RSA’s forfeited amounting to 3,281,040 and 61,703 shares, respectively, there remain 1,958,427 shares available under the Restated Plan for future issuance.
The DeepHealth options were issued outside of the Restated Plan and are a direct result of our acquisition and not included in the share count of the Restated Plan.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.20.2
SUBSEQUENT EVENTS
9 Months Ended
Sep. 30, 2020
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
Formation of majority owned subsidiary
On November 1, 2020 we formed in conjunction with Simi Valley Hospital and Health Services ("Simi Adventist") the Simi Valley Imaging Group, LLC (“SVIG”), consisting of three multi-modality imaging centers located in Simi Valley, CA. RadNet will hold a 60% economic interest in SVIG and Simi Adventist will have the remaining 40% interest.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.20.2
SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
REVENUES REVENUES - Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period when our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payors. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.
As it relates to the Group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by them as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.
Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.
Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.
Our total service revenues during the three and nine months ended September 30, 2020 and 2019 are presented in the table below based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in thousands):
 Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
Commercial insurance$160,524 $163,152 $412,415 $475,064 
Medicare62,704 61,599 154,847 175,825 
Medicaid7,098 7,128 18,072 21,564 
Workers' compensation/personal injury7,183 10,865 25,705 32,950 
Other patient revenue8,328 6,085 17,211 17,947 
Management fee revenue2,675 1,792 8,574 5,662 
Teleradiology and Software revenue2,349 4,412 8,319 12,861 
Other5,869 6,875 15,617 20,878 
Service fee revenue256,730 261,908 660,760 762,751 
Revenue under capitation arrangements35,046 30,784 103,145 90,587 
Total service revenue$291,776 $292,692 $763,905 $853,338 

COVID-19 PANDEMIC AND CARES ACT FUNDING - On March 11, 2020 the World Health Organization (WHO) designated COVID-19 as a global pandemic. Patient volumes and the related revenues for our services were significantly impacted during the latter portion of the first quarter through the middle of the third quarter of 2020 as a result of federal, state and local government mandated restrictions requiring many people to remain at home and forced the closure of or limitations on certain businesses, as well as suspended elective procedures by health care facilities. Many of these restrictions have been eased or completely lifted across the states the Company operates in however, we are unable to predict the future impact of the pandemic on our operations.

During the nine months ended September 30, 2020, we received $39.4 million of accelerated Medicare payments, $5.0 million from Blue Cross, $25.7 million from the general distribution and $4.0 million from the Paycheck Protection Program established through the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. The accelerated Medicare payments are recorded under the caption “ Deferred Revenue“ in our condensed consolidated balance sheet and will be repaid beginning in 2021. The general distribution funds were accounted for as government grants and recognized as other revenue, once reasonable assurance that the applicable terms and conditions required to retain the funds were met, under the caption “Provider relief funding” in our condensed Consolidated Statements of Operations

During the three months ended September 30, 2020, the Department of Health and Human Services significantly changed the measurement of Provider Relief Funds that providers are able to retain. We received approximately $0.2 million in
funding and based on our assessment of the likelihood of meeting the applicable terms and conditions of the general distribution we continue to recognized the funds received as other revenue.

The CARES Act also providers for a payment deferral of the employer portion of Social Security tax incurred during the pandemic, allowing half of such payroll taxes to be deferred until December 2021 and the remaining half until December 2022. At September 30, 2020, the Company had deferred $10.8 million of Social Security taxes. These payment deferrals are recorded as payroll tax liability under the caption “Accounts payable, accrued expenses and other” in our condensed consolidated balance sheet.
We believe the extent of the COVID-19 pandemic’s impact on our operating results and financial condition has been and will continue to be driven by many factors, most of which are beyond our control and ability to forecast. Such factors include, but are not limited to, the scope and duration of stay-at-home practices, business closures and restrictions, suspensions of elective procedures and continued decline in procedure volumes for an indeterminable length of time and incremental expenses required for supplies and personal protective equipment. Because of these uncertainties, we cannot estimate the length or impact of the pandemic on our business. If we incur declines in cash flows and results of operations, such declines could have an impact on the inputs and assumptions used in significant accounting estimates, including implicit prices concessions related to uninsured patient accounts, and potential impairment of goodwill and long-lived assets. During the third quarter of 2020, procedure volumes increased and have had a positive impact on our patient revenue. However, the impact of COVID-19 in future periods may vary and could adversely impact our results of operations.
RECLASSIFICATION RECLASSIFICATION –We have reclassified certain amounts previously classified as held for sale related to property and equipment and goodwill to conform to our 2020 presentation.
ACCOUNTS RECEIVABLE ACCOUNTS RECEIVABLE - Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience. In regards to the credit loss standard, we have concluded that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses estimated under the Current Expected Credit Loss ("CECL") model.
DEFERRED REVENUE DEFERRED REVENUE - As noted above, in April of 2020, we received approximately $39.4 million in advanced Medicare payments from the Centers for Medicare and Medicaid Services ("CMS") as part of the expanded Accelerated and Advance Payment Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. As these payments are required to be repaid to CMS beginning 120 days after their receipt through offsets from new Medicare claims over a three month period, we have recorded amounts received to deferred revenue which will be amortized as Medicare reimbursements are earned. In addition, in May of 2020 we received $5.0 million in advance payments from an insurance carrier with similar repayment terms as the CMS.
DEFERRED FINANCING COSTS DEFERRED FINANCING COSTS - Costs of financing are deferred and amortized using the effective interest rate method. Deferred financing costs, net of accumulated amortization, were $1.9 million and $1.6 million, as of September 30, 2020 and December 31, 2019, respectively and related to our Barclays line of credit. See Note 5, Credit Facilities and Notes Payable for more information.
PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation of property and equipment is performed using the straight-line method over the estimated useful lives of the assets acquired, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred.
BUSINESS COMBINATION BUSINESS COMBINATION - When the qualifications for business combination accounting treatment are met, it requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.
GOODWILL AND INDEFINITE LIVED INTANGIBLES
GOODWILL AND INDEFINITE LIVED INTANGIBLES - Goodwill at September 30, 2020 totaled $470.7 million. Indefinite lived intangible assets at September 30, 2020 were $11.3 million. Goodwill and Indefinite Lived Intangibles are recorded as a result of business combinations. When we determine the carrying value of reporting unit exceeds its fair value an impairment charge would be recognized and should not exceed the total amount of goodwill allocated to that reporting unit. We tested goodwill and indefinite lived intangibles for impairment on October 1, 2019, noting no impairment. In addition to the annual impairment test, we regularly assess if an event has occurred which would require interim impairment testing. We considered the current and expected future economic and market conditions surrounding the novel strain of coronavirus ("COVID-19") pandemic and did not identify an indication of goodwill impairment being more likely than not through September 30, 2020. Activity in goodwill for the nine months ended September 30, 2020 is provided below (in thousands):
Balance as of December 31, 2019$441,973 
Goodwill acquired through the acquisition of Olney Open MRI, LLC601 
Goodwill acquired through the acquisition of MRI at Woodbridge, LLC1,833 
Goodwill acquired through the acquisition of DeepHealth, Inc.23,396 
Goodwill acquired through the acquisition of AZ-Tech Radiology & Open MRI, LLC2,882 
Balance as of September 30, 2020$470,685 
INCOME TAXES
INCOME TAXES - Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized.
We recorded an income tax expense of $3.8 million, or an effective tax rate of 27.2%, for the three months ended September 30, 2020 compared to an income tax expense of $1.8 million, or an effective tax rate of 26.3% for the three months ended September 30, 2019. We recorded an income tax benefit of $5.0 million, or an effective tax rate of 28.3%, for the nine months ended September 30, 2020 compared to an income tax expense of $3.6 million , or an effective tax rate of 24.8% for the nine months ended September 30, 2019.The income tax rates for the three and nine months ended September 30, 2020 diverge from the federal statutory rate due to (i) noncontrolling interests due to the controlled partnerships; (ii) effects of state income taxes; and (iii) excess tax benefits attributable to share-based compensation.
We believe no significant changes in the unrecognized tax benefits will occur within the next 12 months.
On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"). The CARES Act, among other things, includes certain income tax provisions for individuals and corporations; however, these benefits do not impact the Company’s current tax provision.
LEASES LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long term operating lease liability in our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liability, and long-term finance lease liability in our consolidated balance sheets.  ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have elected to account for the components as a single lease component, as permitted. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the ROU asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. ROU assets are tested for impairment if circumstances suggest that the carrying amount may not be recoverable. Our ROU assets consist of facility and equipment assets on operating leases. No events have occurred such as fire, flood, or other acts which have impaired the integrity of our ROU assets in 2020. Our facility leases require us to maintain insurance policies which would cover major damage to our facilities. We maintain business interruption insurance to cover loss of business due to a facility becoming non-operational under certain circumstances. Our equipment leases are covered by warranty and service contracts which cover repairs and provide regular maintenance to keep the equipment in functioning order.
EQUITY BASED COMPENSATION EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated as of April 20, 2015, and again on March 9, 2017 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved 14,000,000 shares of common stock for issuance under the Restated Plan which can be issued in the form of options, stock awards, stock appreciation rights, stock units, and cash awards. Stock options generally vest over three to five years and expire five to ten years from date of grant. We determine the compensation expense for each stock option award using the Black Scholes, or similar valuation model. Those models require that our management make certain estimates concerning risk free interest rates and volatility in the trading price of our common stock. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. In connection with our acquisition of DeepHealth Inc. on June 1, 2020, we assumed the DeepHealth, Inc. 2017 Stock Incentive Plan, including outstanding options awards that can be exercised for our common stock. No additional awards will be granted under the DeepHealth, Inc. 2017 Equity Incentive Plan. See Note 4, Facility Acquisitions and Note 6, Stock-Based Compensation, for more information.
COMPREHENSIVE INCOME (LOSS) COMPREHENSIVE INCOME (LOSS) - ASC 220 establishes rules for reporting and displaying comprehensive income or loss and its components. Our unrealized gains or losses on foreign currency translation adjustments, interest rate cap and swap agreements are included in comprehensive loss and are included in the consolidated statements of comprehensive income (loss) for the three and nine months ended September 30, 2020 and 2019
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. Based on current information, we do not believe that reasonably possible or probable losses associated with pending legal proceedings would either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. Therefore, if one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.
DERIVATIVE INSTRUMENTS
DERIVATIVE INSTRUMENTS
2016 CAPS
In the fourth quarter of 2016, we entered into two forward interest rate cap agreements ("2016 Caps"). The 2016 Caps will mature in September and October 2020. The 2016 Caps had notional amounts of $150,000,000 and $350,000,000, respectively. Under these arrangements, the Company purchased a cap on 3 month LIBOR at 2.0%. We incurred a $5.3 million premium to enter into the 2016 Caps which is being accrued over the life of the agreements.
At inception, we designated our 2016 Caps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss of the hedge (i.e. change in fair value) is reported as a component of comprehensive loss in the consolidated statement of equity since such hedge has been determined to be effective. See Fair Value Measurements section below for the fair value of the 2016 Caps at September 30, 2020.
A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss of the 2016 Caps is as follows (amounts in thousands):
For the three months ended September 30, 2020
AccountJuly 1, 2020 BalanceAmount of comprehensive gain recognized on derivative net of taxesSeptember 30, 2020 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes(1,409)195 (1,214)Liabilities and Equity
For the nine months ended September 30, 2020
AccountJanuary 1, 2020 BalanceAmount of comprehensive gain recognized on derivative net of taxesSeptember 30, 2020 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes(1,877)663 (1,214)Liabilities and Equity
2019 SWAPS
In the second quarter of 2019, we entered into four forward interest rate agreements ("2019 Swaps"). The 2019 Swaps have total notional amounts of $500,000,000, consisting of two agreements of $50,000,000 each and two agreements of $200,000,000 each. The 2019 Swaps will secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They will mature in October 2023 for the smaller notional and October 2025 for the larger notional. Under these arrangements, we arranged the 2019 Swaps with locked in 1 month LIBOR rates at 1.96% for the $100,000,000 notional and at 2.05% for the $400,000,000 notional. As of the effective date, we will be liable for premium payments if interest rates decline below arranged rates, but will receive interest payments if rates remain above the arranged rates.
At inception, we designated our 2019 Swaps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e. change in fair value) is reported as a component of comprehensive loss in the consolidated statement of equity. The remaining gain or loss, if any, is recognized currently in earnings. As a result of the economic impact of the coronavirus pandemic, which precipitated a reduction in interest rates , the cash flows for both our $400,000,000 notional interest rate swap contract locked in at 2.05% due October 2025 and our $100,000,000 notional interest rate swap contract locked in at 1.96% do not match the cash flows for our First Lien Term Loans and so we have determined that they are not currently effective as cash flow hedges. Accordingly, all changes in their fair value after April 1, 2020 for the $400,000,000 notional and after July 1, 2020 for the $100,000,000 notional will be recognized in earnings. As of July 1, 2020, the total change in fair value relating to swaps included in other comprehensive income was approximately $24.4 million, net of taxes. This amount will be amortized to interest expense through October 2025 at approximately $0.4 million per month.
A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss of the 2019 swaps which remain ineffective is as follows (amounts in thousands):
For the three months ended September 30, 2020
AccountJuly 1, 2020 BalanceAmount of comprehensive loss recognized on derivative net of taxesAmount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxesSeptember 30, 2020 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes$(24,406)$— $969 $(23,437)Liabilities and Equity
For the nine months ended September 30, 2020
AccountJanuary 1, 2020 BalanceAmount of comprehensive loss recognized on derivative net of taxesAmount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxesSeptember 30, 2020 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes$(5,870)$(19,428)$1,861 $(23,437)Liabilities and Equity
A tabular presentation of the effect of derivative instruments on our statement of operations of the 2019 Swaps for the Swaps that became ineffective during the third quarter is as follows (amounts in thousands):
For the three months ended September 30, 2020
Ineffective interest rate swapAmount of loss recognized in income on derivative (current period ineffective portion)Location of loss recognized in Income on derivative (current period ineffective portion)Amount of loss reclassified from accumulated OCI into income (prior period effective portion)Location of gain (Loss) reclassified from accumulated OCI into income (prior period effective portion)
Interest rate contracts$(679)Other income (expense)$(1,312)Equity and Interest Expense
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:
Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.
Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.
Derivatives:
The tables below summarize the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets on our condensed consolidated balance sheets, as follows (in thousands):
 As of September 30, 2020
Level 1Level 2Level 3Total
Current and long term liabilities    
2016 caps - Interest Rate Contracts$— $182 $— $182 
2019 swaps - Interest Rate Contracts$— $39,983 $— $39,983 
 As of December 31, 2019
Level 1Level 2Level 3Total
Current and long term liabilities    
2016 caps - Interest Rate Contracts$— $1,081 $— $1,081 
2019 swaps - Interest Rate Contracts$— $9,477 $— $9,477 
The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty’s forward LIBOR curve. The forward LIBOR curve is readily available in the public markets or can be derived from information available in the public markets.
Long Term Debt:
The table below summarizes the estimated fair value compared to our face value of our long-term debt as follows (in thousands):
 As of September 30, 2020
Level 1Level 2Level 3Total Fair ValueTotal Face Value
First Lien Term Loans and SunTrust Term Loan$— $663,140 $— $663,140 $673,227 
 As of December 31, 2019
Level 1Level 2Level 3TotalTotal Face Value
First Lien Term Loans and SunTrust Term Loan$— $708,948 $— $708,948 $705,699 
As of September 30, 2020 and at December 31, 2019 our Barclays revolving credit facility had no balance outstanding. Our SunTrust revolving credit facility relating to our consolidated subsidiary NJIN, had no principal amount outstanding at September 30, 2020 and at December 31, 2019.
The estimated fair value of our long-term debt, which is discussed in Note 5, was determined using Level 2 inputs primarily related to comparable market prices.
We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our finance lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.
EARNINGS PER SHARE EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):
 Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Net income (loss) attributable to RadNet, Inc.'s common stockholders$6,156 $3,195 $(20,797)$4,360 
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period51,358,603 49,807,460 50,746,380 49,597,138 
Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders$0.12 $0.06 $(0.41)$0.09 
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period51,358,603 49,807,460 50,746,380 49,597,138 
Add nonvested restricted stock subject only to service vesting120,605 200,567 191,375 
Add additional shares issuable upon exercise of stock options and warrants476,607 352,333 324,793 
Weighted average number of common shares used in calculating diluted net income per share51,955,815 50,360,360 50,746,380 50,113,306 
Diluted net income (loss) per share attributable to RadNet, Inc.'s common stockholders$0.12 $0.06 $(0.41)$0.09 
Stock options and non vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:
Nonvested restricted stock subject to service vesting— — 331,659 — 
Shares issuable upon the exercise of stock options:48,948 — 933,370 — 
EQUITY INVESTMENTS AT FAIR VALUE EQUITY INVESTMENTS AT FAIR VALUE–Accounting guidance requires entities to measure equity investments at fair value, with any changes in fair value recognized in net income. If there is no readily determinable fair value, the guidance allows entities the ability to measure investments at cost, adjusted for observable price changes and impairments, with changes recognized in net income.
INVESTMENTS IN JOINT VENTURES
INVESTMENT IN JOINT VENTURES – We have 12 unconsolidated joint ventures with ownership interests ranging from 35% to 55%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures is accounted for under the equity method, since RadNet does not have a controlling financial interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of September 30, 2020.
Joint venture investment contribution
In the month of August 2020, we made additional cash contributions to our Santa Monica Imaging Group, LLC partnership in the amount of $1.6 million in support of its expanded operations. We maintain our 35% economic interest in the partnership.

Joint venture investment and financial information
The following table is a summary of our investment in joint ventures during the nine months ended September 30, 2020 (in thousands):
Balance as of December 31, 2019$34,470 
Equity in earnings in these joint ventures5,176 
Distribution of earnings(5,706)
Equity contributions in existing joint ventures1,631 
Balance as of September 30, 2020$35,571 
We charged management service fees from the centers underlying these joint ventures of approximately $2.7 million and $1.8 million for the three months ended September 30, 2020 and 2019, respectively, and $8.6 million and $7.8 million for the nine months ended September 30, 2020 and 2019, respectively. We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures.
The following table is a summary of key balance sheet data for these joint ventures as of September 30, 2020 and December 31, 2019 and income statement data for the nine months ended September 30, 2020 and 2019 (in thousands):
Balance Sheet Data:September 30, 2020December 31, 2019
Current assets$26,618 $27,427 
Noncurrent assets70,576 61,037 
Current liabilities(10,487)(9,217)
Noncurrent liabilities(22,751)(18,872)
Total net assets$63,956 $60,375 
Book value of RadNet joint venture interests$29,121 $28,001 
Cost in excess of book value of acquired joint venture interests and other6,450 6,469 
Total value of Radnet joint venture interests$35,571 $34,470 
Total book value of other joint venture partner interests$34,835 $32,374 
Income statement data for the nine months ended September 30,20202019
Net revenue$78,988 $80,115 
Net income$13,651 $13,718 
RECENT ACCOUNTING AND REPORTING STANDARDS RECENT ACCOUNTING AND REPORTING STANDARDS
Accounting standards adopted

In June 2016, the FASB issued ASU No. 2016-13 ("ASU 2016-13), Financial Instruments - Credit Losses. ASU 2016-13 replaces the incurred loss methodology previously utilized for valuing financial instruments with an expected loss methodology that is referred to as the current expected credit loss (CECL) methodology. We prospectively adopted the standard on January 1, 2020 and the adoption did not have a material impact to the condensed consolidated financial statements, resulting in no adjustments to our prior year earnings. See the Accounts Receivable section to Note 2 for further information on our allowances for credit losses.

In August 2018, the FASB issued ASU No. 2018-15 (“ASU 2018-15”), Intangibles-Goodwill and Other-Internal-Use Software. ASU 2018-15 aligns the requirements for deferring implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This ASU is effective in the first quarter of 2020 with early adoption permitted and can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The adoption of this standard did not have a material impact on our condensed consolidated balance sheet.

In March 2020, the FASB issued ASU 2020-03 ("ASU 2020-03"), Codification Improvements to Financial Instruments. The amendments in this update represent changes to clarify or improve the codification and correct unintended application. ASU 2020-03 was effective immediately upon issuance and its adoption did not have a material impact on our financial statements.

In August 2018, the FASB issued ASU No. 2018-13 ("ASU 2018-13"), Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurements. This standard removes, modifies and adds certain disclosures related to recurring and nonrecurring fair value measurements. We adopted ASC 2018-13 effective January 1, 2020 and it had no effect on our disclosures.

Accounting standards not yet adopted
 
In December 2019, the FASB issued ASU 2019-12 ("ASU 2019-12"), Income Taxes (Topic 740). ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other areas of the standard. ASU 2019-12 will be effective beginning in the first quarter of 2021. Early adoption is permitted. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. We are currently evaluating the impact this ASU will have on our financial statements and related disclosures as well as the timing of adoption.

In January 2020, the FASB issued ASU 2020-01 ("ASU 2020-01"), Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), clarifying the interaction between accounting standards related to equity securities, equity method investments, and certain derivatives. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020. We do not expect the adoption of this guidance will have a material impact on our financial statements.

In March 2020, the FASB issued ASU 2020-04 ("ASU 2020-04"), Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting. ASU 2020-04 provides optional expedients and exceptions for applying generally accepted accounting principles to certain contract modifications and hedging relationships that reference London Inter-bank Offered Rate (LIBOR) or another reference rate expected to be discontinued. The guidance is effective upon issuance and generally can be applied through December 31, 2022. We are currently evaluating the potential impact of ASU 2020-04 on our financial statements.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.20.2
SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Service Fee Revenue
Our total service revenues during the three and nine months ended September 30, 2020 and 2019 are presented in the table below based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in thousands):
 Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
Commercial insurance$160,524 $163,152 $412,415 $475,064 
Medicare62,704 61,599 154,847 175,825 
Medicaid7,098 7,128 18,072 21,564 
Workers' compensation/personal injury7,183 10,865 25,705 32,950 
Other patient revenue8,328 6,085 17,211 17,947 
Management fee revenue2,675 1,792 8,574 5,662 
Teleradiology and Software revenue2,349 4,412 8,319 12,861 
Other5,869 6,875 15,617 20,878 
Service fee revenue256,730 261,908 660,760 762,751 
Revenue under capitation arrangements35,046 30,784 103,145 90,587 
Total service revenue$291,776 $292,692 $763,905 $853,338 
Schedule of goodwill and other intangible assets Activity in goodwill for the nine months ended September 30, 2020 is provided below (in thousands):
Balance as of December 31, 2019$441,973 
Goodwill acquired through the acquisition of Olney Open MRI, LLC601 
Goodwill acquired through the acquisition of MRI at Woodbridge, LLC1,833 
Goodwill acquired through the acquisition of DeepHealth, Inc.23,396 
Goodwill acquired through the acquisition of AZ-Tech Radiology & Open MRI, LLC2,882 
Balance as of September 30, 2020$470,685 
Effect of derivative instruments on comprehensive income A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss of the 2016 Caps is as follows (amounts in thousands):
For the three months ended September 30, 2020
AccountJuly 1, 2020 BalanceAmount of comprehensive gain recognized on derivative net of taxesSeptember 30, 2020 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes(1,409)195 (1,214)Liabilities and Equity
For the nine months ended September 30, 2020
AccountJanuary 1, 2020 BalanceAmount of comprehensive gain recognized on derivative net of taxesSeptember 30, 2020 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes(1,877)663 (1,214)Liabilities and Equity
A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss of the 2019 swaps which remain ineffective is as follows (amounts in thousands):
For the three months ended September 30, 2020
AccountJuly 1, 2020 BalanceAmount of comprehensive loss recognized on derivative net of taxesAmount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxesSeptember 30, 2020 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes$(24,406)$— $969 $(23,437)Liabilities and Equity
For the nine months ended September 30, 2020
AccountJanuary 1, 2020 BalanceAmount of comprehensive loss recognized on derivative net of taxesAmount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxesSeptember 30, 2020 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes$(5,870)$(19,428)$1,861 $(23,437)Liabilities and Equity
A tabular presentation of the effect of derivative instruments on our statement of operations of the 2019 Swaps for the Swaps that became ineffective during the third quarter is as follows (amounts in thousands):
For the three months ended September 30, 2020
Ineffective interest rate swapAmount of loss recognized in income on derivative (current period ineffective portion)Location of loss recognized in Income on derivative (current period ineffective portion)Amount of loss reclassified from accumulated OCI into income (prior period effective portion)Location of gain (Loss) reclassified from accumulated OCI into income (prior period effective portion)
Interest rate contracts$(679)Other income (expense)$(1,312)Equity and Interest Expense
Schedule of fair value of assets and liabilities The tables below summarize the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets on our condensed consolidated balance sheets, as follows (in thousands):
 As of September 30, 2020
Level 1Level 2Level 3Total
Current and long term liabilities    
2016 caps - Interest Rate Contracts$— $182 $— $182 
2019 swaps - Interest Rate Contracts$— $39,983 $— $39,983 
 As of December 31, 2019
Level 1Level 2Level 3Total
Current and long term liabilities    
2016 caps - Interest Rate Contracts$— $1,081 $— $1,081 
2019 swaps - Interest Rate Contracts$— $9,477 $— $9,477 
The table below summarizes the estimated fair value compared to our face value of our long-term debt as follows (in thousands):
 As of September 30, 2020
Level 1Level 2Level 3Total Fair ValueTotal Face Value
First Lien Term Loans and SunTrust Term Loan$— $663,140 $— $663,140 $673,227 
 As of December 31, 2019
Level 1Level 2Level 3TotalTotal Face Value
First Lien Term Loans and SunTrust Term Loan$— $708,948 $— $708,948 $705,699 
Earnings per share Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):
 Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Net income (loss) attributable to RadNet, Inc.'s common stockholders$6,156 $3,195 $(20,797)$4,360 
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period51,358,603 49,807,460 50,746,380 49,597,138 
Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders$0.12 $0.06 $(0.41)$0.09 
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period51,358,603 49,807,460 50,746,380 49,597,138 
Add nonvested restricted stock subject only to service vesting120,605 200,567 191,375 
Add additional shares issuable upon exercise of stock options and warrants476,607 352,333 324,793 
Weighted average number of common shares used in calculating diluted net income per share51,955,815 50,360,360 50,746,380 50,113,306 
Diluted net income (loss) per share attributable to RadNet, Inc.'s common stockholders$0.12 $0.06 $(0.41)$0.09 
Stock options and non vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:
Nonvested restricted stock subject to service vesting— — 331,659 — 
Shares issuable upon the exercise of stock options:48,948 — 933,370 — 
Investment in joint ventures
The following table is a summary of our investment in joint ventures during the nine months ended September 30, 2020 (in thousands):
Balance as of December 31, 2019$34,470 
Equity in earnings in these joint ventures5,176 
Distribution of earnings(5,706)
Equity contributions in existing joint ventures1,631 
Balance as of September 30, 2020$35,571 
Joint venture investment and financial information
The following table is a summary of key balance sheet data for these joint ventures as of September 30, 2020 and December 31, 2019 and income statement data for the nine months ended September 30, 2020 and 2019 (in thousands):
Balance Sheet Data:September 30, 2020December 31, 2019
Current assets$26,618 $27,427 
Noncurrent assets70,576 61,037 
Current liabilities(10,487)(9,217)
Noncurrent liabilities(22,751)(18,872)
Total net assets$63,956 $60,375 
Book value of RadNet joint venture interests$29,121 $28,001 
Cost in excess of book value of acquired joint venture interests and other6,450 6,469 
Total value of Radnet joint venture interests$35,571 $34,470 
Total book value of other joint venture partner interests$34,835 $32,374 
Income statement data for the nine months ended September 30,20202019
Net revenue$78,988 $80,115 
Net income$13,651 $13,718 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.20.2
CREDIT FACILITY AND NOTES PAYABLE (Tables)
9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
Schedule of notes payable, line of credit and capital lease obligations
As of September 30, 2020 and December 31, 2019 our debt obligations consisted of the following (in thousands):
September 30,
2020
December 31,
2019
First Lien Term Loans collateralized by RadNet's tangible and intangible assets$620,727 $649,824 
Discounts on First Lien Term Loans(10,669)(13,579)
SunTrust Term Loan Agreement collateralized by NJIN's tangible and intangible assets52,500 55,875 
Paycheck Protection Program loans at 1% due April 2022
4,037 — 
Equipment note payable at 4.6%, due through 2020, collateralized by medical equipment
47 275 
Total debt obligations666,642 692,395 
Less: current portion(39,463)(39,691)
Long term portion debt obligations$627,179 $652,704 
Schedule of first lien credit agreement
Included in our condensed consolidated balance sheets at September 30, 2020 are $620.7 million of First Lien Term Loans and $52.5 million of SunTrust Term Loan debt for a combined total of $673.2 million of total term loan debt (exclusive of unamortized discounts of $10.7 million) in thousands:
 Face ValueDiscountTotal Carrying
Value
First Lien Term Loans$620,727 $(10,669)$610,058 
SunTrust Term Loan52,500 — 52,500 
Total Term Loans$673,227 $(10,669)$662,558 
Schedule of leverage ratio
Our First Lien Term Loans bear interest at either an Adjusted Eurodollar Rate or a Base Rate, plus an applicable margin according to the following schedule:
First Lien Leverage RatioEurodollar Rate SpreadBase Rate Spread
> 5.50x4.50%3.50%
> 4.00x but ≤ 5.50x3.75%2.75%
>3.50x but ≤ 4.00x3.50%2.50%
≤ 3.50x3.25%2.25%
Our SunTrust Term Loan bears interest at either an Adjusted Eurodollar Rate or a Base Rate, plus an applicable margin according to the following schedule:

Pricing LevelLeverage RatioApplicable Margin for Eurodollar LoansApplicable Margin for Base Rate LoansApplicable Margin for Letter of Credit FeesApplicable Percentage for Commitment Fee
I
Greater than or equal to 3.00:1.00
2.75%
per annum
1.75%
per annum
2.75%
per annum
0.45%
per annum
II
Less than 3.00:1.00 but greater than or equal to 2.50:1.00
2.25%
per annum
1.25%
per annum
2.25%
per annum
0.40%
per annum
III
Less than 2.50:1.00 but greater than or equal to
2.00:1.00
2.00%
per annum
1.00%
per annum
2.00%
per annum
0.35%
per annum
IV
Less than 2.00:1.00 but greater than or equal to 1.50:1.00
1.75%
per annum
0.75%
per annum
1.75%
per annum
0.30%
per annum
V
Less than 1.50:1.00
1.50%
per annum
0.50%
per annum
1.50%
per annum
0.30%
per annum
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.20.2
STOCK-BASED COMPENSATION (Tables)
9 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of options activity The following summarizes all of our option transactions for the nine months ended September 30, 2020:
Outstanding Options
Under the 2006 Plan
SharesWeighted Average
Exercise price
Per Common Share
Weighted Average
Remaining
Contractual Life
(in years)
Aggregate
Intrinsic
Value
Balance, December 31, 2019478,951 $8.21 
Granted48,948 20.43 
Balance, September 30, 2020527,899 9.34 6.59$3,419,956 
Exercisable at September 30, 2020298,863 7.48 5.852,353,438 
Outstanding Options
Under the Deep Health Plan
SharesWeighted Average
Exercise price
Per Common Share
Weighted Average
Remaining
Contractual Life
(in years)
Aggregate
Intrinsic
Value
Balance, December 31, 2019— 
Granted, June 1, 2020412,434 $— 
Exercised(6,963)— 
Balance, September 30, 2020405,471 — 8.65$6,223,980 
Exercisable at September 30, 202024,211 — 8.65371,639 
Schedule of RSA activity The following summarizes all unvested RSA’s activities during the nine months ended September 30, 2020:
 RSA'sWeighted-Average
Remaining
Contractual
Term (Years)
Weighted-Average
Fair Value
RSA's unvested at December 31, 2019387,934 $11.61 
Changes during the period
Granted457,596 $19.66 
Vested(513,871)$15.47 
RSA's unvested at September 30, 2020331,659 1.11$16.67 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.20.2
NATURE OF BUSINESS (Details Narrative)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
USD ($)
Center
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
Center
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Apr. 12, 2018
Business Acquisition [Line Items]            
Number of centers | Center 334   334      
Ownership percentage           25.00%
BRMG and NY Groups revenues $ 38,300 $ 40,600 $ 104,800 $ 116,900    
BRMG and NY Groups operating expenses 38,300 40,600 104,800 116,900    
Management services provided to BRMG and NY Groups 169,000 $ 154,500 433,300 $ 456,100    
BRMG and NY Groups accounts receivable 1,717,866   1,717,866   $ 1,646,986  
BRMG and NY Groups accounts payable $ 1,471,745   $ 1,471,745   1,413,847  
ScriptSender LLC            
Business Acquisition [Line Items]            
Ownership percentage 49.00%   49.00%      
Chief Executive Officer | Beverly Radiology Medical Group III            
Business Acquisition [Line Items]            
Ownership percentage 99.00%   99.00%      
Board Member | Beverly Radiology Medical Group III            
Business Acquisition [Line Items]            
Ownership percentage 1.00%   1.00%      
Variable Interest Entity, Primary Beneficiary            
Business Acquisition [Line Items]            
BRMG and NY Groups accounts receivable $ 84,500   $ 84,500   100,300  
BRMG and NY Groups accounts payable $ 10,700   $ 10,700   $ 7,000  
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.20.2
SIGNIFICANT ACCOUNTING POLICIES (Details - Revenue) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue from External Customer [Line Items]        
Service fee revenue, net of contractual allowances and discounts $ 291,776 $ 292,692 $ 763,905 $ 853,338
Total service revenue 291,776 292,692 763,905 853,338
Commercial insurance        
Revenue from External Customer [Line Items]        
Service fee revenue, net of contractual allowances and discounts 160,524 163,152 412,415 475,064
Medicare        
Revenue from External Customer [Line Items]        
Service fee revenue, net of contractual allowances and discounts 62,704 61,599 154,847 175,825
Medicaid        
Revenue from External Customer [Line Items]        
Service fee revenue, net of contractual allowances and discounts 7,098 7,128 18,072 21,564
Workers' compensation/personal injury        
Revenue from External Customer [Line Items]        
Service fee revenue, net of contractual allowances and discounts 7,183 10,865 25,705 32,950
Other patient revenue        
Revenue from External Customer [Line Items]        
Service fee revenue, net of contractual allowances and discounts 8,328 6,085 17,211 17,947
Management fee revenue        
Revenue from External Customer [Line Items]        
Service fee revenue, net of contractual allowances and discounts 2,675 1,792 8,574 5,662
Teleradiology and Software revenue        
Revenue from External Customer [Line Items]        
Service fee revenue, net of contractual allowances and discounts 2,349 4,412 8,319 12,861
Other        
Revenue from External Customer [Line Items]        
Service fee revenue, net of contractual allowances and discounts 5,869 6,875 15,617 20,878
Service fee revenue        
Revenue from External Customer [Line Items]        
Service fee revenue, net of contractual allowances and discounts 256,730 261,908 660,760 762,751
Revenue under capitation arrangements        
Revenue from External Customer [Line Items]        
Service fee revenue, net of contractual allowances and discounts $ 35,046 $ 30,784 $ 103,145 $ 90,587
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF ACCOUNTING POLICIES (Details Narrative)
1 Months Ended 3 Months Ended 9 Months Ended
Nov. 05, 2019
USD ($)
Mar. 01, 2018
USD ($)
Feb. 01, 2018
USD ($)
shares
Mar. 24, 2017
USD ($)
Aug. 31, 2020
USD ($)
May 31, 2020
USD ($)
Apr. 30, 2020
USD ($)
Sep. 30, 2020
USD ($)
numberOfAgreement
shares
Sep. 30, 2019
USD ($)
Mar. 31, 2019
Sep. 30, 2020
USD ($)
numberOfAgreement
shares
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
joint_venture
Oct. 11, 2019
shares
Jun. 30, 2019
USD ($)
Jan. 01, 2019
USD ($)
Apr. 12, 2018
Property, Plant and Equipment [Line Items]                                  
Provider relief funding               $ 221,000 $ 0   $ 25,696,000 $ 0          
Contracts receivable, factoring receivable               20,400,000     20,400,000            
Deferred financing costs, net of accumulated amortization               1,900,000     1,900,000   $ 1,600,000        
Goodwill               470,685,000     470,685,000   441,973,000        
Indefinite-lived intangible assets               11,300,000     11,300,000            
Income tax expense               $ 3,825,000 $ 1,816,000   $ (5,029,000) $ 3,556,000          
Effective tax rate               27.20% 26.30%   28.30% 24.80%          
Amount of loss recognized in income on derivative (current period ineffective portion)               $ 24,400,000                  
Monthly amortization of deferred hedge gains               400,000                  
Total credit facilities outstanding               0     $ 0   0        
Ownership percentage                                 25.00%
Aggregate cost               63,956,000     63,956,000   60,375,000        
Advance for future software subscription fees               31,482,000     31,482,000   $ 45,004,000        
Number of unconsolidated joint ventures | joint_venture                         12        
Management service fees               2,700,000 $ 1,800,000   $ 8,600,000 $ 7,800,000          
Minimum                                  
Property, Plant and Equipment [Line Items]                                  
Share-based payment award, award vesting period                     3 years            
Share-based payment award, expiration period                     5 years            
Maximum                                  
Property, Plant and Equipment [Line Items]                                  
Share-based payment award, award vesting period                     5 years            
Share-based payment award, expiration period                     10 years            
Medic Vision                                  
Property, Plant and Equipment [Line Items]                                  
Ownership percentage   14.21%   12.50%                          
Payments to acquire equity method investments   $ 200,000   $ 1,000,000.0                          
Option to purchase additional equity method investment       $ 1,400,000                          
Ownership percentage diluted   1.96%                              
Initial ownership percentage after dilution   12.25%                              
Aggregate cost               1,200,000     $ 1,200,000            
Turner Imaging                                  
Property, Plant and Equipment [Line Items]                                  
Payments to acquire equity method investments     $ 2,000,000.0                            
Number of shares purchased (in shares) | shares     2,100,000                            
Preferred stock issued upon conversion (in shares) | shares                           80,000      
WhiteRabbit.ai Inc.                                  
Property, Plant and Equipment [Line Items]                                  
Payments to acquire equity method investments $ 1,000,000.0                                
Payments to fund loan to related parties $ 2,500,000                                
Advance for future software subscription fees               $ 4,000,000.0     $ 4,000,000.0            
Santa Monica Imaging Group, LLC                                  
Property, Plant and Equipment [Line Items]                                  
Ownership percentage         35.00%                        
Payments to acquire additional interest in subsidiaries         $ 1,600,000                        
Restated Plan                                  
Property, Plant and Equipment [Line Items]                                  
Shares authorized (in shares) | shares               14,000,000     14,000,000            
Restated Plan | Minimum                                  
Property, Plant and Equipment [Line Items]                                  
Share-based payment award, award vesting period                     3 years            
Share-based payment award, expiration period                     5 years            
Restated Plan | Maximum                                  
Property, Plant and Equipment [Line Items]                                  
Share-based payment award, award vesting period                     5 years            
Share-based payment award, expiration period                     10 years            
2016 Caps                                  
Property, Plant and Equipment [Line Items]                                  
Number of forward interest rate cap agreements | numberOfAgreement               2     2            
Premium liability for 2016 Caps               $ 5,300,000     $ 5,300,000            
2016 Caps | September 2020                                  
Property, Plant and Equipment [Line Items]                                  
Notional amounts               150,000,000     150,000,000            
2016 Caps | October 2020                                  
Property, Plant and Equipment [Line Items]                                  
Notional amounts               $ 350,000,000     $ 350,000,000            
2019 SWAPS                                  
Property, Plant and Equipment [Line Items]                                  
Number of forward interest rate cap agreements | numberOfAgreement               4     4            
Notional amounts                             $ 500,000,000    
2019 SWAPS | October 2023                                  
Property, Plant and Equipment [Line Items]                                  
Notional amounts                             50,000,000    
2019 SWAPS | October 2025                                  
Property, Plant and Equipment [Line Items]                                  
Notional amounts                             200,000,000    
Amounts returned to property and equipment | Minimum                                  
Property, Plant and Equipment [Line Items]                                  
PPE estimated useful lives                     3 years            
Amounts returned to property and equipment | Maximum                                  
Property, Plant and Equipment [Line Items]                                  
PPE estimated useful lives                     15 years            
Leasehold Improvements | Minimum                                  
Property, Plant and Equipment [Line Items]                                  
PPE estimated useful lives                     3 years            
Leasehold Improvements | Maximum                                  
Property, Plant and Equipment [Line Items]                                  
PPE estimated useful lives                     15 years            
2016 Caps | London Interbank Offered Rate (LIBOR)                                  
Property, Plant and Equipment [Line Items]                                  
Basis spread on variable rate               2.00%     2.00%            
2019 swaps - Interest Rate Contracts | 2019 SWAPS                                  
Property, Plant and Equipment [Line Items]                                  
Notional amounts                             100,000,000    
2019 swaps - Interest Rate Contracts | 2019 SWAPS1                                  
Property, Plant and Equipment [Line Items]                                  
Notional amounts                             $ 400,000,000    
2019 swaps - Interest Rate Contracts | London Interbank Offered Rate (LIBOR) | 2019 SWAPS                                  
Property, Plant and Equipment [Line Items]                                  
Basis spread on variable rate                             1.96%    
2019 swaps - Interest Rate Contracts | London Interbank Offered Rate (LIBOR) | 2019 SWAPS1                                  
Property, Plant and Equipment [Line Items]                                  
Basis spread on variable rate                             2.05%    
Revolving Credit Facility                                  
Property, Plant and Equipment [Line Items]                                  
Deferred financing costs, net of accumulated amortization               $ 1,900,000     $ 1,900,000            
Dignity Health | Glendale Advanced Imaging | Joint Venture | Minimum                                  
Property, Plant and Equipment [Line Items]                                  
Variable interest entity, ownership percentage                   35.00%              
Dignity Health | Glendale Advanced Imaging | Joint Venture | Maximum                                  
Property, Plant and Equipment [Line Items]                                  
Variable interest entity, ownership percentage                   55.00%              
Promissory Note | Turner Imaging                                  
Property, Plant and Equipment [Line Items]                                  
Convertible promissory note                               $ 100,000  
COVID-19 Pandemic                                  
Property, Plant and Equipment [Line Items]                                  
Advance medicare payments             $ 39,400,000                    
Advance insurance carrier payments           $ 5,000,000.0                      
Deferred social security taxes               10,800,000     10,800,000            
First Lien Credit Agreement | Line of Credit | Barclays | Revolving Credit Facility                                  
Property, Plant and Equipment [Line Items]                                  
Total credit facilities outstanding               0     0   $ 0        
Paycheck Protection Program loans at 1% due April 2022 | COVID-19 Pandemic                                  
Property, Plant and Equipment [Line Items]                                  
Face Value               $ 4,000,000.0     $ 4,000,000.0            
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.2
SIGNIFICANT ACCOUNTING POLICIES (Details - Goodwill)
$ in Thousands
9 Months Ended
Sep. 30, 2020
USD ($)
Goodwill [Roll Forward]  
Goodwill, beginning balance $ 441,973
Goodwill, ending balance 470,685
Olney Open MRI, LLC  
Goodwill [Roll Forward]  
Goodwill acquired through acquisitions 601
MRI at Woodbridge, LLC  
Goodwill [Roll Forward]  
Goodwill acquired through acquisitions 1,833
DeepHealth, Inc.  
Goodwill [Roll Forward]  
Goodwill acquired through acquisitions 23,396
AZ Tech Radiology & Open MRI, LLC  
Goodwill [Roll Forward]  
Goodwill acquired through acquisitions $ 2,882
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.20.2
SIGNIFICANT ACCOUNTING POLICIES (Details - Gain on Derivative) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Offsetting Assets [Line Items]        
Change in fair value of cash flow hedge, net of taxes $ 195 $ (5,283) $ (18,764) $ (14,481)
Amount of loss reclassified from accumulated OCI into income (prior period effective portion) 969 $ 0 1,861 $ 0
2016 caps - Interest Rate Contracts        
Offsetting Assets [Line Items]        
Change in fair value of cash flow hedge, net of taxes 195   663  
2019 swaps - Interest Rate Contracts        
Offsetting Assets [Line Items]        
Change in fair value of cash flow hedge, net of taxes 0   (19,428)  
Amount of loss reclassified from accumulated OCI into income (prior period effective portion) 969   1,861  
Other income (expense) | 2019 swaps - Interest Rate Contracts        
Offsetting Assets [Line Items]        
Amount of loss recognized in income on derivative (current period ineffective portion) 679   4,523  
Equity and Interest Expense | 2019 swaps - Interest Rate Contracts        
Offsetting Assets [Line Items]        
Amount of loss reclassified from accumulated OCI into income (prior period effective portion) (1,312)   (2,204)  
Accumulated Other Comprehensive Loss, net of taxes | 2016 caps - Interest Rate Contracts        
Offsetting Assets [Line Items]        
Derivative instrument, beginning balance (1,409)   (1,877)  
Derivative instrument, ending balance (1,214)   (1,214)  
Accumulated Other Comprehensive Loss, net of taxes | 2019 swaps - Interest Rate Contracts        
Offsetting Assets [Line Items]        
Derivative instrument, beginning balance (24,406)   (5,870)  
Derivative instrument, ending balance $ (23,437)   $ (23,437)  
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF ACCOUNTING POLICIES (Details - Fair Value Measurements) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
First Lien Term Loans and SunTrust Term Loan $ 673,227 $ 705,699
Estimate of Fair Value Measurement    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
First Lien Term Loans and SunTrust Term Loan 663,140 708,948
Estimate of Fair Value Measurement | Fair Value, Inputs, Level 1    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
First Lien Term Loans and SunTrust Term Loan 0 0
Estimate of Fair Value Measurement | Fair Value, Inputs, Level 2    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
First Lien Term Loans and SunTrust Term Loan 663,140 708,948
Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
First Lien Term Loans and SunTrust Term Loan 0 0
2016 caps - Interest Rate Contracts    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Interest Rate Contracts 182 1,081
2016 caps - Interest Rate Contracts | Fair Value, Inputs, Level 1    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Interest Rate Contracts 0 0
2016 caps - Interest Rate Contracts | Fair Value, Inputs, Level 2    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Interest Rate Contracts 182 1,081
2016 caps - Interest Rate Contracts | Fair Value, Inputs, Level 3    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Interest Rate Contracts 0 0
2019 swaps - Interest Rate Contracts    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Interest Rate Contracts 39,983 9,477
2019 swaps - Interest Rate Contracts | Fair Value, Inputs, Level 1    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Interest Rate Contracts 0 0
2019 swaps - Interest Rate Contracts | Fair Value, Inputs, Level 2    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Interest Rate Contracts 39,983 9,477
2019 swaps - Interest Rate Contracts | Fair Value, Inputs, Level 3    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Interest Rate Contracts $ 0 $ 0
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF ACCOUNTING POLICIES (Details - Earnings Per Share) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Accounting Policies [Abstract]        
Net income (loss) attributable to RadNet, Inc.'s common stockholders $ 6,156 $ 3,195 $ (20,797) $ 4,360
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS        
Weighted average number of common shares outstanding during the period (in shares) 51,358,603 49,807,460 50,746,380 49,597,138
Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders (in dollars per share) $ 0.12 $ 0.06 $ (0.41) $ 0.09
Nonvested restricted stock subject only to service vesting (in shares) 120,605 200,567 191,375
Additional shares issuable upon exercise of stock options and warrants (in shares) 476,607 352,333 324,793
Weighted average number of common shares used in calculating diluted net income per share (in shares) 51,955,815 50,360,360 50,746,380 50,113,306
Diluted net income per share attributable to RadNet, Inc.'s common stockholders (in dollars per share) $ 0.12 $ 0.06 $ (0.41) $ 0.09
Nonvested restricted stock subject to service vesting        
Weighted average shares for which the exercise price exceeds average market price of common stock (in shares) 48,948 0 933,370 0
Restricted Stock        
Nonvested restricted stock subject to service vesting        
Weighted average shares for which the exercise price exceeds average market price of common stock (in shares) 0 0 331,659 0
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF ACCOUNTING POLICIES (Details - Investment in Joint Ventures) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Roll Forward]        
Beginning balance     $ 34,470  
Equity in earnings in these joint ventures $ 2,276 $ 1,955 5,176 $ 6,072
Distributions from joint ventures     (5,706)  
Equity contributions in existing joint ventures     1,631  
Ending balance $ 35,571   $ 35,571  
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF ACCOUNTING POLICIES (Details - Key Financial Data on Joint Ventures) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Balance Sheet Data:      
Current assets $ 26,618   $ 27,427
Noncurrent assets 70,576   61,037
Current liabilities (10,487)   (9,217)
Noncurrent liabilities (22,751)   (18,872)
Total net assets 63,956   60,375
Book value of RadNet joint venture interests 29,121   28,001
Cost in excess of book value of acquired joint venture interests and other 6,450   6,469
Total value of Radnet joint venture interests 35,571   34,470
Total book value of other joint venture partner interests 34,835   $ 32,374
Net revenue 78,988 $ 80,115  
Net income $ 13,651 $ 13,718  
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.20.2
FACILITY ACQUISITIONS AND DISPOSITIONS (Details Narrative)
9 Months Ended
Aug. 31, 2020
USD ($)
Center
Jun. 01, 2020
USD ($)
$ / shares
shares
Mar. 02, 2020
USD ($)
Jan. 02, 2020
USD ($)
Sep. 30, 2020
USD ($)
$ / shares
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
$ / shares
Business Acquisition [Line Items]              
Goodwill acquired         $ 470,685,000   $ 441,973,000
Common stock - par value (in dollars per share) | $ / shares         $ 0.0001   $ 0.0001
Proceeds from the sale of equity interests in a joint venture         $ 0 $ 132,000  
Imaging On Call              
Business Acquisition [Line Items]              
Proceeds from the sale of equity interests in a joint venture   $ 1,000.0          
AZ Tech Radiology & Open MRI, LLC              
Business Acquisition [Line Items]              
Number of businesses acquired | Center 8            
Purchase consideration $ 5,500,000            
Fixed assets acquired 2,500,000            
Right-of-use asset required 7,600,000            
Other assets acquired 100,000            
Operating lease liabilities acquired 7,600,000            
Goodwill acquired $ 2,900,000            
MRI at Woodbridge, LLC              
Business Acquisition [Line Items]              
Purchase consideration     $ 2,600,000        
Fixed assets acquired     500,000        
Right-of-use asset required     1,100,000        
Operating lease liabilities acquired     1,100,000        
Goodwill acquired     1,800,000        
Intangible assets acquired     300,000        
Finance lease liabilities acquired     $ 100,000        
Olney Open MRI, LLC              
Business Acquisition [Line Items]              
Purchase consideration       $ 1,800,000      
Fixed assets acquired       800,000      
Right-of-use asset required       1,300,000      
Operating lease liabilities acquired       1,300,000      
Goodwill acquired       600,000      
Intangible assets acquired       $ 300,000      
DeepHealth Inc.              
Business Acquisition [Line Items]              
Purchase consideration   34,600,000          
Goodwill acquired   $ 23,400,000          
Shares issued (in shares) | shares   915,132          
Common stock - par value (in dollars per share) | $ / shares   $ 16.93          
Shares issued at execution (in shares) | shares   823,615          
Shares issued after execution (in shares) | shares   91,517          
Shares issued after acquisition, term   18 months          
Fair value of shares issued at execution   $ 13,900,000          
Fair value of shares issued after execution   1,500,000          
Fair value of replacement awards attributable to pre-combination   2,000,000.0          
Contingent consideration, fair value   17,000,000.0          
Business acquisition, closing costs   $ 100,000          
Contingent consideration, milestone one, shares issued (in shares) | shares   390,789          
Contingent consideration, milestone two, shares issued (in shares) | shares   586,184          
Contingent consideration, milestone three, shares issued (in shares) | shares   195,393          
Current assets acquired   $ 100,000          
Deferred tax liabilities acquired   3,500,000          
Intangible assets acquired   $ 14,800,000          
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.20.2
CREDIT FACILITY AND NOTES PAYABLE (Details - Schedule of debt) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Debt Instrument [Line Items]    
Equipment note payable at 4.6%, due through 2020, collateralized by medical equipment $ 47 $ 275
Total debt obligations 666,642 692,395
Less: current portion (39,463) (39,691)
Long term portion debt obligations $ 627,179 652,704
Paycheck Protection Program loans at 1% due April 2022    
Debt Instrument [Line Items]    
Interest rate, stated percentage 1.00%  
Term Loan | First Lien Term Loan    
Debt Instrument [Line Items]    
Debt $ 620,727 649,824
Discounts on First Lien Term Loans (10,669) (13,579)
Term Loan | SunTrust Term Loan Agreement collateralized by NJIN's tangible and intangible assets    
Debt Instrument [Line Items]    
Debt 52,500 $ 55,875
Term Loan | Paycheck Protection Program loans at 1% due April 2022    
Debt Instrument [Line Items]    
Debt $ 4,037  
Equipment Notes Payable    
Debt Instrument [Line Items]    
Interest rate, stated percentage 4.60%  
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.20.2
CREDIT FACILITY AND NOTES PAYABLE (Details Narrative)
9 Months Ended 12 Months Ended
Apr. 18, 2019
USD ($)
Aug. 31, 2018
Jul. 01, 2016
Sep. 30, 2020
USD ($)
loan
Dec. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Aug. 22, 2017
USD ($)
Debt Instrument [Line Items]              
Total credit facilities outstanding       $ 0   $ 0  
Deferred financing costs, net of accumulated amortization       1,900,000   1,600,000  
Term Loan              
Debt Instrument [Line Items]              
Debt instrument face value       673,227,000      
FirstLienTermLoansAMember              
Debt Instrument [Line Items]              
Discounts on term loans       10,700,000      
First Lien Credit Agreement Seventh Amendment              
Debt Instrument [Line Items]              
Deferred financing costs, net of accumulated amortization $ 700,000            
Debt issuance costs 4,400,000            
Debt discount 2,100,000            
Amortization of deferred issuance costs 1,600,000            
Revolving Credit Facility              
Debt Instrument [Line Items]              
Letters of credit outstanding       6,300,000      
Deferred financing costs, net of accumulated amortization       $ 1,900,000      
Effective interest rate       6.00%      
Barclays | Revolving Credit Facility              
Debt Instrument [Line Items]              
Line of credit facility, remaining borrowing capacity       $ 188,700,000      
Barclays | Revolving Credit Facility | Letter of Credit              
Debt Instrument [Line Items]              
Commitment fee percentage       0.25%      
Unused capacity, commitment fee percentage       0.50%      
SunTrust | Term Loan              
Debt Instrument [Line Items]              
Periodic payment, principal         $ 800,000    
Periodic payment, percent         5.00%    
Periodic payment amortization increase         $ 400,000    
SunTrust | Revolving Credit Facility | Line of Credit              
Debt Instrument [Line Items]              
Maximum borrowing capacity       $ 30,000,000.0      
First Lien Term Loan | Term Loan              
Debt Instrument [Line Items]              
Debt instrument face value       620,727,000      
Discounts on term loans       10,669,000   13,579,000  
First Lien Term Loan | Barclays | Term Loan              
Debt Instrument [Line Items]              
Periodic payment, principal       9,700,000      
Restated Agreement | Term Loan              
Debt Instrument [Line Items]              
Debt instrument face value       52,500,000      
First Lien Credit Agreement | Barclays | Revolving Credit Facility | Line of Credit              
Debt Instrument [Line Items]              
Total credit facilities outstanding       0   $ 0  
First Lien Credit Agreement | SunTrust | Revolving Credit Facility | Line of Credit              
Debt Instrument [Line Items]              
Total credit facilities outstanding       0      
First Lien Credit Agreement Eighth Amendment | Barclays | Revolving Credit Facility | Line of Credit              
Debt Instrument [Line Items]              
Maximum borrowing capacity       195,000,000.0      
Line of credit facility, increase borrowing capacity       57,500,000      
Debt issuance costs       $ 700,000      
First Lien Credit Agreement, Sixth Amendment | Medium-term Notes              
Debt Instrument [Line Items]              
Total credit facilities outstanding             $ 100,000,000.0
First Lien Credit Agreement, Sixth Amendment | Revolving Credit Facility | Line of Credit              
Debt Instrument [Line Items]              
Line of credit facility, increase borrowing capacity $ 20,000,000.0            
Paycheck Protection Program Loans              
Debt Instrument [Line Items]              
Interest rate, stated percentage       1.00%      
Pricing Level III | Restated Agreement | Revolving Credit Facility              
Debt Instrument [Line Items]              
Commitment fee percentage   2.00%          
Unused capacity, commitment fee percentage   0.35%          
Eurodollar | First Lien Credit Agreement, Sixth Amendment | Revolving Credit Facility | Line of Credit              
Debt Instrument [Line Items]              
Effective interest rate       1.00%      
Eurodollar | >3.50x but ≤ 4.00x | First Lien Credit Agreement | Revolving Credit Facility | Line of Credit              
Debt Instrument [Line Items]              
Basis spread on variable rate     3.50%        
Eurodollar | >3.50x but ≤ 4.00x | First Lien Credit Agreement, Sixth Amendment | Revolving Credit Facility | Line of Credit              
Debt Instrument [Line Items]              
Basis spread on variable rate       3.75%      
Eurodollar | Pricing Level III | Restated Agreement | Revolving Credit Facility              
Debt Instrument [Line Items]              
Basis spread on variable rate   2.00%   2.00%      
Base Rate | First Lien Credit Agreement, Sixth Amendment | Revolving Credit Facility | Line of Credit              
Debt Instrument [Line Items]              
Effective interest rate       3.25%      
Base Rate | >3.50x but ≤ 4.00x | First Lien Credit Agreement | Revolving Credit Facility | Line of Credit              
Debt Instrument [Line Items]              
Basis spread on variable rate     2.50%        
Base Rate | >3.50x but ≤ 4.00x | First Lien Credit Agreement, Sixth Amendment | Revolving Credit Facility | Line of Credit              
Debt Instrument [Line Items]              
Basis spread on variable rate       2.75%      
Base Rate | Pricing Level III | Restated Agreement | Revolving Credit Facility              
Debt Instrument [Line Items]              
Basis spread on variable rate   1.00%          
COVID-19 Pandemic | Paycheck Protection Program Loans              
Debt Instrument [Line Items]              
Debt instrument face value       $ 4,000,000.0      
Interest rate, stated percentage       1.00%      
PPP loans, maturity term       2 years      
Number of PPP loans received | loan       4      
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.20.2
CREDIT FACILITY AND NOTES PAYABLE (Details - Term Loans) - Term Loan
Sep. 30, 2020
USD ($)
Debt Instrument [Line Items]  
Face Value $ 673,227,000
Discount (10,669,000)
Total Carrying Value 662,558,000
First Lien Term Loan  
Debt Instrument [Line Items]  
Face Value 620,727,000
Discount (10,669,000)
Total Carrying Value 610,058,000
Restated Agreement  
Debt Instrument [Line Items]  
Face Value 52,500,000
Discount 0
Total Carrying Value $ 52,500,000
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.20.2
CREDIT FACILITY AND NOTES PAYABLE (Details - Margin Spread Based on Leverage Ratio) - First Lien Credit Agreement - Line of Credit - Revolving Credit Facility
Jul. 01, 2016
Eurodollar | > 5.50x  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 4.50%
Eurodollar | > 4.00x but ≤ 5.50x  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 3.75%
Eurodollar | >3.50x but ≤ 4.00x  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 3.50%
Eurodollar | ≤ 3.50x  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 3.25%
Base Rate | > 5.50x  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 3.50%
Base Rate | > 4.00x but ≤ 5.50x  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 2.75%
Base Rate | >3.50x but ≤ 4.00x  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 2.50%
Base Rate | ≤ 3.50x  
Line of Credit Facility [Line Items]  
Basis spread on variable rate 2.25%
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.20.2
CREDIT FACILITY AND NOTES PAYABLE (Details - Margin Spread Based on Leverage Ratio, Debt Instrument) - Restated Agreement
9 Months Ended
Aug. 31, 2018
Sep. 30, 2020
Pricing Level I    
Debt Instrument [Line Items]    
Leverage ratio, greater than 3.00  
Pricing Level I | Revolving Credit Facility    
Debt Instrument [Line Items]    
Commitment fee percentage 2.75%  
Unused capacity, commitment fee percentage 0.45%  
Pricing Level I | Eurodollar | Revolving Credit Facility    
Debt Instrument [Line Items]    
Basis spread on variable rate 2.75%  
Pricing Level I | Base Rate | Revolving Credit Facility    
Debt Instrument [Line Items]    
Basis spread on variable rate 1.75%  
Pricing Level II    
Debt Instrument [Line Items]    
Leverage ratio, greater than 2.50  
Leverage ratio, less than 3.00  
Pricing Level II | Revolving Credit Facility    
Debt Instrument [Line Items]    
Commitment fee percentage 2.25%  
Unused capacity, commitment fee percentage 0.40%  
Pricing Level II | Eurodollar | Revolving Credit Facility    
Debt Instrument [Line Items]    
Basis spread on variable rate 2.25%  
Pricing Level II | Base Rate | Revolving Credit Facility    
Debt Instrument [Line Items]    
Basis spread on variable rate 1.25%  
Pricing Level III    
Debt Instrument [Line Items]    
Leverage ratio, greater than 2.00  
Leverage ratio, less than 2.50  
Pricing Level III | Revolving Credit Facility    
Debt Instrument [Line Items]    
Commitment fee percentage 2.00%  
Unused capacity, commitment fee percentage 0.35%  
Pricing Level III | Eurodollar | Revolving Credit Facility    
Debt Instrument [Line Items]    
Basis spread on variable rate 2.00% 2.00%
Pricing Level III | Base Rate | Revolving Credit Facility    
Debt Instrument [Line Items]    
Basis spread on variable rate 1.00%  
Pricing Level IV    
Debt Instrument [Line Items]    
Leverage ratio, greater than 1.50  
Leverage ratio, less than 2.00  
Pricing Level IV | Revolving Credit Facility    
Debt Instrument [Line Items]    
Commitment fee percentage 1.75%  
Unused capacity, commitment fee percentage 0.30%  
Pricing Level IV | Eurodollar | Revolving Credit Facility    
Debt Instrument [Line Items]    
Basis spread on variable rate 1.75%  
Pricing Level IV | Base Rate | Revolving Credit Facility    
Debt Instrument [Line Items]    
Basis spread on variable rate 0.75%  
Pricing Level V    
Debt Instrument [Line Items]    
Leverage ratio, less than 1.50  
Pricing Level V | Revolving Credit Facility    
Debt Instrument [Line Items]    
Commitment fee percentage 1.50%  
Unused capacity, commitment fee percentage 0.30%  
Pricing Level V | Eurodollar | Revolving Credit Facility    
Debt Instrument [Line Items]    
Basis spread on variable rate 1.50%  
Pricing Level V | Base Rate | Revolving Credit Facility    
Debt Instrument [Line Items]    
Basis spread on variable rate 0.50%  
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.20.2
STOCK-BASED COMPENSATION (Details Narrative) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized stock-based compensation expense $ 0.7 $ 0.7  
Unrecognized expense weighted average period   1 year 8 months 4 days  
Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based payment award, award vesting period   3 years  
Share-based payment award, expiration period   5 years  
Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based payment award, award vesting period   5 years  
Share-based payment award, expiration period   10 years  
Equity Option      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Options outstanding (in shares) 527,899 527,899 478,951
Exercisable shares (in shares) 298,863 298,863  
Options exercised (in shares)   0  
Options granted (in shares)   48,948  
Restricted Stock      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Awards issued to date (in shares) 6,551,872 6,551,872  
RSA's unvested (in shares) 331,659 331,659  
Future Service      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Options granted (in shares)   26,078  
Restated Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares authorized (in shares) 14,000,000 14,000,000  
Awards issued to date (in shares) 15,384,316 15,384,316  
Options cancelled (in shares)   3,281,040  
RSA's forfeited (in shares)   61,703  
Shares available for future issuance, options, warrants, shares of restricted stock and other bonus awards (in shares) 1,958,427 1,958,427  
Restated Plan | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based payment award, award vesting period   3 years  
Share-based payment award, expiration period   5 years  
Restated Plan | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based payment award, award vesting period   5 years  
Share-based payment award, expiration period   10 years  
DeepHealth Inc.      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized stock-based compensation expense $ 4.3 $ 4.3  
Unrecognized expense weighted average period   2 years 6 months 10 days  
Options granted (in dollars per share) $ 16.93    
DeepHealth Inc. | Equity Option      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Options granted (in shares) 412,434    
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.20.2
STOCK-BASED COMPENSATION (Details-Outstanding options and warrants) - Equity Option
$ / shares in Units, $ in Thousands
9 Months Ended
Sep. 30, 2020
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Begining Balance (in shares) 478,951
Granted (in shares) 48,948
Options exercised (in shares) 0
Ending Balance (in shares) 527,899
Exercisable at the end (in shares) 298,863
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]  
Begining Balance (in dollars per share) | $ / shares $ 8.21
Granted (in dollars per share) | $ / shares 20.43
Ending Balance (in dollars per share) | $ / shares 9.34
Exercisable at the end (in dollars per share) | $ / shares $ 7.48
Weighted Average Remaining Contractual Life  
Balance at end of period 6 years 7 months 2 days
Exercisable at the end 5 years 10 months 6 days
Aggregate Intrinsic Value  
Aggregate value outstanding | $ $ 3,419,956
Aggregate value exercisable | $ $ 2,353,438
DeepHealth, Inc.  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Begining Balance (in shares) 0
Granted (in shares) 412,434
Options exercised (in shares) (6,963)
Ending Balance (in shares) 405,471
Exercisable at the end (in shares) 24,211
Weighted Average Remaining Contractual Life  
Balance at end of period 8 years 7 months 24 days
Exercisable at the end 8 years 7 months 24 days
Aggregate Intrinsic Value  
Aggregate value outstanding | $ $ 6,223,980
Aggregate value exercisable | $ $ 371,639
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.20.2
STOCK-BASED COMPENSATION (Details - RSU's) - Restricted Stock
9 Months Ended
Sep. 30, 2020
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]  
RSA's outstanding, beginning balance (in shares) | shares 387,934
RSA's granted (in shares) | shares 457,596
RSA's vested (in shares) | shares (513,871)
RSA's outstanding, ending balance (in shares) | shares 331,659
Weighted-Average Remaining Contractual Term (Years) 1 year 1 month 9 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Weighted-average fair value, beginning balance (in dollars per share) | $ / shares $ 11.61
Weighted-average fair value, granted (in dollars per share) | $ / shares 19.66
Weighted-average fair value, vested (in dollars per share) | $ / shares 15.47
Weighted-average fair value, ending balance (in dollars per share) | $ / shares $ 16.67
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.20.2
SUBSEQUENT EVENTS (Details) - Subsequent Event - Investments in Majority-owned Subsidiaries
Nov. 01, 2020
Center
Subsequent Event [Line Items]  
Number of assets acquired 3
Business acquisition, percentage of voting interests acquired 60.00%
Simi Valley Hospital and Health Services  
Subsequent Event [Line Items]  
Business acquisition, percentage of voting interests acquired 40.00%
XML 49 R9999.htm IDEA: XBRL DOCUMENT v3.20.2
Label Element Value
DeepHealth, Inc. [Member]  
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned $ 13,900,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued 823,615
Nulogix [Member]  
Equity Method Investment, Ownership Percentage us-gaap_EquityMethodInvestmentOwnershipPercentage 75.00%
Payments to Acquire Equity Method Investments us-gaap_PaymentsToAcquireEquityMethodInvestments $ 1,500,000
Ventura County Imaging Group, LLC [Member]  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment 4,300,000
Hudson Valley Radiology Associates [Member] | Variable Interest Entity, Not Primary Beneficiary [Member]  
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned $ 6,000,000.0
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued 440,207
EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ɓ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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 296 395 1 false 100 0 false 8 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.radnet.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) Sheet http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) Statements 2 false false R3.htm 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) Sheet http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) Statements 5 false false R6.htm 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Statements 6 false false R7.htm 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 2101101 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION Sheet http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION NATURE OF BUSINESS AND BASIS OF PRESENTATION Notes 8 false false R9.htm 2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIES SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 2114103 - Disclosure - RECENT ACCOUNTING AND REPORTING STANDARDS Sheet http://www.radnet.com/role/RECENTACCOUNTINGANDREPORTINGSTANDARDS RECENT ACCOUNTING AND REPORTING STANDARDS Notes 10 false false R11.htm 2115104 - Disclosure - FACILITY ACQUISITIONS AND DISPOSITIONS Sheet http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONS FACILITY ACQUISITIONS AND DISPOSITIONS Notes 11 false false R12.htm 2117105 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE Notes http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLE CREDIT FACILITY AND NOTES PAYABLE Notes 12 false false R13.htm 2124106 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.radnet.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 13 false false R14.htm 2129107 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.radnet.com/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 14 false false R15.htm 2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 15 false false R16.htm 2305301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIES 16 false false R17.htm 2318302 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Tables) Notes http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLETables CREDIT FACILITY AND NOTES PAYABLE (Tables) Tables http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLE 17 false false R18.htm 2325303 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.radnet.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://www.radnet.com/role/STOCKBASEDCOMPENSATION 18 false false R19.htm 2402401 - Disclosure - NATURE OF BUSINESS (Details Narrative) Sheet http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative NATURE OF BUSINESS (Details Narrative) Details http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION 19 false false R20.htm 2406402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details - Revenue) Sheet http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue SIGNIFICANT ACCOUNTING POLICIES (Details - Revenue) Details http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables 20 false false R21.htm 2407403 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details Narrative) Sheet http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative SUMMARY OF ACCOUNTING POLICIES (Details Narrative) Details 21 false false R22.htm 2408404 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details - Goodwill) Sheet http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill SIGNIFICANT ACCOUNTING POLICIES (Details - Goodwill) Details http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables 22 false false R23.htm 2409405 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details - Gain on Derivative) Sheet http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative SIGNIFICANT ACCOUNTING POLICIES (Details - Gain on Derivative) Details http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables 23 false false R24.htm 2410406 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details - Fair Value Measurements) Sheet http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements SUMMARY OF ACCOUNTING POLICIES (Details - Fair Value Measurements) Details 24 false false R25.htm 2411407 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details - Earnings Per Share) Sheet http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare SUMMARY OF ACCOUNTING POLICIES (Details - Earnings Per Share) Details 25 false false R26.htm 2412408 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details - Investment in Joint Ventures) Sheet http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsInvestmentinJointVentures SUMMARY OF ACCOUNTING POLICIES (Details - Investment in Joint Ventures) Details 26 false false R27.htm 2413409 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details - Key Financial Data on Joint Ventures) Sheet http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures SUMMARY OF ACCOUNTING POLICIES (Details - Key Financial Data on Joint Ventures) Details 27 false false R28.htm 2416410 - Disclosure - FACILITY ACQUISITIONS AND DISPOSITIONS (Details Narrative) Sheet http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative FACILITY ACQUISITIONS AND DISPOSITIONS (Details Narrative) Details http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONS 28 false false R29.htm 2419411 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Details - Schedule of debt) Notes http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt CREDIT FACILITY AND NOTES PAYABLE (Details - Schedule of debt) Details http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLETables 29 false false R30.htm 2420412 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Details Narrative) Notes http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative CREDIT FACILITY AND NOTES PAYABLE (Details Narrative) Details http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLETables 30 false false R31.htm 2421413 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Details - Term Loans) Notes http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsTermLoans CREDIT FACILITY AND NOTES PAYABLE (Details - Term Loans) Details http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLETables 31 false false R32.htm 2422414 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Details - Margin Spread Based on Leverage Ratio) Notes http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio CREDIT FACILITY AND NOTES PAYABLE (Details - Margin Spread Based on Leverage Ratio) Details http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLETables 32 false false R33.htm 2423415 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Details - Margin Spread Based on Leverage Ratio, Debt Instrument) Notes http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument CREDIT FACILITY AND NOTES PAYABLE (Details - Margin Spread Based on Leverage Ratio, Debt Instrument) Details http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLETables 33 false false R34.htm 2426416 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) Sheet http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative STOCK-BASED COMPENSATION (Details Narrative) Details http://www.radnet.com/role/STOCKBASEDCOMPENSATIONTables 34 false false R35.htm 2427417 - Disclosure - STOCK-BASED COMPENSATION (Details-Outstanding options and warrants) Sheet http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants STOCK-BASED COMPENSATION (Details-Outstanding options and warrants) Details http://www.radnet.com/role/STOCKBASEDCOMPENSATIONTables 35 false false R36.htm 2428418 - Disclosure - STOCK-BASED COMPENSATION (Details - RSU's) Sheet http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsRSUs STOCK-BASED COMPENSATION (Details - RSU's) Details http://www.radnet.com/role/STOCKBASEDCOMPENSATIONTables 36 false false R37.htm 2430419 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.radnet.com/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details http://www.radnet.com/role/SUBSEQUENTEVENTS 37 false false R9999.htm Uncategorized Items - rdnt-20200930.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - rdnt-20200930.htm Cover 38 false false All Reports Book All Reports rdnt-20200930.htm q32020exhibit311.htm q32020exhibit312.htm q32020exhibit321.htm q32020exhibit322.htm rdnt-20200930.xsd rdnt-20200930_cal.xml rdnt-20200930_def.xml rdnt-20200930_lab.xml rdnt-20200930_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true JSON 56 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rdnt-20200930.htm": { "axisCustom": 2, "axisStandard": 31, "contextCount": 296, "dts": { "calculationLink": { "local": [ "rdnt-20200930_cal.xml" ] }, "definitionLink": { "local": [ "rdnt-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "rdnt-20200930.htm" ] }, "labelLink": { "local": [ "rdnt-20200930_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "rdnt-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "rdnt-20200930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 560, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 2, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 7 }, "keyCustom": 51, "keyStandard": 344, "memberCustom": 60, "memberStandard": 35, "nsprefix": "rdnt", "nsuri": "http://www.radnet.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.radnet.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114103 - Disclosure - RECENT ACCOUNTING AND REPORTING STANDARDS", "role": "http://www.radnet.com/role/RECENTACCOUNTINGANDREPORTINGSTANDARDS", "shortName": "RECENT ACCOUNTING AND REPORTING STANDARDS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115104 - Disclosure - FACILITY ACQUISITIONS AND DISPOSITIONS", "role": "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONS", "shortName": "FACILITY ACQUISITIONS AND DISPOSITIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117105 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE", "role": "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLE", "shortName": "CREDIT FACILITY AND NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124106 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://www.radnet.com/role/STOCKBASEDCOMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129107 - Disclosure - SUBSEQUENT EVENTS", "role": "http://www.radnet.com/role/SUBSEQUENTEVENTS", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPrincipalTransactionsRevenueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPrincipalTransactionsRevenueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318302 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Tables)", "role": "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLETables", "shortName": "CREDIT FACILITY AND NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325303 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i949cafed8cd44d929d2f3beaa3acf0d8_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "rdnt:NumberOfCenters", "reportCount": 1, "unitRef": "center", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - NATURE OF BUSINESS (Details Narrative)", "role": "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative", "shortName": "NATURE OF BUSINESS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i3f6ab2013b9d4a8b8ac77b36b85c854d_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityRevenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i949cafed8cd44d929d2f3beaa3acf0d8_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)", "role": "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i949cafed8cd44d929d2f3beaa3acf0d8_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i3f6ab2013b9d4a8b8ac77b36b85c854d_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details - Revenue)", "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details - Revenue)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfPrincipalTransactionsRevenueTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i3f6ab2013b9d4a8b8ac77b36b85c854d_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i3f6ab2013b9d4a8b8ac77b36b85c854d_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueNotFromContractWithCustomer", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details Narrative)", "role": "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative", "shortName": "SUMMARY OF ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i3f6ab2013b9d4a8b8ac77b36b85c854d_D20200701-20200930", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i3ca1dfb7e9fe4481a03a08ec4ed83139_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details - Goodwill)", "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details - Goodwill)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i812d1f3338f848fbb0cae71405a11682_D20200101-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i3f6ab2013b9d4a8b8ac77b36b85c854d_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details - Gain on Derivative)", "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details - Gain on Derivative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i2ae781a9e9de432895fcc55db7b0b610_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i949cafed8cd44d929d2f3beaa3acf0d8_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410406 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details - Fair Value Measurements)", "role": "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements", "shortName": "SUMMARY OF ACCOUNTING POLICIES (Details - Fair Value Measurements)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i949cafed8cd44d929d2f3beaa3acf0d8_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i3f6ab2013b9d4a8b8ac77b36b85c854d_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411407 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details - Earnings Per Share)", "role": "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare", "shortName": "SUMMARY OF ACCOUNTING POLICIES (Details - Earnings Per Share)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i3f6ab2013b9d4a8b8ac77b36b85c854d_D20200701-20200930", "decimals": "0", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesRestrictedStock", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:InvestmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i3ca1dfb7e9fe4481a03a08ec4ed83139_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412408 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details - Investment in Joint Ventures)", "role": "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsInvestmentinJointVentures", "shortName": "SUMMARY OF ACCOUNTING POLICIES (Details - Investment in Joint Ventures)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:InvestmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentDividendsOrDistributions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "rdnt:JointVentureInvestmentAndFinancialInformationTableTextBlock", "us-gaap:InvestmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i949cafed8cd44d929d2f3beaa3acf0d8_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413409 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details - Key Financial Data on Joint Ventures)", "role": "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures", "shortName": "SUMMARY OF ACCOUNTING POLICIES (Details - Key Financial Data on Joint Ventures)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "rdnt:JointVentureInvestmentAndFinancialInformationTableTextBlock", "us-gaap:InvestmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i949cafed8cd44d929d2f3beaa3acf0d8_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i949cafed8cd44d929d2f3beaa3acf0d8_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416410 - Disclosure - FACILITY ACQUISITIONS AND DISPOSITIONS (Details Narrative)", "role": "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative", "shortName": "FACILITY ACQUISITIONS AND DISPOSITIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i6e52cfe398fa4efabaa39a7aee14b01c_D20200601-20200601", "decimals": "-2", "lang": "en-US", "name": "us-gaap:ProceedsFromDivestitureOfInterestInJointVenture", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i949cafed8cd44d929d2f3beaa3acf0d8_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermLoansPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419411 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Details - Schedule of debt)", "role": "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt", "shortName": "CREDIT FACILITY AND NOTES PAYABLE (Details - Schedule of debt)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i949cafed8cd44d929d2f3beaa3acf0d8_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermLoansPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i949cafed8cd44d929d2f3beaa3acf0d8_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "role": "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i949cafed8cd44d929d2f3beaa3acf0d8_I20200930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:LineOfCredit", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i949cafed8cd44d929d2f3beaa3acf0d8_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCredit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420412 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Details Narrative)", "role": "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "shortName": "CREDIT FACILITY AND NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i0a84159a6d674db38efa7bbccb1be3e3_I20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "ia9a34455b88e496f99f11135df67cea7_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421413 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Details - Term Loans)", "role": "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsTermLoans", "shortName": "CREDIT FACILITY AND NOTES PAYABLE (Details - Term Loans)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "ia9a34455b88e496f99f11135df67cea7_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "rdnt:ScheduleOfLeverageRatioTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i843b248c0d484e4c80e2fdd2f502195c_D20160701-20160701", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422414 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Details - Margin Spread Based on Leverage Ratio)", "role": "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "shortName": "CREDIT FACILITY AND NOTES PAYABLE (Details - Margin Spread Based on Leverage Ratio)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "rdnt:ScheduleOfLeverageRatioTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i843b248c0d484e4c80e2fdd2f502195c_D20160701-20160701", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "ia5c31aa95d9342c4ba31e43e8ecb8e1f_I20180831", "decimals": "INF", "first": true, "lang": "en-US", "name": "rdnt:DebtInstrumentCovenantLiquidityRatioRequiredMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423415 - Disclosure - CREDIT FACILITY AND NOTES PAYABLE (Details - Margin Spread Based on Leverage Ratio, Debt Instrument)", "role": "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "shortName": "CREDIT FACILITY AND NOTES PAYABLE (Details - Margin Spread Based on Leverage Ratio, Debt Instrument)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "ia5c31aa95d9342c4ba31e43e8ecb8e1f_I20180831", "decimals": "INF", "first": true, "lang": "en-US", "name": "rdnt:DebtInstrumentCovenantLiquidityRatioRequiredMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i949cafed8cd44d929d2f3beaa3acf0d8_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426416 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)", "role": "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "shortName": "STOCK-BASED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "iaab629f0885047bfac5042b54e4cf7b0_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427417 - Disclosure - STOCK-BASED COMPENSATION (Details-Outstanding options and warrants)", "role": "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants", "shortName": "STOCK-BASED COMPENSATION (Details-Outstanding options and warrants)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "iaab629f0885047bfac5042b54e4cf7b0_I20191231", "decimals": "2", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i24073316903a4b80852ce62f50a13e5f_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428418 - Disclosure - STOCK-BASED COMPENSATION (Details - RSU's)", "role": "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsRSUs", "shortName": "STOCK-BASED COMPENSATION (Details - RSU's)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i24073316903a4b80852ce62f50a13e5f_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "ic97e88dc3d0b400f82757dbc8ca7b075_I20201101", "decimals": "INF", "first": true, "lang": "en-US", "name": "rdnt:NumberOfAssetsAcquired", "reportCount": 1, "unique": true, "unitRef": "center", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430419 - Disclosure - SUBSEQUENT EVENTS (Details)", "role": "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails", "shortName": "SUBSEQUENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "ic97e88dc3d0b400f82757dbc8ca7b075_I20201101", "decimals": "INF", "first": true, "lang": "en-US", "name": "rdnt:NumberOfAssetsAcquired", "reportCount": 1, "unique": true, "unitRef": "center", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i3f6ab2013b9d4a8b8ac77b36b85c854d_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "role": "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i3f6ab2013b9d4a8b8ac77b36b85c854d_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OperatingCostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i3f6ab2013b9d4a8b8ac77b36b85c854d_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)", "role": "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i3f6ab2013b9d4a8b8ac77b36b85c854d_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i3e1e45a341fa4faa80a854e436e843dc_I20181231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited)", "role": "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i3e1e45a341fa4faa80a854e436e843dc_I20181231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "role": "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": "-3", "lang": "en-US", "name": "rdnt:OperatingLeaseRightofUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION", "role": "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION", "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i7d337e311ea047289cd379605dc1a780_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i6ef5f4569a454da5b5b38254fa362064_I20200601", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - rdnt-20200930.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - rdnt-20200930.htm", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rdnt-20200930.htm", "contextRef": "i6ef5f4569a454da5b5b38254fa362064_I20200601", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 100, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Current" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative", "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r377" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative", "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r373" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "rdnt_A2019SWAPS1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2019 SWAPS1 [Member]", "label": "2019 SWAPS1 [Member]", "terseLabel": "2019 SWAPS1" } } }, "localname": "A2019SWAPS1Member", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_A2019SWAPSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2019 SWAPS [Member]", "label": "2019 SWAPS [Member]", "terseLabel": "2019 SWAPS" } } }, "localname": "A2019SWAPSMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_AZTechMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "AZ Tech Radiology & Open MRI, LLC [Member]", "label": "AZ Tech [Member]", "terseLabel": "AZ Tech Radiology & Open MRI, LLC" } } }, "localname": "AZTechMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_AdvanceMedicarePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Advance Medicare Payments", "label": "Advance Medicare Payments", "terseLabel": "Advance medicare payments" } } }, "localname": "AdvanceMedicarePayments", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_AggregateIntrinsicValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aggregate Intrinsic Value", "label": "Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "AggregateIntrinsicValue", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "stringItemType" }, "rdnt_AssetAcquisitionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "stringItemType" }, "rdnt_AssetAcquisitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Asset Acquisition [Axis]", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_AwardsIssuedToDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Awards issued to date", "label": "Awards issued to date", "terseLabel": "Awards issued to date (in shares)" } } }, "localname": "AwardsIssuedToDate", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative" ], "xbrltype": "sharesItemType" }, "rdnt_BarclaysMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Barclays [Member]", "label": "Barclays [Member]", "terseLabel": "Barclays" } } }, "localname": "BarclaysMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_BeverlyRadiologyMedicalGroupIIIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Beverly Radiology Medical Group III [Member]", "label": "Beverly Radiology Medical Group III [Member]", "terseLabel": "Beverly Radiology Medical Group III" } } }, "localname": "BeverlyRadiologyMedicalGroupIIIMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_BoardMemberMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Board Member [Member]", "label": "Board Member [Member]", "terseLabel": "Board Member" } } }, "localname": "BoardMemberMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_BusinessAcquisitionContingentConsiderationArrangementsEquityInterestIssuedorIssuableNumberofShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Contingent Consideration Arrangements, Milestone One, Equity Interest Issued or Issuable, Number of Shares", "label": "Business Acquisition, Contingent Consideration Arrangements, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Contingent consideration, milestone one, shares issued (in shares)" } } }, "localname": "BusinessAcquisitionContingentConsiderationArrangementsEquityInterestIssuedorIssuableNumberofShares", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "sharesItemType" }, "rdnt_BusinessAcquisitionContingentConsiderationArrangementsMilestoneThreeEquityInterestIssuedorIssuableNumberofShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Contingent Consideration Arrangements, Milestone Three, Equity Interest Issued or Issuable, Number of Shares", "label": "Business Acquisition, Contingent Consideration Arrangements, Milestone Three, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Contingent consideration, milestone three, shares issued (in shares)" } } }, "localname": "BusinessAcquisitionContingentConsiderationArrangementsMilestoneThreeEquityInterestIssuedorIssuableNumberofShares", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "sharesItemType" }, "rdnt_BusinessAcquisitionContingentConsiderationArrangementsMilestoneTwoEquityInterestIssuedorIssuableNumberofShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Contingent Consideration Arrangements, Milestone Two, Equity Interest Issued or Issuable, Number of Shares", "label": "Business Acquisition, Contingent Consideration Arrangements, Milestone Two, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Contingent consideration, milestone two, shares issued (in shares)" } } }, "localname": "BusinessAcquisitionContingentConsiderationArrangementsMilestoneTwoEquityInterestIssuedorIssuableNumberofShares", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "sharesItemType" }, "rdnt_BusinessAcquisitionEquityInterestIssuedorIssuableFairValueOfReplacementAwards": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Equity Interest Issued or Issuable, Fair Value Of Replacement Awards", "label": "Business Acquisition, Equity Interest Issued or Issuable, Fair Value Of Replacement Awards", "terseLabel": "Fair value of replacement awards attributable to pre-combination" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedorIssuableFairValueOfReplacementAwards", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_BusinessAcquisitionEquityInterestIssuedorIssuableFairValueOfSharesIssuedAfterExecution": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Equity Interest Issued or Issuable, Fair Value Of Shares Issued After Execution", "label": "Business Acquisition, Equity Interest Issued or Issuable, Fair Value Of Shares Issued After Execution", "terseLabel": "Fair value of shares issued after execution" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedorIssuableFairValueOfSharesIssuedAfterExecution", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_BusinessAcquisitionEquityInterestIssuedorIssuableFairValueOfSharesIssuedAtExecution": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Equity Interest Issued or Issuable, Fair Value Of Shares Issued At Execution", "label": "Business Acquisition, Equity Interest Issued or Issuable, Fair Value Of Shares Issued At Execution", "terseLabel": "Fair value of shares issued at execution" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedorIssuableFairValueOfSharesIssuedAtExecution", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_BusinessAcquisitionEquityInterestIssuedorIssuableMaximumNumberofSharesIssuedAfterExecution": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Equity Interest Issued or Issuable, Maximum Number of Shares Issued After Execution", "label": "Business Acquisition, Equity Interest Issued or Issuable, Maximum Number of Shares Issued After Execution", "terseLabel": "Shares issued after execution (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedorIssuableMaximumNumberofSharesIssuedAfterExecution", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "sharesItemType" }, "rdnt_BusinessAcquisitionEquityInterestIssuedorIssuableNumberofSharesAtExecution": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares At Execution", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares At Execution", "terseLabel": "Shares issued at execution (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedorIssuableNumberofSharesAtExecution", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "sharesItemType" }, "rdnt_BusinessAcquisitionEquityInterestIssuedorIssuableNumberofSharesIssuedAfterAcquisitionTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Issued After Acquisition Term", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Issued After Acquisition Term", "terseLabel": "Shares issued after acquisition, term" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedorIssuableNumberofSharesIssuedAfterAcquisitionTerm", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "durationItemType" }, "rdnt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Other", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Other", "terseLabel": "Other assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOther", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFinanceLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Finance Lease Liabilities", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Finance Lease Liabilities", "terseLabel": "Finance lease liabilities acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFinanceLeaseLiabilities", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Liabilities", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Liabilities", "terseLabel": "Operating lease liabilities acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Right Of Use Asset", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Right Of Use Asset", "terseLabel": "Right-of-use asset required" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRightOfUseAsset", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_COVID19PandemicMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "COVID-19 Pandemic [Member]", "label": "COVID-19 Pandemic [Member]", "terseLabel": "COVID-19 Pandemic" } } }, "localname": "COVID19PandemicMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_CapitationArrangementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Capitation Arrangements [Member]", "label": "Capitation Arrangements [Member]", "terseLabel": "Revenue under capitation arrangements", "verboseLabel": "Revenue under capitation arrangements" } } }, "localname": "CapitationArrangementsMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue" ], "xbrltype": "domainItemType" }, "rdnt_Caps2016Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "2016 Caps [Member]", "terseLabel": "2016 Caps" } } }, "localname": "Caps2016Member", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_CommercialInsurance1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commercial Insurance1 [Member]", "label": "Commercial Insurance1 [Member]", "terseLabel": "Commercial insurance" } } }, "localname": "CommercialInsurance1Member", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue" ], "xbrltype": "domainItemType" }, "rdnt_ContractsReceivableFactoringReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contracts Receivable, Factoring Receivable", "label": "Contracts Receivable, Factoring Receivable", "terseLabel": "Contracts receivable, factoring receivable" } } }, "localname": "ContractsReceivableFactoringReceivable", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_ContributionsFromNoncontrollingInterests": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "label": "Contributions from noncontrolling interests", "terseLabel": "Contribution from noncontrolling partner" } } }, "localname": "ContributionsFromNoncontrollingInterests", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "rdnt_DebtInstrumentCovenantLeverageRatioMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum", "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum", "terseLabel": "Leverage ratio, less than" } } }, "localname": "DebtInstrumentCovenantLeverageRatioMaximum", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument" ], "xbrltype": "pureItemType" }, "rdnt_DebtInstrumentCovenantLiquidityRatioRequiredMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant, Liquidity Ratio Required, Minimum", "label": "Debt Instrument, Covenant, Liquidity Ratio Required, Minimum", "terseLabel": "Leverage ratio, greater than" } } }, "localname": "DebtInstrumentCovenantLiquidityRatioRequiredMinimum", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument" ], "xbrltype": "pureItemType" }, "rdnt_DebtInstrumentNumberofLoansReceived": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Number of Loans Received", "label": "Debt Instrument, Number of Loans Received", "terseLabel": "Number of PPP loans received" } } }, "localname": "DebtInstrumentNumberofLoansReceived", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "integerItemType" }, "rdnt_DebtInstrumentPeriodicPaymentPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Periodic Payment, Percent", "label": "Debt Instrument, Periodic Payment, Percent", "terseLabel": "Periodic payment, percent" } } }, "localname": "DebtInstrumentPeriodicPaymentPercent", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "percentItemType" }, "rdnt_DebtInstrumentPeriodicPaymentTermsAmortizationIncrease": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Periodic Payment Terms, Amortization Increase", "label": "Debt Instrument, Periodic Payment Terms, Amortization Increase", "terseLabel": "Periodic payment amortization increase" } } }, "localname": "DebtInstrumentPeriodicPaymentTermsAmortizationIncrease", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_DeepHealthInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "DeepHealth, Inc. [Member]", "label": "DeepHealth, Inc. [Member]", "terseLabel": "DeepHealth, Inc." } } }, "localname": "DeepHealthInc.Member", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "domainItemType" }, "rdnt_DeepHealthIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deep Health, Inc. [Member]", "label": "Deep Health Inc [Member]", "terseLabel": "DeepHealth Inc." } } }, "localname": "DeepHealthIncMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_DignityHealthMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Dignity Health [Member]", "terseLabel": "Dignity Health" } } }, "localname": "DignityHealthMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_EquipmentAcquiredAndLeaseholdImprovements": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "label": "Equipment acquired and leasehold improvements", "terseLabel": "Equipment acquired and leasehold improvements" } } }, "localname": "EquipmentAcquiredAndLeaseholdImprovements", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "rdnt_EquityContributionsInJointVentures": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity Contributions In Joint Ventures", "label": "Equity Contributions In Joint Ventures", "terseLabel": "Equity contributions in existing joint ventures" } } }, "localname": "EquityContributionsInJointVentures", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsInvestmentinJointVentures" ], "xbrltype": "monetaryItemType" }, "rdnt_EquityMethodInvestmentInitialOwnershipPercentageAfterDilution": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Method Investment, Initial Ownership Percentage After Dilution", "label": "Equity Method Investment, Initial Ownership Percentage After Dilution", "terseLabel": "Initial ownership percentage after dilution" } } }, "localname": "EquityMethodInvestmentInitialOwnershipPercentageAfterDilution", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "percentItemType" }, "rdnt_EquityMethodInvestmentSharesPurchased": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Method Investment, Shares Purchased", "label": "Equity Method Investment, Shares Purchased", "terseLabel": "Number of shares purchased (in shares)" } } }, "localname": "EquityMethodInvestmentSharesPurchased", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "sharesItemType" }, "rdnt_EquityMethodInvestmentsOptionToPurchaseAdditionalEquityMethodInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity Method Investments, Option To Purchase Additional Equity Method Investment", "label": "Equity Method Investments, Option To Purchase Additional Equity Method Investment", "terseLabel": "Option to purchase additional equity method investment" } } }, "localname": "EquityMethodInvestmentsOptionToPurchaseAdditionalEquityMethodInvestment", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_EquityMethodInvestmentsOwnershipInterestPercentageAcquired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Method Investments, Ownership Interest Percentage Acquired", "label": "Equity Method Investments, Ownership Interest Percentage Acquired", "terseLabel": "Ownership percentage diluted" } } }, "localname": "EquityMethodInvestmentsOwnershipInterestPercentageAcquired", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "percentItemType" }, "rdnt_FirstLienCreditAgreementEighthAmendmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First Lien Credit Agreement Eighth Amendment", "label": "First Lien Credit Agreement Eighth Amendment [Member]", "terseLabel": "First Lien Credit Agreement Eighth Amendment" } } }, "localname": "FirstLienCreditAgreementEighthAmendmentMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_FirstLienCreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "First Lien Credit Agreement [Member]", "terseLabel": "First Lien Credit Agreement" } } }, "localname": "FirstLienCreditAgreementMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_FirstLienCreditAgreementSeventhAmendmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First Lien Credit Agreement Seventh Amendment [Member]", "label": "First Lien Credit Agreement Seventh Amendment [Member]", "terseLabel": "First Lien Credit Agreement Seventh Amendment" } } }, "localname": "FirstLienCreditAgreementSeventhAmendmentMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_FirstLienCreditAgreementSixthAmendmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First Lien Credit Agreement Sixth Amendment [Member]", "label": "First Lien Credit Agreement Sixth Amendment [Member]", "terseLabel": "First Lien Credit Agreement, Sixth Amendment" } } }, "localname": "FirstLienCreditAgreementSixthAmendmentMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_FirstLienTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "First Lien Term Loan [Member]", "terseLabel": "First Lien Term Loan" } } }, "localname": "FirstLienTermLoanMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsTermLoans" ], "xbrltype": "domainItemType" }, "rdnt_FirstLienTermLoansAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "FirstLienTermLoansAMember", "terseLabel": "FirstLienTermLoansAMember" } } }, "localname": "FirstLienTermLoansAMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_FutureServiceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Future Services [Member]", "label": "Future Service [Member]", "terseLabel": "Future Service" } } }, "localname": "FutureServiceMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_GlendaleAdvancedImagingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Glendale Advanced Imaging [Member]", "terseLabel": "Glendale Advanced Imaging" } } }, "localname": "GlendaleAdvancedImagingMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_HealthCareManagementServiceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Health Care, Management Service [Member]", "label": "Health Care, Management Service [Member]", "terseLabel": "Management fee revenue" } } }, "localname": "HealthCareManagementServiceMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue" ], "xbrltype": "domainItemType" }, "rdnt_HealthCarePatientServiceOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Health Care, Patient Service Other [Member]", "label": "Health Care, Patient Service Other [Member]", "terseLabel": "Other patient revenue" } } }, "localname": "HealthCarePatientServiceOtherMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue" ], "xbrltype": "domainItemType" }, "rdnt_HudsonValleyRadiologyAssociatesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hudson Valley Radiology Associates [Member]", "label": "Hudson Valley Radiology Associates [Member]", "terseLabel": "Hudson Valley Radiology Associates" } } }, "localname": "HudsonValleyRadiologyAssociatesMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "domainItemType" }, "rdnt_ImagingOnCallMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Imaging On Call [Member]", "label": "Imaging On Call [Member]", "terseLabel": "Imaging On Call" } } }, "localname": "ImagingOnCallMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_IncreaseDecreaseInOtherNoncashItem": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase Decrease In Other Noncash Item", "label": "Increase Decrease In Other Noncash Item", "negatedTerseLabel": "Other non-cash items included in cost of operations" } } }, "localname": "IncreaseDecreaseInOtherNoncashItem", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "rdnt_IncreaseDecreaseinOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase Decrease in Operating Lease Liability", "label": "Increase Decrease in Operating Lease Liability", "negatedTerseLabel": "Operating lease liability" } } }, "localname": "IncreaseDecreaseinOperatingLeaseLiability", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "rdnt_InvestmentsInAndAdvanceToAffiliatesSubsidiariesAssociatesAndJointVenturesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Roll Forward]", "terseLabel": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Roll Forward]" } } }, "localname": "InvestmentsInAndAdvanceToAffiliatesSubsidiariesAssociatesAndJointVenturesRollForward", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsInvestmentinJointVentures" ], "xbrltype": "stringItemType" }, "rdnt_JointVentureInvestmentAndFinancialInformationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Joint Venture Investment And Financial Information", "label": "Joint Venture Investment And Financial Information [Table Text Block]", "terseLabel": "Joint venture investment and financial information" } } }, "localname": "JointVentureInvestmentAndFinancialInformationTableTextBlock", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "rdnt_JointVentureMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Joint Venture [Member]", "terseLabel": "Joint Venture" } } }, "localname": "JointVentureMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_KeyFinancialDataForJointVenturesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Key financial data for joint ventures", "label": "Key financial data for joint ventures", "terseLabel": "Balance Sheet Data:" } } }, "localname": "KeyFinancialDataForJointVenturesAbstract", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures" ], "xbrltype": "stringItemType" }, "rdnt_LeverageRatioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leverage Ratio [Axis]", "label": "Leverage Ratio [Axis]", "terseLabel": "Leverage Ratio [Axis]" } } }, "localname": "LeverageRatioAxis", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "stringItemType" }, "rdnt_LeverageRatioDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Leverage Ratio [Axis]", "label": "Leverage Ratio [Domain]", "terseLabel": "Leverage Ratio [Domain]" } } }, "localname": "LeverageRatioDomain", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_LeverageRatioFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leverage Ratio Four [Member]", "label": "Leverage Ratio Four [Member]", "terseLabel": "\u2264 3.50x" } } }, "localname": "LeverageRatioFourMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio" ], "xbrltype": "domainItemType" }, "rdnt_LeverageRatioOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leverage Ratio One [Member]", "label": "Leverage Ratio One [Member]", "terseLabel": "> 5.50x" } } }, "localname": "LeverageRatioOneMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio" ], "xbrltype": "domainItemType" }, "rdnt_LeverageRatioThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leverage Ratio Three [Member]", "label": "Leverage Ratio Three [Member]", "terseLabel": ">3.50x but \u2264 4.00x" } } }, "localname": "LeverageRatioThreeMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_LeverageRatioTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leverage Ratio Two [Member]", "label": "Leverage Ratio Two [Member]", "terseLabel": "> 4.00x but \u2264 5.50x" } } }, "localname": "LeverageRatioTwoMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio" ], "xbrltype": "domainItemType" }, "rdnt_LineofCreditFacilityIncreaseBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Line of Credit Facility, Increase Borrowing Capacity", "label": "Line of Credit Facility, Increase Borrowing Capacity", "terseLabel": "Line of credit facility, increase borrowing capacity" } } }, "localname": "LineofCreditFacilityIncreaseBorrowingCapacity", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_LongtermDebtShorttermDebtandCapitalLeaseObligationsCurrentMaturities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-term Debt, Short-term Debt and Capital Lease Obligations, Current Maturities", "label": "Long-term Debt, Short-term Debt and Capital Lease Obligations, Current Maturities", "negatedLabel": "Less: current portion" } } }, "localname": "LongtermDebtShorttermDebtandCapitalLeaseObligationsCurrentMaturities", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt" ], "xbrltype": "monetaryItemType" }, "rdnt_LongtermDebtShorttermDebtandCapitalLeaseObligationsExcludingCurrentMaturities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-term Debt, Short-term Debt and Capital Lease Obligations, Excluding Current Maturities", "label": "Long-term Debt, Short-term Debt and Capital Lease Obligations, Excluding Current Maturities", "terseLabel": "Long term portion debt obligations" } } }, "localname": "LongtermDebtShorttermDebtandCapitalLeaseObligationsExcludingCurrentMaturities", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt" ], "xbrltype": "monetaryItemType" }, "rdnt_LongtermDebtShorttermDebtandCapitalLeaseObligationsIncludingCurrentMaturities": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-term Debt, Short-term Debt and Capital Lease Obligations, Including Current Maturities", "label": "Long-term Debt, Short-term Debt and Capital Lease Obligations, Including Current Maturities", "totalLabel": "Total debt obligations" } } }, "localname": "LongtermDebtShorttermDebtandCapitalLeaseObligationsIncludingCurrentMaturities", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt" ], "xbrltype": "monetaryItemType" }, "rdnt_MRIatWoodbridgeLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "MRI at Woodbridge, LLC [Member]", "label": "MRI at Woodbridge, LLC [Member]", "terseLabel": "MRI at Woodbridge, LLC" } } }, "localname": "MRIatWoodbridgeLLCMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_ManagementServiceFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Management service fees.", "label": "Management service fees", "terseLabel": "Management service fees" } } }, "localname": "ManagementServiceFees", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_MedicVisionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Medic Vision [Member]", "terseLabel": "Medic Vision" } } }, "localname": "MedicVisionMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_Medicaid1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicaid1 [Member]", "label": "Medicaid1 [Member]", "terseLabel": "Medicaid" } } }, "localname": "Medicaid1Member", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue" ], "xbrltype": "domainItemType" }, "rdnt_Medicare1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare1 [Member]", "label": "Medicare1 [Member]", "terseLabel": "Medicare" } } }, "localname": "Medicare1Member", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue" ], "xbrltype": "domainItemType" }, "rdnt_MonthlyAmortizationOfDeferredHedgeGains": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Monthly Amortization Of Deferred Hedge Gains", "label": "Monthly Amortization Of Deferred Hedge Gains", "terseLabel": "Monthly amortization of deferred hedge gains" } } }, "localname": "MonthlyAmortizationOfDeferredHedgeGains", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_NulogixMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nulogix", "label": "Nulogix [Member]", "terseLabel": "Nulogix" } } }, "localname": "NulogixMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "domainItemType" }, "rdnt_NumberOfAssetsAcquired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Assets Acquired", "label": "Number Of Assets Acquired", "terseLabel": "Number of assets acquired" } } }, "localname": "NumberOfAssetsAcquired", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "integerItemType" }, "rdnt_NumberOfCenters": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Centers", "label": "Number Of Centers", "terseLabel": "Number of centers" } } }, "localname": "NumberOfCenters", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "integerItemType" }, "rdnt_NumberofUnconsolidatedJointVentures": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Unconsolidated Joint Ventures", "label": "Number of Unconsolidated Joint Ventures", "terseLabel": "Number of unconsolidated joint ventures" } } }, "localname": "NumberofUnconsolidatedJointVentures", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "integerItemType" }, "rdnt_October2020CapMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "October 2020 [Member]", "terseLabel": "October 2020" } } }, "localname": "October2020CapMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_October2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "October 2023 [Member]", "label": "October 2023 [Member]", "terseLabel": "October 2023" } } }, "localname": "October2023Member", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_October2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "October 2025 [Member]", "label": "October 2025 [Member]", "terseLabel": "October 2025" } } }, "localname": "October2025Member", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_OlneyOpenMRILLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Olney Open MRI, LLC [Member]", "label": "Olney Open MRI, LLC [Member]", "terseLabel": "Olney Open MRI, LLC" } } }, "localname": "OlneyOpenMRILLCMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill" ], "xbrltype": "domainItemType" }, "rdnt_OperatingLeaseRightofUseAssetAmortization": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Lease Right of Use Asset Amortization", "label": "Operating Lease Right of Use Asset Amortization", "terseLabel": "Amortization of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightofUseAssetAmortization", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "rdnt_PaycheckProtectionProgramLoansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Paycheck Protection Program Loans [Member]", "label": "Paycheck Protection Program Loans [Member]", "terseLabel": "Paycheck Protection Program loans at 1% due April 2022", "verboseLabel": "Paycheck Protection Program Loans" } } }, "localname": "PaycheckProtectionProgramLoansMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_PaymentstoAcquireInterestinJointVentureAndContributionsToExistingJointVenture": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments to Acquire Interest in Joint Venture And Contributions To Existing Joint Venture", "label": "Payments to Acquire Interest in Joint Venture And Contributions To Existing Joint Venture", "negatedLabel": "Equity contributions in existing and purchase of interest in joint ventures" } } }, "localname": "PaymentstoAcquireInterestinJointVentureAndContributionsToExistingJointVenture", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "rdnt_PricingLevelIIIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pricing Level III [Member]", "label": "Pricing Level III [Member]", "terseLabel": "Pricing Level III" } } }, "localname": "PricingLevelIIIMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_PricingLevelIIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pricing Level II [Member]", "label": "Pricing Level II [Member]", "terseLabel": "Pricing Level II" } } }, "localname": "PricingLevelIIMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument" ], "xbrltype": "domainItemType" }, "rdnt_PricingLevelIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pricing Level I [Member]", "label": "Pricing Level I [Member]", "terseLabel": "Pricing Level I" } } }, "localname": "PricingLevelIMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument" ], "xbrltype": "domainItemType" }, "rdnt_PricingLevelIVMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pricing Level IV [Member]", "label": "Pricing Level IV [Member]", "terseLabel": "Pricing Level IV" } } }, "localname": "PricingLevelIVMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument" ], "xbrltype": "domainItemType" }, "rdnt_PricingLevelVMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pricing Level V [Member]", "label": "Pricing Level V [Member]", "terseLabel": "Pricing Level V" } } }, "localname": "PricingLevelVMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument" ], "xbrltype": "domainItemType" }, "rdnt_ProceedsFromGovernmentAssistance": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From Government Assistance", "label": "Proceeds From Government Assistance", "terseLabel": "Proceeds from Payment Protection Program" } } }, "localname": "ProceedsFromGovernmentAssistance", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "rdnt_ProceedsReceivedFromInsurance": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Proceeds Received From Insurance", "label": "Proceeds Received From Insurance", "terseLabel": "Advance insurance carrier payments" } } }, "localname": "ProceedsReceivedFromInsurance", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_PropertyAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Propery and equipment, net [Member]", "terseLabel": "Amounts returned to property and equipment" } } }, "localname": "PropertyAndEquipmentMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_PropertyPlantandEquipmentNetIncludingRightofUseAssets": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Property Plant and Equipment Net Including Right of Use Assets", "label": "Property Plant and Equipment Net Including Right of Use Assets", "totalLabel": "Total property, equipment and right-of-use assets" } } }, "localname": "PropertyPlantandEquipmentNetIncludingRightofUseAssets", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "rdnt_RestatedAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restated Agreement [Member]", "label": "Restated Agreement [Member]", "terseLabel": "SunTrust Term Loan Agreement collateralized by NJIN's tangible and intangible assets", "verboseLabel": "Restated Agreement" } } }, "localname": "RestatedAgreementMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsTermLoans" ], "xbrltype": "domainItemType" }, "rdnt_RestatedPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restated Plan [Member]", "terseLabel": "Restated Plan" } } }, "localname": "RestatedPlanMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_SantaMonicaImagingGroupLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Santa Monica Imaging Group, LLC", "label": "Santa Monica Imaging Group, LLC [Member]", "terseLabel": "Santa Monica Imaging Group, LLC" } } }, "localname": "SantaMonicaImagingGroupLLCMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_ScheduleOfLeverageRatioTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Leverage Ratio [Table Text Block]", "label": "Schedule Of Leverage Ratio [Table Text Block]", "terseLabel": "Schedule of leverage ratio" } } }, "localname": "ScheduleOfLeverageRatioTableTextBlock", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLETables" ], "xbrltype": "textBlockItemType" }, "rdnt_ScriptSenderLlcMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "ScriptSender LLC [Member]", "terseLabel": "ScriptSender LLC" } } }, "localname": "ScriptSenderLlcMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_September2020CapMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "September 2020 [Member]", "terseLabel": "September 2020" } } }, "localname": "September2020CapMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrossValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Gross, Value", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Gross, Value", "terseLabel": "Issuance of common stock upon exercise of options" } } }, "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrossValue", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "rdnt_SimiValleyHospitalAndHealthServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Simi Valley Hospital and Health Services", "label": "Simi Valley Hospital and Health Services [Member]", "terseLabel": "Simi Valley Hospital and Health Services" } } }, "localname": "SimiValleyHospitalAndHealthServicesMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "rdnt_SocialSecurityTaxEmployerDeferralCARESAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Social Security Tax, Employer, Deferral, CARES Act", "label": "Social Security Tax, Employer, Deferral, CARES Act", "terseLabel": "Deferred social security taxes" } } }, "localname": "SocialSecurityTaxEmployerDeferralCARESAct", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rdnt_StockIssuedDuringPeriodSharesIssuedForReturnOfCapital": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Issued During Period, Shares, Issued for Return of Capital", "label": "Stock Issued During Period, Shares, Issued for Return of Capital", "terseLabel": "Issuance of common stock for purchase of Nulogix (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForReturnOfCapital", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "rdnt_StockIssuedDuringPeriodValueIssuedForReturnOfCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Stock Issued During Period, Value, Issued for Return of Capital", "label": "Stock Issued During Period, Value, Issued for Return of Capital", "negatedTerseLabel": "Issuance of common stock for purchase of Nulogix" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForReturnOfCapital", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "rdnt_StockholdersEquityDeficitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Total Radnet, Inc.'s Equity [Member]", "terseLabel": "Total Radnet, Inc.'s Equity" } } }, "localname": "StockholdersEquityDeficitMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "rdnt_SunTrustMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "SunTrust [Member]", "label": "SunTrust [Member]", "terseLabel": "SunTrust" } } }, "localname": "SunTrustMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_TeleradiologyandSoftwareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Teleradiology and Software [Member]", "label": "Teleradiology and Software [Member]", "terseLabel": "Teleradiology and Software revenue" } } }, "localname": "TeleradiologyandSoftwareMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue" ], "xbrltype": "domainItemType" }, "rdnt_TermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Term Loan [Member]", "terseLabel": "Term Loan" } } }, "localname": "TermLoanMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsTermLoans" ], "xbrltype": "domainItemType" }, "rdnt_TotalBookValueOfOtherJointVenturePartnerInterests": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total book value of other joint venture partner interests", "label": "Total book value of other joint venture partner interests", "terseLabel": "Total book value of other joint venture partner interests" } } }, "localname": "TotalBookValueOfOtherJointVenturePartnerInterests", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures" ], "xbrltype": "monetaryItemType" }, "rdnt_TurnerImagingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Turner Imaging [Member]", "terseLabel": "Turner Imaging" } } }, "localname": "TurnerImagingMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_VenturaCountyImagingGroupLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ventura County Imaging Group, LLC [Member]", "label": "Ventura County Imaging Group, LLC [Member]", "terseLabel": "Ventura County Imaging Group, LLC" } } }, "localname": "VenturaCountyImagingGroupLLCMember", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "domainItemType" }, "rdnt_WeightedAverageRemainingContractualLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted Average Remaining Contractual Life abstract", "label": "Weighted Average Remaining Contractual Life", "terseLabel": "Weighted Average Remaining Contractual Life" } } }, "localname": "WeightedAverageRemainingContractualLife", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "stringItemType" }, "rdnt_WhiteRabbit.aiInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "WhiteRabbit.ai Inc. [Member]", "label": "WhiteRabbit.ai Inc. [Member]", "terseLabel": "WhiteRabbit.ai Inc." } } }, "localname": "WhiteRabbit.aiInc.Member", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "rdnt_WorkersCompensationPersonalInjury1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Workers' Compensation/Personal Injury1 [Member]", "label": "Workers' Compensation/Personal Injury1 [Member]", "terseLabel": "Workers' compensation/personal injury" } } }, "localname": "WorkersCompensationPersonalInjury1Member", "nsuri": "http://www.radnet.com/20200930", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue" ], "xbrltype": "domainItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r371" ], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r53", "r113" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r144", "r193", "r195", "r363", "r364" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable, accrued expenses and other" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r6", "r22", "r146", "r147", "r194" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesFairValueDisclosure": { "auth_ref": [ "r41" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of accrued expenses.", "label": "Accrued Liabilities, Fair Value Disclosure", "terseLabel": "Interest Rate Contracts" } } }, "localname": "AccruedLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r59", "r68", "r269" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss, net of taxes" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r57", "r58", "r59" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r56", "r59", "r61", "r270" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r23" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r201", "r203", "r231", "r232" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net (loss) income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDeferredCharges": { "auth_ref": [ "r74" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of amortization of deferred charges applied against earnings during the period.", "label": "Amortization of Deferred Charges", "terseLabel": "Amortization of deferred issuance costs" } } }, "localname": "AmortizationOfDeferredCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDeferredHedgeGains": { "auth_ref": [ "r100" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense charged against earnings by an Entity to record deferred gains and losses on hedge instruments. Examples include gain on economic hedges, amortization of gain on designated fair value hedge and so forth.", "label": "Amortization of Deferred Hedge Gains", "verboseLabel": "Amortization of cash flow hedge" } } }, "localname": "AmortizationOfDeferredHedgeGains", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r73", "r100", "r311" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of deferred financing costs and loan discount" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Weighted average shares for which the exercise price exceeds average market price of common stock (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r140", "r343", "r353" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "BRMG and NY Groups accounts receivable", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited", "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r9", "r49" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r205", "r229" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsRSUs" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r248", "r249" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "terseLabel": "Business acquisition, closing costs" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": { "auth_ref": [ "r255" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned", "terseLabel": "Equity interest issued, value assigned" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Shares issued (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative", "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Business acquisition, percentage of voting interests acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r252", "r253", "r254" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Purchase consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r99", "r256" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "auth_ref": [ "r251" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets", "terseLabel": "Current assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r236", "r251" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "terseLabel": "Deferred tax liabilities acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r250", "r251" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Intangible assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r250", "r251" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Fixed assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.", "label": "Business Combination, Separately Recognized Transactions [Axis]", "terseLabel": "Business Combination, Separately Recognized Transactions [Axis]" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction.", "label": "Business Combination, Separately Recognized Transactions [Domain]", "terseLabel": "Business Combination, Separately Recognized Transactions [Domain]" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r106", "r245" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "BUSINESS COMBINATION" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r4", "r120", "r134" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "NATURE OF BUSINESS AND BASIS OF PRESENTATION" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r31", "r102" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r96", "r102", "r104" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENTS, end of period", "periodStartLabel": "CASH AND CASH EQUIVALENTS, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r96", "r307" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassificationOfVariableInterestEntityDomain": { "auth_ref": [ "r271", "r272", "r274", "r276" ], "lang": { "en-US": { "role": { "documentation": "Categorization of Variable Interest Entities (VIE) for consolidation and (or) disclosure purposes, whether individually or in aggregate, by: (1) VIEs consolidated because the entity is the primary beneficiary, (2) VIEs not consolidated because the entity is not the primary beneficiary, and (3) VIEs or potential VIEs that are not consolidated because necessary information is not available. In general, a VIE is a corporation, partnership, trust, or any other legal structure used for business purposes that either (a) does not have equity investors with voting rights or (b) has equity investors that do not provide sufficient financial resources for the entity to support its activities. A VIE often holds financial assets, including loans or receivables, real estate or other property. A VIE may be essentially passive or it may engage in research and development or other activities on behalf of another company.", "label": "Variable Interest Entity, Classification [Domain]", "terseLabel": "Variable Interest Entity, Classification [Domain]" } } }, "localname": "ClassificationOfVariableInterestEntityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r177" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Promissory Note" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r106", "r176", "r368", "r369" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock - par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical", "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock - shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock - shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r20", "r184" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock - shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r20" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock - $0.0001 par value, 200,000,000 shares authorized; 51,596,098 and 50,314,328 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r105", "r210" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "EQUITY BASED COMPENSATION" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r63", "r65", "r66" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r63", "r65", "r261", "r262", "r279" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Less comprehensive income attributable to noncontrolling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r63", "r65", "r260", "r279" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "COMPREHENSIVE INCOME (LOSS)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "COMPREHENSIVE INCOME (LOSS)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r18", "r19", "r185", "r186" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Preferred stock issued upon conversion (in shares)" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CreditDerivativesByContractTypeAxis": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Information by major type of contract of credit derivatives.", "label": "Credit Derivatives Contract Type [Axis]", "terseLabel": "Credit Derivatives Contract Type [Axis]" } } }, "localname": "CreditDerivativesByContractTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CreditDerivativesContractTypeDomain": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Represents major types of credit derivative contracts.", "label": "Credit Derivatives Contract Type [Domain]", "terseLabel": "Credit Derivatives Contract Type [Domain]" } } }, "localname": "CreditDerivativesContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock": { "auth_ref": [ "r183", "r314" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for debt and capital lease obligations can be reported. Information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. Also includes descriptions and amounts of capital leasing arrangements that consist of direct financing, sales type and leveraged leases. Disclosure may include the effect on the balance sheet and the income statement resulting from a change in lease classification for leases that at inception would have been classified differently had guidance been in effect at the inception of the original lease.", "label": "Debt and Capital Leases Disclosures [Text Block]", "terseLabel": "CREDIT FACILITY AND NOTES PAYABLE" } } }, "localname": "DebtAndCapitalLeasesDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLE" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r15", "r16", "r17", "r344", "r345", "r352" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsTermLoans", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r17", "r179", "r345", "r352" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Total Carrying Value" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsTermLoans" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r310", "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face Value", "verboseLabel": "Debt instrument face value" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsTermLoans", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r303" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "First Lien Term Loans and SunTrust Term Loan" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r43", "r181", "r310" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate, stated percentage", "verboseLabel": "Interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsTermLoans" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsTermLoans", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r44" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Periodic payment, principal" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r44", "r114", "r185", "r187", "r188", "r189", "r309", "r310", "r313", "r351" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsTermLoans" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "PPP loans, maturity term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r309", "r313" ], "calculation": { "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt": { "order": 1.0, "parentTag": "rdnt_LongtermDebtShorttermDebtandCapitalLeaseObligationsIncludingCurrentMaturities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Discounts on First Lien Term Loans", "terseLabel": "Discounts on term loans" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r309", "r313" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Current", "terseLabel": "Debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r309", "r310", "r311", "r312", "r313" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "negatedLabel": "Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsTermLoans" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r35", "r106" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "DEFERRED FINANCING COSTS" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals.", "label": "Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance", "terseLabel": "Shares available for future issuance, options, warrants, shares of restricted stock and other bonus awards (in shares)" } } }, "localname": "DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r311" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r35", "r311" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Deferred financing costs, net of accumulated amortization" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "auth_ref": [ "r35", "r311" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Noncurrent, Net", "terseLabel": "Deferred financing costs" } } }, "localname": "DeferredFinanceCostsNoncurrentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r241" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets, net of current portion" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r28" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssets": { "auth_ref": [ "r35" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.", "label": "Deposits Assets", "terseLabel": "Deposits and other" } } }, "localname": "DepositsAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r100", "r137" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotionalAmount": { "auth_ref": [ "r281", "r282", "r284" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative asset.", "label": "Derivative Asset, Notional Amount", "terseLabel": "Notional amounts" } } }, "localname": "DerivativeAssetNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNumberOfInstrumentsHeld": { "auth_ref": [ "r282", "r284" ], "lang": { "en-US": { "role": { "documentation": "The number of derivative instruments of a particular derivative asset or group of derivative assets held by the entity.", "label": "Derivative Asset, Number of Instruments Held", "terseLabel": "Number of forward interest rate cap agreements" } } }, "localname": "DerivativeAssetNumberOfInstrumentsHeld", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "integerItemType" }, "us-gaap_DerivativeBasisSpreadOnVariableRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage points added to the reference rate to compute the variable rate on the interest rate derivative.", "label": "Derivative, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DerivativeBasisSpreadOnVariableRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r288" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Amount of loss recognized in income on derivative (current period ineffective portion)" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r287", "r289", "r292", "r295" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r106", "r119", "r280", "r283", "r285", "r286", "r297" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "DERIVATIVE INSTRUMENTS" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DueFromRelatedPartiesCurrent": { "auth_ref": [ "r7", "r10", "r21", "r111", "r319" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).", "label": "Due from Related Parties, Current", "terseLabel": "Due from affiliates" } } }, "localname": "DueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToAffiliateCurrent": { "auth_ref": [ "r13", "r112", "r319", "r365" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Affiliate, Current", "terseLabel": "Due to affiliates" } } }, "localname": "DueToAffiliateCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r72", "r121", "r126", "r127", "r128", "r129", "r133", "r350", "r362" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders (in dollars per share)", "verboseLabel": "BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r72", "r121", "r126", "r127", "r128", "r129", "r133", "r350", "r362" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS (in dollars per share)", "verboseLabel": "Diluted net income per share attributable to RadNet, Inc.'s common stockholders (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted, Other Disclosures [Abstract]", "terseLabel": "Nonvested restricted stock subject to service vesting" } } }, "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r106", "r130", "r131", "r132" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "EARNINGS PER SHARE" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r307" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r117", "r237", "r238" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized expense weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r228" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure": { "auth_ref": [ "r298" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of equity issued in a business combination.", "label": "Equity Issued in Business Combination, Fair Value Disclosure", "terseLabel": "Contingent consideration, fair value" } } }, "localname": "EquityIssuedInBusinessCombinationFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentAggregateCost": { "auth_ref": [ "r32" ], "calculation": { "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.", "label": "Equity Method Investment, Aggregate Cost", "terseLabel": "Aggregate cost", "totalLabel": "Total net assets" } } }, "localname": "EquityMethodInvestmentAggregateCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r70", "r95", "r100", "r360" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "negatedTerseLabel": "Distributions from joint ventures" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsInvestmentinJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets": { "auth_ref": [ "r2", "r109", "r154", "r158", "r306" ], "calculation": { "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures": { "order": 2.0, "parentTag": "us-gaap_EquityMethodInvestmentAggregateCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of assets reported by an equity method investment of the entity.", "label": "Equity Method Investment, Summarized Financial Information, Assets", "terseLabel": "Noncurrent assets" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets": { "auth_ref": [ "r2", "r109", "r154", "r158", "r306" ], "calculation": { "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures": { "order": 1.0, "parentTag": "us-gaap_EquityMethodInvestmentAggregateCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of current assets reported by an equity method investment of the entity.", "label": "Equity Method Investment, Summarized Financial Information, Current Assets", "terseLabel": "Current assets" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities": { "auth_ref": [ "r2", "r109", "r154", "r158", "r306" ], "calculation": { "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures": { "order": 3.0, "parentTag": "us-gaap_EquityMethodInvestmentAggregateCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of current liabilities reported by an equity method investment of the entity.", "label": "Equity Method Investment, Summarized Financial Information, Current Liabilities", "negatedLabel": "Current liabilities" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities": { "auth_ref": [ "r2", "r109", "r154", "r158", "r306" ], "calculation": { "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures": { "order": 4.0, "parentTag": "us-gaap_EquityMethodInvestmentAggregateCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of liabilities reported by an equity method investment of the entity.", "label": "Equity Method Investment, Summarized Financial Information, Liabilities", "negatedLabel": "Noncurrent liabilities" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss": { "auth_ref": [ "r2", "r109", "r154", "r158", "r306" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) reported by an equity method investment of the entity.", "label": "Equity Method Investment, Summarized Financial Information, Net Income (Loss)", "verboseLabel": "Net income" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue": { "auth_ref": [ "r2", "r158" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue from sale of product and rendering of service reported by equity method investee.", "label": "Equity Method Investment, Summarized Financial Information, Revenue", "terseLabel": "Net revenue" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets": { "auth_ref": [ "r157" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.", "label": "Equity Method Investment, Underlying Equity in Net Assets", "terseLabel": "Cost in excess of book value of acquired joint venture interests and other" } } }, "localname": "EquityMethodInvestmentUnderlyingEquityInNetAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r32", "r141", "r153" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Book value of RadNet joint venture interests" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r32", "r95", "r106", "r156", "r306" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "EQUITY INVESTMENTS AT FAIR VALUE" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Equity Method Investments [Table Text Block]", "verboseLabel": "Investment in joint ventures" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimate of Fair Value Measurement" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements" ], "xbrltype": "domainItemType" }, "us-gaap_EurodollarMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.", "label": "Eurodollar [Member]", "terseLabel": "Eurodollar" } } }, "localname": "EurodollarMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r298", "r304", "r305" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r298", "r304" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Schedule of fair value of assets and liabilities" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r197", "r198", "r200", "r299", "r325" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r298", "r301" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r300" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r197", "r198", "r200", "r299", "r326" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r197", "r198", "r200", "r299", "r327" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r197", "r198", "r200", "r299", "r328" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r316" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Current finance lease liability" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r316" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Long-term finance lease liability" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialGuaranteeInsuranceContractsFutureExpectedPremiumRevenueToBeRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unearned premium revenue under contracts issued by an insurance entity that provide protection to the holder of a financial obligation from a financial loss in the event of a default.", "label": "Financial Guarantee Insurance Contracts, Unearned Premium Revenue", "terseLabel": "Premium liability for 2016 Caps" } } }, "localname": "FinancialGuaranteeInsuranceContractsFutureExpectedPremiumRevenueToBeRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r100", "r168", "r171" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "negatedLabel": "Loss on sale and disposal of equipment and other" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": { "auth_ref": [ "r290" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.", "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings", "terseLabel": "Amount of loss recognized in income on derivative (current period ineffective portion)" } } }, "localname": "GainLossOnFairValueHedgesRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r160", "r161" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, ending balance", "periodStartLabel": "Goodwill, beginning balance", "terseLabel": "Goodwill", "verboseLabel": "Goodwill acquired" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited", "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r162" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill acquired through acquisitions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": { "auth_ref": [ "r106", "r167" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.", "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]", "terseLabel": "GOODWILL AND INDEFINITE LIVED INTANGIBLES" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill" ], "xbrltype": "stringItemType" }, "us-gaap_HealthCareOtherMember": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Service provided for maintenance, diagnosis and treatment of physical and mental health, classified as other.", "label": "Health Care, Other [Member]", "terseLabel": "Other" } } }, "localname": "HealthCareOtherMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue" ], "xbrltype": "domainItemType" }, "us-gaap_HealthCarePatientServiceMember": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility.", "label": "Health Care, Patient Service [Member]", "terseLabel": "Service fee revenue", "verboseLabel": "Service fee revenue" } } }, "localname": "HealthCarePatientServiceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r116" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "INCOME (LOSS) BEFORE INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r70", "r100", "r138", "r153", "r348", "r360" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "Equity in earnings of joint ventures", "terseLabel": "Equity in earnings in these joint ventures" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsInvestmentinJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": { "auth_ref": [ "r100" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.", "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions", "negatedLabel": "Equity in earnings of joint ventures" } } }, "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r110", "r139", "r243" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "(Provision for) benefit from income taxes", "terseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r67", "r106", "r234", "r235", "r239", "r240", "r242", "r244", "r370" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r99" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable, accrued expenses and other" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r99" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r99" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r99" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "verboseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1": { "auth_ref": [ "r287", "r290" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain (loss) included in earnings related to the fair value of the hedged item in an interest rate fair value hedge, offset by the gain (loss) on the hedging instrument to the extent that the fair value hedge is determined to be effective.", "label": "Increase (Decrease) in Fair Value of Hedged Item in Interest Rate Fair Value Hedge", "negatedTerseLabel": "Non-cash change in fair value of interest rate hedge" } } }, "localname": "IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r99" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r99" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]", "terseLabel": "Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r129" ], "calculation": { "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "terseLabel": "Additional shares issuable upon exercise of stock options and warrants (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r167" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r165", "r166" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r76", "r182" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r294" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Equity and Interest Expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r93", "r97", "r103" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid during the period for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCapMember": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount.", "label": "Interest Rate Cap [Member]", "terseLabel": "2016 caps - Interest Rate Contracts" } } }, "localname": "InterestRateCapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "2019 swaps - Interest Rate Contracts" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "INVESTMENTS IN JOINT VENTURES" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "auth_ref": [ "r32" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Investment in joint ventures", "verboseLabel": "Total value of Radnet joint venture interests" } } }, "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsInvestmentinJointVentures", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsKeyFinancialDataonJointVentures" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesCategorizationAxis": { "auth_ref": [ "r367" ], "lang": { "en-US": { "role": { "documentation": "Information by category of investments used to group investments in and advances to affiliates.", "label": "Investments in and Advances to Affiliates Categorization [Axis]", "terseLabel": "Investments in and Advances to Affiliates Categorization [Axis]" } } }, "localname": "InvestmentsInAndAdvancesToAffiliatesCategorizationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesCategorizationDomain": { "auth_ref": [ "r367" ], "lang": { "en-US": { "role": { "documentation": "Used to categorize investments in and advances of affiliate. Lists the categories for (1) Investments in majority owned subsidiaries, segregating subsidiaries consolidated; (2) other controlled companies; and (3) other affiliates.", "label": "Investments in and Advances to Affiliates Categorization [Domain]", "terseLabel": "Investments in and Advances to Affiliates Categorization [Domain]" } } }, "localname": "InvestmentsInAndAdvancesToAffiliatesCategorizationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsInMajorityOwnedSubsidiariesMember": { "auth_ref": [ "r366" ], "lang": { "en-US": { "role": { "documentation": "A category that identifies investments in majority owned subsidiaries. This member would be expected to be further segregated into consolidated subsidiaries.", "label": "Investments in Majority-owned Subsidiaries [Member]", "terseLabel": "Investments in Majority-owned Subsidiaries" } } }, "localname": "InvestmentsInMajorityOwnedSubsidiariesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit outstanding" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r40" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "BRMG and NY Groups accounts payable", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited", "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r347", "r358" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "LONG-TERM LIABILITIES" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r17", "r345", "r352" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Total credit facilities outstanding" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r37", "r114" ], "lang": { "en-US": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Commitment fee percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r37" ], "lang": { "en-US": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Line of credit facility, remaining borrowing capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r37", "r114" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Unused capacity, commitment fee percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r17", "r180", "r345", "r355" ], "calculation": { "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt": { "order": 2.0, "parentTag": "rdnt_LongtermDebtShorttermDebtandCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r44" ], "calculation": { "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt": { "order": 3.0, "parentTag": "rdnt_LongtermDebtShorttermDebtandCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable, Noncurrent", "terseLabel": "Equipment note payable at 4.6%, due through 2020, collateralized by medical equipment" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r44" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "terseLabel": "Notes payable, net of current portion" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsTermLoans", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r44", "r178" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsTermLoans", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MediumTermNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instruments with maturities ranging from five to ten years.", "label": "Medium-term Notes [Member]", "terseLabel": "Medium-term Notes" } } }, "localname": "MediumTermNotesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r3", "r257" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "FACILITY ACQUISITIONS AND DISPOSITIONS" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r48", "r346", "r357" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r190" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedTerseLabel": "Distributions paid to noncontrolling interests" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r190", "r263", "r264" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "negatedTerseLabel": "Purchase of noncontrolling interests" } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r96" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r96" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r96", "r98", "r101" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r62", "r64", "r71", "r101", "r131", "r349", "r361" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss) attributable to RadNet, Inc.'s common stockholders", "totalLabel": "NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r62", "r64", "r266", "r278" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net income attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]", "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r122" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]", "terseLabel": "RECENT ACCOUNTING AND REPORTING STANDARDS" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/RECENTACCOUNTINGANDREPORTINGSTANDARDS" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "RECENT ACCOUNTING AND REPORTING STANDARDS" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": { "auth_ref": [ "r191", "r263", "r268" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.", "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest", "terseLabel": "Sale of noncontrolling interests, net of taxes" } } }, "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other expenses" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Current portion of notes payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Equipment Notes Payable" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsScheduleofdebt" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfBusinessesAcquired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of businesses acquired by the entity during the period.", "label": "Number of Businesses Acquired", "terseLabel": "Number of businesses acquired" } } }, "localname": "NumberOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "integerItemType" }, "us-gaap_OffsettingAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Offsetting Assets [Line Items]", "terseLabel": "Offsetting Assets [Line Items]" } } }, "localname": "OffsettingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r51", "r52" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]", "terseLabel": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "Operating Costs and Expenses", "terseLabel": "Cost of operations, excluding depreciation and amortization" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "INCOME FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r316" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r316" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r315" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 2.0, "parentTag": "rdnt_PropertyPlantandEquipmentNetIncludingRightofUseAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Assets [Abstract]", "terseLabel": "OTHER ASSETS" } } }, "localname": "OtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent": { "auth_ref": [ "r260", "r261", "r269" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent", "terseLabel": "Change in cumulative foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location in other comprehensive income.", "label": "Other Comprehensive Income Location [Axis]", "terseLabel": "Other Comprehensive Income Location [Axis]" } } }, "localname": "OtherComprehensiveIncomeLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in other comprehensive income.", "label": "Other Comprehensive Income Location [Domain]", "terseLabel": "Other Comprehensive Income Location [Domain]" } } }, "localname": "OtherComprehensiveIncomeLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "auth_ref": [ "r55", "r57" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "terseLabel": "Change in fair value of cash flow hedge, net of taxes", "verboseLabel": "Change in fair value of cash flow hedge, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r57", "r60" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": { "order": 4.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "negatedTerseLabel": "Amount of loss reclassified from accumulated OCI into income (prior period effective portion)" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r54", "r308" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Expenses [Abstract]", "terseLabel": "OTHER INCOME AND EXPENSES" } } }, "localname": "OtherExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expenses" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r91" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Additional deferred finance costs on revolving loan amendment" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBuildings": { "auth_ref": [ "r85" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for acquisition of buildings (properties) whether for investment or use.", "label": "Payments to Acquire Buildings", "negatedTerseLabel": "Purchase of imaging facilities and other acquisitions" } } }, "localname": "PaymentsToAcquireBuildings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r84" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "terseLabel": "Payments to acquire equity method investments" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInterestInJointVenture": { "auth_ref": [ "r84" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.", "label": "Payments to Acquire Interest in Joint Venture", "terseLabel": "Payments to acquire additional interest in subsidiaries" } } }, "localname": "PaymentsToAcquireInterestInJointVenture", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r86" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Equity investments at fair value" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": { "auth_ref": [ "r85" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Payments to Acquire Other Property, Plant, and Equipment", "negatedTerseLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": { "auth_ref": [ "r83", "r318" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.", "label": "Payments to Fund Long-term Loans to Related Parties", "terseLabel": "Payments to fund loan to related parties" } } }, "localname": "PaymentsToFundLongtermLoansToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToMinorityShareholders": { "auth_ref": [ "r92" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.", "label": "Payments to Noncontrolling Interests", "negatedTerseLabel": "Distributions paid to noncontrolling interests" } } }, "localname": "PaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r205", "r229" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r302" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsFairValueMeasurements" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r8", "r29", "r30" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "verboseLabel": "Advance for future software subscription fees" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.", "label": "Reclassification, Policy [Policy Text Block]", "terseLabel": "RECLASSIFICATION" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromContributedCapital": { "auth_ref": [ "r87" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period.", "label": "Proceeds from Contributed Capital", "terseLabel": "Contribution from noncontrolling partner" } } }, "localname": "ProceedsFromContributedCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfInterestInJointVenture": { "auth_ref": [ "r80" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting.", "label": "Proceeds from Divestiture of Interest in Joint Venture", "terseLabel": "Proceeds from the sale of equity interests in a joint venture" } } }, "localname": "ProceedsFromDivestitureOfInterestInJointVenture", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "auth_ref": [ "r80", "r95" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.", "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "terseLabel": "Nulogix return of capital" } } }, "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r88" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from debt issuance, net of issuing costs" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r87", "r230" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from issuance of common stock upon exercise of options" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r88", "r115" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from revolving credit facility" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r81" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": { "auth_ref": [ "r82" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.", "label": "Proceeds from Sales of Business, Affiliate and Productive Assets", "terseLabel": "Proceeds from sale of noncontrolling interest" } } }, "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r62", "r64", "r94", "r140", "r143", "r260", "r265", "r267", "r278", "r279" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net (loss) income", "totalLabel": "NET INCOME (LOSS)", "verboseLabel": "NET INCOME (LOSS)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r34", "r170" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r11", "r12", "r170", "r359" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 1.0, "parentTag": "rdnt_PropertyPlantandEquipmentNetIncludingRightofUseAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetIncludingAndExcludingCapitalLeasedAssetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment, Net, Including and Excluding Capital Leased Asset [Abstract]", "terseLabel": "PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS" } } }, "localname": "PropertyPlantAndEquipmentNetIncludingAndExcludingCapitalLeasedAssetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r33", "r106", "r170" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r11", "r169" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "PPE estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r106", "r148", "r150", "r151", "r152" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "ACCOUNTS RECEIVABLE" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r322" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r199", "r320", "r321", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r90" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedLabel": "Payments on term loan debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r90", "r115" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedLabel": "Payments on revolving credit facility" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": { "auth_ref": [ "r89" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.", "label": "Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security", "negatedLabel": "Principal payments on notes and leases payable" } } }, "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsRSUs", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r24", "r190", "r356" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r192", "r193" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Service fee revenue, net of contractual allowances and discounts", "verboseLabel": "Total service revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r107", "r196" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "DEFERRED REVENUE" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueNotFromContractWithCustomer": { "auth_ref": [ "r69" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue that is not accounted for under Topic 606.", "label": "Revenue Not from Contract with Customer", "terseLabel": "Provider relief funding" } } }, "localname": "RevenueNotFromContractWithCustomer", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r107", "r108" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "REVENUES" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r69", "r135", "r136", "r142" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "verboseLabel": "Total service revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "REVENUE" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r248", "r249" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/FACILITYACQUISITIONSANDDISPOSITIONSDetailsNarrative", "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Effect of derivative instruments on comprehensive income" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r44", "r114", "r185", "r187", "r188", "r189", "r309", "r310", "r313", "r351" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of first lien credit agreement" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of notes payable, line of credit and capital lease obligations" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Earnings per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsRevenue" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r163", "r164" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGoodwill" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of goodwill and other intangible assets" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of RSA activity" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPrincipalTransactionsRevenueTextBlock": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of revenue by reporting categories or types of financial instruments, including derivatives but excluding dividends and interests, from trading for own account by broker dealers.", "label": "Schedule of Principal Transactions Revenue [Table Text Block]", "terseLabel": "Service Fee Revenue" } } }, "localname": "ScheduleOfPrincipalTransactionsRevenueTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r34", "r170" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r205", "r229" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsRSUs" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r211", "r223", "r225" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of options activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuritiesFinancingTransactionAxis": { "auth_ref": [ "r50", "r118", "r329" ], "lang": { "en-US": { "role": { "documentation": "Information by type of securities financing transactions, including, but not limited to those measured at fair value or cost.", "label": "Securities Financing Transaction [Axis]", "terseLabel": "Securities Financing Transaction [Axis]" } } }, "localname": "SecuritiesFinancingTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SecuritiesFinancingTransactionTypeDomain": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "Measurement of financing transaction securities held.", "label": "Securities Financing Transaction [Domain]", "terseLabel": "Securities Financing Transaction [Domain]" } } }, "localname": "SecuritiesFinancingTransactionTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r100", "r173", "r174", "r175" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r99" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Share-based payment award, award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "RSA's forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r221" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "RSA's granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsRSUs" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r221" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value, granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsRSUs" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "RSA's unvested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-average fair value, ending balance (in dollars per share)", "periodStartLabel": "Weighted-average fair value, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsRSUs" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsRSUs" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted-Average Remaining Contractual Term (Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsRSUs" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "RSA's vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsRSUs" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value, vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsRSUs" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsRSUs" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r212", "r214" ], "lang": { "en-US": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "RSA's outstanding, ending balance (in shares)", "periodStartLabel": "RSA's outstanding, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsRSUs" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsRSUs" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Exercisable at the end (in shares)", "terseLabel": "Exercisable shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Exercisable at the end (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "terseLabel": "Options cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "netLabel": "Options granted (in shares)", "terseLabel": "Issuance of common stock upon exercise of options (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r229" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate value outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r213", "r229" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Begining Balance (in shares)", "terseLabel": "Options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending Balance (in dollars per share)", "periodStartLabel": "Begining Balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r202", "r209" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsRSUs" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Share-based payment award, expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r229" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "periodEndLabel": "Aggregate value exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Balance at end of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable at the end" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r14", "r344", "r354" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "verboseLabel": "Convertible promissory note" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r38" ], "lang": { "en-US": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r36" ], "lang": { "en-US": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r120" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r47", "r184" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r19", "r20", "r190" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance of common stock for acquisition (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r46", "r184", "r185", "r190" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Issuance of common stock for purchase of membership interest in HVRA (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r19", "r20", "r184", "r190" ], "lang": { "en-US": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "negatedTerseLabel": "Forfeiture of restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r19", "r20", "r184", "r190" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock under the equity compensation plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r19", "r20", "r184", "r190", "r216" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Options exercised (in shares)", "terseLabel": "Options exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r47", "r184", "r190" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance of common stock for acquisition" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r47", "r184", "r190" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of common stock for purchase of membership interest in HVRA" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": { "auth_ref": [ "r19", "r20", "r184", "r190" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures", "negatedLabel": "Forfeiture of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r19", "r20", "r190", "r204", "r224" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock under the equity compensation plan" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Equity Option" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsNarrative", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONDetailsOutstandingoptionsandwarrants" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r25", "r26", "r149" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total RadNet, Inc.'s stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r258", "r259", "r277" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSunaudited", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity including the portion attributable to noncontrolling interests, after the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance", "periodEndLabel": "Derivative instrument, ending balance", "periodStartLabel": "Derivative instrument, beginning balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailsGainonDerivative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r323" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r323" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r323" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUBSEQUENTEVENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r100" ], "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives", "negatedLabel": "Non-cash change in fair value of interest rate hedge" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnusualOrInfrequentItemAxis": { "auth_ref": [ "r78" ], "lang": { "en-US": { "role": { "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Axis]", "terseLabel": "Unusual or Infrequent Item, or Both [Axis]" } } }, "localname": "UnusualOrInfrequentItemAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualOrInfrequentItemDomain": { "auth_ref": [ "r78" ], "lang": { "en-US": { "role": { "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Domain]", "terseLabel": "Unusual or Infrequent Item, or Both [Domain]" } } }, "localname": "UnusualOrInfrequentItemDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis": { "auth_ref": [ "r271", "r272", "r276" ], "lang": { "en-US": { "role": { "documentation": "Information by category of Variable Interest Entity (VIE).", "label": "Variable Interest Entities [Axis]", "terseLabel": "Variable Interest Entities [Axis]" } } }, "localname": "VariableInterestEntitiesByClassificationOfEntityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityExpense": { "auth_ref": [ "r275" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense between the reporting entity and the Variable Interest Entity (VIE).", "label": "Variable Interest Entity, Measure of Activity, Expense", "terseLabel": "BRMG and NY Groups operating expenses" } } }, "localname": "VariableInterestEntityActivityBetweenVIEAndEntityExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax": { "auth_ref": [ "r275" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Description of the amount of pre-tax income (loss) derived by the reporting entity from the Variable Interest Entity (VIE).", "label": "Variable Interest Entity, Measure of Activity, Income or Loss before Tax", "terseLabel": "Management services provided to BRMG and NY Groups" } } }, "localname": "VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues": { "auth_ref": [ "r275" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of income between the reporting entity and the Variable Interest Entity (VIE).", "label": "Variable Interest Entity, Measure of Activity, Revenues", "terseLabel": "BRMG and NY Groups revenues" } } }, "localname": "VariableInterestEntityActivityBetweenVIEAndEntityRevenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Not Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Not Primary Beneficiary" } } }, "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_VariableInterestEntityOwnershipPercentage": { "auth_ref": [ "r273" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).", "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage", "terseLabel": "Variable interest entity, ownership percentage" } } }, "localname": "VariableInterestEntityOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Primary Beneficiary" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatio", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsMarginSpreadBasedonLeverageRatioDebtInstrument", "http://www.radnet.com/role/CREDITFACILITYANDNOTESPAYABLEDetailsNarrative", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r125", "r129" ], "calculation": { "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average number of common shares used in calculating diluted net income per share (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r123", "r129" ], "calculation": { "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average number of common shares outstanding during the period (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "WEIGHTED AVERAGE SHARES OUTSTANDING" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "auth_ref": [ "r124" ], "calculation": { "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.", "label": "Weighted Average Number of Shares, Restricted Stock", "terseLabel": "Nonvested restricted stock subject only to service vesting (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesRestrictedStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.radnet.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailsEarningsPerShare" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(m))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e2646-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33912-111571" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r257": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5710-111685" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "d", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5747-111685" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5747-111685" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5708775-113959" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28567-108399" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r314": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r322": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r324": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=35711157&loc=d3e42567-110969" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(1)(a)(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r372": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r373": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r374": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r375": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r376": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r377": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=49176635&loc=d3e9760-107771" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=SL94080555-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" } }, "version": "2.1" } ZIP 57 0000790526-20-000007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000790526-20-000007-xbrl.zip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

D%-.%Q0]YXC8+N[\Z_,3@ @RZK[(OGYDY MZ1[:]Y%FT3%%:\*HH/B-?[<1SLPOY:2@F;C*9$;6X

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